UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TOTENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

MYOKARDIA, INC. (Name of Subject Company (Issuer))

GOTHAM MERGER SUB INC. (Offeror)

A Wholly Owned Subsidiary of

BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror)

(Names of Filing Persons (identifying status as offeror, issuer or other person))

Common Stock, par value $0.0001 per share (Title of Class of Securities)

62857M105 (CUSIP Number of Class of Securities)

Sandra Leung, Esq. Executive Vice President & General Counsel

Casarine Chong, Esq. Senior Vice President & Associate General Counsel

Bristol-Myers Squibb Company 430 East 29th Street, 14th Floor

New York, NY 10016 (212) 546-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

Copiesto:Daniel E. Wolf, Esq.

Jonathan L. Davis, Esq.Maggie D. Flores, Esq.Kirkland & Ellis LLP601 Lexington AvenueNew York, NY 10022

(212) 446-4800

CALCULATION OF FILING FEE

Transaction Valuation* Amount of Filing Fee**

$13,071,333,804.79 $1,426,082.52

* EstimatedsolelyforpurposesofcalculatingthefilingfeepursuanttoRule0-11(d)undertheSecuritiesExchangeActof1934,asamended(the“ExchangeAct”).TheTransactionValuewascalculatedbyadding(i)theproductof(A)53,322,904outstandingshares(“Shares”)ofcommonstockofMyoKardia,Inc.and(B)$225.00(the“Offer Price”);(ii)theproductof(A)4,745,419Sharessubjecttoissuancepursuanttostockoptionsgrantedandoutstandingand(B)$182.41,whichisthedifferencebetweenthe$225.00persharetenderofferpriceand$42.59,theaverageweightedexercisepriceofsuchoptions(allofwhichare“in-the-money”);(iii)theproductof(A)outstandingrestrictedstockunitsinrespectof894,749Sharessubjecttosuchrestrictedstockunitswithany applicable performance conditions deemedto be achieved at target performance (which is the sameas at maximumperformance) and (B) the OfferPrice;and(iv)theproductof(A)30,000ShareswhichareestimatedtobesubjecttooutstandingpurchaserightsundertheMyoKardia,Inc.AmendedandRestatedEmployeeStockPurchasePlanand(B)theOfferPrice.

TheforegoingfigureshavebeenprovidedbyMyoKardia,Inc.totheOfferorandParentofOfferorandareasofOctober13,2020,themostrecentpracticabledate.** The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act, by multiplying the Transaction Valuation by

0.0001091. ☐ ChecktheboxifanypartofthefeeisoffsetasprovidedbyRule0-11(a)(2)andidentifythefilingwithwhichtheoffsettingfeewaspreviouslypaid.Identify

thepreviousfilingbyregistrationstatementnumber,ortheFormorScheduleandthedateofitsfiling.

AmountPreviouslyPaid:None FilingParty:N/AFormofRegistrationNo.:N/A DateFiled:N/A

 ☐ Checktheboxifthefilingrelatessolelytopreliminarycommunicationsmadebeforethecommencementofatenderoffer.Checktheappropriateboxesbelowtodesignateanytransactionstowhichthestatementrelates:

☑ Third-partyoffersubjecttoRule14d-1. ☐ IssuertenderoffersubjecttoRule13e-4. ☐ Going-privatetransactionsubjecttoRule13e-3. ☐ AmendmenttoSchedule13DunderRule13d-2.

Checkthefollowingboxifthefilingisafinalamendmentreportingtheresultsofthetenderoffer: ☐Ifapplicable,checktheappropriatebox(es)belowtodesignatetheappropriateruleprovision(s)reliedupon:

 ☐ Rule13e-4(i)(Cross-BorderIssuerTenderOffer) ☐ Rule14d-1(d)(Cross-BorderThirdPartyTenderOffer)

Items1through9andItem11.

ThisTenderOfferStatementonScheduleTO(the“Schedule TO”)relatestotheofferbyGothamMergerSubInc.,aDelawarecorporationandawhollyownedsubsidiaryofBristol-MyersSquibbCompany,aDelawarecorporation, topurchaseall outstandingshares of commonstock, par value$0.0001pershare(the“Shares”) of MyoKardia, Inc., aDelaware corporation (the “Company”), at $225.00 per Share, net to the seller in cash, without interest and lessapplicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, datedOctober 19, 2020 (the “Offer to Purchase”), and in the related Letter of Transmittal, copies of which are attachedheretoasExhibits(a)(1)(i)and(a)(1)(ii), respectively(which,togetherwithanyamendmentsorsupplementsthereto,collectivelyconstitutethe“Offer”).

The information set forth in the Offer to Purchase, including all schedules thereto, is hereby expressly incorporatedhereinbyreferenceinresponsetoalloftheitemsofthisScheduleTO,exceptasotherwisesetforthbelow.

Item10. FinancialStatements.

Notapplicable.

Item12. Exhibits.

Exhibit No. Description

(a)(1)(i)* OffertoPurchase,datedasofOctober19,2020.

(a)(1)(ii)* FormofLetterofTransmittal(includingGuidelinesforCertificationofTaxpayerIdentificationNumberonIRSFormW-9).

(a)(1)(iii)* FormofNoticeofGuaranteedDelivery.

(a)(1)(iv)* FormofLettertoBrokers,Dealers,CommercialBanks,TrustCompaniesandOtherNominees.

(a)(1)(v)* FormofLettertoClientsforusebyBrokers,Dealers,CommercialBanks,TrustCompaniesandOtherNominees.

(a)(1)(vi)* SummaryAdvertisement,aspublishedinThe Wall Street JournalonOctober19,2020.

(a)(5)(i) JointPressReleaseofBristol-MyersSquibbCompanyandMyoKardia,Inc.datedOctober5,2020(incorporatedbyreferencetoExhibit99.1oftheBristol-MyersSquibbCompanyCurrentReportonForm8-K(FileNo.001-01136)filedwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(ii) InvestorRelationsPresentationdatedOctober5,2020(incorporatedbyreferencetoExhibit99.2ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(iii) InvestorRelationsCallTranscriptdatedOctober5,2020(incorporatedbyreferencetoExhibit99.3ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(iv) TransactionInfographicdatedOctober5,2020(incorporatedbyreferencetoExhibit99.4ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(v) SocialMediaContentdatedOctober5,2020(incorporatedbyreferencetoExhibit99.5ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(vi) EnterpriseLetterdatedOctober5,2020(incorporatedbyreferencetoExhibit99.6ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(vii) Bristol-MyersSquibbEmployeeQ&AdatedOctober5,2020(incorporatedbyreferencetoExhibit99.7ofthefirstBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(viii) TranscriptofInterviewwithBristol-MyersSquibbChiefExecutiveOfficerdatedOctober5,2020(incorporatedbyreferencetoExhibit99.1ofthesecondBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober6,2020).

1

Exhibit No. Description

(a)(5)(ix) SocialMediaContentdatedOctober5,2020(incorporatedbyreferencetoExhibit99.2ofthesecondBristol-MyersSquibbCompanyPre-CommencementCommunicationonScheduleTOfiledwiththeSecuritiesandExchangeCommissiononOctober6,2020).

(a)(5)(x) MyoKardia,Inc.CurrentReportonForm8-KdatedOctober5,2020(incorporatedbyreferencetotheMyoKardia,Inc.CurrentReportonForm8-K(FileNo.001-37609)filedwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(xi) EmailfromTassosGianakakos,ChiefExecutiveOfficerofMyoKardia,Inc.,toemployeesonOctober5,2020(incorporatedbyreferencetoExhibit99.1ofthefirstMyoKardia,Inc.Solicitation/RecommendationStatementonSchedule14D-9filedwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(a)(5)(xii) MyoKardia,Inc.EmployeeQ&AfirstusedonOctober5,2020(incorporatedbyreferencetoExhibit99.2ofthefirstMyoKardia,Inc.Solicitation/RecommendationStatementonSchedule14D-9filedwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(b) Notapplicable.

(d)(1) AgreementandPlanofMerger,datedasofOctober3,2020,byandamongBristol-MyersSquibbCompany,GothamMergerSubInc.andMyoKardia,Inc.(incorporatedbyreferencetoExhibit2.1oftheMyoKardia,Inc.CurrentReportonForm8-K(FileNo.001-37609)filedwiththeSecuritiesandExchangeCommissiononOctober5,2020).

(d)(2)* ConfidentialityAgreement,datedasofSeptember17,2020,betweenBristol-MyersSquibbCompanyandMyoKardia,Inc.

(d)(3)* ExclusivityAgreement,datedasofSeptember25,2020,betweenBristol-MyersSquibbCompanyandMyoKardia,Inc.

(d)(4)* TenderandSupportAgreement,datedasofOctober3,2020,betweenBristol-MyersSquibbCompany,GothamMergerSubInc.,andTassosGianakakos.

(g) Notapplicable.

(h) Notapplicable.

* Filedherewith

2

SIGNATURES

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certify that theinformationsetforthinthisstatementistrue,completeandcorrect.

Date:October19,2020

GOTHAMMERGERSUBINC.

By: /s/BrianP.Heaphy

Name: BrianP.Heaphy

Title: VicePresident

BRISTOL-MYERSSQUIBBCOMPANY

By: /s/KatherineR.Kelly

Name: KatherineR.Kelly

Title: CorporateSecretary

3

TABLE OF CONTENTS

Exhibit (a)(1)(i)

Offer to Purchase for Cash All Outstanding Shares of Common Stock

of

MYOKARDIA, INC.at

$225.00 Net Per Share

by

GOTHAM MERGER SUB INC.

a wholly owned subsidiary of

BRISTOL-MYERS SQUIBB COMPANYTHE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONEMINUTE AFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE

OFFER IS EXTENDED OR EARLIER TERMINATED.

THISOFFERISBEINGMADEPURSUANTTOTHEAGREEMENTANDPLANOFMERGER,DATEDASOFOCTOBER3,2020,(TOGETHERWITHANYAMENDMENTSORSUPPLEMENTSTHERETO,THE“MERGERAGREEMENT”) BY AND AMONG MYOKARDIA, INC., A DELAWARE CORPORATION (“MYOKARDIA”),BRISTOL-MYERS SQUIBB COMPANY, A DELAWARE CORPORATION (“PARENT”) AND GOTHAMMERGERSUBINC., ADELAWARECORPORATIONANDAWHOLLYOWNEDSUBSIDIARYOFPARENT(“PURCHASER”). PURCHASER IS OFFERING TO PURCHASE ALL OF THE OUTSTANDING SHARES OFCOMMONSTOCK(THE“SHARES”),PARVALUE$0.0001PERSHARE,OFMYOKARDIAFOR$225.00PERSHARE,NETTOTHESELLERINCASH,WITHOUTINTERESTANDLESSANYREQUIREDWITHHOLDINGTAXES, UPON THE TERMS AND SUBJECT TO THE CONDITIONS SET FORTH IN THIS OFFER TOPURCHASE AND THE RELATED LETTER OF TRANSMITTAL (WHICH, TOGETHER WITH ANYAMENDMENTS OR SUPPLEMENTS HERETO AND THERETO, COLLECTIVELY CONSTITUTE THE“OFFER”).UNDERNOCIRCUMSTANCESWILLWEPAYINTERESTONTHECONSIDERATIONPAIDFORSHARESPURSUANTTOTHEOFFER,REGARDLESSOFANYEXTENSIONOFTHEOFFERORANYDELAYINMAKINGSUCHPAYMENT. THEMERGERAGREEMENTPROVIDES, AMONGOTHERTHINGS, THATAS SOON AS PRACTICABLE FOLLOWING (BUT IN ANY EVENT ON THE SAME DATE AS) THEACCEPTANCEOFTHESHARESFORPAYMENT(THE“OFFERACCEPTANCETIME”), SUBJECTTOTHESATISFACTIONORWAIVEROFTHEOTHERCONDITIONSSETFORTHIN THEMERGERAGREEMENTAND IN ANY EVENT NO LATER THAN ONE BUSINESS DAY FOLLOWING THE SATISFACTION ORWAIVEROFSUCHCONDITIONS, PURCHASERWILLBEMERGEDWITHANDINTOMYOKARDIA(THE“MERGER”), WITHOUT A VOTE OF THE STOCKHOLDERS OF MYOKARDIA IN ACCORDANCE WITHSECTION251(H)OFTHEDELAWAREGENERALCORPORATIONLAW(THE“DGCL”).

THE BOARD OF DIRECTORS OF MYOKARDIA, AT A MEETING DULY CALLED AND HELD,UNANIMOUSLY ADOPTED RESOLUTIONS (A) DETERMINING THAT THE MERGER AGREEMENTAND THE TRANSACTIONS CONTEMPLATED BY THE MERGER AGREEMENT, INCLUDING THEOFFER AND THE MERGER (THE “TRANSACTIONS”), ARE ADVISABLE, FAIR TO AND IN THE BESTINTERESTS OF MYOKARDIA AND ITS STOCKHOLDERS, (B) AUTHORIZING AND APPROVING THEEXECUTION, DELIVERY AND PERFORMANCE BY MYOKARDIA OF THE MERGER AGREEMENTAND THE CONSUMMATION BY MYOKARDIA OF THE TRANSACTIONS, (C) RESOLVING THAT THEMERGER WILL BE EFFECTED UNDER SECTION 251(H) OF THE DGCL AND THAT THE MERGERWILL BE CONSUMMATED AS SOON AS PRACTICABLE FOLLOWING THE

TABLE OF CONTENTS

OFFER ACCEPTANCE TIME, AND (D) RECOMMENDING THAT MYOKARDIA’S STOCKHOLDERSACCEPT THE OFFER AND TENDER THEIR SHARES IN THE OFFER. MYOKARDIA HAS BEENADVISED THAT ALL OF ITS DIRECTORS AND EXECUTIVE OFFICERS INTEND TO TENDER ALL OFTHEIR TRANSFERRABLE SHARES PURSUANT TO THE OFFER.

THE OFFER IS NOT CONDITIONED ON OBTAINING FINANCING OR THE FUNDING THEREOF.HOWEVER, THE OFFER IS SUBJECT TO VARIOUS OTHER CONDITIONS, INCLUDING, AMONGOTHER THINGS, THAT THE NUMBER OF SHARES VALIDLY TENDERED (AND NOT PROPERLYWITHDRAWN) PRIOR TO THE EXPIRATION OF THE OFFER (BUT EXCLUDING SHARES TENDEREDPURSUANT TO GUARANTEED DELIVERY PROCEDURES THAT HAVE NOT YET BEEN “RECEIVED”,AS DEFINED BY SECTION 251(H)(6) OF THE DGCL), TOGETHER WITH THE SHARES THEN OWNEDBY PARENT OR PURCHASER, REPRESENTS AT LEAST ONE SHARE MORE THAN 50% OF THETHEN OUTSTANDING SHARES. A SUMMARY OF THE PRINCIPAL TERMS OF THE OFFER,INCLUDING THE CONDITIONS, APPEARS ON PAGES (1) THROUGH (8).

A SUMMARY OF THE PRINCIPAL TERMS OF THE OFFER IS PROVIDED HEREIN UNDER THEHEADING “SUMMARY TERM SHEET”. THIS OFFER TO PURCHASE AND THE RELATED LETTER OFTRANSMITTAL CONTAIN IMPORTANT INFORMATION, AND YOU SHOULD READ BOTHCAREFULLY BEFORE DECIDING WHETHER TO TENDER YOUR SHARES.

QUESTIONS, REQUESTS FOR ASSISTANCE AND REQUESTS FOR ADDITIONAL COPIES OF THISOFFER TO PURCHASE, THE LETTER OF TRANSMITTAL AND THE NOTICE OF GUARANTEEDDELIVERY MAY BE DIRECTED TO THE INFORMATION AGENT AT THE ADDRESS ANDTELEPHONE NUMBER SET FORTH ON THE BACK COVER OF THIS OFFER TO PURCHASE.STOCKHOLDERS ALSO MAY CONTACT THEIR BROKERS, DEALERS, BANKS, TRUST COMPANIESOR OTHER NOMINEES FOR ASSISTANCE CONCERNING THE OFFER.

October19,2020

TABLE OF CONTENTS

IMPORTANT

IfyoudesiretotenderalloranyportionofyourSharesintheOffer,thisiswhatyoumustdo:

• Ifyouarearecordholder(i.e.,astockcertificateoruncertificatedstockinbook-entryformhasbeenissuedtoyou),youmustcompleteandsigntheenclosedLetterofTransmittal,inaccordancewiththeinstructionsprovidedtherein, andsendit withyour stockcertificate andanyother documents required in the Letter ofTransmittal to Equiniti Trust Company, the depositary for the Offer (the “Depositary”), or follow theproceduresforbook-entrytransfersetforthinSection3ofthisOffertoPurchase.Thesematerialsmustreachthe Depositary prior to the expiration of the Offer. Detailed instructions are contained in the Letter ofTransmittalandin“TheOffer—Section3—ProceduresforTenderingShares”ofthisOffertoPurchase.

• If you are a record holder and your stock is certificated but your stock certificate is not available or youcannotdeliverittotheDepositarypriortotheexpirationoftheOffer,youmaybeabletotenderyourSharesusing the enclosed Notice of Guaranteed Delivery. Please call MacKenzie Partners, Inc., the informationagentfortheOffer,tollfree,at1-800-322-2885forassistance.See“TheOffer—Section3—ProceduresforTenderingShares”forfurtherdetails.

• If you hold your Shares through a broker, dealer, commercial bank, trust company or other nominee, youmust contact your broker, dealer, commercial bank, trust company or other nominee and give instructionsthatyourSharesbetendered.

The Letter of Transmittal, the certificates for the Shares and any other required documents must reach theDepositary prior to the expiration of the Offer (currently scheduled for midnight (New York City time), oneminute after 11:59 p.m. New York City time, on November 16, 2020, unless extended or earlier terminated),unless the procedures for guaranteed delivery described in “The Offer—Section 3—Procedure for TenderingShares” of this Offer to Purchase are followed.

This transaction has not been approved or disapproved by the U.S. Securities and Exchange Commission (the“SEC”) or any state securities commission nor has the SEC or any state securities commission passed upon thefairness or merits of this transaction or upon the accuracy or adequacy of the information contained in thisOffer to Purchase or the Letter of Transmittal. Any representation to the contrary is unlawful.

* * *

Questions and requests for assistance may be directed to the information agent at the address and telephone numberset forth on the back cover of this Offer to Purchase. Additional copies of this Offer to Purchase, the Letter ofTransmittal, the Notice of Guaranteed Delivery and other related materials may be obtained from the informationagent or from your broker, dealer, commercial bank, trust company or other nominee. Copies of these materials mayalso be found at the website maintained by the SEC at www.sec.gov. You may also contact your broker, dealer,commercial bank, trust company or other nominee for assistance.

TABLE OF CONTENTS

TABLE OF CONTENTS

  Page

SUMMARYTERMSHEET 1

INTRODUCTION 9

THEOFFER 13

1.TermsoftheOffer 13

2.AcceptanceforPaymentandPaymentforShares 14

3.ProceduresforTenderingShares 15

4.WithdrawalRights 17

5.MaterialU.S.FederalIncomeTaxConsequences 18

6.PriceRangeofShares;Dividends 20

7.PossibleEffectsoftheOfferontheMarketfortheShares;StockExchangeListing;RegistrationundertheExchangeAct;MarginRegulations 20

8.CertainInformationConcerningMyoKardia 22

9.CertainInformationConcerningPurchaserandParent 22

10.SourceandAmountofFunds 23

11.BackgroundoftheOffer;ContactswithMyoKardia 23

12.PurposeoftheOffer;PlansforMyoKardia;StockholderApproval;AppraisalRights 28

13.TheTransactionDocuments 30

14.DividendsandDistributions 46

15.ConditionstotheOffer 47

16.CertainLegalMatters;RegulatoryApprovals 49

17.FeesandExpenses 53

18.Miscellaneous 53

SCHEDULE I

DirectorsandExecutiveOfficersofParent Sch-I-1

DirectorsandExecutiveOfficersofPurchaser Sch-I-6

TABLE OF CONTENTS

SUMMARY TERM SHEET

GothamMergerSubInc.(“Purchaser”),awhollyownedsubsidiaryofBristol-MyersSquibbCompany(“Parent”),isofferingtopurchasealloftheoutstandingsharesofcommonstock,parvalue$0.0001pershare,ofMyoKardia,Inc.(“MyoKardia”)for$225.00pershare(the“Offer Price”),nettothesellerofsuchSharesincash,withoutinterestandlessanyrequiredwithholdingtaxes,uponthetermsandsubjecttotheconditionssetforthinthisOffertoPurchase,therelatedLetterofTransmittal,andpursuanttotheAgreementandPlanofMerger,datedasofOctober3,2020,byandamongMyoKardia,ParentandPurchaser(the“Merger Agreement”).Thefollowingaresomeofthequestionsyou,asaMyoKardiastockholder,mayhave,andanswerstothosequestions.This summary term sheet is not meant to be asubstitute for the more detailed information contained in the remainder of this Offer to Purchase, and youshould carefully read this Offer to Purchase and the accompanying Letter of Transmittal in their entiretybecause the information in this summary term sheet is not complete and additional important information iscontained in the remainder of this Offer to Purchase and the related Letter of Transmittal.Thissummarytermsheetincludescross-referencestoothersectionsofthisOffertoPurchasetodirectyoutothesectionsoftheOffertoPurchasecontainingamorecompletedescriptionofthetopicscoveredinthissummarytermsheet.Unlessthecontextotherwise requires, the terms “we,” “us” and “our” refer to Purchaser. The information concerning MyoKardiacontainedhereinandelsewhereintheOffertoPurchasehasbeenprovidedtoParentandPurchaserbyMyoKardiaorhasbeentakenfromorisbaseduponpubliclyavailabledocumentsorrecordsofMyoKardiaonfilewiththeSECorother public sources at the time of the Offer. Parent and Purchaser have not independently verified the accuracy orcompletenessofsuchinformation.

Securities Sought Alloftheoutstandingsharesofcommonstock,parvalue$0.0001pershare(the“Shares”),ofMyoKardia.

Price Offered Per Share $225.00, net to the seller in cash, without interest, andsubject to deduction for any required withholding oftaxes.

Scheduled Expiration of Offer Midnight (NewYork City time), one minute after 11:59p.m.NewYorkCitytime,onNovember16,2020,unlesstheOfferisextendedorearlierterminated.

Purchaser Gotham Merger Sub Inc., a Delaware corporation and awholly owned subsidiary of Bristol-Myers SquibbCompany,aDelawarecorporation.

Who is offering to buy my securities?

OurnameisGothamMergerSubInc.,awhollyownedsubsidiaryofParent.WeareaDelawarecorporationformedforthepurposeofmakingthistenderofferforalloftheoutstandingSharesandcompletingtheprocessbywhichwewillbemergedwithandintoMyoKardia.Seethe“Introduction”tothisOffertoPurchaseand“TheOffer—Section9—CertainInformationConcerningPurchaserandParent.”

What securities are you offering to purchase?

WeareofferingtopurchasealloftheoutstandingShares,onthetermsandsubjecttotheconditionssetforthinthisOffer to Purchase and the related Letter of Transmittal. We refer to each share of MyoKardia common stock as a“Share.”Seethe“Introduction”tothisOffertoPurchaseand“TheOffer—Section1—TermsoftheOffer.”

Why are you making the Offer?

Weare making the Offer to acquire the entire equity interest in MyoKardia. If the Offer is consummated, upon theterms and subject to the conditions set forth in the Merger Agreement and in accordance with the provisions of theGeneralCorporationLawoftheStateofDelaware(the“DGCL”),PurchaserwillbemergedwithandintoMyoKardia(the“Merger”),withMyoKardiasurvivingtheMerger.UponconsummationoftheMerger,MyoKardiawillceasetobeapubliclytradedcompanyandwillbecomeawhollyownedsubsidiaryofParent.

1

TABLE OF CONTENTS

How much are you offering to pay for my securities and what is the form of payment? Will I have to pay anyfees or commissions?

Weareofferingtopay$225.00perShare,nettothesellerincash,withoutinterestandlessanyrequiredwithholdingtaxes.IfyouaretherecordholderofyourShares(i.e.,astockcertificateoruncertificatedstockinbook-entryformhasbeenissuedtoyou)andyoudirectlytenderyourSharestoPurchaserintheOffer,youwillnothavetopaybrokeragefeesorsimilar expenses. If youownyourSharesthroughabroker, dealer, commercial bank,trust companyorothernominee, and your broker, dealer, commercial bank, trust company or other nominee tenders your Shares on yourbehalf,thentheymaychargeyouafeefordoingso.Youshouldconsultyourbroker,dealer,commercialbank,trustcompany or other nominee to determine whether any charges will apply. See the “Introduction” to this Offer toPurchaseand“TheOffer—Section2—AcceptanceforPaymentandPaymentforShares.”

Do you have the financial resources to pay for the Shares?

Yes. Wehave sufficient resources available to make the payment for your Shares. Based upon MyoKardia’s filingswith the SEC and more recent information provided to Purchaser by MyoKardia, we estimate that we will needapproximately $13.1 billion to acquire MyoKardia pursuant to the Offer andthe Merger, to payamounts payable inrespectoftheMyoKardiaStockOptions,theMyoKardiaRSUAwardstheMyoKardiaPSUAwards(eachasdefinedbelow),topayrelatedfeesandexpensesandtopayallotheramountsthatmaybecomedueandpayableasaresultoftheOfferandtheMerger.ParentanditscontrolledaffiliatesexpecttocontributeorotherwiseadvancetoPurchaserthefundsnecessarytoconsummatetheOfferandtheMergerandtopayrelatedfeesandexpenses.ItisanticipatedthatallofsuchfundswillbeobtainedfromParent’soritscontrolledaffiliates’generalcorporatefunds.

TheOfferisnotconditioneduponanyfinancingarrangementsorthefundingthereof.See“TheOffer—Section10—SourceandAmountofFunds.”

Is your financial condition relevant to my decision to tender in the Offer?

No.WedonotthinkourfinancialconditionisrelevanttoyourdecisionwhethertotenderSharesandaccepttheOfferbecause:

• theOfferisbeingmadeforalloutstandingSharessolelyforcash;

• as described above, we, through Parent and its controlled affiliates, have sufficient funds available topurchaseallSharesvalidlytendered,andnotwithdrawn,intheOfferandtoprovidefundingfortheMerger,whichisexpectedtooccurassoonaspracticablefollowing(butinanyeventonthesamedayas)theOfferAcceptanceTime(asdefinedbelow),subjecttothesatisfactionorwaiveroftheotherconditionssetforthintheMergerAgreementandinanyeventnolaterthanonebusinessdayfollowingthesatisfactionorwaiverofsuchconditions;

• consummationoftheOfferisnotsubjecttoanyfinancingcondition;and

• ifweconsummatetheOffer,weexpecttoacquireanyremainingSharesforthesamecashperSharepriceintheMerger.

See“TheOffer—Section10—SourceandAmountofFunds.”

What are the most significant conditions to the Offer?

NotwithstandinganyotherprovisionoftheMergerAgreementortheOfferandinadditionto(andnotinlimitationof)ourrighttoextendandamendtheOfferpursuanttotheprovisionsoftheMergerAgreement,wewillnotberequiredto(and Parent will not be required to cause Purchaser to) accept for payment or, subject to any applicable rules andregulationsoftheSEC,includingRule14e-1(c)undertheExchangeAct,payforanySharesvalidlytenderedandnotproperly withdrawn pursuant to the Offer if any of the following conditions, among other conditions, exist or haveoccurredandarecontinuingatthescheduledExpirationTimeoftheOffer:

• thenumberofSharesvalidlytendered(andnotproperlywithdrawn)priortotheexpirationoftheOffer(butexcludingSharestenderedpursuanttoguaranteeddeliveryproceduresthathavenotyetbeen“received”,asdefined by Section 251(h)(6) of the DGCL), together with the Shares then owned by Parent or Purchaser,does not represent at least one Share more than 50% of the then outstanding Shares (the “MinimumCondition”);

2

TABLE OF CONTENTS

• anyRestraintisineffectenjoining,makingillegalorotherwiseprohibitingconsummationoftheOfferortheMerger (the “Restraints Condition”); “Restraints” means any outstanding order, judgment, injunction,ruling, writ, stipulation, settlement, award, finding, determination or decree of any governmental authorityenacted, promulgated, issued, entered, amended or enforced or deemed applicable by any governmentalauthorityofcompetentjurisdictionoranyapplicableLaw;“Law(s)”meanslaws(whetherforeign,federal,state, provincial, local, municipal, common or otherwise), statutes, treaties, directives, ordinances, codes,acts,constitutions,conventions,executiveorders,decrees,rulesorregulationsenacted,adopted,promulgatedorappliedbyanygovernmentalauthority;

• there is anActioninstitutedor pendingbya governmental authority of competent jurisdictionseekinganyjudgment(a)toprevent,prohibitormakeillegaltheconsummationoftheOfferortheMerger,(b)toprohibitParent’sabilitytovote,transfer,receivedividendsorotherwiseexercisefullrightsofownershipwithrespectto the stockof MyoKardia or (c) in connectionwith the Offer or the Merger, to prohibit, limit, restrain orimpair in any material respect Parent’s ability to own, control, direct, manage, or operate or to retain orchangeanymaterial portionof theassets, licenses, operations, rights, product lines, businesses or intereststherein of MyoKardia or its subsidiaries or any of the material assets, licenses, operations, rights, productlines, businesses or interests therein of Parent or its subsidiaries (other than, in each case, a DivestitureAction(asdefinedbelow)requiredtobetakenbyParentandPurchaserpursuanttotheMergerAgreement)(the “Actions Condition”); an “Action” means any pending or threatened legal or administrative claim,audit, arbitration, proceeding, suit, charge, complaint, arbitration or action by or before any governmentalauthority;

• the waiting period (andanyextension thereof) applicable to the consummation of the Offer or the MergerundertheHart-Scott-RodinoAntitrustImprovementsActof1976,asamended,andtherulesandregulationspromulgatedthereunder(the“HSR Act”)hasneitherexpirednorhasearlyterminationthereofbeengrantedorthereisineffectanyvoluntaryagreementbetweenParent,PurchaserorMyoKardiaandtheFederalTradeCommission or the Department of Justice pursuant to which Parent, Purchaser or MyoKardia will notconsummatetheMergerforanyperiodoftime(the“Governmental Consents Condition”);

• thereisaninaccuracyintherepresentationsandwarrantiesmadebyMyoKardiaintheMergerAgreement,subject to the materiality andother qualifications set forth in the Merger Agreement, as describedin moredetailin“TheOffer—Section15—ConditionstotheOffer”;

• MyoKardia has not complied with or performed in all material respects its obligations required to becompliedwithorperformedbyitpriortothescheduledExpirationTimeundertheMergerAgreement;and

• sincethedateoftheMergerAgreementtherehasbeenaMaterialAdverseEffect(asdefinedintheMergerAgreement and described in more detail in “The Offer—Section 15—Conditions to the Offer”) that iscontinuingasofthescheduledExpirationTime.

OtherconditionstotheOfferaredescribedin“TheOffer—Section15—ConditionstotheOffer.”Seealso“TheOffer—Section 16—Certain Legal Matters; Regulatory Approvals.” Consummation of the Offer is not conditioned onobtainingfinancingorthefundingthereof.

Is there an agreement governing the Offer?

Yes. MyoKardia, Parent andPurchaser haveenteredintotheAgreement andPlanofMerger, datedasof October3,2020.PursuanttotheMergerAgreement,thepartieshaveagreedon,amongotherthings,thetermsandconditionsofthe Offer and, following consummation of the Offer, the Merger of Purchaser with and into MyoKardia. See the“Introduction” to this Offer to Purchase and “The Offer—Section 13—The Transaction Documents—The MergerAgreement.”

What does MyoKardia’s board of directors think about the Offer?

MyoKardia’sboardofdirectors(the“MyoKardia Board”),atameetingdulycalledandheld,unanimouslyadoptedresolutions:

• determiningthattheMergerAgreementandtheTransactionsareadvisable,fairtoandinthebestinterestsofMyoKardiaanditsstockholders;

3

TABLE OF CONTENTS

• authorizingandapprovingtheexecution,deliveryandperformancebyMyoKardiaoftheMergerAgreementandtheconsummationbyMyoKardiaoftheTransactions;

• resolving that the Merger will be effected under Section 251(h) of the DGCLand that the Merger will beconsummatedassoonaspracticablefollowingtheOfferAcceptanceTime;and

• recommendingthatMyoKardia’sstockholdersaccepttheOfferandtendertheirSharesintheOffer.

MyoKardia will file a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC (the“Schedule 14D-9”)indicatingtheapprovaloftheMergerAgreement,theOffer,theMergerandtheothertransactionscontemplatedbytheMergerAgreementbytheMyoKardiaBoardandrecommendingthatMyoKardia’sstockholderstendertheirSharesintheOffer.

See“TheOffer—Section11—BackgroundoftheOffer;ContactswithMyoKardia”and“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement.”WeexpectthatamorecompletedescriptionofthereasonsfortheMyoKardiaBoard’sapprovaloftheOfferandtheMergerwillbesetforthintheSchedule14D-9filedwiththeSECandmailedtoMyoKardiastockholders.

How long do I have to decide whether to tender my Shares in the Offer?

Youhaveuntil midnight(NewYorkCitytime),oneminuteafter11:59p.m.NewYorkCitytime,onNovember16,2020,todecidewhethertotenderyourSharesintheOffer.See“TheOffer—Section1—TermsoftheOffer.”IfyoucannotdelivereverythingrequiredtomakeavalidtendertoEquinitiTrustCompany,thedepositaryfortheOffer(the“Depositary”),priortosuchtime,youmaybeabletouseaguaranteeddeliveryprocedure,whichisdescribedin“TheOffer—Section 3—Procedures for Tendering Shares.” In addition, if we extend the Offer as described belowunder“Introduction”tothisOffertoPurchase,youwillhaveanadditionalopportunitytotenderyourShares.PleasebeawarethatifyourSharesareheldbyabroker,dealer,commercialbank,trustcompanyorothernominee,theymayrequireadvancenotificationbeforetheexpirationtimeoftheOffer.

When and how will I be paid for my tendered Shares?

InaccordancewiththetermsandconditionsoftheMergerAgreement,andsubjectonlytothesatisfactionorwaiver(totheextentsuchwaiverispermittedbytheMergerAgreementandapplicableLaw)oftheconditionstotheOffersetforth in “The Offer—Section 15—Conditions of the Offer” and, for the avoidance of doubt, no other conditions,Purchaser will (and Parent will cause Purchaser to), at or as promptly as practicable following the expiration of theOffer,irrevocablyacceptforpayment(suchtimeofacceptanceforpayment,the“Offer Acceptance Time”)and,atoraspromptlyaspracticablefollowingtheOfferAcceptanceTime(andinanyeventwithinthreebusinessdays),payforallSharesvalidlytenderedandnotproperlywithdrawnpursuanttotheOffer.

Wewill payfor your validly tendered andnot properly withdrawnShares bydepositingthe purchase price with theDepositary,whichwillactasyouragentforthepurposeofreceivingpaymentsfromPurchaserandtransmittingsuchpaymentstoyou.Inallcases,paymentfortenderedShareswillbemadeonlyaftertimelyreceiptbytheDepositaryofcertificatesforsuchShares(orofaconfirmationofabook-entrytransferofsuchSharesasdescribedin“TheOffer—Section 3—Procedures for Tendering Shares”), a properly completed and duly executed Letter of Transmittal (ormanuallysignedfacsimilethereof)andanyotherrequireddocumentsforsuchShares.

Can the Offer be extended and under what circumstances?

Yes.If,atthethen-scheduledexpirationoftheOffer,anyoftheconditionstotheOffer(the“Offer Conditions”)havenot been satisfied or waived by Parent and Purchaser (to the extent such waiver is permitted under the MergerAgreementandapplicableLaw),then(a)wemay,inoursolediscretion(andwithouttheconsentofMyoKardiaoranyotherperson)and(b)uponMyoKardia’swrittenrequest,wewill,andParentwillcausePurchaserto,extendtheOfferononeor moreoccasions in consecutive increments of upto tenbusiness dayseach(eachsuchincrement to endat5:00p.m.,NewYorkCitytime,onthelastbusinessdayofsuchincrement)inordertopermitthesatisfactionofsuchOffer Condition(s); provided, however, that (i) we will not be required to extend the Offer to a date later than theOutsideDate(asdefinedbelow)andwewillnotbepermittedtoextendtheoffertoadatelaterthantheOutsideDatewithoutthepriorwrittenconsentofMyoKardiaand(ii)ifatanythenscheduledexpirationoftheOffer,alloftheOfferConditions(otherthantheMinimumConditionandanyOfferConditionsthatarebytheirnaturetobesatisfiedattheOffer Acceptance Time) have been satisfied or waived (to the extent permitted by the Merger Agreement andapplicableLaw)andtheMinimumConditionhasnotbeensatisfied,wewillnotberequiredto

4

TABLE OF CONTENTS

(and Parent will not be required to cause Purchaser to) extend the Offer for more than three additional consecutiveincrementsoftenbusinessdays(orsuchshorterperiodsasmaybeagreedtobyMyoKardiaandPurchaser).WewillextendtheOfferfortheminimumperiodrequiredbyapplicableLaw,interpretationorpositionoftheSECoritsstaffor The NASDAQ Global Select Market (the “NASDAQ”) or its staff. We will not, and Parent will not permitPurchaserto,extendtheOfferinanymannerexceptasrequiredorexpresslypermittedassetforthinthisparagraph.See“TheOffer—Section1—TermsoftheOffer.”The“Outside Date”meansMarch3,2021;providedthat,ifasoffivebusinessdayspriortosuchdate,anyof(a)theRestraintsCondition(iftheRestraintrelatestoanAntitrustLaw),(b) the Actions Conditions (if the Actionrelates to an Antitrust Law)and(c) the Governmental Consents Conditionwill not have been satisfied or waived(to the extent permitted bythe Merger Agreement andapplicable Law), thenParentorMyoKardiamayextendtheOutsideDateforanadditionalthirtydays.

Will you provide a subsequent offering period?

Wedonotpresentlyintendtoofferasubsequentofferingperiod.

How will I be notified if the Offer is extended?

If we extend the Offer, we will inform the Depositary of that fact and will make a public announcement of theextension no later than 9:00 a.m., New York City time, on the business day after the day on which the Offer wasscheduledtoexpire.

How do I tender my Shares?

IfyouwishtoaccepttheOffer,thisiswhatyoumustdo:

• Ifyouarearecordholder(i.e.,astockcertificateoruncertificatedstockinbook-entryformhasbeenissuedtoyou),youmustcompleteandsigntheenclosedLetterofTransmittal,inaccordancewiththeinstructionsprovidedtherein,andsenditwithyourstockcertificatesandanyotherdocumentsrequiredintheLetterofTransmittal totheDepositaryorfollowtheproceduresforbook-entrytransfersetforthinSection3ofthisOffer toPurchase. Thesematerials must reachtheDepositaryprior totheexpirationoftheOffer. Detailedinstructions are contained in the Letter of Transmittal and in “The Offer—Section 3—Procedures forTenderingShares.”

• If you are a record holder and your stock is certificated, but your stock certificate is not available or youcannotdeliverittotheDepositarypriortotheexpirationoftheOffer,youmaybeabletotenderyourSharesusing the enclosed Notice of Guaranteed Delivery. Please call MacKenzie Partners, Inc., the InformationAgent, toll free, at 1-800-322-2885or by email at tenderoffer@mackenziepartners.comfor assistance. See“TheOffer—Section3—ProceduresforTenderingShares”forfurtherdetails.

• If you hold your Shares through a broker, dealer, commercial bank, trust company or other nominee, youmust contact your broker, dealer, commercial bank, trust company or other nominee and give instructionsthatyourSharesbetendered.

How do I tender Shares that are not represented by a certificate?

If you directly hold uncertificated Shares in an account with MyoKardia’s transfer agent, Computershare TrustCompany,N.A.,youshouldfollowtheinstructionsforbook-entrytransferofyourSharesasdescribedinSection3ofthis Offer to Purchase and in the attached Letter of Transmittal. If you hold your uncertificated MyoKardia Sharesthrough a broker, dealer, commercial bank, trust company or other nominee, you must contact your broker, dealer,commercialbank,trustcompanyorothernomineeandgiveinstructionsthatyourMyoKardiaSharesbetendered.

Until what time can I withdraw tendered Shares?

YoucanwithdrawsomeoralloftheSharesthatyoupreviouslytenderedintheOfferatanytimepriortotheexpirationtimeoftheOffer(asitmaybeextendedfromtimetotime).Further,ifwehavenotacceptedyourSharesforpaymentbyDecember18,2020,youmaywithdrawthematanytimeafterDecember18,2020.OnceweacceptyourtenderedShares for payment upon expiration of the Offer, however, you will no longer be able to withdrawthem. See “TheOffer—Section4—WithdrawalRights.”

5

TABLE OF CONTENTS

How do I withdraw tendered Shares?

TowithdrawSharesthat youpreviouslytenderedintheOffer, youmust deliver awrittennoticeof withdrawal, or afacsimileofone,whichincludestherequiredinformation,totheDepositarywhileyouhavetherighttowithdrawsuchShares. If you tendered Shares by giving instructions to a broker, dealer, commercial bank, trust company or othernominee, then youmust instruct the broker, dealer, commercial bank, trust companyor other nominee to arrange towithdrawtheShares.See“TheOffer—Section4—WithdrawalRights.”

Can holders of stock options and/or restricted stock units participate in the Offer?

TheOfferisonlyfortheoutstandingsharesofcommonstockofMyoKardiathatarenotsubjecttovestingconditionsandnotfor(a)anyoptionstopurchaseShares,whethergrantedunderaMyoKardiaStockPlan(asdefinedbelow)orotherwise(“MyoKardia Stock Options”),oranyoptionstopurchaseSharesgrantedundertheMyoKardiaESPP(asdefinedbelow),(b)anyawardofrestrictedstockunitssubjectonlytotime-basedvestingconditions,whethergrantedunderaMyoKardiaStockPlanorotherwise(“MyoKardia RSU Awards”),or(c)anyawardofrestrictedstockunitssubject to performance-based vesting conditions, whether granted under a MyoKardia Stock Plan or otherwise(“MyoKardia PSU Awards”).If youholdunexercisedMyoKardiaStockOptionsandyouwishtoparticipateintheOffer, youmust exercise your MyoKardia Stock Options (to the extent they are exercisable) in accordance with thetermsoftheawardagreementandtendersuchSharesreceivedupontheexerciseinaccordancewiththetermsoftheOffer.“MyoKardia Stock Plan”meanseachoftheMyoKardia,Inc.2012EquityIncentivePlan,asamended,andtheMyoKardia, Inc. 2015 Stock Option and Incentive Plan, as amended. Holders of unexercisable MyoKardia StockOptionswillbeunabletoexercisesuchMyoKardiaStockOptionsandarenoteligibletoparticipateintheOfferwithrespecttotheSharesunderlyingsuchMyoKardiaStockOptions,unlesstheybecomeexercisablebytheirtermspriortotheOfferAcceptanceTime.

PriortothetimeatwhichtheMergerbecomeseffective(the“Merger Effective Time”),theMyoKardiaBoard(or,ifappropriate, any committee thereof administering the MyoKardia Stock Plans) will adopt such resolutions and takesuch other lawful actions (which, in each case, do not involve the payment of any consideration in excess of, or inaddition to, the consideration described in clauses (a) through (c) below) as may be required to provide that,immediately prior to the Merger Effective Time, by virtue of the Merger and without any action on the part of theholderthereof:

(a)eachMyoKardiaStockOption,whethervestedorunvested,thatisoutstandingandunexercisedimmediatelypriortotheMergerEffectiveTimewill becancelledandautomaticallyconvertedintosolelytherighttoreceive, foreachShareunderlyingsuchMyoKardiaStockOption,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw,anamountincashfromParentorthesurvivingcorporationequaltotheexcessof(i)theOfferPriceover(ii)thepershareexercisepriceofsuchMyoKardiaStockOption(the“Option Payment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaStockOptionwill onlybeentitledtoreceivetheOptionPaymentinrespectofsuchcancelledMyoKardiaStockOption(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaStockOptions”);

(b)eachMyoKardiaRSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTime,whethervestedorunvested,willbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaRSUAward,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw, an amount in cash from Parent or the surviving corporation equal to the Offer Price (the “RSU AwardPayment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaRSUAwardwillonlybeentitledtoreceivetheRSUAwardPaymentinrespectofsuchcancelledMyoKardiaRSUAward(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaRSUAwards”);and

(c)eachMyoKardiaPSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTimewillbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaPSUAward,without interest and subject to deduction for any required withholding under applicable tax law, an amount in cashfromParentorthesurvivingcorporationequaltotheOfferPrice,whichamountwillbepayableonthesamescheduleand subject to the same vesting conditions (including any acceleration of vesting conditions) as applied to theMyoKardiaPSUAwardimmediatelypriortotheMergerEffectiveTime(the“PSU Award Payment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaPSUAwardwillonlybeentitledtoreceivethePSUAwardPaymentinrespectofsuchcancelledMyoKardiaPSUAward(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaPSUAwards”).

6

TABLE OF CONTENTS

AspromptlyasreasonablypracticablefollowingthedateoftheMergerAgreement,MyoKardiawilltakesuchactions(totheextentnotalreadytakenpriortothedateoftheMergerAgreement)withrespecttotheMyoKardiaAmendedand Restated Employee Stock Purchase Plan (the “MyoKardia ESPP”) as may be required to provide that (a)participationfollowingthedateoftheMergerAgreementwill belimitedtothoseemployeeswhoparticipatedintheMyoKardiaESPPimmediatelypriortotheexecutionanddeliveryoftheMergerAgreement,(b)participantsmaynotincrease their payroll deductions or purchase elections from those in effect immediately prior to the execution anddeliveryoftheMergerAgreement(unlessotherwiserequiredbytheInternalRevenueCodeof1986,asamended(the“Code”)), (c) no new offering period will commence, nor will any existing offering period be extended, after theexecutionanddeliveryoftheMergerAgreement,(d)eachparticipant’soutstandingrighttopurchaseSharesundertheMyoKardiaESPPwillterminateonthedayimmediatelypriortothedayonwhichtheMergerEffectiveTimeoccurs(ifnotearlierterminatedpursuanttothetermsoftheMyoKardiaESPP);providedthatall amountsallocatedtoeachparticipant’s account under the MyoKardia ESPP as of such date will be returned to the participant by MyoKardiapursuanttothetermsoftheMyoKardiaESPP,and(e)theMyoKardiaESPPwillterminatenolaterthanimmediatelyprior to the Merger Effective Time. See “The Offer—Section 13—The Transaction Documents—The MergerAgreement—MyoKardiaAmendedandRestatedEmployeeStockPurchasePlan.”

Will the Offer be followed by a Merger if not all of the Shares are tendered in the Offer? If the Offer iscompleted, will MyoKardia continue as a public company?

IftheMinimumConditionissatisfiedandtheOfferisconsummated,subjecttothesatisfactionorwaiveroftheotherconditions to the Merger, we will effect the Merger of Purchaser into MyoKardia as promptly as practicable inaccordance with the terms of the Merger Agreement without a vote or any further action by the stockholders ofMyoKardiapursuanttoSection251(h)oftheDGCL.PursuanttotheMergerAgreement,iftheMinimumConditionisnotsatisfied,wearenotrequiredto(norarewepermittedwithoutMyoKardia’sconsentto)acceptSharesforpurchaseintheOffernorwillwebeabletoconsummatetheMerger.

However,iftheOfferisconsummated,weexpecttocompletetheMergerpursuanttotheapplicableprovisionsoftheDGCL,afterwhichthesurvivingcorporationwillbeawhollyownedsubsidiaryofParentandtheShareswillnolongerbepubliclytraded.IftheMergertakesplace,allremainingstockholders(otherthanMyoKardia,anyofitssubsidiaries,Parent, PurchaseroranysubsidiaryofParent, oranystockholderswhohaveproperlyexercisedtheirappraisalrightsunderDelawarelaw)willreceivethepriceperSharepaidintheOffer.Seethe“Introduction”tothisOffertoPurchaseand“TheOffer—Section12—Purposeof the Offer; Plans for MyoKardia; Stockholder Approval; Appraisal Rights”and“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement.”

If I decide not to tender, how will the Offer affect my Shares?

IftheMergerisconsummatedbetweenMyoKardiaandPurchaser,MyoKardiastockholdersnottenderingtheirSharesin the Offer (other than MyoKardia, any of its subsidiaries, Parent, Purchaser or any subsidiary of Parent, or anystockholders whohaveproperlyexercisedtheir appraisal rights under Delawarelaw)will receivecashinanamountequaltothepriceperSharepaidintheOffer,lessanyrequiredwithholdingtaxes.IfweacceptandpurchaseSharesinthe Offer, we will consummate the Merger as soon as practicable without a vote of or any further action by thestockholders of MyoKardia, pursuant to Delaware law. Therefore, if the Merger takes place and you do not validlyexercise your appraisal rights under Section 262 of the DGCL, the only difference to you between tendering yourSharesandnottenderingyourSharesisthatyouwillbepaidearlierifyoutenderyourShares.

WhileweintendtoconsummatetheMergerassoonaspracticableafterweconsummatetheOffer,iftheMergerdoesnottakeplaceandtheOfferisconsummated,theremaybesofewremainingstockholdersandpubliclytradedSharesthattherewillnolongerbeanactiveorliquidpublictradingmarket(or,possibly,anypublictradingmarket)forSharesheldbystockholdersotherthanPurchaser.WecannotpredictwhetherthereductioninthenumberofSharesthatmightotherwise trade publicly would have an adverse or beneficial effect on the market price for, or marketability of, theShares. Also, MyoKardia may no longer be required to make filings with the SEC or otherwise may no longer berequired to comply with the SEC rules relating to publicly held companies. See “The Offer—Section 7—PossibleEffects of the Offer on the Market for the Shares; Stock Exchange Listing; Registration under the Exchange Act;MarginRegulations”and“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement.”

AssumingtheMinimumConditionissatisfiedandwepurchasethetenderedSharesintheOffer,nostockholdervotewillberequiredtoconsummatetheMerger,andwedonotexpecttheretobeasignificantperiodoftimebetween

7

TABLE OF CONTENTS

the consummation of the Offer and the consummation of the Merger. See “The Offer—Section 12—Purpose of theOffer;PlansforMyoKardia;StockholderApproval;AppraisalRights—NoStockholderApproval.”

Are appraisal rights available in either the Offer or the Merger?

No appraisal rights are available in connection with the Offer. However, pursuant to the DGCL, if the Merger isconsummated, any stockholder whodoes not tender its Shares in the Offer, whois entitled to demandand properlydemandsappraisalofsuchSharespursuantto,andwhofullycompliesinallrespectswith,theapplicableprovisionsofSection 262 of the DGCL, will have the right to choose not to accept the consideration payable for their SharespursuanttotheMerger, andinsteadtodemandanappraisal oftheir SharesbytheCourtofChanceryoftheStateofDelawareandreceiveacashpaymentofthe“fairvalue”oftheirSharesasoftheMergerEffectiveTimeasdeterminedbytheCourtofChanceryoftheStateofDelaware.The“fairvalue”ofsuchSharesasoftheMergerEffectiveTimemaybemorethan,lessthan,orequaltotheOfferPrice.See“TheOffer—Section12—PurposeoftheOffer;PlansforMyoKardia;StockholderApproval;AppraisalRights—AppraisalRights.”

What is the market value of my Shares as of a recent date?

OnOctober2, 2020,thelast full tradingdaybeforeweannouncedourintentiontocommencetheOffer, thehighestintraday sale price of the Shares on the NASDAQGlobal Select Market (“NASDAQ”) was $140.93 per share. OnOctober16,2020,thelastfulltradingdaybeforethedateofthisOffertoPurchase,theclosingpriceoftheSharesonNASDAQwas$222.00.PleaseobtainarecentquotationfortheSharesbeforedecidingwhetherornottotenderyourShares.

Have any stockholders already agreed to tender their Shares in the Offer or to otherwise support the Offer?

Yes.OnOctober3,2020,concurrentlywiththeexecutionoftheMergerAgreement,TassosGianakakos,MyoKardia’sPresidentandChiefExecutiveOfficer,enteredintoaTenderandSupportAgreement(the“Support Agreement”)withParentandPurchaser.AsofOctober3,2020,theoutstandingsharesofCompanyCommonStockbeneficiallyownedbyMr.Gianakakosrepresented1.2%ofthetotal outstandingsharesofCompanyCommonStock. See“TheOffer—Section13—TheTransactionDocuments—TheTenderandSupportAgreement.”

What are the material U.S. federal income tax consequences of exchanging my Shares pursuant to the Offer?

Ingeneral,yourexchangeofSharesforcashpursuanttotheOfferwillbeataxabletransactionforU.S.federalincometaxpurposesandmayalsobeataxabletransactionunderapplicablestate, local orforeignincomeorothertaxlaws.You should consult your tax advisor about the tax consequences to you of exchanging your Shares pursuant to theOffer in light of your particular circumstances. See “The Offer—Section 5—Material U.S. Federal Income TaxConsequences.”

Who can I talk to if I have questions about the Offer?

You can call MacKenzie Partners, Inc., the Information Agent, toll free, at 1-800-322-2885 or by email attenderoffer@mackenziepartners.com.SeethebackcoverofthisOffertoPurchase.

8

TABLE OF CONTENTS

TotheStockholdersofMyoKardia:

INTRODUCTION

Gotham Merger Sub Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Bristol-MyersSquibbCompany,aDelawarecorporation(“Parent”),isofferingtopurchasealloutstandingshares(the“Shares”)ofcommonstock,parvalue$0.0001pershare,ofMyoKardia,Inc.,aDelawarecorporation(“MyoKardia”),for$225.00per Share (the “Offer Price”), net to the seller of such Shares in cash, without interest and less any requiredwithholdingtaxes,uponthetermsandsubjecttotheconditionssetforthinthisOffertoPurchaseandtherelatedLetterof Transmittal (which, as amended or supplemented fromtime to time, together constitute the “Offer”). Unless thecontextrequiresotherwise,theterms“we”and“our”refertoPurchaser.

IfyouaretherecordholderofyourShares(i.e.,astockcertificateoruncertificatedstockinbook-entryformhasbeenissuedtoyou),youwillnotberequiredtopaybrokeragefees,commissionsor,exceptassetforthinInstruction6oftheLetterofTransmittal,stocktransfertaxesontheexchangeofSharesforcashpursuanttotheOffer.However,ifyoudonotcompleteandsigntheIRSFormW-9thatisincludedintheLetterofTransmittal(orotherapplicableform),youmaybesubjecttobackupwithholdingatacurrentrateof24%onthegrossproceedspayabletoyou.See“TheOffer—Section3—ProceduresforTenderingShares—BackupWithholding.”Backupwithholdingisnotanadditionaltaxandany amounts withheld under the backup withholding rules will be refunded or credited against your U.S. federalincome tax liability, provided the required information is timely furnished to the Internal Revenue Service.StockholderswithSharesheldinstreet namebyabroker, dealer, commercial bank,trust companyorothernomineeshouldconsult withtheirnomineetodetermineiftheywill bechargedanytransactionfees. Wewill payall chargesand expenses of Equiniti Trust Company, the depositary for the Offer (the “Depositary”) andMacKenzie Partners,Inc.,theinformationagentfortheOffer(the“Information Agent”)incurredinconnectionwiththeOffer.See“TheOffer—Section17—FeesandExpenses.”

WearemakingtheOfferpursuanttotheAgreementandPlanofMerger, datedasofOctober3,2020(the“MergerAgreement”),amongMyoKardia,ParentandPurchaser.TheMergerAgreementprovides,amongotherthings,thatassoon as practicable following (but in any event on the same date as) the Offer Acceptance Time, subject to thesatisfaction or waiver of the other conditions set forth in the Merger Agreement and in any event no later than onebusinessdayfollowingthesatisfactionorwaiverofsuchconditions, Purchaserwill mergewithandintoMyoKardia(the“Merger”),withMyoKardiacontinuingasthesurvivingcorporationandawhollyownedsubsidiaryofParent.Attheeffective timeof theMerger (the “Merger Effective Time”), eachoutstandingShare(other thanSharesheldbyMyoKardia, any of its subsidiaries, Parent, Purchaser or any subsidiary of Parent, or any stockholders who haveproperlyexercisedtheirappraisalrightsunderSection262oftheDelawareGeneralCorporationLaw(the“DGCL”))will beconvertedintotherighttoreceivetheOfferPriceincash,withoutinterest andlessanyrequiredwithholdingtaxes.TheMergerissubjecttothesatisfactionorwaiverofcertainconditionsdescribedin“TheOffer—Section13—The Transaction Documents—The Merger Agreement—Conditions to the Merger.” “The Offer—Section 13—TheTransaction Documents—The Merger Agreement” contains a more detailed description of the Merger Agreement.“Section 5—Material U.S. Federal Income Tax Consequences” summarizes the material U.S. federal income taxconsequencesofthesaleofSharesintheOfferandtheMerger.

TheOfferisonlyfortheoutstandingsharesofcommonstockofMyoKardiathatarenotsubjecttovestingconditionsandnotfor(a)anyoptionstopurchaseShares,whethergrantedunderaMyoKardiaStockPlan(asdefinedbelow)orotherwise(“MyoKardia Stock Options”)oranyoptionstopurchaseSharesgrantedundertheMyoKardiaESPP(asdefinedbelow),(b)anyawardofrestrictedstockunitssubjectonlytotime-basedvestingconditions,whethergrantedunderaMyoKardiaStockPlanorotherwise(“MyoKardia RSU Awards”),or(c)anyawardofrestrictedstockunitssubject to performance-based vesting conditions, whether granted under a MyoKardia Stock Plan or otherwise(“MyoKardia PSU Awards”).If youholdunexercisedMyoKardiaStockOptionsandyouwishtoparticipateintheOffer, youmust exercise your MyoKardia Stock Options (to the extent they are exercisable) in accordance with thetermsoftheawardagreementandtendersuchSharesreceivedupontheexerciseinaccordancewiththetermsoftheOffer.“MyoKardia Stock Plan”meanseachoftheMyoKardia,Inc.2012EquityIncentivePlan,asamended,andtheMyoKardia, Inc. 2015 Stock Option and Incentive Plan, as amended. Holders of unexercisable MyoKardia StockOptionswillbeunabletoexercisesuchMyoKardiaStockOptionsandarenoteligibletoparticipateintheOfferwithrespecttotheSharesunderlyingsuchMyoKardiaStockOptions,unlesstheybecomeexercisablebytheirtermspriortotheOfferAcceptanceTime.

Prior to Merger Effective Time, the MyoKardia Board (or, if appropriate, any committee thereof administering theMyoKardiaStockPlans)willadoptsuchresolutionsandtakesuchotherlawfulactions(which,ineachcase,donot

9

TABLE OF CONTENTS

involve the payment of any consideration in excess of, or in addition to, the consideration described in clauses (a)through(c)below)asmayberequiredtoprovidethat,immediatelypriortotheMergerEffectiveTime,byvirtueoftheMergerandwithoutanyactiononthepartoftheholderthereof:

(a)eachMyoKardiaStockOption,whethervestedorunvested,thatisoutstandingandunexercisedimmediatelypriortotheMergerEffectiveTimewill becancelledandautomaticallyconvertedintosolelytherighttoreceive, foreachShareunderlyingsuchMyoKardiaStockOption,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw,anamountincashfromParentorthesurvivingcorporationequaltotheexcessof(i)theOfferPriceover(ii)thepershareexercisepriceofsuchMyoKardiaStockOption(the“Option Payment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaStockOptionwill onlybeentitledtoreceivetheOptionPaymentinrespectofsuchcancelledMyoKardiaStockOption(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaStockOptions”);

(b)eachMyoKardiaRSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTime,whethervestedorunvested,willbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaRSUAward,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw, an amount in cash from Parent or the surviving corporation equal to the Offer Price (the “RSU AwardPayment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaRSUAwardwillonlybeentitledtoreceivetheRSUAwardPaymentinrespectofsuchcancelledMyoKardiaRSUAward(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaRSUAwards”);and

(c)eachMyoKardiaPSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTimewillbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaPSUAward,without interest and subject to deduction for any required withholding under applicable tax law, an amount in cashfromParentorthesurvivingcorporationequaltotheOfferPrice,whichamountwillbepayableonthesamescheduleand subject to the same vesting conditions (including any acceleration of vesting conditions) as applied to theMyoKardiaPSUAwardimmediatelypriortotheMergerEffectiveTime(the“PSU Award Payment”);fromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardiaPSUAwardwillonlybeentitledtoreceivethePSUAwardPaymentinrespectofsuchcancelledMyoKardiaPSUAward(See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—MyoKardiaPSUAwards”).

AspromptlyasreasonablypracticablefollowingthedateoftheMergerAgreement,MyoKardiawilltakesuchactions(totheextentnotalreadytakenpriortothedateoftheMergerAgreement)withrespecttotheMyoKardiaAmendedand Restated Employee Stock Purchase Plan (the “MyoKardia ESPP”) as may be required to provide that (a)participationfollowingthedateoftheMergerAgreementwill belimitedtothoseemployeeswhoparticipatedintheMyoKardiaESPPimmediatelypriortotheexecutionanddeliveryoftheMergerAgreement,(b)participantsmaynotincrease their payroll deductions or purchase elections from those in effect immediately prior to the execution anddeliveryoftheMergerAgreement(unlessotherwiserequiredbytheInternalRevenueCodeof1986,asamended(the“Code”)), (c) no new offering period will commence, nor will any existing offering period be extended, after theexecutionanddeliveryoftheMergerAgreement,(d)eachparticipant’soutstandingrighttopurchaseSharesundertheMyoKardiaESPPwillterminateonthedayimmediatelypriortothedayonwhichtheMergerEffectiveTimeoccurs(ifnotearlierterminatedpursuanttothetermsoftheMyoKardiaESPP);providedthatall amountsallocatedtoeachparticipant’s account under the MyoKardia ESPP as of such date will be returned to the participant by MyoKardiapursuanttothetermsoftheMyoKardiaESPP,and(e)theMyoKardiaESPPwillterminatenolaterthanimmediatelyprior to the Merger Effective Time. See “The Offer—Section 13—The Transaction Documents—The MergerAgreement—MyoKardiaAmendedandRestatedEmployeeStockPurchasePlan.”

MyoKardia’s board of directors, (the “MyoKardia Board”), at a meeting duly called and held, unanimouslyadopted resolutions (a) determining that the Merger Agreement and the transactions contemplated by theMerger Agreement, including the Offer and the Merger (the “Transactions”), are advisable, fair to and in thebest interests of MyoKardia and its stockholders, (b) authorizing and approving the execution, delivery andperformance by MyoKardia of the Merger Agreement and the consummation by MyoKardia of theTransactions, (c) resolving that the Merger will be effected under Section 251(h) of the DGCL and that theMerger will be consummated as soon as practicable following the Offer Acceptance Time and (d) recommendingthat MyoKardia’s stockholders accept the Offer and tender their Shares in the Offer.

MyoKardiawillfileitsTenderOfferSolicitation/RecommendationStatementonSchedule14D-9(the“Schedule 14D-9”)withtheSECanddisseminatetheSchedule14D-9toholdersofShares,inconnectionwith

10

TABLE OF CONTENTS

the Offer. The Schedule 14D-9 will include a more complete description of the MyoKardia Board’s reasons forauthorizingandapprovingtheMergerAgreementandthetransactionscontemplatedtherebyandthereforestockholdersareencouragedtoreviewtheSchedule14D-9carefullyandinitsentirety.

NotwithstandinganyotherprovisionoftheMergerAgreementortheOfferandinadditionto(andnotinlimitationof)Purchaser’srighttoextendandamendtheOfferpursuanttotheprovisionsoftheMergerAgreement, Purchaserwillnot be required to (and Parent will not be required to cause Purchaser to) accept for payment or, subject to anyapplicable rules and regulations of the SEC, including Rule 14e-1(c) under the Exchange Act, pay for any Sharesvalidly tendered and not properly withdrawn pursuant to the Offer if any of the following conditions, among otherconditions,existorhaveoccurredandarecontinuingatthescheduledExpirationTimeoftheOffer:(a)thenumberofShares validly tendered (and not properly withdrawn) prior to the expiration of the Offer (but excluding Sharestenderedpursuanttoguaranteeddeliveryproceduresthathavenotyetbeen“received”,asdefinedbySection251(h)(6)of the General Corporation Law of the State of Delaware (the “DGCL”)), together with the Shares then owned byParent or Purchaser, does not represent at least one Share more than 50% of the then outstanding Shares (the“Minimum Condition”); (b) any Restraint is in effect enjoining, making illegal or otherwise prohibitingconsummationoftheOfferortheMerger(the“Restraints Condition”);“Restraints”meansanyoutstandingorder,judgment,injunction,ruling,writ,stipulation,settlement,award,finding,determinationordecreebyanygovernmentalauthority enacted, promulgated, issued, entered, amended or enforced or deemed applicable by any governmentalauthority of competent jurisdiction or any applicable Law; (c) there is an Action instituted or pending by agovernmental authority of competent jurisdiction seeking any judgment (i) to prevent, prohibit or make illegal theconsummation of the Offer or the Merger, (ii) to prohibit Parent’s ability to vote, transfer, receive dividends orotherwiseexercisefullrightsofownershipwithrespecttothestockofMyoKardiaor(iii)inconnectionwiththeOfferor the Merger, to prohibit, limit, restrain or impair in any material respect Parent’s ability to own, control, direct,manage,oroperateortoretainorchangeanymaterialportionoftheassets,licenses,operations,rights,productlines,businessesorintereststhereinofMyoKardiaoritssubsidiariesoranyofthematerialassets,licenses,operations,rights,productlines,businessesorintereststhereinofParentoritssubsidiaries(otherthan,ineachcase,aDivestitureAction(as defined below) required to be taken by Parent and Purchaser pursuant to the Merger Agreement) (the “ActionsCondition”);an“Action”meansanypendingor,totheknowledgeofMyoKardia,threatenedlegaloradministrativeclaim, audit, arbitration, proceeding, suit, charge, complaint, arbitration or action by or before any governmentalauthority;(d)thewaitingperiod(andanyextensionthereof)applicabletotheconsummationoftheOfferortheMergerunder the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulationspromulgatedthereunder(the“HSR Act”)hasneitherexpirednorhasearlyterminationthereofbeengrantedorthereisineffectanyvoluntaryagreementbetweenParent,PurchaserorMyoKardiaandtheFederalTradeCommissionortheDepartment of Justice pursuant to which Parent, Purchaser or MyoKardia will not consummate the Merger for anyperiod of time (the “Governmental Consents Condition”); (e) there is an inaccuracy in the representations andwarrantiesmadebyMyoKardiaintheMergerAgreement,subjecttothematerialityandotherqualificationssetforthinthe Merger Agreement, as described in more detail in “The Offer—Section 15—Conditions to the Offer”; (f)MyoKardiahasnotcompliedwithorperformedinallmaterialrespectsitsobligationsrequiredtobecompliedwithorperformed by it prior to the scheduled Expiration Time under the Merger Agreement; and (g) since the date of theMerger Agreement there has been a Material Adverse Effect (as defined in the Merger Agreement and described inmore detail in “The Offer—Section 15—Conditions to the Offer”) that is continuing as of the scheduled ExpirationTime.

The Offer is not conditioned upon Parent or Purchaser obtaining financing or the funding thereof. These and otherconditionstotheOfferaredescribedin“TheOffer—Section15—ConditionstotheOffer”and“TheOffer—Section16—CertainLegalMatters;RegulatoryApprovals.”

According to MyoKardia, as of the close of business on October 1, 2020, the most recent practicable date,(a) 53,308,689 Shares were issued and outstanding, (b) no Shares were held by MyoKardia as treasury stock,(c)1,245,815ShareswerereservedandavailableforissuancepursuanttotheMyoKardiaStockPlans,(d)4,734,132SharesweresubjecttoMyoKardiaStockOptions(whichhaveaweightedaverageexercisepriceof$42.60pershare),(e)891,821SharesweresubjecttooutstandingMyoKardiaRSUAwards,(f)83,175SharesweresubjecttooutstandingMyoKardiaPSUAwardsattarget(whichisthesameasmaximum)performance,(g)1,579,961ShareswerereservedandavailableforpurchaseundertheMyoKardiaESPP,and(h)nosharesofpreferredstockwereissuedoroutstanding.

11

TABLE OF CONTENTS

AssumingnoadditionalSharesareissuedpriortotheexpirationoftheOfferandbasedontheSharesoutstandingasofOctober13, 2020,weanticipate that theMinimumConditionwouldbesatisfiedif approximately26,661,453SharesarevalidlytenderedandnotproperlywithdrawnpursuanttotheOfferpriortotheexpirationoftheOffer(excludinganySharesthathavenotyetbeen“received”,asdefinedbySection251(h)(6)oftheDGCL).

We currently intend, as soon as practicable following (but in any event on the same date as) the Offer AcceptanceTime,subjecttothesatisfactionorwaiveroftheotherconditionssetforthintheMergerAgreementandinanyeventno later than one business day following the satisfaction or waiver of such conditions, to consummate the Mergerpursuant to the Merger Agreement. Following the Merger, the directors of Purchaser will be the directors ofMyoKardia.

Section 251(h) of the DGCLprovides that, if following consummation of a tender offer for any and all shares of apublic Delaware corporation that would otherwise be entitled to vote on a merger (other than shares held by theacquiringentityanditsaffiliates), thestockirrevocablyacceptedforpurchasepursuanttosuchofferandreceivedbytheDepositary,priortoexpirationofsuchoffer,plusthestockotherwiseownedbytheacquiringentityequalsatleastthe amount of shares of each class of stock of the target corporation that would otherwise be required for thestockholdersofthetarget corporationtoadoptamergeragreementwiththeacquiringentity, andeachshareofeachclassorseriesofstockofthetargetcorporationnotirrevocablyacceptedforpurchaseintheofferisconvertedintotherighttoreceivethesameconsiderationaswaspayableinthetenderoffer, thetarget corporationcaneffect amergerwithout the vote of the stockholders of the target corporation. Therefore, the parties have agreed, and the MergerAgreement requires, that, subject to the conditions specified in the Merger Agreement, the Merger will becomeeffective as soonas practicable after the consummation(within the meaningof Section 251(h) of the DGCL)of theOffer,withoutavoteofMyoKardiastockholders,inaccordancewithSection251(h)oftheDGCL.See“TheOffer—Section12—PurposeoftheOffer;PlansforMyoKardia;StockholderApproval;AppraisalRights.”

TheOffer is conditioneduponthefulfillment oftheconditionsdescribedin“TheOffer—Section15—ConditionstotheOffer.”TheOfferwillexpireatmidnight(NewYorkCitytime),oneminuteafter11:59p.m.NewYorkCitytime,onNovember16,2020,unlessweextendtheOffer.See“TheOffer—Section13—TheTransactionDocuments—TheMergerAgreement—ExtensionsoftheOffer.”

ThisOffertoPurchasedoesnotconstituteasolicitationofproxies,andPurchaserisnotsolicitingproxiesinconnectionwiththeOfferortheMerger.IftheMinimumConditionissatisfiedandPurchaserconsummatestheOffer,Purchaserwill consummate the Merger pursuant to Section 251(h) of the DGCL without the approval of MyoKardia’sstockholders.

THIS OFFER TO PURCHASE AND THE RELATED LETTER OF TRANSMITTAL CONTAINIMPORTANT INFORMATION, AND YOU SHOULD CAREFULLY READ BOTH IN THEIR ENTIRETYBEFORE YOU MAKE A DECISION WITH RESPECT TO THE OFFER.

12

TABLE OF CONTENTS

THE OFFER

1. Terms of the Offer

UponthetermsandsubjecttotheconditionsoftheOffer,wewillacceptforpaymentandpayforallSharesthatarevalidlytenderedandnotvalidlywithdrawninaccordancewiththeproceduressetforthin“—Section3—ProceduresforTenderingShares”atorpriortotheExpirationTime(asdefinedbelow).TheOfferwillexpireatmidnight(NewYorkCitytime),oneminuteafter11:59p.m.NewYorkCitytime,onNovember16,2020(suchinitialexpirationdateandtimeoftheOffer,the“Initial Expiration Time”)or,iftheOfferhasbeenextendedpursuanttoandinaccordancewiththeMergerAgreement,thedateandtimetowhichtheOfferhasbeensoextended(theInitialExpirationTime,orsuchlaterexpirationdateandtimetowhichtheOfferhasbeensoextended,the“Expiration Time”).No“subsequentofferingperiod”inaccordancewithRule14d-11oftheSecuritiesExchangeActof1934,asamended(togetherwiththerulesandregulationspromulgatedthereunder,the“Exchange Act”)willbeavailable.

TheOfferissubjecttotheconditions(the“Offer Conditions”)setforthin“—Section15—ConditionstotheOffer,”which include, among other things, satisfaction of the Minimum Condition, the Restraints Condition, the ActionsCondition and the Governmental Consents Condition. See “—Section 16—Certain Legal Matters; RegulatoryApprovals.”SubjecttothesatisfactionandwaiveroftheconditionstotheOffer,wewillacceptandpayforallSharesvalidlytenderedandnotvalidlywithdrawnpursuanttotheOfferpromptlyaftertheExpirationTime.

PursuanttothetermsoftheMergerAgreement,if,atthethen-scheduledExpirationTime,anyoftheOfferConditionshas not been satisfied or waived by Parent and Purchaser (to the extent such waiver is permitted under the MergerAgreementandapplicableLaw),then(a)wemay,inoursolediscretion(andwithouttheconsentofMyoKardiaoranyotherperson)and(b)uponMyoKardia’swrittenrequest,wewill,andParentwillcausePurchaserto,extendtheOfferononeor moreoccasions in consecutive increments of upto tenbusiness dayseach(eachsuchincrement to endat5:00p.m.,NewYorkCitytime,onthelastbusinessdayofsuchincrement)inordertopermitthesatisfactionofsuchOffer Condition(s); provided, however, that (i) we will not be required to extend the Offer to a date later than theOutsideDate(asdefinedbelow)andwewillnotbepermittedtoextendtheoffertoadatelaterthantheOutsideDatewithoutthepriorwrittenconsentofMyoKardiaand(ii)ifatanythenscheduledexpirationoftheOffer,alloftheOfferConditions(otherthantheMinimumConditionandanyOfferConditionsthatarebytheirnaturetobesatisfiedattheOffer Acceptance Time) have been satisfied or waived (to the extent permitted by the Merger Agreement andapplicableLaw)andtheMinimumConditionhasnotbeensatisfied,wewillnotberequiredto(andParentwillnotberequiredtocausePurchaserto)extendtheOfferformorethanthreeadditionalconsecutiveincrementsoftenbusinessdays (or such shorter periods as may be agreed to by MyoKardia and Purchaser). We will extend the Offer for theminimumperiodrequiredbyapplicableLaw,interpretationorpositionoftheSECoritsstafforTheNASDAQGlobalSelectMarket(the“NASDAQ”)oritsstaff.Wewillnot,andParentwillnotpermitPurchaserto,extendtheOfferinany manner except as required or expressly permitted as set forth in this paragraph. See “—Section 4—WithdrawalRights.”

Totheextentpermittedbylaw,Purchaseralsoexpresslyreservestheexclusiverightto(a)increasetheOfferPrice,(b)waiveanyoftheOfferConditions(asdefinedbelow)otherthantheMinimumCondition,theTerminationCondition(asdefinedbelow),theRestraintsConditionortheGovernmentalConsentsConditionand(c)makeanyotherchangesto the terms and conditions of the Offer not inconsistent with the terms of the Merger Agreement, provided thatMyoKardia’sconsentisrequiredforPurchaserto(i)exceptinconnectionwithastocksplit,recapitalizationorotherlikechangewithrespecttotheShares, decreasetheOfferPrice,(ii) changetheformofconsiderationpayableintheOffer,(iii)decreasethemaximumnumberofSharessoughttobepurchasedintheOffer,(iv)imposeanyconditionstotheOfferotherthantheOfferConditions,(v)amend,modifyorsupplementanyoftheOfferConditionsinamannerthatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholdersofShares,(vi)amend,modifyorwaivetheMinimumCondition,theTerminationCondition,theRestraintsConditionortheGovernmentalConsentsCondition,(vii)extendorotherwisechangetheexpirationdateoftheOffer,exceptasdescribedunder“—Section13—TheTransactionDocuments—TheMergerAgreement—ExtensionsoftheOffer”or(viii)otherwiseamend,modifyorsupplementanyoftheothertermsoftheOfferinanymannerthatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholdersofShares.

IfwemakeamaterialchangetothetermsoftheOfferorwaiveamaterialconditiontotheOffer,wewillextendtheOffer and disseminate additional tender offer materials, in each case, to the extent required by applicable Law. Theminimumperiodduringwhichatenderoffermustremainopenfollowingmaterial changesinthetermsoftheoffer,otherthanachangeinpriceorachangeinpercentageofsecuritiessought,dependsuponthefactsandcircumstances,includingthematerialityofthechanges.Inapublishedrelease,theSEChasstatedthatinitsviewanoffermust

13

TABLE OF CONTENTS

remainopenforaminimumperiodoftimefollowingamaterialchangeinthetermsofsuchofferandthatthewaiverofa conditionsuchas the MinimumConditionis a material changein the termsof an offer. Therelease states that anoffershouldremainopenforaminimumoffivebusinessdaysfromthedatethematerialchangeisfirstpublished,sentor given to stockholders, and that if material changes are made with respect to information that approaches thesignificanceofpriceandthepercentageofsecuritiessought(including,fortheavoidanceofdoubt,achangeinpriceorpercentageofsecuritiessought),aminimumoftenbusinessdaysgenerallyisrequiredtoallowadequatedisseminationand investor response. If, prior to the Expiration Time, Purchaser increases the consideration being paid forShares accepted for payment pursuant to the Offer, such increased consideration will be paid to all stockholderswhose Shares are purchased pursuant to the Offer, whether or not such Shares were tendered prior to theannouncement of the increase in consideration.

Any extension, termination or amendment of the Offer will be followed as promptly as practicable by a publicannouncementthereof. Withoutlimitingthemannerinwhichwemaychoosetomakeanypublicannouncement, wewill have no obligation (except as otherwise required by applicable Law) to publish, advertise or otherwisecommunicate any suchpublic announcement other than by issuinga press release to a national newsservice. In thecaseofanextensionoftheOffer,wewillmakeapublicannouncementofsuchextensionnolaterthan9:00a.m.,NewYorkCitytime,onthenextbusinessdayafterthepreviouslyscheduledExpirationTime.

TheMergerAgreementdoesnotcontemplateasubsequentofferingperiodfortheOffer.

As soon as practicable following (but in any event on the same day as) the Offer Acceptance Time, subject to thesatisfaction or waiver of the other conditions set forth in the Merger Agreement and in any event no later than onebusiness day following the satisfaction or waiver of such conditions, Purchaser and Parent expect to complete theMergerwithoutavoteofthestockholdersofMyoKardiapursuanttoSection251(h)oftheDGCL.WedonotexpecttheretobeasignificantperiodoftimebetweentheconsummationoftheOfferandtheconsummationoftheMerger.

MyoKardia has provided Purchaser with its stockholder list, security position listings and certain other informationregardingthebeneficialownersofSharesforthepurposeofdisseminatingtheOffertoholdersofShares.WewillsendthisOffertoPurchase,therelatedLetterofTransmittalandotherrelateddocumentstorecordholdersofSharesandtobrokers,dealers, commercial banks,trustcompaniesandothernomineeswhosenamesappearonthestockholderlistor,ifapplicable,whoarelistedasparticipantsinaclearingagency’ssecuritypositionlistingforsubsequenttransmittaltobeneficialownersofShares.

2. Acceptance for Payment and Payment for Shares

Upon the terms and subject to the conditions to the Offer, we will, at or as promptly as practicable following theExpirationTime,acceptforpayment(suchtimeofacceptanceforpayment,the“Offer Acceptance Time”)and,atoras promptly as practicable following the Offer Acceptance Time (and in any event within three business daysthereafter),payfor,allSharesvalidlytenderedandnotproperlywithdrawnpursuanttotheOfferpriortotheExpirationTime.Forinformationwithrespecttoapprovalsorotheractionsthatweareormayberequiredtoobtainpriortothecompletion of the Offer, including under the HSR Act, see “—Section 16—Certain Legal Matters; RegulatoryApprovals.”

We will pay for Shares accepted for payment pursuant to the Offer by depositing the purchase price with theDepositary,whichwillactasyouragentforthepurposeofreceivingpaymentsfromPurchaserandtransmittingsuchpaymentstoyou.Uponthedeposit of suchfundswiththeDepositary, Purchaser’sobligationtomakesuchpaymentwill be satisfied in full, and tendering stockholders must thereafter look solely to the Depositary for payment ofamountsowedtothembyreasonoftheacceptanceforpaymentofSharespursuanttotheOffer.

Inallcases,paymentforSharesacceptedforpaymentwillbemadeonlyaftertimelyreceiptbytheDepositaryof(a)certificatesforsuchShares(orofaconfirmationofabook-entrytransferofsuchSharesintotheDepositary’saccountat the Book-Entry Transfer Facility (as defined below)), (b) a properly completed and duly executed Letter ofTransmittal (oramanuallysignedfacsimilethereof), withanyrequiredsignatureguarantees, orinconnectionwithabook-entry transfer, an Agent’s Message (defined in “—Section 3—Procedures for Tendering Shares—Book-EntryDelivery”)and(c)anyotherrequireddocuments.ForadescriptionoftheproceduresfortenderingSharespursuanttothe Offer, see “—Section 3—Procedures for Tendering Shares.” Accordingly, payment may be made to tenderingstockholdersatdifferenttimesifdeliveryoftheSharesandotherrequireddocumentsoccursatdifferenttimes.

ForthepurposesoftheOffer, wewill bedeemedtohaveacceptedforpaymenttenderedShareswhen,asandif wegiveoralorwrittennoticeofouracceptancetotheDepositary.

14

TABLE OF CONTENTS

Under no circumstances will we pay interest on the consideration paid for Shares pursuant to the Offer,regardless of any extension of the Offer or any delay in making such payment.

IfwedonotacceptforpaymentanytenderedSharespursuanttotheOfferforanyreason,orifyousubmitcertificatesfor more Shares than are tendered, we will return certificates (or cause to be issued new certificates) representingunpurchasedoruntenderedShares,withoutexpensetoyou(or,inthecaseofSharesdeliveredbybook-entrytransferintotheDepositary’saccountattheBook-EntryTransferFacilitypursuanttotheproceduressetforthin“Section3—Procedures for Tendering Shares,” the Shares will be credited to an account maintained at the Depository TrustCompany(the“Book-Entry Transfer Facility”)),promptlyfollowingtheexpiration,terminationorwithdrawaloftheOffer.

Wereservetheright to transfer or assign, in accordancewiththetermsof theMerger Agreement, in wholeor fromtimetotimeinpart,tooneormoreofouraffiliatestherighttopurchaseSharestenderedpursuanttotheOffer,butanysuch transfer or assignment will not relieve Purchaser of our obligations under the Offer or prejudice your rights toreceivepaymentforSharesvalidlytenderedandacceptedforpayment.

3. Procedures for Tendering Shares

ValidTenderofShares

Except as set forth below, in order for you to tender Shares in the Offer, the Depositary must receive the Letter ofTransmittal (or a manually signed facsimile thereof), properly completed and signed, together with any requiredsignature guarantees, or an Agent’s Message in connection with a book-entry delivery of Shares, and any otherrequired documents, at one of its addresses set forth on the back cover of this Offer to Purchase on or prior to theExpiration Time and either (a) you must deliver certificates for the Shares representing tendered Shares to theDepositary or youmust causeyour Shares to betenderedpursuant to theprocedurefor book-entry transfer set forthbelow and the Depositary must receive timely confirmation of the book-entry transfer of the Shares into theDepositary’s account at the Book-Entry Transfer Facility or (b) you must comply with the guaranteed deliveryproceduressetforthbelow.

The method of delivery of Shares, including through the Book-Entry Transfer Facility, and all other requireddocuments, is at your election and sole risk, and delivery will be deemed made only when actually received bythe Depositary. If certificates for Shares are sent by mail, we recommend that you use registered mail withreturn receipt requested, properly insured, in time to be received on or prior to the Expiration Time. In allcases, you should allow sufficient time to ensure timely delivery.

The tender of Shares pursuant to any one of the procedures described above will constitute your acceptance of theOffer, as well asyourrepresentationandwarrantythat (a) youowntheSharesbeingtendered, (b) youhavethefullpowerandauthoritytotender,sell,assignandtransfertheSharestendered,asspecifiedintheLetterofTransmittaland(c)whentheSharesareacceptedforpaymentbyPurchaser,wewillacquiregoodandunencumberedtitlethereto,freeandclearofanyliens,restrictions,chargesorencumbrancesandnotbesubjecttoanyadverseclaims.Ouracceptancefor paymentof Sharestenderedbyyoupursuant totheOffer will constitute abindingagreement betweenPurchaserwithrespecttosuchShares,uponthetermsandsubjecttotheconditionstotheOffer.

Book-EntryDelivery

TheDepositaryhasestablishedorwillestablishanaccountwithrespecttotheSharesforthepurposesoftheOfferatthe Book-Entry Transfer Facility. Any financial institution that is a participant in the system of the Book-EntryTransfer Facility may deliver Shares by causing the Book-Entry Transfer Facility to transfer such Shares into theDepositary’saccountinaccordancewiththeproceduresoftheBook-EntryTransferFacility.

However,althoughdeliveryofSharesmaybeeffectedthroughbook-entrytransfer,eithertheLetterofTransmittal(ora manually signed facsimile thereof) properly completed and duly executed together with any required signatureguaranteesoranAgent’sMessageinlieuoftheLetterofTransmittalandanyotherrequireddocumentsmust,inanycase,bereceivedbytheDepositaryatoneofitsaddressessetforthonthebackcoverofthisOffertoPurchasebytheExpirationTime,ortheguaranteeddeliveryproceduredescribedbelowmustbecompliedwith.

“Agent’s Message” means a message transmitted by the Book-Entry Transfer Facility to, and received by, theDepositaryandformingapartofabook-entryconfirmationstatingthattheBook-EntryTransferFacilityhasreceivedanexpressacknowledgmentfromtheparticipantintheBook-EntryTransferFacilitytenderingtheSharesthatarethe

15

TABLE OF CONTENTS

subjectofsuchbook-entryconfirmationthatsuchparticipanthasreceivedandagreestobeboundbythetermsoftheLetterofTransmittalandthatwemayenforcethatagreementagainsttheparticipant.

RequireddocumentsmustbetransmittedtoandreceivedbytheDepositaryatoneofitsaddressessetforthonthebackcoverpageofthisOffertoPurchasepriortotheExpirationTime.Delivery of the enclosed Letter of Transmittal andany other required documents to the Book-Entry Transfer Facility does not constitute delivery to theDepositary.

SignatureGuarantees

AllsignaturesonaLetterofTransmittalmustbeguaranteedbyafinancialinstitution(includingmostbanks,savingsandloanassociations andbrokerage houses) that is a member of a recognized Medallion ProgramapprovedbyTheSecuritiesTransferAssociation,Inc.,includingtheSecuritiesTransferAgentsMedallionProgram(STAMP),theStockExchangeMedallionProgram(SEMP)andtheNewYorkStockExchange,Inc.MedallionSignatureProgram(MSP)oranyother“eligibleguarantorinstitution”(assuchtermisdefinedinRule17Ad-15undertheExchangeAct)(each,an“Eligible Institution”), unless the Shares tenderedare tendered(a) bya registered holder of Shares whohas notcompletedeithertheboxlabeled“SpecialPaymentInstructions”ortheboxlabeled“SpecialDeliveryInstructions”onthe Letter of Transmittal or (b) for the account of an Eligible Institution. See Instructions 1 and 5 of the Letter ofTransmittal.

If the Shares are certificated and are registered in the name of a person other than the signer of the Letter ofTransmittal, or if paymentis tobemadeto, orcertificates fortheSharesforunpurchasedSharesaretobeissuedorreturnedto,apersonotherthantheregisteredholder,thenthetenderedcertificatesfortheSharesmustbeendorsedoraccompanied by appropriate stock powers, signed exactly as the name or names of the registered holder or holdersappear on the certificates for the Shares, with the signatures on the certificates for the Shares or stock powersguaranteedbyanEligibleInstitutionasprovidedintheLetterofTransmittal.SeeInstructions1and5oftheLetterofTransmittal.

IftheSharesarecertificatedandthecertificatesrepresentingtheSharesareforwardedseparatelytotheDepositary,aproperlycompletedanddulyexecutedLetterofTransmittal(oramanuallysignedfacsimilethereof)mustaccompanyeachdeliveryofcertificatesfortheShares.

GuaranteedDelivery

IfyouwishtotenderSharespursuanttotheOfferandcannotdeliversuchSharesandallotherrequireddocumentstotheDepositaryorcannotcompletetheprocedurefordeliverybybook-entrytransferpriortotheExpirationTime,youmayneverthelesstendersuchSharesifallofthefollowingconditionsaremet:

• suchtenderismadebyorthroughanEligibleInstitution;

• aproperlycompletedanddulyexecutedNoticeofGuaranteedDeliveryintheformprovidedbyPurchaserwiththisOffertoPurchaseisreceivedbytheDepositarybytheExpirationTime;and

• thecertificatesforallsuchtenderedShares(oraconfirmationofabook-entrytransferofsuchSharesintotheDepositary’s account at the Book-Entry Transfer Facility), together with a properly completed and dulyexecutedLetterofTransmittal(oramanuallysignedfacsimilethereof)togetherwithanyrequiredsignatureguarantee(oranAgent’sMessage)andanyotherrequireddocuments,arereceivedbytheDepositarywithintwoNASDAQtradingdaysafterthedateofexecutionoftheNoticeofGuaranteedDelivery.

TheNoticeofGuaranteedDeliverymaybetransmittedbyfacsimiletransmissionormailedtotheDepositaryandmustincludeaguaranteebyanEligibleInstitutionintheformsetforthinsuchNotice.

BackupWithholding

UndertheU.S.federalincometaxlaws,theDepositarygenerallywillberequiredtowithholdattheapplicablebackupwithholdingrate(currently24%)fromanypaymentsmadetoU.S.personspursuanttotheOffer,unlessyouprovidethe Depositary with your correct taxpayer identification number and certify that you are not subject to such backupwithholding by completing the IRS Form W-9 included in the Letter of Transmittal or otherwise establish anexemption from backup withholding. If you are a non-U.S. person, you generally will not be subject to backupwithholdingifyoucertifyyourforeignstatusontheappropriateIRSFormW-8.

16

TABLE OF CONTENTS

AppointmentofProxy

ByexecutingaLetterofTransmittal,youirrevocablyappointourdesigneesasyourattorneys-in-factandproxies,withfull power of substitution, in the manner set forth in the Letter of Transmittal to the full extent of your rights withrespecttotheSharestenderedandacceptedforpaymentbyPurchaser(andanyandallotherSharesorothersecuritiesissuedorissuableinrespectofsuchSharesonorafterthedateofthisOffertoPurchase).Allsuchpowersofattorneyand proxies are irrevocable and coupled with an interest in the tendered Shares. Such appointment is effective onlyuponouracceptanceforpaymentofsuchSharesinaccordancewiththetermsoftheOffer.Uponsuchacceptanceforpayment,allpriorpowersofattorneyandproxiesandconsentsgrantedbyyouwithrespecttosuchSharesandothersecuritieswill,withoutfurtheraction,berevoked,andnosubsequentpowersofattorneyorproxiesmaybegivennorsubsequent written consents executed (and, if previously given or executed, will cease to be effective). Upon suchacceptance for payment, our designees will be empoweredto exercise all of your votingandother rights as they, intheir solediscretion, maydeemproperat anyannual, special oradjournedmeetingofMyoKardia’sstockholders, bywritten consent or otherwise. We reserve the right to require that, in order for Shares to be validly tendered,immediatelyuponouracceptanceforpaymentofsuchShares,weareabletoexercisefullvotingrightswithrespecttosuchSharesandothersecurities(includingvotingatanymeetingofstockholdersthenscheduledoractingbywrittenconsentwithoutameeting).

The foregoing powers of attorney and proxies are effective only upon acceptance for payment of Sharespursuant to the Offer. The Offer does not constitute a solicitation of proxies, absent a purchase of Shares, forany meeting of MyoKardia’s stockholders.

DeterminationofValidity

We will determine, in our sole discretion, all questions as to the form of documents and the validity, eligibility(includingtimeofreceipt)andacceptanceforpaymentofanytenderofShares,andourdeterminationwillbefinalandbinding.WereservetheabsoluterighttorejectanyoralltendersofSharesthatwedeterminenottobeinproperformor the acceptance for payment of or payment for which may, in the opinion of our counsel, be unlawful. We alsoreserve the absolute right to waive any defect or irregularity in any tender of Shares. No tender of Shares will bedeemedtohavebeenvalidlymadeuntil all defects andirregularities withrespect tosuchtender havebeencuredorwaived.NoneofPurchaser,theDepositary,theInformationAgentoranyotherpersonwillbeunderanydutytogivenotificationofanydefectorirregularityintendersorwaiverofanysuchdefectorirregularityorincuranyliabilityforfailure to give any such notification. Subject to applicable Lawas applied by a court of competent jurisdiction, ourinterpretationofthetermsandconditionsoftheOffer(includingtheLetterofTransmittalandtheinstructionsthereto)will be final andbinding. Tenderingstockholders havethe right to challengeour determination withrespect to theirShares.

4. Withdrawal Rights

ExceptasdescribedinthisSection4,tendersofSharesmadeintheOfferareirrevocable.Youmaywithdrawsomeorall of theSharesthat youhavepreviouslytenderedintheOffer at anytimebefore theExpirationTimeand, if suchShareshavenotyetbeenacceptedforpaymentasprovidedherein,anytimeafterDecember18,2020,whichis60daysfromthedateofthecommencementoftheOffer.

If weextend the period of timeduring whichthe Offer is open, are delayed in accepting for payment or payingforShares or are unable to accept for payment or pay for Shares pursuant to the Offer for any reason, then, withoutprejudicetoourrightsundertheOffer,theDepositarymay,onourbehalf,retainallSharestendered,andsuchSharesmaynotbewithdrawnexcepttotheextentthatyoudulyexercisewithdrawalrightsasdescribedinthisSection4.

Foryourwithdrawaltobeeffective,awrittenorfacsimiletransmissionnoticeofwithdrawalwithrespecttotheSharesmustbetimelyreceivedbytheDepositaryatoneofitsaddressessetforthonthebackcoverofthisOffertoPurchase,and the notice of withdrawal must specify the name of the person who tendered the Shares to be withdrawn, thenumberofSharestobewithdrawnandthenameoftheregisteredholderofShares,ifdifferentfromthatofthepersonwhotendered such Shares. If the Shares to be withdrawnhave been delivered to the Depositary, a signed notice ofwithdrawalwith(exceptinthecaseofSharestenderedbyanEligibleInstitution)signaturesguaranteedbyanEligibleInstitutionmust besubmittedbefore therelease of suchShares. In addition, suchnotice must specify, in thecaseofSharestenderedbydeliveryofcertificates,theserialnumbersshownonthespecificcertificatesevidencingtheSharestobewithdrawnor,inthecaseofSharestenderedbybook-entrytransfer,thenameandnumberoftheaccountattheBook-EntryTransferFacilitytobecreditedwiththewithdrawnShares.Withdrawalsmaynot

17

TABLE OF CONTENTS

berescinded,andShareswithdrawnwillthereafterbedeemednotvalidlytendered.However,withdrawnSharesmayberetenderedatanytimebeforetheExpirationTimebyagainfollowinganyoftheproceduresdescribedin“—Section3—ProceduresforTenderingShares.”

Wewill determine, inoursolediscretion,all questionsastotheformandvalidity(includingtimeofreceipt) ofanynoticeofwithdrawal.NoneofPurchaser,theDepositary,theInformationAgentoranyotherpersonwillbeunderanyduty to give notification of any defect or irregularity in any notice of withdrawal or waiver of any such defect orirregularity or incur anyliability for failure to giveanysuchnotification. Subject to applicable Lawas applied byacourtofcompetentjurisdiction,ourdeterminationwillbefinalandbinding.TenderingstockholdershavetherighttochallengeourdeterminationwithrespecttotheirShares.

5. Material U.S. Federal Income Tax Consequences

Thefollowingsummarydiscusses the material U.S. federal incometax consequences to U.S. Holders andNon-U.S.Holders (in each case, as defined below) who tender Shares pursuant to the Offer. This discussion is based on theInternal Revenue Code of 1986, as amended (the “Code”), applicable Treasury regulations promulgated under theCode,administrativeinterpretations, andjudicialdecisionsasineffectasofthedateofthisOffertoPurchase,all ofwhichmaychange,possiblywithretroactiveeffect.

This discussion addresses only the consequences of the tender of Shares pursuant to the Offer held as capital assetswithin the meaning of Section 1221 of the Code (generally, property held for investment). It does not address allaspectsofU.S.federalincometaxationthatmayberelevanttoaholderofSharesinlightofsuchholder’sparticularcircumstances,ortoaholderofSharesthatissubjecttospecialrules,suchas:

• afinancialinstitutionorinsurancecompany;

• amutualfund;

• apass-throughentityorinvestorsinsuchentity;

• atax-exemptorganization;

• adealerorbrokerinsecurities;

• apersonwhosefunctionalcurrencyisnottheU.S.dollar;

• aformercitizenorformerlong-termresidentoftheUnitedStates;

• aregulatedinvestmentcompanyorrealestateinvestmenttrust;

• astockholderthatholdsitsSharesthroughindividualretirementorothertax-deferredaccounts;

• atraderinsecuritieswhoelectstoapplyamark-to-marketmethodofaccounting;

• astockholderthatholdsSharesaspartofahedge,appreciatedfinancialposition,straddle,orconversionorintegratedtransaction;

• astockholderthatacquiredSharesthroughtheexerciseofcompensatoryoptionsorstockpurchaseplansorotherwiseascompensation;

• aU.S.expatriateorentitycoveredbytheanti-inversionrulesundertheCode;

• apersonwhoactuallyorconstructivelyownsmorethan5%oftheShares;

• apersonwhoholdsbothSharesandBristol-MyersSquibbcommonstock;

• astockholderthat enteredintotheSupport Agreementaspart ofthetransactionsdescribedinthisOffer toPurchase;

• apersonsubjecttospecialtaxaccountingrules(includingrulesrequiringrecognitionofgrossincomebasedonataxpayer’sapplicablefinancialstatement);and

• apersonsubjecttothebaseerosionandanti-abusetax.

18

TABLE OF CONTENTS

For purposes of this discussion, a “U.S. Holder”is a beneficial owner of Shares that is for U.S. federal incometaxpurposes:

• anindividualwhoisacitizenorresidentoftheUnitedStates;

• acorporation,orotherentityorarrangementtaxableasacorporationforU.S.federalincometaxpurposes,createdororganizedinorunderthelawsoftheUnitedStatesoranystatethereinortheDistrictofColumbia;

• anestate,theincomeofwhichissubjecttoU.S.federalincometaxationregardlessofitssource;or

• atrust(a)thatissubjecttotheprimarysupervisionofacourtwithintheUnitedStatesandallthesubstantialdecisionsofwhicharecontrolledbyoneormoreU.S.personsor(b)thathasavalidelectionineffectunderapplicableU.S.TreasuryregulationstobetreatedasaU.S.person.

A“Non-U.S. Holder”isabeneficialownerofSharesthatisneitheraU.S.HoldernorapartnershipforU.S.federalincometaxpurposes.

If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes)holdsShares,theU.S.federalincometaxtreatmentofapartnerinthepartnershipwillgenerallydependuponthestatusof the partner andthe activities of the partner andthe partnership. Apartner of a partnership holdingShares shouldconsultitstaxadvisorsregardingthetaxconsequencestoitofthetenderofSharespursuanttotheOffer.

This discussion of material U.S. federal incometax consequences is not a complete description of all potential U.S.federal incometaxconsequences of thetender of Shares pursuant to theOffer. This discussiondoesnot address taxconsequencesthatmayvarywith,orarecontingenton,individualcircumstances.Inaddition,itdoesnotaddressanyalternative minimum tax, any non-income tax or any non-U.S., state or local tax consequences of the Offer or thepotential applicationoftheMedicarecontributiontaxonnetinvestmentincome.Accordingly, eachholderofSharesshouldconsult its taxadvisor todeterminetheparticular U.S.federal, state or local or non-U.S.incomeorother taxconsequencestoitoftheOffer,includingtheapplicationandeffectofanyU.S.federal,state,localandforeignincome,estate,giftandothertaxlawstothereceiptofcashinexchangeforSharespursuanttotheOffer.

U.S.Holders

ThetenderofSharesbyaU.S.HolderpursuanttotheOfferwillbeataxabletransactionforU.S.federalincometaxpurposesandmayalsobeataxabletransactionunderapplicablestate,local,non-U.S.andothertaxlaws.Ingeneral,ifa U.S. Holder exchanges Shares pursuant to the Offer, such U.S. Holder will recognize gain or loss equal to thedifference between its adjusted tax basis in its Shares and the amount of cash received in exchange therefor(determinedbeforethedeductionofbackupwithholding,ifany).Gainorlosswillbedeterminedseparatelyforeachblockof Shares(i.e., Shares acquiredfor thesamecost in a single transaction) tenderedpursuant totheOffer. Suchgain or loss generally will be capital gain or loss and generally will be long-term capital gain or loss if the U.S.Holder’sholdingperiodintheSharesismorethanoneyearasofthedateofthetenderofsuchSharespursuanttotheOffer. Long-term capital gains of non-corporate taxpayers generally are subject to U.S. federal income tax atpreferentialrates.Thedeductionofcapitallossesissubjecttolimitations.

Non-U.S.Holders

PaymentsmadetoaNon-U.S.HolderwithrespecttoSharestenderedintheOffergenerallywillnotbesubjecttoU.S.federalincometax,unless:

• the gain, if any, onShares is effectively connectedwith the conduct bythe Non-U.S. Holder of a trade orbusiness in the United States (and, if certain income tax treaties apply, is attributable to the Non-U.S.Holder’spermanentestablishmentintheUnitedStates);or

• the Non-U.S. Holder is an individual who was present in the United States for 183 days or more in thetaxableyearofsaleandcertainotherconditionsaremet.

GaindescribedinthefirstbulletpointabovewillbesubjecttotaxonanetincomebasisinthesamemannerasiftheNon-U.S. Holder were a U.S. Holder (unless an applicable incometax treaty provides otherwise). Additionally, anygaindescribedinthefirstbulletpointaboveofaNon-U.S.Holderthatisacorporationalsomaybesubjectto

19

TABLE OF CONTENTS

anadditional“branchprofitstax”ata30%rate(orlowerrateprovidedbyanapplicableincometaxtreaty). ANon-U.S.Holderdescribedinthesecondbulletpointabovewillbesubjecttotaxatarateof30%(oralowerrateprovidedby an applicable income tax treaty) on any capital gain realized, which may be offset by U.S.-source capital lossesrecognizedinthesametaxableyear.

InformationReportingandBackupWithholding

Proceeds from the sale of Shares pursuant to the tender generally are subject to information reporting, and may besubjecttobackupwithholdingattheapplicablerate(currently24%)ifthestockholderorotherpayeefailstoprovideavalid taxpayer identification number and comply with certain certification procedures or otherwise establish anexemptionfrombackupwithholding.BackupwithholdingisnotanadditionalU.S.federalincometax.Rather,theU.S.federalincometaxliabilityofthepersonsubjecttobackupwithholdingwillbereducedbytheamountoftaxwithheld.If withholding results in an overpayment of taxes, a refund may generally be obtained provided, that the requiredinformationistimelyfurnishedtotheInternalRevenueService.See“—Section3—ProceduresforTenderingShares—BackupU.S.FederalIncomeTaxWithholding.”

6. Price Range of Shares; Dividends

AccordingtoMyoKardia’sAnnualReportonForm10-KfortheperiodendedDecember31,2019,theSharesarelistedandprincipallytradedonNASDAQunderthesymbol“MYOK.”ThefollowingtablesetsforththehighandlowsalepricesperShareonNASDAQwithrespecttotheperiodsindicatedandasreportedbypublishedfinancialsources:

High Low

2018

FirstQuarter $ 62.83 $ 41.00

SecondQuarter $ 52.00 $ 41.90

ThirdQuarter $ 67.45 $ 49.35

FourthQuarter $ 67.79 $ 44.99

2019

FirstQuarter $ 56.03 $ 39.01

SecondQuarter $ 54.67 $ 44.68

ThirdQuarter $ 61.88 $ 47.53

FourthQuarter $ 74.98 $ 50.49

2020

FirstQuarter $ 78.28 $ 43.50

SecondQuarter $126.30 $ 42.65

ThirdQuarter $139.22 $ 88.60

FourthQuarter(throughOctober16,2020) $224.00 $136.83

MyoKardiadoesnotpaycashdividendsontheSharesand,underthetermsoftheMergerAgreement,MyoKardiaisnotpermittedtoestablisharecorddatefor, declare, set asidefor payment, authorizeorpayanydividendon, oranyotherdistributioninrespectof,anySharesorotherequityorvotinginterests,otherthandividendspaidbyanywhollyowned subsidiary of MyoKardia to MyoKardia or any other wholly owned subsidiary of MyoKardia. If we acquirecontrol of MyoKardia, we currently intend that no dividends will be declared on the Shares prior to the MergerEffectiveTime.

OnOctober2,2020,thelastfulltradingdaybeforetheannouncementoftheMergerAgreement,theMergerandtheOffer, the highest reported intraday sale price per Share on NASDAQwas $140.93 in published financial sources.BetweenOctober2,2020andOctober16,2020,thehighestdailyintradaysalepriceperShareonNASDAQrangedbetween$140.93and$224.00.OnOctober16,2020,thelastfulltradingdaybeforethedateofthisOffertoPurchase,thehighestreportedintradaysalepriceperShareonNASDAQwas$222.11.Please obtain a recent quotation for theShares before deciding whether or not to tender.

7. Possible Effects of the Offer on the Market for the Shares; Stock Exchange Listing; Registration under theExchange Act; Margin Regulations

Assuming the Minimum Condition is satisfied and we purchase the Shares in the Offer, no stockholder vote willbe required to consummate the Merger. Following the consummation of the Offer and subject to the

20

TABLE OF CONTENTS

satisfaction or waiver of the remaining conditions contained in the Merger Agreement, we intend toconsummate the Merger as soon as practicable. We do not expect there to be a significant period of timebetween consummation of the Offer and consummation of the Merger.

PossibleEffectsoftheOfferontheMarketfortheShares

While we intend to consummate the Merger as soon as practicable after consummation of the Offer, if the Offer isconsummatedbuttheMergerdoesnotoccur,thenumberofstockholders,andthenumberofSharesthatarestillinthehandsofthepublic,maybesosmallthattherewillnolongerbeanactiveorliquidpublictradingmarket(orpossiblyany public trading market) for Shares held by stockholders other than Purchaser. We cannot predict whether thereductioninthenumberofSharesthatmightotherwisetradepubliclywouldhaveanadverseorbeneficialeffectonthemarket price for, or marketability of, the Shares or whether such reduction would cause future market prices to begreaterorlessthanthepricepaidintheOffer.IftheMergerisconsummated,stockholdersnottenderingtheirSharesinthe Offer (MyoKardia, anyof its subsidiaries, Parent, Purchaser or anysubsidiary of Parent, or anypersonwhohasproperly exercised his appraisal rights under Section262of the DGCL)will receive cashin anamount equal to thepriceperSharepaidintheOffer.

StockExchangeListing

While we intend to consummate the Merger as soon as practicable after consummation of the Offer, if the Offer isconsummatedbuttheMergerdoesnotoccur,dependinguponthenumberofSharespurchasedpursuanttotheOffer,the Shares may no longer meet the standards for continued listing on the NASDAQ Global Select Market, theNASDAQGlobal Market or the NASDAQCapital Market. If, as a result of the purchase of Shares pursuant to theOffer, theSharesnolonger meet thecriteria for continuedlistingonanysuchNASDAQmarket, themarket for theShares could be adversely affected. According to NASDAQ’s published guidelines, the Shares would not meet thecriteria for continued listing on any such NASDAQmarket if, among other things, (a) the number of publicly heldShareswerelessthan1,000,000,(b)themarketvalueofthelistedShareswerelessthan$8,000,000or(c)therewerefewerthan300stockholders.

IfNASDAQweretodelisttheShares,itispossiblethattheShareswouldtradeonanothersecuritiesexchangeorintheover-the-countermarketandthatpricequotationsfortheShareswouldbereportedbysuchexchangeorothersources.TheextentofthepublicmarketfortheSharesandavailabilityofsuchquotationswould,however,dependuponsuchfactorsasthenumberofholdersand/ortheaggregatemarketvalueofthepubliclyheldSharesatsuchtime,theinterestin maintaining a market in the Shares on the part of securities firms, the possible termination of registration of theSharesundertheExchangeActandotherfactors.

RegistrationundertheExchangeAct

TheSharesarecurrentlyregisteredundertheExchangeAct. WhileweintendtoconsummatetheMergerassoonaspracticableafterconsummationoftheOffer,iftheOfferisconsummatedbuttheMergerdoesnotoccur,thepurchaseoftheSharespursuanttotheOffermayresultintheSharesbecomingeligibleforderegistrationundertheExchangeAct. Registrationmaybeterminateduponapplicationof MyoKardia totheSECif theSharesare neither listedonanationalsecuritiesexchangenorheldby300ormoreholdersofrecord.TerminationoftheregistrationoftheSharesunder the Exchange Act, assuming there are no other securities of MyoKardia subject to registration, wouldsubstantiallyreducetheinformationrequiredtobefurnishedbyMyoKardiatoholdersofSharesandtotheSECandwould make certain of the provisions of the Exchange Act, such as the short-swing profit recovery provisions ofSection16(b)thereof,therequirementtofurnishaproxystatementpursuanttoSection14(a)thereofinconnectionwithastockholder’smeetingandtherelatedrequirementtofurnishanannualreporttostockholders,andtherequirementsofRule 13e-3 thereof with respect to “going private” transactions, no longer applicable to MyoKardia. Furthermore,“affiliates”ofMyoKardiaandpersonsholding“restrictedsecurities”ofMyoKardiamaybedeprivedoftheabilitytodispose of such securities pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended. IfregistrationoftheSharesundertheExchangeActwereterminated,theShareswouldnolongerbe“marginsecurities”oreligibleforstockexchangelisting.

Following the purchase of Shares in the Offer and subject to the satisfaction or waiver of the remaining conditionscontained in the Merger Agreement, we will consummate the Merger as soon as practicable, following which theShareswillnolongerbepubliclytraded.FollowingtheconsummationoftheMerger,weintendtotakestepstocausetheterminationoftheregistrationofSharesundertheExchangeActaspromptlyaspracticableandmayinthefuturetakestepstocausethesuspensionofallofMyoKardia’sreportingobligationsundertheExchangeAct.

21

TABLE OF CONTENTS

MarginRegulations

TheSharesarecurrently“marginsecurities”undertheregulationsoftheBoardofGovernorsoftheFederalReserveSystem(the“Federal Reserve Board”),whichhastheeffect,amongotherthings,ofallowingbrokerstoextendcreditonthecollateralofsuchShares.Dependinguponfactorssimilartothosedescribedaboveregardinglistingandmarketquotations, following the purchase of Shares pursuant to the Offer, the Shares might no longer constitute “marginsecurities”forthepurposesoftheFederalReserveBoard’smarginregulationsand,therefore,couldnolongerbeusedascollateralforloansmadebybrokers.

8. Certain Information Concerning MyoKardia

The information concerning MyoKardia contained in this Offer to Purchase has been taken from or based uponpubliclyavailabledocumentsandrecordsonfilewiththeSECandotherpublicsourcesandisqualifiedinitsentiretybyreferencethereto.

According to MyoKardia’s public filings with the SEC, MyoKardia was incorporated in Delaware in 2012.MyoKardia’sprincipalexecutiveofficesarelocatedat1000SierraPointParkway,Brisbane,CA94005.ThetelephonenumberofMyoKardia’sprincipalexecutiveofficesis(650)741-0900.

The following description of MyoKardia and its business has been taken from MyoKardia’s public filings with theSEC, and is qualified in its entirety by reference to such filings. MyoKardia is a clinical-stage biopharmaceuticalcompanypioneeringaprecisionmedicineapproachtodiscover,developandcommercializetargetedtherapiesforthetreatment of serious and neglected rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment ofcardiomyopathies, a group of diseases of the heart muscle. MyoKardia’s pipeline includes: mavacamten, MYK-224andLUS-1,whicharebeingstudiedforthetreatmentofhypertrophiccardiomyopathyandforthetreatmentofdiseasesofdiastolicdysfunction;anddanicamtiv(formerlyMYK-491)andACT-1,beingstudiedforthetreatmentofdiseasesof systolic dysfunction and atrial cardiomyopathies. MyoKardia also has a series of discovery-stage programs beingstudiedforthetreatmentofadditionalgeneticcardiomyopathies.

AdditionalInformation

MyoKardiaissubjecttotheinformationalandreportingrequirementsoftheExchangeActandinaccordancetherewithfiles and furnishes periodic reports, proxy statements and other information with the SEC relating to its business,financialconditionandothermatters.Youmayreadandcopyanysuchreports,statementsorotherinformationattheSEC’sPublicReferenceRoomlocatedat100FStreet,N.E.,Room1580,Washington,D.C.20549.Pleasecall1-800-SEC-0330 for further information on the operation of the Public Reference Room. MyoKardia’s filings are alsoavailabletothepublicfromcommercialdocumentretrievalservicesandattheSEC’swebsiteathttp://www.sec.gov.The SEC’s website address is not intended to function as a hyperlink, and the information contained in the SEC’swebsiteisnotincorporatedbyreferenceinthisOffertoPurchaseandyoushouldnotconsideritaspartoftheOffertoPurchase.

9. Certain Information Concerning Purchaser and Parent

WeareaDelawarecorporationincorporatedonOctober1,2020,withprincipalexecutiveofficesat430E.29thStreet,14FL,NewYork,NY10016.Thetelephonenumberofourprincipalexecutiveofficesis(212)546-4000.Todate,wehaveengagedinnoactivitiesotherthanthoseincidentaltoourformationandtheOffer.

ParentisaDelawarecorporation,withprincipalexecutiveofficesat430E.29thStreet,14FL,NewYork,NY10016.The telephone number of its principal executive offices is (212) 546-4000. Parent is a global biopharmaceuticalcompanywhosemissionistodiscover,developanddeliverinnovativemedicinesthathelppatientsprevailoverseriousdiseases.Parentisengagedinthediscovery,development,licensing,manufacturing,marketing,distributionandsaleofbiopharmaceutical products on a global basis. For more information, please visit www.BMS.com. The informationcontainedin,accessiblefromorconnectedtoParent’swebsiteisnotincorporatedinto,orotherwiseapartof,thisOffertoPurchaseoranyofParent’sfilingswiththeSEC.Thewebsiteaddressreferredtointhisparagraphisaninactivetextreferenceandisnotintendedtobeanactuallinktothewebsite.

Thename,businessaddress,currentprincipaloccupationoremployment,five-yearemploymenthistoryandcitizenshipofeachdirectorandexecutiveofficerofParentandPurchaserandcertainotherinformationaresetforthonScheduleIhereto.NeitherParentnorPurchaserisanaffiliateofMyoKardia.

22

TABLE OF CONTENTS

WedonotbelieveourfinancialconditionorthefinancialconditionofParentisrelevanttoyourdecisionwhethertotenderyourSharesandaccepttheOfferbecause(a)theOfferisbeingmadeforalloutstandingSharessolelyforcash,(b)we,throughParentanditscontrolledaffiliates,willhavesufficientfundstopurchaseallSharesvalidlytendered,and not withdrawn, in the Offer and to provide funding for the Merger, which is expected to follow as soon aspracticablefollowing(butinanyeventonthesamedayas)theOfferAcceptanceTime,subjecttothesatisfactionorwaiver of the other conditions set forth in the Merger Agreement and in any event no later than one business dayfollowingthesatisfactionorwaiverofsuchconditions,(c)consummationoftheOfferisnotsubjecttoanyfinancingcondition,and(d)ifweconsummatetheOffer,weexpecttoacquireanyremainingSharesforthesamecashperSharepriceintheMerger.

PursuanttoRule14d-3undertheExchangeAct,wehavefiledwiththeSECaTenderOfferStatementonScheduleTO(whichwerefertoasthe“Schedule TO”),ofwhichthisOffertoPurchaseformsapart,andexhibitstotheScheduleTO. The Schedule TOand the exhibits thereto, as well as other information filed by Parent and Purchaser with theSEC,areavailableforinspectionattheSEC’sPublicReferenceRoomat100FStreet,N.E.,Washington,D.C.20549.Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Copies of suchinformationmaybeobtainablebymail,uponpaymentoftheSEC’scustomarycharges,bywritingtotheSECattheaddressabove.TheSECalsomaintainsawebsiteontheInternetatwww.sec.govthatcontainstheScheduleTOandtheexhibitstheretoandotherinformationthatParenthasfiledelectronicallywiththeSEC.

ThePurchaserandParenthavemadenoarrangementsinconnectionwiththeOffertoprovideholdersofSharesaccesstoourcorporatefilesortoobtaincounselorappraisalservicesatourexpense.Foradiscussionofappraisalrights,see“TheOffer—Section12—PurposeoftheOffer;PlansforMyoKardia;StockholderApproval;AppraisalRights.”

10. Source and Amount of Funds

Weestimatethatwewillneedapproximately$13.1billiontopurchaseallSharespursuanttotheOfferandtheMerger,topayallamountsinrespectofoutstandingMyoKardiaStockOptions,MyoKardiaRSUAwardsandMyoKardiaPSUAwardsheldbyMyoKardiaemployees,topayrelatedfeesandexpensesandtopayallotheramountsthatmaybecomedue and payable as a result of the Offer and the Merger. Parent and its controlled affiliates expect to contribute orotherwise advanceto Purchaser thefundsnecessaryto consummate theOffer andtheMerger andto paytherelatedfees and expenses. It is anticipated that all of such funds will be obtained from Parent’s or its controlled affiliates’generalcorporatefunds.NeitherwenorParenthasanyalternativefinancingplansorarrangements.

TheOfferisnotconditioneduponanyfinancingarrangementsorsubjecttoafinancingcondition.

11. Background of the Offer; Contacts with MyoKardia

The following is a description of contacts between representatives of Parent and representatives of MyoKardia thatresulted in the execution of the Merger Agreement and the agreements related to the Offer. For a review ofMyoKardia’s additional activities, pleaserefer totheSchedule14D-9that will befiledbyMyoKardia withtheSECanddisseminatedtoholdersofSharesinconnectionwiththeOffer.

Members of management and the board of directors of Parent (the “Parent Board”) regularly review and assessParent’sperformanceandoperations,financialcondition,andindustryandregulatorydevelopmentsinthecontextofParent’slong-termstrategicgoalsandplans.Thesereviewshaveincludedconsideration,fromtimetotime,ofpotentialopportunities toenhancestockholder value, includingpotential strategic acquisitions anddivestitures, collaborations,investments and other strategic transactions and opportunities. These reviews also have included consideration ofwhether suchpotential opportunities to enhancestockholder valuewouldfurther Parent’s strategic objectives anditsabilitytoservepatients,aswellasthepotentialbenefitsandrisksofthosetransactionsinlightof,amongotherthings,Parent’scompetitivepositionandthebusinessandregulatoryenvironmentfacedbyParent(includingdevelopmentsinthebiopharmaceuticalindustry).

InMarch2019, Parent enteredintoa confidentiality agreement withMyoKardia tofacilitate discussionsregardingapotential strategic partnership with respect to danicamtiv, which included meetings among representatives ofMyoKardiaandParentatMyoKardia’sofficesinSanFrancisco,CaliforniainAugust2019andattheAmericanHeartAssociationConferenceinPhiladelphia, PennsylvaniainNovember2019. Theparties continuedtohaveintermittentdiscussions through early 2020, including a discussion of MyoKardia’s early stage pipeline and a potential genetherapycollaborationattheJ.P.MorganAnnualHealthcareConferenceinSanFrancisco,CaliforniainJanuary2020.

23

TABLE OF CONTENTS

OnApril23,2020,arepresentativeofParentcontactedJakeBauer,ChiefBusinessOfficerofMyoKardia,torequestanintroductorymeetingwithElizabethMily,thenewExecutiveVicePresident,Strategy&BusinessDevelopmentatParent,aswellasabroadeningofthediscussionsbetweenthepartiesbeyonddanicamtiv.Thereafter,onMay20,2020,June2, 2020andJune12, 2020, representatives of MyoKardia andParent hadpreliminary, high-level conversationsregardingthepotentialoutlineforabroadercollaborationbetweentheparties.

On July 2, 2020, MyoKardia and Parent entered into a confidentiality agreement, effective as of June 29, 2020, tofacilitate discussions regarding a potential strategic partnership between the parties more broadly related toMyoKardia’sprogramsandtechnology.

On July 2, 2020, representatives of MyoKardia provided a presentation to representatives of Parent regarding theMyoKardiapipelineincludingmavacamteninconnectionwithpotentialstrategicpartnershipdiscussions.

On July 10, 2020, representatives of Parent provided a presentation to representatives of MyoKardia regarding thecapabilitiesofParentandahigh-leveloutlineofapotentialframeworkforaglobalstrategicpartnership.

On August 18, 2020, Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Parent, and TassosGianakakos,PresidentandChiefExecutiveOfficerofMyoKardia,spoketelephonicallyregardingapotentialstrategicpartnershipbetweenthepartiesinthecardiovascularspace.

On August 27, 2020, members of the senior leadership teams of MyoKardia and Parent had a meeting to continuediscussionsregardingpotentialopportunitiesforastrategicpartnership.

OnAugust 31, 2020, the Science and Technology Committee of the Parent Board convened to discuss pipeline andcardiovascular-related opportunities presented by a potential strategic partnership with MyoKardia. Informationsessionswereheldlaterintheday,aswellasthefollowingday,withotherParentBoarddirectorstoreviewspecificfinancial terms and implications of a range of potential transactions involving MyoKardia, including a potentialacquisitionofMyoKardiabyParent.

OnSeptember1,2020,ataspecialmeetingoftheParentBoard,membersofParentmanagementandrepresentativesofGordanDyal &Co. discussed with the Parent Board the potential merits of engaging in a strategic transaction withMyoKardia.TheParentBoarddiscussedthepossibilityofmakinganacquisitionproposaltoMyoKardiaandpotentialvaluation for any such transaction. After discussion, the Parent Board determined that it was advisable to explore apotential acquisition of MyoKardia and, in connection therewith, authorized and directed Dr. Caforio to approachMr.GianakakostoindicateParent’spotentialinterestinacquiringMyoKardiainanallcashtransaction.

OnSeptember2,2020,Dr.CaforiocontactedMr.GianakakosviatelephoneandinformedhimofParent’sinterestinexploring a potential acquisition of MyoKardia and intent to send a proposal letter to this effect. During thisconversation, Dr. Caforio indicated that he had received authority fromthe Board of Directors of Parent to offer toacquireall of theoutstandingSharesat apriceof$185.00perShareincash. Dr. Caforioalsonotedthat Parent waswell-positionedtoconductduediligencequickly.Dr.Caforioindicatedthattheproposalletterwouldincludearequestfor an exclusive period of negotiations. Mr. Gianakakos responded that, while MyoKardia’s strategic plan did notcontemplateasaleofMyoKardia,hewoulddiscusstheproposalwiththeMyoKardiaBoard.

LateronSeptember2,2020,Dr.CaforiosentalettertoMr.Gianakakoscontaininganon-bindingproposaltoacquirealloftheoutstandingSharesfor$185.00perShareincash(the“September 2nd Proposal”),subjecttothecompletionof due diligence and the negotiation and execution of definitive agreements. The letter indicated that Parent waspreparedtoengageimmediatelyinordertocompleteduediligenceandenterintoadefinitiveagreementbytheendofthemonth, andnotedthat theproposal assumedaperiodofexclusivity tonegotiate satisfactorytermsandfinalize amutually acceptable definitive agreement. The letter stated that the proposal would expire on September 30, 2020.Shortly following receipt of the letter, Mr. Gianakakos reached out to members of the MyoKardia Board to informthemoftheSeptember2ndProposal.

OnSeptember7,2020,Mr.GianakakosspoketelephonicallywithDr.CaforioandconveyedtheMyoKardiaBoard’sviewthat theSeptember 2ndProposal didnot adequately reflect MyoKardia’s valueandwasinsufficient to proceedwithfurtherdiscussionsregardingapotentialtransaction.Mr.GianakakosfurthersuggestedtoDr.Caforiothatcertainnon-publiclydiscloseddataandevents (includingregulatorymilestonesandCompanyplanstobegincertainclinicaltrials)constitutedadditionalareasofvaluemeritingconsiderationbytheParentBoard.

OnSeptember10,2020,Dr.CaforiocontactedMr.Gianakakosrequestingatimetofurtherspeak.Laterintheday,Dr.CaforioandMr.GianakakoshadatelephoneconversationduringwhichMr.Gianakakosprovidedadditional

24

TABLE OF CONTENTS

informationonthedataandeventsdiscussedontheirSeptember7,2020call,includingtheCompany’sprospects.Dr.Caforio also asked questions of Mr. Gianakakos to better understand MyoKardia’s position and the status ofMyoKardia’s products. Followingthe discussion, Dr. Caforio stated that he would have further discussions with theParentBoardandthenfollowupwithMr.Gianakakos.

OnSeptember13,2020,theParentBoardheldameeting,withmembersofParentmanagementandrepresentativesofGordanDyal &Co. in attendance. At this meeting, Dr. Caforio reported to the Parent Board his conversations withMr. Gianakakos on September 7, 2020 and September 10, 2020, including the information that had been shared byMr.Gianakakosduringthosediscussions.Followingsuchdiscussion,theParentBoardacknowledgedthepotentialforadditionalareasofvalueashighlightedbyMr.GianakakosonthecallsonSeptember7,2020andSeptember10,2020subjecttofurtherduediligence.TheBoardauthorizedDr.CaforiotomakearevisedproposalonbehalfofParenttoacquirealloftheoutstandingSharesofMyoKardia.

Later on September 13, 2020, Dr. Caforio contacted Mr. Gianakakos and made a verbal, non-binding proposal onbehalfofParenttoacquirealloftheoutstandingSharesatapriceof$210.00perShareincash(the“September 13thProposal”),whichreflectedthediligenceParentperformedtodatetoconfirmvaluearoundMyoKardia’spipelineandadditional valueidentifiedwithrespecttoMyoKardia’sbusiness. Duringthistelephonecall, Dr.Caforiorequestedaperiod of exclusive negotiations and reiterated Parent’s desire to complete due diligence and enter into a definitiveagreementbytheendofthemonth.Mr.GianakakosrespondedthathewoulddiscusstheSeptember13thProposalwiththeMyoKardiaBoard.

OnSeptember16,2020,Mr.GianakakoscontactedDr.CaforioandadvisedhimthattheMyoKardiaBoardwouldnotpermitParenttoconductfullduediligenceuntil ParentprovidedanimprovedproposalacceptabletotheMyoKardiaBoard;however,seniormanagementofMyoKardiawouldprovideParentwithsomelimitedduediligenceinformationifitwouldassistParentinre-evaluatingitspositiononvalue.Dr.Caforioagreedtoproceedinthismanner.

Later on September 16, 2020, Ms. Mily contacted Mr. Bauer to discuss next steps with respect to the limited duediligenceprocess.Followingthisconversation,Mr.BauerprovidedanewformofconfidentialityagreementtoParenttobeenteredintoinconnectionwiththepotentialacquisitionofMyoKardia,whichwasnegotiatedoverthenextfewdays.

On September 18, 2020, MyoKardia and Parent entered into the confidentiality agreement, effective as ofSeptember 17, 2020, which included customary non-disclosure provisions and a standstill provision that prohibitedParent, foranagreed-uponperiodfromthedateoftheagreement, fromofferingtoacquireoracquiringMyoKardia,andfromtakingcertainotheractions,includingsolicitingproxies,withoutthepriorwrittenconsentofMyoKardia.Theconfidentialityagreementprovidedfortheterminationofthestandstillprovisiononcustomaryterms,includinguponMyoKardia’sentryintoadefinitiveagreementwithathirdpartyprovidingforasaleofMyoKardia,andalsoallowedParenttomakeconfidentialacquisitionproposalstotheMyoKardiaBoardatanytime.

LateronSeptember18,2020,ParentsentalistofpriorityduediligenceitemstoMyoKardia.

On September 19, 2020, Mr. Bauer had a telephone call with Ms. Mily to discuss the priority due diligence itemsrequestedbyParentandscheduletherelatedmanagementpresentations.

On September 20, 2020, MyoKardia provided access to a virtual data room to representatives of Parent, whichcontainedcertainpriorityduediligencematerials.

OnSeptember21,2020,membersofMyoKardia’sseniormanagementmadepresentationstorepresentativesofParentregardingMyoKardiaanditsprograms.FromSeptember21to23,2020,Parentmadeseveralrequestsforadditionaldue diligence items, and representatives of MyoKardia had further conversations with representatives of Parentregarding these items. During this period, MyoKardia also provided representatives of Parent with access to certainwrittenmaterialsinresponsetothepriorityduediligenceitemsthathadbeenrequested.

OnSeptember23,2020,theScienceandTechnologyCommitteeoftheParentBoardconvenedtodiscusstheresultsofthe due diligence conducted to date, including due diligence findings with respect to MyoKardia’s products andproductpipelineopportunities.

OnSeptember23,2020,Dr.CaforiocontactedMr.GianakakosviatelephonetodiscusstheresultsofParent’sprioritydue diligence review. Dr. Caforio thanked the MyoKardia team for the priority due diligence, noted that the duediligencediscussionsandmaterialsprovidedhadbeenhelpful,andindicatedthathewasspeakingwithhisBoardof

25

TABLE OF CONTENTS

Directorsthefollowingday.Duringthisconversation,Mr.GianakakosnotedthattheMyoKardiaBoardwasexpectingadditional value to be derived from Parent’s priority due diligence review without indicating a specific price.Mr.GianakakosalsonotedMyoKardia’spotentialasastand-alonecompanyandtheexpectationthatthepricewouldreflectsuchpotential.

On September 24, 2020, the Parent Board held a special meeting to review, discuss and approve a revised cashproposalfortheacquisitionofMyoKardia,withmembersofParentmanagementandrepresentativesofGordanDyal&Co. in attendance. At this meeting, the Parent Board discussed the potential transaction, including with respect toproposed valuation in light of feedback Dr. Caforio had received from Mr. Gianakakos and the preliminary duediligence findings. Following discussion, the Parent Board approved and authorized Dr. Caforio to make a revisedproposalonbehalfofParenttoacquirealloftheoutstandingSharesofMyoKardia.

OnSeptember24,2020,Dr.CaforiocontactedMr.Gianakakosandmadeaverbal,non-bindingproposalonbehalfofParent to acquire all of the outstanding Shares at a price of $220.00 per Share in cash (the “September 24thProposal”). During this telephone call, Dr. Caforio indicated that the proposal was conditioned on: (1) fullconfirmatoryduediligencestartingbytheweekend;(2)atargetsigningdateofOctober1standnolaterthanOctober5th; (3) entry intoanexclusive periodof negotiations; and(4) a termination fee of 3.5%of equity value, plus othercustomarytransactionterms.Mr.GianakakosrespondedthathewoulddiscusstheSeptember24thProposalwiththeMyoKardiaBoard.

On September 25, 2020, Mr. Gianakakos spoke telephonically with Dr. Caforio. During this conversation,Mr. Gianakakos indicated that the MyoKardia Board had authorized him to continue discussions with Dr. Caforioregardinganimprovedoffer,notedMyoKardiamanagement’sconfidenceintheprospectsofMyoKardiaandthevalueof MyoKardia’s programs and pipeline, and suggested that a more significant premium to the current trading pricerangewasappropriategivenMyoKardia’spotentialasastand-alonecompany.Dr.Caforioindicatedthathehadverylimited,ifany,flexibilityabovethepreviouslyofferedpriceof$220.00perShareandwouldrequirefurtherdiscussionwithhis BoardofDirectors. Mr. Gianakakosrespondedthat hewouldspeakwiththeMyoKardiaBoardaswell andreverttoDr.Caforiolaterintheday.

LateronSeptember25,2020,Mr.GianakakosspoketelephonicallywithDr.Caforiotocontinuetonegotiatetheprice.During this conversation, Dr. Caforio made a verbal, non-binding proposal on behalf of Parent to acquire all of theoutstandingSharesatapriceof$225.00perSharesubjecttoexclusivenegotiationsbetweenthepartiestofacilitateatargeted announcement date of October 5, 2020 (the “September 25th Proposal”). Mr. Gianakakos stated that hewouldrecommendtotheMyoKardiaBoardtoenterintoexclusivenegotiationsatthatprice.Mr.GianakakosandDr.CaforioalsodiscussedtheterminationfeepreviouslyproposedbyParentwithoutreachingagreement.

Inaddition, onSeptember 25, 2020, Mr. Bauer hadatelephonecall withMs. Milyduringwhichtheydiscussedtheconfirmatoryduediligenceprocessandtimingconsiderations.Thereafter,arepresentativeofParentsentadraftletteragreement to Mr. Bauer that requested a period of exclusive negotiations through October 12, 2020. Followingnegotiation between the parties, MyoKardia and Parent entered into a letter agreement providing for exclusivenegotiationsbetweenthepartiesuntilthefirsttooccurof:(1)theexecutionofadefinitivemergeragreementbetweenthepartieswithrespecttoatransaction;(2)receiptbyMyoKardiaofwrittennoticefromParentadvisingMyoKardiathatParentisnolongeractivelypursuingthetransaction;(3)thetimeatwhichParentreduced,orproposedareductionin,the$225.00perSharepurchasepriceofferedbyDr.Caforioearlierintheday;and(4)8:00a.m.(NewYorktime)onOctober5,2020.

Later in the day on September 25, 2020, representatives of Kirkland &Ellis LLP(“Kirkland”), outside counsel toParent, provided to Goodwin Procter LLP (“Goodwin”) an initial draft of the Merger Agreement for the proposedtransaction,whichprovidedforthetransactiontobestructuredasacashtenderofferfollowedimmediatelybyaback-endmerger,andincluded,amongotherthings,(1)adefinitionof“MaterialAdverseEffect”,whichgenerallydefinesthe standard for closing risk, without exceptions for regulatory, clinical or similar events or developments, (2) anindication that Parent was open to discussing appropriate treatment of outstanding Company equity awards inconnection with the Transactions, (3) limitations on the efforts obligations of Parent to obtain required antitrustapprovals,(4)therightofMyoKardiatoacceptaSuperiorProposalafterprovidingParentwitharighttomatchsuchproposal, with a “Superior Proposal” defined as a bona fide proposal to acquire 100% of the stock or assets ofMyoKardiathatisdeemedtobemorefavorabletoMyoKardia’sstockholdersfromafinancialpointofviewthantheOfferandtheMerger,(5)aterminationfeeequalto3.5%oftheequityvalueofthetransactionpayablebyMyoKardiaincertaincircumstances,and(6)therequestforMr.GianakakostoexecutetheSupportAgreementinfavorofParent.

26

TABLE OF CONTENTS

Inaddition, onSeptember 25, 2020, MyoKardia providedParent andits representatives withexpandedaccess tothevirtualdataroominorderforParenttoperformitsconfirmatoryduediligenceinvestigation.Followingsuchaccesstothevirtualdataroom,representativesofMyoKardiaandParenthadanumberofconferencecallstodiscussitemsonduediligencerequestlistssubsequentlyprovidedbyParent.

OnSeptember27,2020,Mr.BauerhadtelephoneconversationswithrepresentativesofParentregardingthestatusoftheirduediligencereview.

OnSeptember28,2020,GoodwinsentareviseddraftoftheMergerAgreementtoKirkland,whichincluded,amongotherthings,(1)exceptionstothedefinitionof“MaterialAdverseEffect”foranyregulatory,clinicalandsimilareventsrelatedtotheproductsorproductcandidatesofMyoKardiaoranycompetitorofMyoKardia,(2)acceleratedvestingofall time-based equity awards at closing, (3) more stringent efforts obligations of Parent to obtain required antitrustapprovals, (4) a “Superior Proposal” defined as a bona fide proposal to acquire a majority of the stock or assets ofMyoKardiathatisdeemedtobemorefavorabletoMyoKardia’sstockholdersfromafinancialpointofviewthantheOfferandtheMerger,and(5)aterminationfeeequalto2.5%oftheequityvalueofthetransaction.

AlsoonSeptember28,2020,Mr.BauerhadfurthertelephoneconversationswithrepresentativesofParentregardingthestatusoftheirduediligencereview.

LateronSeptember28,2020,KirklandprovidedtoGoodwinaninitialdraftoftheSupportAgreementtobeexecutedbyMr.GianakakospertherequestofParent,underwhichMr.Gianakakoswouldagree,amongotherthings,totendertheSharesbeneficiallyownedbyhimintotheOffer.

OnSeptember30,2020,KirklandsentareviseddraftoftheMergerAgreementtoGoodwinthatincludedsubstantiallythe same definitions of “Material Adverse Effect” and “Superior Proposal” previously proposed by Parent and aterminationfeeequalto3.5%oftheequityvalueofthetransaction.

OnOctober1,2020,Dr.CaforioandMr.Gianakakosspoketelephonicallyregardingthetransactionstatusandtiming.

AlsoonOctober1,2020,Mr.Bauerhadatelephonecall withMs.Milyduringwhichtheydiscussedthetransactionstatusandtiming,aswellascertainopenissuesintheMergerAgreement.

In addition, on October 1, 2020, Goodwin sent a revised draft of the Merger Agreement to Kirkland. Thereafter,GoodwinhadaconferencecallwithKirklandtodiscusstheopenissuesintheMergerAgreementwithafocusonthedefinitionof“CompanyMaterialAdverseEffect”,thedefinitionof“SuperiorProposal”,andthesizeoftheterminationfeepayablebyMyoKardia.

On October 2, 2020, representatives of MyoKardia, Parent, Goodwin and Kirkland had multiple conference calls todiscussandresolvetheopenitemsintheMergerAgreementrelatedtothetreatmentofMyoKardia’semployeesintheproposed transaction, including (1) the level of compensation and benefits to be provided generally to Companyemployeesaftertheclosing,(2)thetreatmentofannualbonusesforfiscalyear2020,(3)theseverancebenefitspayabletocertainnon-executiveemployees,(4)employeeretentionmatters,and(5)thelimitationsonMyoKardia’sabilitytohireandcompensatenewemployeespriortotheclosing.

AlsoonOctober2,2020,Dr.CaforiocontactedMr.Gianakakosviatelephonetodiscussthestatusofthetransactionand the remaining open items in the Merger Agreement. Thereafter, Ms. Mily contacted Mr. Bauer to resolve theremaining open items in the Merger Agreement, and Kirkland subsequently sent a revised draft of the MergerAgreementtoGoodwinreflectingthisdiscussion,whichincludedMyoKardia’srequestedexceptionstothedefinitionof“MaterialAdverseEffect”andthesamedefinitionof“SuperiorProposal”andthesameterminationfeeassetforthinKirkland’spriordraft.

OnOctober3,2020,representativesofGoodwinandKirklandfinalizedthetransactiondocumentation, includingtheMergerAgreementandtheSupportAgreementtobeexecutedbyMr.Gianakakos.

AlsoonOctober3,2020,ataspecialmeetingoftheParentBoard,membersofParentmanagementandrepresentativesofGordanDyal&Co.providedtheParentBoardwithanupdateonthetermsoftheproposedtransaction.Followingadiscussion of the terms of the proposed transaction, the Parent Board unanimously approvedthe execution, deliveryand performance of the Merger Agreement and the completion of the transactions contemplated by the MergerAgreement,includingtheOfferandtheMerger.

27

TABLE OF CONTENTS

AlsoonOctober3,2020,Mr.BauerhadseveralconversationswithrepresentativesofParentregardingthetransactionstatus,includingatelephonecallwithMs.MilyduringwhichsheconfirmedthatthetransactionhadbeenapprovedbytheBoardofDirectorsofParent.

LateronOctober3,2020,Mr.GianakakosinformedDr.CaforiooftheMyoKardiaBoard’sapprovalofthetransaction.

During the evening of October 3, 2020, MyoKardia, Parent and Purchaser executed the Merger Agreement, andMr.Gianakakos,ParentandPurchaserexecutedtheSupportAgreement.

Before the opening of trading of the stock markets on October 5, 2020, MyoKardia and Parent issued a joint pressreleaseannouncingtheexecutionoftheMergerAgreementandtheforthcomingcommencementofatenderofferbyPurchasertoacquirealloftheoutstandingSharesattheOfferPrice,representingapremiumof61%overtheclosingpriceof$139.60onOctober2,2020.

OnOctober19,2020,PurchasercommencedtheOfferandMyoKardiafiledtheSchedule14D-9.

12. Purpose of the Offer; Plans for MyoKardia; Stockholder Approval; Appraisal Rights

PurposeoftheOffer;PlansforMyoKardia

ThepurposeoftheOfferandtheMergerisforParenttoacquiretheentireequityinterestinMyoKardia.TheOffer,asthefirstoftwostepsintheacquisitionofMyoKardia,isintendedtofacilitatetheacquisitionofalloftheShares.ThepurposeoftheMergeristoacquireallcapitalstockofMyoKardianotpurchasedpursuanttotheOfferorotherwiseandtocauseMyoKardiatobecomeawhollyownedsubsidiaryofParent.

Wecurrentlyintend,assoonaspracticablefollowing(butinanyeventonthesamedayas)theOfferAcceptanceTime,subjecttothesatisfactionorwaiveroftheotherconditionssetforthintheMergerAgreementandinanyeventnolaterthanonebusinessdayfollowingthesatisfactionorwaiverofsuchconditions,toconsummatetheMergerpursuanttotheMergerAgreement.Asdescribedin“—Section13—TheTransactionDocuments—TheMergerAgreement—TheMerger”, theSharesacquiredintheOffer will becanceledintheMerger andthecapital stockof MyoKardia as thesurvivingcorporationwillbethecapitalstockofPurchaser.ThedirectorsofPurchaserimmediatelypriortotheMergerEffective Time will be the directors of MyoKardia as the surviving corporation immediately following the MergerEffective Time, until their respective successors are duly elected or appointed and qualified or their earlier death,resignation or removal in accordance with the charter and bylaws of MyoKardia as the surviving corporation. Theofficers of MyoKardia immediately prior to the Merger Effective Time will be the officers of MyoKardia as thesurvivingcorporationuntiltheirrespectivesuccessorsareappointedandqualifiedortheirearlierdeath,resignationorremovalinaccordancewiththecharterandbylawsofMyoKardiaasthesurvivingcorporation.See“—Section13—The Transaction Documents—The Merger Agreement—The Merger.” Upon completion of the Merger, the SharescurrentlylistedontheNASDAQwillceasetobelistedontheNASDAQandwillsubsequentlybederegisteredundertheExchangeAct.

IfyousellyourSharesintheOffer,youwillceasetohaveanyequityinterestinMyoKardiaoranyrighttoparticipateinitsearningsandfuturegrowth.IfyoudonottenderyourShares,buttheMergerisconsummated,youalsowillnolongerhaveanequityinterestinMyoKardia.Similarly,aftersellingyourSharesintheOfferorthesubsequentMerger,youwillnotbeartheriskofanydecreaseinthevalueofMyoKardia.

ExceptasdescribedaboveorelsewhereinthisOffertoPurchaseandexceptforthetransactionscontemplatedintheMergerAgreement,Purchaserhasnopresentplansorproposalsthatwouldrelatetoorresultin(a)anyextraordinarycorporate transaction involving MyoKardia or any of its subsidiaries (such as a merger, reorganization, liquidation,relocationofanyoperationsorsaleorothertransferofamaterialamountofassets),(b)anychangeintheMyoKardiaBoardormanagement,(c)anymaterialchangeinMyoKardia’scapitalizationordividendpolicy,(d)anyothermaterialchangeinMyoKardia’scorporatestructureorbusiness,(e)anyclassofequitysecuritiesofMyoKardiabeingdelistedfromanationalsecuritiesexchangeorceasingtobeauthorizedtobequotedinanautomatedquotationsystemoperatedbyanationalsecuritiesassociationor(f)anyclassofequitysecuritiesofMyoKardiabecomingeligibleforterminationofregistrationpursuanttoSection12(g)oftheExchangeAct.

NoStockholderApproval

IftheOfferisconsummated,wedonotanticipateseekingtheapprovalofMyoKardia’sremainingpublicstockholdersbefore effecting the Merger. Section 251(h) of the DGCL provides that, subject to certain statutory provisions, iffollowingconsummationofatenderofferforanyandallsharesofapublicDelawarecorporationthat

28

TABLE OF CONTENTS

wouldotherwisebeentitledtovoteonthemerger(otherthansharesheldbytheacquiringentityanditsaffiliates),thestockirrevocablyacceptedforpurchasepursuanttosuchofferandreceivedbytheDepositarypriortotheexpirationofsuchoffer,plusthestockotherwiseownedbytheacquirerequalsatleasttheamountofsharesofeachclassofstockofthetargetcorporationthatwouldotherwiseberequiredforthestockholdersofthetargetcorporationtoadoptamergeragreement with the acquiring entity, and each share of each class or series of stock of the target corporation notirrevocably accepted for purchase in the offer is converted into the right to receive the same consideration for theirstockinthemergeraswaspayableinthetenderoffer,thetargetcorporationcaneffectamergerwithoutthevoteofthestockholders of the target corporation. Therefore, the parties have agreed, and the Merger Agreement requires, that,subjecttotheconditionsspecifiedintheMergerAgreement,theMergerwillbecomeeffectiveassoonaspracticableaftertheconsummationoftheOffer,withoutavoteofMyoKardiastockholders,inaccordancewithSection251(h)oftheDGCL.

AppraisalRights

NoappraisalrightsareavailableinconnectionwiththeOffer.However,iftheMergerisconsummated,pursuanttotheDGCL, stockholders who do not tender their Shares in the Offer, who are entitled to demand and properly demandappraisal ofsuchSharespursuant to, andwhofullycomplyinall respectswith, theapplicableprovisionsofSection262oftheDGCL,willhavetherighttochoosenottoaccepttheconsiderationpayablefortheirSharespursuanttotheMerger,andinsteadtodemandanappraisaloftheirSharesbytheCourtofChanceryoftheStateofDelawareandtoreceiveacashpaymentofthe“fairvalue”oftheirSharesasoftheMergerEffectiveTimeoftheMergerasdeterminedbytheCourtofChanceryoftheStateofDelaware. The“fair value”ofsuchSharesmaybemorethan,lessthan, orequaltotheOfferPrice.

UnderSection262oftheDGCL,whereamerger is approvedunderSection251(h), either aconstituent corporationbeforetheeffectivedateofthemerger,orthesurvivingcorporationwithin10daysthereafter,willnotifyeachoftheholdersofanyclassorseriesofstockofsuchconstituentcorporationwhoareentitledtoseekappraisaloftheapprovalofthemergerorconsolidationandthatappraisalrightsareavailableforanyorallsharesofsuchclassorseriesofstockof such constituent corporation, andwill include in suchnotice a copyof Section 262of the DGCL.The Schedule14D-9 will constitute the formal notice of appraisal rights under Section 262 of the DGCL.

AswillbedescribedmorefullyintheSchedule14D-9,inordertoexerciseappraisalrightsunderSection262oftheDGCLinconnectionwiththeMerger,astockholdermustdoallofthefollowing:

• within the later of the consummation of the Offer and 20 days after the mailing of the Schedule 14D-9,delivertoMyoKardiaawrittendemandforappraisalofSharesheld,whichdemandmustreasonablyinformMyoKardiaoftheidentityofthestockholderandthatthestockholderisdemandingappraisal;

• nottendertheirSharesintheOffer;

• continuously hold of record the Shares from the date on which the written demand for appraisal is madethroughtheMergerEffectiveTime;and

• strictlyfollowthestatutoryproceduresforperfectingappraisalrightsunderSection262oftheDGCL.

AnyholderofShareswhowishestoexercisesuchappraisalrightsorwhowishestopreservehis,heroritsrighttodosoinconnectionwiththeMerger,shouldreviewtheSchedule14D-9andSection262oftheDGCLcarefullybecausefailuretotimelyandproperlycomplywiththeproceduresspecifiedwillresultinthelossofappraisalrightsundertheDGCL.

The foregoing summary of the rights of MyoKardia’s stockholders to appraisal rights under the DGCL inconnection with the Merger does not purport to be a complete statement of the procedures to be followed by thestockholders of MyoKardia desiring to exercise appraisal rights in connection with the Merger and is qualifiedin its entirety by reference to Section 262 of the DGCL. The proper exercise of appraisal rights in connectionwith the Merger requires strict adherence to the applicable provisions of the DGCL. A copy of Section 262 of theDGCL is set forth in MyoKardia’s Schedule 14D-9, Annex C, Section 262 of the General Corporation Law of theState of Delaware.

29

TABLE OF CONTENTS

13. The Transaction Documents

TheMergerAgreement

ThefollowingsummarydescriptionoftheMergerAgreementdoesnotpurporttobecompleteandisqualifiedinitsentiretybyreferencetotheMergerAgreement,acopyofwhichPurchaserhasincludedasExhibit(d)(1)totheTenderOffer Statement on Schedule TO and is incorporated herein by reference. Stockholders and other interested partiesshouldreadtheMergerAgreementforamorecompletedescriptionoftheprovisionssummarizedbelow.Capitalizedterms used herein and not otherwise defined have the respective meanings set forth in the Merger Agreement.Thesummary description has been included in this Offer to Purchase to provide you with information regarding theterms of the Merger Agreement and is not intended to modify or supplement any factual disclosures aboutParent, Purchaser, MyoKardia or their respective affiliates. The representations, warranties and covenantscontained in the Merger Agreement were made only for the purposes of the Merger Agreement, were made as ofspecific dates, were made solely for the benefit of the parties to the Merger Agreement and may not have beenintended to be statements of fact, but rather, as a method of allocating risk and governing the contractual rightsand relationships among the parties to the Merger Agreement. In addition, such representations, warranties andcovenants may have been qualified by certain disclosures not reflected in the text of the Merger Agreement andmay apply standards of materiality and other qualifications and limitations in a way that is different from whatmay be viewed as material by Parent’s or MyoKardia’s stockholders or under federal securities laws. Inreviewing the representations, warranties and covenants contained in the Merger Agreement or anydescriptions thereof in this summary, it is important to bear in mind that investors are not third-partybeneficiaries under the Merger Agreement and that such representations, warranties, covenants or descriptionswere not intended by the parties to the Merger Agreement to be characterizations of the actual state of facts orconditions of Parent, Purchaser, MyoKardia or their respective affiliates. Moreover, information concerning thesubject matter of the representations and warranties may have changed or may change after the date of theMerger Agreement, which subsequent information may or may not be fully reflected in public disclosures. Forthe foregoing reasons, the representations, warranties, covenants or descriptions of those provisions should notbe read alone and should instead be read in conjunction with the other information contained in the reports,statements and filings that Parent, its affiliates and MyoKardia publicly file.

TheOffer

Upon the terms and subject to the conditions set forth in the Merger Agreement, Purchaser will commence a cashtenderoffer(aspromptlyaspracticable,butinnoeventlaterthanOctober19,2020)foralloftheSharesatapurchasepriceof$225.00perShare,nettothesellerofsuchSharesincash,withoutinterestandlessanyrequiredwithholdingtaxes. Purchaser’s obligationto accept for payment andpayfor Shares validly tenderedandnot properly withdrawnpursuant to the Offer is subject to the satisfaction of the MinimumCondition, the Restraints Condition, the ActionsConditionandtheGovernmentalConsentsConditionandthesatisfactionorwaiveroftheotherconditionssetforthin“—Section15—ConditionstotheOffer.”

Totheextentpermittedbylaw,Purchaseralsoexpresslyreservestheexclusiverightto(a)increasetheOfferPrice,(b)waive any of the Offer Conditions other than the Minimum Condition, the Termination Condition, the RestraintsConditionortheGovernmentalConsentsConditionand(c)makeanyotherchangestothetermsandconditionsoftheOffer not inconsistent with the terms of the Merger Agreement, provided that MyoKardia’s consent is required forPurchaserto(i)exceptinconnectionwithastocksplitorotherrecapitalization,decreasetheOfferPrice,(ii)changetheformofconsiderationpayableintheOffer,(iii)decreasethemaximumnumberofSharessoughttobepurchasedintheOffer,(iv)imposeanyconditionstotheOfferotherthantheOfferConditions,(v)amend,modifyorsupplementanyoftheOfferConditionsinamannerthatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholders of Shares, (vi) amend, modify or waive the MinimumCondition, the Termination Condition, the RestraintsConditionortheGovernmentalConsentsCondition,(vii)extendorotherwisechangetheexpirationdateoftheOffer,except asdescribedunder“—Section13—TheTransactionDocuments—TheMergerAgreement—ExtensionsoftheOffer”, or (viii) otherwise amend, modify or supplement any of the other terms of the Offer in any manner thatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholdersofShares.

30

TABLE OF CONTENTS

ExtensionsoftheOffer

PursuanttothetermsoftheMergerAgreement,if,atthethen-scheduledExpirationTime,anyoftheOfferConditionshas not been satisfied or waived by Parent and Purchaser (to the extent such waiver is permitted under the MergerAgreementandapplicableLaw),then(a)Purchasermay,initssolediscretion(andwithouttheconsentofMyoKardiaor any other person) and (b) upon MyoKardia’s written request, Purchaser will, and Parent will cause Purchaser to,extend the Offer on one or more occasions in consecutive increments of up to ten business days each (each suchincrementtoendat5:00p.m.,NewYorkCitytime,onthelastbusinessdayofsuchincrement)inordertopermitthesatisfactionofsuchOfferCondition(s);provided,however,that(i)PurchaserwillnotberequiredtoextendtheOffertoadatelaterthantheOutsideDate(asdefinedbelow)andPurchaserwillnotbepermittedtoextendtheoffertoadatelaterthantheOutsideDatewithoutthepriorwrittenconsentofMyoKardiaand(ii)ifatanythenscheduledexpirationoftheOffer,alloftheOfferConditions(otherthantheMinimumConditionandanyOfferConditionsthatarebytheirnature to be satisfied at the Offer Acceptance Time) have been satisfied or waived (to the extent permitted by theMerger Agreement and applicable Law) and the Minimum Condition has not been satisfied, Purchaser will not berequired to (and Parent will not be required to cause Purchaser to) extend the Offer for more than three additionalconsecutive increments of ten business days (or such shorter periods as may be agreed to by MyoKardia andPurchaser). Purchaser will extend the Offer for the minimum period required by applicable Law, interpretation orpositionoftheSECoritsstaffortheNASDAQoritsstaff.Purchaserwillnot,andParentwillnotpermitPurchaserto,extendtheOfferinanymannerexceptasrequiredorexpresslypermittedassetforthinthisparagraph.

The Merger Agreement obligates Purchaser, subject to the satisfaction or waiver of the conditions set forth in “—Section15—ConditionstotheOffer,”to,atoraspromptlyaspracticableaftertheExpirationTime,irrevocablyacceptfor payment and, at or as promptly as practicable after the Offer Acceptance Time (and in any event within threebusinessdaysthereafter),payforallSharesvalidlytenderedandnotproperlywithdrawnpursuanttotheOffer.

TheMerger

As soon as practicable following (but in any event on the same day as) the Offer Acceptance Time, subject to thesatisfaction or waiver of the other conditions set forth in the Merger Agreement and in any event no later than onebusiness day following the satisfaction or waiver of such conditions and unless applicable Law prohibits or makesillegaltheconsummationoftheMerger,PurchaserwillmergewithandintoMyoKardia,andMyoKardiawillsurviveasawhollyownedsubsidiaryofParent.AttheMergerEffectiveTime,anySharesnotpurchasedpursuanttotheOffer(otherthanSharesownedbyMyoKardia,anyofitssubsidiaries,Parent,PurchaseroranysubsidiaryofParent,oranystockholderswhohaveproperlyexercisedtheirappraisalrightsunderSection262oftheDGCL)willbeautomaticallyconvertedintotherighttoreceive,incashandwithoutinterest,lessanyrequiredwithholdingtaxes,anamountequaltotheOfferPrice.

The certificate of incorporation of MyoKardia as in effect immediately prior to the Merger Effective Time will beamended and restated by virtue of the Merger at the Merger Effective Time to be identical to the certificate ofincorporationincludedasExhibitAtotheMergerAgreement.ThebylawsofMyoKardiaasineffectimmediatelypriortotheMergerEffectiveTimewillbeamendedandrestatedattheMergerEffectiveTimetobeidenticaltothebylawsofPurchaserasineffectimmediatelypriortotheMergerEffectiveTime.ThedirectorsofPurchaserimmediatelypriorto the Merger Effective Time will become the directors of MyoKardia as the surviving corporation until theirrespective successors are duly elected or appointed and qualified or their earlier death, resignation or removal inaccordance with the charter and bylaws of MyoKardia as the surviving corporation. The officers of MyoKardiaimmediately prior to the Merger Effective Timewill remain the officers of MyoKardia as the surviving corporationuntiltheirrespectivesuccessorsareappointedandqualifiedortheirearlierdeath,resignationorremovalinaccordancewiththecharterandbylawsofMyoKardiaasthesurvivingcorporation.

The Merger Agreement provides the Merger will be governed by Section 251(h) of the DGCL and will beeffected without a vote of MyoKardia stockholders.

MyoKardiaStockOptions

TheMerger Agreement provides that, immediately prior to the Merger Effective Time, by virtue of the Merger andwithoutanyactiononthepartoftheholderthereof,eachMyoKardiaStockOption,whethervestedorunvested,thatisoutstanding and unexercised immediately prior to the Merger Effective Time will be cancelled and automaticallyconverted into solely the right to receive, for eachShare underlyingsuchMyoKardia StockOption, without interestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw,anamountincashfromParentor

31

TABLE OF CONTENTS

the surviving corporation equal to the excess of (a) the Offer Price over (b) the per share exercise price of suchMyoKardia Stock Option (the “Option Payment”). From and after the Merger Effective Time, the holder of anycancelled MyoKardia StockOptionwill only be entitled to receive the OptionPayment in respect of suchcancelledMyoKardiaStockOption.

MyoKardiaRSUAwards

The Merger Agreement provides that immediately prior to the Merger Effective Time, by virtue of the Merger andwithoutanyactiononthepartoftheholderthereof,eachMyoKardiaRSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTime,whethervestedorunvested,willbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaRSUAward,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw,anamountincashfromParentorthesurvivingcorporationequaltotheOfferPrice(the“RSU Award Payment”).FromandaftertheMergerEffectiveTime,theholderofanycancelledMyoKardia RSU Award will only be entitled to receive the RSU Award Payment in respect of such cancelledMyoKardiaRSUAward.

MyoKardiaPSUAwards

The Merger Agreement provides that immediately prior the Merger Effective Time, by virtue of the Merger andwithoutanyactiononthepartoftheholderthereof,eachMyoKardiaPSUAwardthatisoutstandingimmediatelypriortotheMergerEffectiveTime,willbecancelledandautomaticallyconvertedintosolelytherighttoreceive,foreachShareunderlyingsuchMyoKardiaPSUAward,withoutinterestandsubjecttodeductionforanyrequiredwithholdingunderapplicabletaxlaw,anamountincashfromParentorthesurvivingcorporationequaltotheOfferPrice,whichamountwillbepayableonthesamescheduleandsubjecttothesamevestingconditions(includinganyaccelerationofvesting conditions) as applied to the MyoKardia PSU Award immediately prior to the Merger Effective Time (the“PSU Award Payment”). Fromand after the Merger Effective Time, the holder of any cancelled MyoKardia PSUAwardwillonlybeentitledtoreceivethePSUAwardPaymentinrespectofsuchcancelledMyoKardiaPSUAward.

PriortotheMergerEffectiveTime,theMyoKardiaBoard(or,ifappropriate,anycommitteethereofadministeringtheMyoKardia StockPlans) will adopt suchresolutions andtakesuchother lawful actions (which, in eachcase, donotinvolvethepaymentofanyconsiderationinexcessof,orinadditionto,theconsiderationdescribedintheforegoingparagraphs)asmayberequiredtoeffecttheforegoingwithrespecttotheMyoKardiaStockOptions,theMyoKardiaRSUAwardsandtheMyoKardiaPSUAwards.

MyoKardiaAmendedandRestatedEmployeeStockPurchasePlan

The Merger Agreement provides that as promptly as reasonably practicable following the date of the MergerAgreement, MyoKardia will take such actions (to the extent not already taken prior to the date of the MergerAgreement)withrespecttotheMyoKardiaAmendedandRestatedEmployeeStockPurchasePlan(the“MyoKardiaESPP”)asmayberequiredtoprovidethat(a)participationfollowingthedateoftheMergerAgreementwillbelimitedtothoseemployeeswhoparticipatedintheMyoKardiaESPPimmediatelyprior totheexecutionanddeliveryoftheMergerAgreement,(b)participantsmaynotincreasetheirpayrolldeductionsorpurchaseelectionsfromthoseineffectimmediately prior totheexecutionanddeliveryof theMerger Agreement (unless otherwiserequiredbytheInternalRevenueCodeof1986,asamended(the“Code”)), (c)nonewofferingperiodwill commence,norwill anyexistingoffering period be extended, after the execution and delivery of the Merger Agreement, (d) each participant’soutstandingrighttopurchaseSharesundertheMyoKardiaESPPwillterminateonthedayimmediatelypriortothedayonwhichtheMergerEffectiveTimeoccurs(ifnotearlierterminatedpursuanttothetermsoftheMyoKardiaESPP);providedthat all amountsallocatedtoeachparticipant’s accountundertheMyoKardiaESPPasofsuchdatewill bereturnedtotheparticipantbyMyoKardiapursuanttothetermsoftheMyoKardiaESPP,and(e)theMyoKardiaESPPwillterminatenolaterthanimmediatelypriortotheMergerEffectiveTime.

RepresentationsandWarranties

IntheMergerAgreement,MyoKardiahasmadecustomaryrepresentationsandwarrantiestoParentandPurchaserthatare subject, in some cases, to specified exceptions and qualifications contained in the Merger Agreement orconfidentialdisclosureschedulesthatMyoKardiadeliveredtoParentandPurchaserinconnectionwiththeexecutionanddeliveryoftheMergerAgreement.Theserepresentationsandwarrantiesrelateto,amongotherthings:(a)due

32

TABLE OF CONTENTS

organization,goodstanding,subsidiariesandorganizationaldocuments;(b)capitalizationandotherequityinterests;(c)authority and noncontravention; (d) governmental approvals; (e) SEC filings, financial statements, undisclosedliabilities and internal controls; (f) absence of certain changes; (g) legal proceedings; (h) compliance with laws andpermits; (i) tax matters; (j) employee benefit plans; (k) labor matters; (l) environmental matters; (m) intellectualproperty;(n)dataprotection,privacyandsecurity;(o)stockholderrightsagreementsandapplicableanti-takeoverlaws;(p) property; (q) contracts; (r) insurance; (s) international trade and anti-corruption; (t) regulatory compliance; (u)broker’sandfinder’sfees;(v)interestedpartytransactions;(w)keyclinicalevents;and(x)Offerdocuments.

In the Merger Agreement, Purchaser and Parent have made customary representations and warranties to MyoKardiathataresubject, insomecases, tospecifiedexceptionsandqualificationscontainedintheMergerAgreement. Theserepresentationsandwarrantiesrelateto,amongotherthings:(a)dueorganizationandgoodstanding;(b)authorityandnoncontravention; (c)governmentapprovals; (d)ownershipandoperationsofPurchaser; (e)sufficiencyoffunds;(f)broker’sandfinder’sfees;(g)nootherrepresentationsandwarranties;(h)Offerdocuments;(i)legalproceedings;(j)ownershipoftheShares;and(k)competingbusinesses.

TherepresentationsandwarrantieswillnotsurviveconsummationoftheMerger.

OperatingCovenants

Pursuant to theMerger Agreement, fromthedate of theMerger Agreement until the Merger Effective Time, unlessParentotherwiseexpresslyconsentsinwritinginadvance(suchconsentnottobeunreasonablywithheld,conditionedordelayed), except (a) as requiredbyapplicable Law,therules or regulations of NASDAQoranyjudgment, (b) asrequiredorexpresslyprovidedbytheMerger Agreement, or (c) asdisclosedinMyoKardia’s confidential disclosureschedules(the“MyoKardia Disclosure Letter”)thatMyoKardiadeliveredtoParentandPurchaserinconnectionwiththe execution of the Merger Agreement, MyoKardia will, and will cause each of its subsidiaries to, (i) carry on itsbusinessintheordinarycourseinallmaterialrespects,and(ii)usecommerciallyreasonableeffortstopreserveitsandeach of its subsidiaries’ business organizations substantially intact and preserve existing relations with employees,customers, suppliers, licensors, licensees, governmental authorities and other persons with whom MyoKardia or itssubsidiaries have significant business relationships; providedthat, in each case, MyoKardia andits subsidiaries maycontinueanyadvisableandreasonablynecessarychangesintheirrespectivebusinesspracticesadoptedpriortothedatehereof in response to COVID-19 and any governmental authority measures in response to COVID-19 (“COVID-19Measures”),andMyoKardiamaytakesuchfurtheractionsadvisableandreasonablynecessaryinresponsetoCOVID-19andanyCOVID-19Measures,includingto(A)protectthehealthandsafetyofMyoKardia’sanditssubsidiaries’employees,suppliers,partnersandotherindividualshavingbusinessdealingswithMyoKardiaanditssubsidiariesor(B) respond to third-party supply or service disruptions caused by COVID-19 or any COVID-19 Measures in acommercially reasonable manner; provided further that, to the extent permitted by applicable Law, MyoKardia willtakereasonable efforts to keepParent reasonablyinformedof, andtotheextent reasonablypracticable, consult withParent prior tothetakingof, anysuchaction(s) that wouldreasonablybeexpectedtohaveamaterial impact ontheoperationsofMyoKardiaanditssubsidiariestakenasawhole.

Without limiting the generality of the foregoing, fromthe date of the Merger Agreement until the Merger EffectiveTime,unlessParentotherwiseexpresslyconsentsinwritinginadvance(suchconsentnottobeunreasonablywithheld,conditioned or delayed), except (a) as required by applicable Law, the rules or regulations of NASDAQ or anyjudgment, (b) as required or expressly provided by the Merger Agreement, or (c) as disclosed in the MyoKardiaDisclosure Letter, MyoKardia, among other things, subject to certain exceptions, will not, and will not permit itssubsidiariesto:

• otherthantransactionsamongMyoKardiaanditswhollyownedsubsidiariesoramongMyoKardia’swhollyowned subsidiaries and certain transactions with respect to MyoKardia Stock Options, MyoKardia RSUAwards,MyoKardiaPSUAwardsortheMyoKardiaESPP,(a)issue, sell, pledge,disposeof, encumberorgrant any shares of its capital stock or other equity or voting interests, or any other securities or rightsconvertible into, exchangeable or exercisable for, or evidencingthe right to subscribe for anyshares of itscapitalstockorotherequityorvotinginterests,oranyrights,warrantsoroptionstopurchaseanysharesofits capital stock or other equity or voting interests or (b) redeem, purchase or otherwise acquire any of itsoutstandingshares of capital stockor other equity or votinginterests, or anyrights, warrants or optionstoacquireanysharesofitscapitalstockorotherequityorvotinginterests;

33

TABLE OF CONTENTS

• establish a record date for, declare, set aside for payment, authorize or pay any dividend on, or make anyotherdistributioninrespectof,anysharesofitscapitalstockorotherequityorvotinginterests,otherthandividends paid by any wholly owned subsidiary of MyoKardia to MyoKardia or any other wholly ownedsubsidiaryofMyoKardia;

• split,combine,subdivideorreclassifyanysharesofitscapitalstockorotherequityorvotinginterests,exceptfor any such transaction by a wholly owned subsidiary of MyoKardia which remains a wholly ownedsubsidiaryafterconsummationofsuchtransaction;

• incur, assume, or otherwise become liable for any indebtedness or guarantee any indebtedness of anotherperson,exceptforintercompanyindebtednessamongMyoKardiaanditswhollyownedsubsidiaries, lettersofcreditenteredintointheordinarycourseofbusinessinconnectionwithcertainintercompanyagreementsamongMyoKardiaanditswhollyownedsubsidiarieswithrespecttorealproperty(“Company Lease”),andotherindebtednessnottoexceed$10,000,000intheaggregate;

• enterintoanyswaporhedgingtransactionorotherderivativeagreementsotherthanintheordinarycourseofbusiness;

• make any loans, capital contributions or advances to any person other than to MyoKardia or any whollyownedsubsidiaryofMyoKardia;

• otherthancertainexceptions,sell,assign,license,transferorleasetoanyperson,ormortgageorotherwiseencumberorsubjecttoanylien,inasingletransactionorseriesofrelatedtransactions,anyofitspropertiesorassetsthathaveacurrentvalueinexcessof$10,000,000intheaggregate;

• makeorauthorizecapitalexpendituresforproperty,plantandequipment,except(a)ascontemplatedbythecapitalexpenditurebudgetofMyoKardiasetforthontheMyoKardiaDisclosureLetter,or(b)otherwiseinan aggregate amount for all such capital expenditures made pursuant to this clause (b) not to exceed$10,000,000;

• make(a)anyacquisition(includingbymerger)ofthecapitalstockoramaterialportionoftheassetsofanyother person (other than any acquisition of supplies, raw materials, inventory or products in the ordinarycourseofbusiness)or(b)anycapitalcontributionsorinvestments(includingthroughanyloansoradvances)inanyotherperson(otherthanMyoKardiaoranydirectorindirectwhollyownedsubsidiaryofMyoKardia),exceptforinvestmentsinshort-termmarketablesecuritiesintheordinarycourseofbusiness;

• exceptasrequiredpursuanttothetermsoftheCompanyPlans(asdefinedbelow)asineffectonthedateoftheMergerAgreementandsetforthontheMyoKardiaDisclosureLetterandmadeavailabletoParent, (a)increase the level of base compensation, wages, bonuses, incentive compensation, pension, severance ortermination pay or any other compensation or benefits, payable or to become payable to any current orformerdirector,officeroremployeeofMyoKardiaoranyofitssubsidiariesattheExecutiveDirectorlevelor above, (b) establish, adopt, enter into, terminate or amend in any respect any (i) collective bargainingagreement or any other contract with any labor union, works council or other labor organization, or(ii) Company Plan (or any benefit or compensation plan, policy, program, contract, agreement orarrangementthatwouldbeaCompanyPlanifineffectonthedateoftheMergerAgreement),(c)takeanyaction to accelerate anyrights or benefits under anyCompanyPlan, including anyaction to accelerate thevesting or funding or payment of any compensation or benefit to any current or former director, officer,employee or independent contractor of MyoKardia or any of its subsidiaries, (d) hire any individual to beemployed by MyoKardia or any of its subsidiaries at the Executive Director level or above or terminate(otherthanforcause)theemploymentofanyindividualemployedbyMyoKardiaoranyofitssubsidiariesattheVicePresidentlevelorabove,(e)(i)payanycompensation,includinganyretentionortransactionbonus(providedthat,theforegoingwillnotrestrictthecontinuedpaymentofbasesalaryintheordinarycourseofbusinessconsistentwithpastpracticeandthepaymentofcompensationexpresslypermittedbytheMergerAgreement),or(ii)provideanybenefits,ineachcase,toanycurrentorformerdirector,officer,employeeorindependentcontractorofMyoKardiaoranyofitssubsidiaries, unless,inthecaseofeachof(e)(i) and(e)(ii), required by any Company Plan (as in effect on the date hereof) that is either (A) set forth on theMyoKardiaDisclosureLetterandmadeavailabletoParentor(B)immaterialandnotrequiredtobesetforthontheMyoKardiaDisclosureLetter,(f)promoteorchangetheemployeegradeortitleofany

34

TABLE OF CONTENTS

employee to a level of Executive Director or above (unless such action does not affect the individual’scompensation or benefits) or demote anyemployeeat the VicePresident level or above, (g) implement orannounce any facility closings or employment losses that implicate the WARNAct, or similar applicableLawsinanyjurisdiction,or(h)recognizeanylaborunion,workscouncil,orotherlabororganizationasthebargainingrepresentativeofanyemployeesofMyoKardiaoranyofitssubsidiaries;

• makeanymaterial changesinfinancial accountingmethods,principlesorpracticesmateriallyaffectingtheconsolidated assets, liabilities or results of operations of MyoKardia and its subsidiaries, except insofar asmayberequired(a)byGAAP,(b)byRegulationS-XundertheSecuritiesAct,or(c)byanygovernmentalauthority or quasi-governmental authority (including the Financial Accounting Standards Board or anysimilarorganization);

• amend MyoKardia’s certificate of incorporation or bylaws or the comparable organizational documents ofanysubsidiaryofMyoKardia;

• settle,orofferorproposetosettle,anyactionmadeorpendingagainstMyoKardiaoranyofitssubsidiaries,other than the settlement of any action in the ordinary course of business that require payments byMyoKardia or any of its subsidiaries (net of insurance proceeds) in an amount not to exceed $500,000individually or $1,000,000 in the aggregate; provided, however, that the foregoing clause will not permitMyoKardiaoranyofitssubsidiariesto(a)settleanyactionthatwouldinvolveinjunctiveorequitablerelief,imposeanyrestrictionsonthebusinessoroperationsofMyoKardiaoranyofitssubsidiaries(or,followingtheMerger, onParent oranyofits affiliates), involveanyadmissionofanywrongdoingbyMyoKardiaoranyofitssubsidiaries,orinvolveanylicense,crosslicenseorsimilararrangementwithrespecttointellectualproperty or (b) settle or propose to settle any Transaction Litigations (as defined below), the treatment ofwhichisaddressedintheMergerAgreement;

• (a)make,changeorrevokeanymaterialtaxelection;(b)changeanyannualtaxaccountingperiod;(c)adoptorchangeanymaterial methodoftaxaccounting; (d)fileanymaterial amendedtaxReturn; (e)consent toanyextensionorwaiverofthelimitationperiodapplicabletoanymaterialtaxclaimorassessment;(f)enterintoanytaxallocation, indemnityorsharingagreement (other thananysuchagreement enteredintointheordinarycourseofbusinesstheprimarypurposeofwhichdoesnotrelatetotaxes);(g)enterintoanymaterialclosingagreementwithrespecttotaxes;or(h)settleorsurrenderanymaterialtaxclaim,auditorassessment;

• (a) enter into, modify in any material respect, amend in any material respect, terminate (other thanexpirations in accordance with their terms) or waive any material rights or claims under certain materialcontracts(“Material Contracts”)setforthintheMergerAgreement,(b)otherthanintheordinarycourseofbusiness, enter into, modify in any material respect, amend in any material respect, terminate (other thanexpirationsinaccordancewiththeirterms)orwaiveanymaterialrightsorclaimsunderanyotherMaterialContract,or(c)exerciseanyoptionsunderanyMaterialContractrelatingtoanymaterial“co-funding”,“co-commercialization” or similar cost-and-profit participation rights (whether an exercise to “opt in” or “optout”ofsuchrights)withrespecttoanyproducttowhichsuchMaterialContractrelates;

• enterinto,failtorenew,amendorterminateinanymaterialrespectanyCompanyLease;

• (a)sell,assign,transfer,convey,license(aslicensor),waiverights,failtomaintainorotherwisedisposeofanymaterialintellectualproperty,exceptfornon-exclusivelicensesofintellectualpropertygrantedtothirdparties,customersordistributorsofMyoKardiaoranyofitssubsidiariesthatareenteredintointheordinarycourse of business consistent with past practice, (b) fail to diligently prosecute or maintain any materialintellectual property registrations or fail to exercise a right of renewal or extension under any contractrelating to, or with respect to, any material intellectual property or (c) disclose any trade secrets ofMyoKardiaoranyofitssubsidiaries(otherthanpursuanttowrittenconfidentialityagreementsenteredintointheordinarycourseofbusinessoranAcceptableConfidentialityAgreementaspermittedundertheMergerAgreement); the “Acceptable Confidentiality Agreement” means any confidentiality agreement enteredintobyMyoKardiaeitherbeforeorafterthedateoftheMergerAgreementthatcontainsprovisionsthatarenot materially less favorable in the aggregate to MyoKardia than those contained in the ConfidentialityAgreement (as defined below) (it being agreed that such confidentiality agreement need not prohibit themakingofaprivateTakeoverProposal(asdefinedbelow)totheMyoKardiaBoardor

35

TABLE OF CONTENTS

otherwisecontainanystandstillorsimilarprovisionthatwouldhavetheeffectofprohibitingthemakingofaprivateTakeoverProposal);providedthatinnoeventwillanAcceptableConfidentialityAgreementincludeprovisionsthatprohibitMyoKardiafromcomplyingwithitsobligationsundertheMergerAgreement;

• adopt a plan or agreement of complete or partial liquidation or dissolution, merger, consolidation,restructuringorotherreorganizationofMyoKardiaoranyofitssubsidiaries;

• qualifyanewsiteforthemanufactureofanyproduct,otherthanintheordinarycourseofbusinessconsistentwithpastpractice;

• enterintooramendanyinterestedpartytransaction;or

• authorizeanyof,orcommitoragree,inwritingorotherwise,totakeanyof,theforegoingactions.

Pursuant to the Merger Agreement, from the date of the Merger Agreement until the Merger Effective Time,MyoKardia will (a) upon request of Parent, provide Parent with a reasonable opportunity to review the materialportionsoftheKeyProductNDA,andanymaterialcorrespondenceorothermaterialcommunicationproposedtobesubmittedorotherwisetransmittedtotheFDAbyMyoKardiawithrespecttotheKeyProductNDA,(b)totheextentreasonablypracticable,consultwithParentinconnectionwithanyproposedmeetingwiththeFDArelatingtotheKeyProductNDA,and(c)keepParentreasonablyinformedofanymaterialcommunication(writtenororal)withorfromtheFDAregardingtheKeyProductNDA.The“Key Product NDA”meansanewdrugapplicationforadrugfiledinaccordancewith21C.F.R.Part314,andallsupplementsfiledpursuanttotherequirementsoftheFDA,includingalldocuments,dataandotherinformationconcerningtheapplicabledrugwhicharenecessaryforFDAapprovaltomarketsuch drug in the United States, and any comparable application submitted to any comparable foreign governmentalauthority, including a Marketing Authorisation Application in the European Union or a New Drug Submission inCanada(“NDA”) seeking regulatory approval of mavacamten for the treatment of obstructive HCMproposed to bemadebyMyoKardia.

NoSolicitation

Pursuant to the Merger Agreement, MyoKardia will and will cause each of its subsidiaries to, and will instruct andcauseitsandtheirRepresentatives(asdefinedbelow)to,amongotherthings:

• immediately ceaseanysolicitation, discussionsor negotiationswithanypersonsthat maybeongoingwithrespect to a Takeover Proposal (as defined below), cease providing any information with respect toMyoKardia and its subsidiaries to such person, and request the prompt return or destruction of allconfidentialinformationconcerningMyoKardiaanditssubsidiariesinsuchperson’spossessionorcontrol;

from the date of the Merger Agreement until the Merger Effective Time or, if earlier, the valid termination of theMerger Agreement in accordance with terms set forth therein, not, directly or indirectly, (a) initiate, solicit orknowingly encourage (including by way of furnishing non-public information) the submission of any inquiries,proposals or offers that constitute, or would reasonably be expected to lead to, a Takeover Proposal, (b) engage in,continueorotherwiseparticipateinanydiscussionsornegotiationsregarding,orfurnishtoanyotherpersonanynon-publicinformationinconnectionwith,orforthepurposeof,encouraginganyinquiry,proposalorofferthatconstitutes,or would reasonably be expected to lead to, a Takeover Proposal, (c) execute or enter into any letter of intent,memorandumofunderstanding,agreementinprinciple,licenseagreement,mergeragreement,acquisitionagreementorother similar agreement relating to a Takeover Proposal or (d) resolve, proposeor agree to doanyof the foregoing.NotwithstandinganythingtothecontrarycontainedintheMergerAgreement,MyoKardiaanditsRepresentativesmaytotheextentreasonablynecessaryinformapersonthathasmadeaninquiry,proposalorofferthatconstitutes,orwouldreasonablybeexpectedtoleadto,aTakeoverProposaloftherelevantprovisionsoftheMergerAgreement.

NotwithstandinganythingtothecontrarysetforthintheMergerAgreement,ifatanytimeonorafterthedateoftheMergerAgreementandpriortotheOfferAcceptanceTime,MyoKardiaoranyofitsRepresentativesreceivesabonafideTakeoverProposal,whichTakeoverProposalwasmadeafterthedateoftheMergerAgreementanddidnotresultfromamaterialbreachoftherestrictionsdescribedabove:

• MyoKardia and its Representatives may contact such person or group of persons making the TakeoverProposal solelytoclarifythetermsandconditionsthereofortorequest that suchTakeoverProposal madeorallybemadeinwritingand;

36

TABLE OF CONTENTS

• if the MyoKardia Board or any committee thereof determines in good faith, after consultation with itsfinancialadvisorsandoutsidelegalcounsel,thatsuchTakeoverProposalconstitutesorwouldreasonablybeexpected to lead to a Superior Proposal (as defined below), and that failure to take such action would beinconsistentwithitsfiduciarydutiesunderapplicableLaw,thenMyoKardiaandanyofitsRepresentativesmay(a)enterintoanAcceptableConfidentialityAgreementwiththepersonorgroupofpersonsmakingtheTakeover Proposal and furnish pursuant to such Acceptable Confidentiality Agreement information(includingnon-publicinformation)withrespecttoMyoKardiaanditssubsidiariestothepersonorgroupofpersons who has made such Takeover Proposal and its or their respective Representatives; provided thatMyoKardia will substantially concurrently provide to Parent any non-public information concerningMyoKardia or any of its subsidiaries that is provided to any person given such access which was notpreviously provided to Parent or its Representatives and (b) following the execution of an AcceptableConfidentialityAgreement,engageinorotherwiseparticipateindiscussionsornegotiationsregardingsuchTakeover Proposal with the person or group of persons making such Takeover Proposal and its or theirRepresentatives.

PriortotheOfferAcceptanceTime,MyoKardiawill notberequiredtoenforce, andwill bepermittedtowaive,anyprovisionofanystandstillorconfidentialityagreementthatprohibitsorpurportstoprohibitthesubmissionormakingofaprivateTakeoverProposaltotheMyoKardiaBoard.

FromandafterthedateoftheMergerAgreementandpriortotheOfferAcceptanceTime,MyoKardiawillpromptly(andinanyeventwithin24hours)notifyParentinwritingintheeventthatMyoKardiaoranyofitssubsidiariesoritsor their Representatives receives any inquiry, proposal or offer that constitutes, or would reasonably be expected toleadto,aTakeoverProposalandwilldisclosetoParentthematerialtermsandconditionsofanysuchinquiry,proposalorofferandtheidentityofthepersonorgroupofpersonsmakingsuchinquiry,proposaloroffer(andprovideParentwith a copy of any such written proposal or offer and copies of any written materials related thereto exchangedbetweenMyoKardiaandsuchperson),andMyoKardiawillkeepParentinformedonareasonablypromptbasisofthestatusof,andanymaterialdevelopmentswithrespectto(andinanyeventwithin24hoursofanysuchdevelopment),any such Takeover Proposal (including any changes to the material terms thereof). For the avoidance of doubt, allinformationprovidedtoParentpursuanttothisparagraphwillbesubjecttothetermsoftheConfidentialityAgreement.

The term “Representatives” means, with respect to any person, its and its subsidiaries’ and controlled affiliates’directors,officers,employees,consultants,agents,financialadvisors,investmentbankers,attorneys,accountants,otheradvisors,andotherrepresentatives(actinginsuchcapacity)retainedbyoractingonbehalfofsuchperson.

Theterm“Takeover Proposal”meansaproposalorofferfromanypersonor“group”(withinthemeaningofSection13(d)oftheExchangeAct)(otherthanParentanditssubsidiaries)relatingto,inasingletransactionorseriesofrelatedtransactions, any direct or indirect (a) acquisition or exclusive license of 20%or more of the consolidated assets ofMyoKardiaanditssubsidiaries(basedonthefairmarketvaluethereof,asdeterminedingoodfaithbytheMyoKardiaBoardoranycommitteethereof),includingthroughtheacquisitionofequityinterestsinorothercapitalstockofoneormore subsidiaries of MyoKardia owning such assets, (b) acquisition of beneficial ownership of 20%or more of theShares,(c)tenderofferorexchangeofferthatifconsummatedwouldresultinanypersonorgroupbeneficiallyowning20% or more of the Shares, or (d) merger, consolidation, share exchange, business combination, recapitalization,liquidation, dissolution or similar transaction involving MyoKardia pursuant to which such person or group (or thestockholdersofanyperson)wouldacquire,directlyorindirectly,20%ormoreoftheconsolidatedassetsofMyoKardiaanditssubsidiaries(basedonthefairmarketvaluethereof,asdeterminedingoodfaithbytheMyoKardiaBoardoranycommitteethereof),beneficialownershipof20%ormoreoftheShares,or20%ormoreoftheaggregatevotingpowerof MyoKardia or of the surviving entity in a merger, consolidation, share exchange or other business combinationinvolving MyoKardia or the resulting direct or indirect parent of MyoKardia or such surviving entity; provided,however,thattheMergerAgreementandtheTransactionswillnotbedeemedaTakeoverProposal.

The term “Superior Proposal” means any bona fide written Takeover Proposal that the MyoKardia Board or anycommitteethereofhasdeterminedinitsgoodfaithjudgment(a)wouldbemorefavorabletoMyoKardia’sstockholdersfromafinancialpointofviewthantheTransactions,takingintoaccountalllegal,regulatory,financial,financingandotheraspects ofsuchproposal andoftheMergerAgreement, and(b)is reasonablylikelytobecompleted; providedthat for purposes of the definition of “Superior Proposal”, the references to “20%” in the definition of TakeoverProposalwillbedeemedtobereferencesto“100%”.

37

TABLE OF CONTENTS

Theterm“Intervening Event”meansanevent,developmentorchangeincircumstancesarisingoroccurringafterthedateoftheMergerAgreementthatmateriallyaffectsMyoKardiaanditssubsidiaries,takenasawhole,andwhichwasnotknownorreasonablyforeseeablebytheMyoKardiaBoard(or,ifknown,thematerialconsequencesofwhichwerenotreasonablyforeseeablebytheMyoKardiaBoard)asoforpriortothedateoftheMergerAgreement;providedthatinnoeventwill(a)thereceipt,existenceortermsofaTakeoverProposalor(b)clearanceoftheMergerundertheHSRActconstituteanInterveningEvent.

MyoKardiaBoardRecommendation

MyoKardiahasrepresentedtoPurchaserandParentintheMergerAgreementthattheMyoKardiaBoard,atameetingdulycalledandheld,unanimouslyadoptedresolutions:

• determiningthattheMergerAgreementandtheTransactionsareadvisable,fairtoandinthebestinterestsofMyoKardiaanditsstockholders;

• authorizingandapprovingtheexecution,deliveryandperformancebyMyoKardiaoftheMergerAgreementandtheconsummationbyMyoKardiaoftheTransactions;

• resolving that the Merger will be effected under Section 251(h) of the DGCLand that the Merger will beconsummatedassoonaspracticablefollowingtheOfferAcceptanceTime;and

• resolvingtorecommendthatMyoKardia’sstockholdersaccepttheOfferandtendertheirSharesintheOffer(suchrecommendation,the“MyoKardia Board Recommendation”).

MyoKardia has also agreed that neither the MyoKardia Board nor any committee thereof will: (a)(i) withhold,withdraworqualify(ormodifyinamanneradversetoParent),orpubliclyproposetowithhold,withdraworqualify(ormodify in a manner adverse to Parent), the MyoKardia Board Recommendation (or fail to include the MyoKardiaBoard recommendation in the Schedule 14D-9) (any action described in this clause (a)(i), an “Intervening EventAdverse Recommendation Change”),(ii)afterpublicannouncementofaTakeoverProposal(otherthanatenderorexchangeoffer), fail to publicly reaffirmthe MyoKardia BoardRecommendation upona written request therefor byParentbytheearlieroftenbusinessdaysfollowingawrittenrequestbyParentandtwobusinessdayspriortothethen-scheduled Expiration Time; provided that Parent may make only one such request with respect to any TakeoverProposal, (iii) recommend the approval or adoption of, or approve or adopt, or publicly propose to recommend,approve or adopt, any Takeover Proposal or (iv) with respect to a tender or exchange offer constituting a TakeoverProposal,failtopubliclyrecommendagainstsuchtenderorexchangeofferorfailtopubliclyreaffirmtheMyoKardiaBoardRecommendationwithintenbusinessdaysofsuchtenderorexchangeofferhavingbeencommencedwithinthemeaning of Rule 14d-2 under the Exchange Act (any action described in this clause (a) being referred to as an“Adverse Recommendation Change”);provided,however,thatitisunderstoodandagreedthattheMyoKardiaBoardor any committee thereof (A) may make or cause MyoKardia to make a customary “stop, look and listen”communicationand(B)inthecaseofatenderorexchangeofferconstitutingaTakeoverProposal,mayelecttotakenoposition with respect to such Takeover Proposal until the close of business on the tenth business day after thecommencementofsuchTakeoverProposalpursuanttoRule14e-2undertheExchangeAct,ineachcasewithoutsuchaction being considered an Adverse Recommendation Change; or (b) execute or enter into (or cause or permitMyoKardia or any of its subsidiaries to execute or enter into) any letter of intent, memorandum of understanding,agreementinprinciple,licenseagreement,mergeragreement,acquisitionagreementorothersimilaragreementrelatingto a Takeover Proposal, other than any Acceptable Confidentiality Agreement (each, a “Company AcquisitionAgreement”). NotwithstandingtheforegoinglimitationsbutsubjecttoMyoKardia’scompliancewiththelimitationsdescribedinthe“—LastLook”sectionbelow,priortotheOfferAcceptanceTime,butnotafter,theMyoKardiaBoardoranycommitteethereofmay(I)makeanAdverseRecommendationChangeor(II)causeMyoKardiatoenterintoaCompanyAcquisitionAgreementwithrespecttoaTakeoverProposalthatdidnotresultfromamaterialbreachoftherestrictionsdescribedintheMergerAgreementandterminatetheMergerAgreement,iftheMyoKardiaBoardoranycommitteethereofhasdeterminedingoodfaith,afterconsultationwithitsfinancialadvisorsandoutsidelegalcounsel,that(x)inthecaseofanInterveningEventAdverseRecommendationChange,suchAdverseRecommendationChangeisnotmadeinresponsetoaTakeoverProposalandismadeinresponsetoanInterveningEvent(asdefinedbelow),andfailuretotakesuchactionwouldbeinconsistentwiththedirectors’fiduciarydutiesunderapplicableLawand(y)inthecaseof(a)clause(I)wheresuchAdverseRecommendationChangeismadeinresponsetoaTakeoverProposalor(b)clause(II),suchTakeoverProposalconstitutesaSuperiorProposal.

38

TABLE OF CONTENTS

LastLook

Prior to taking any of the actions (the “Permitted Actions”) expressly permitted by the last paragraph of the “—MyoKardiaBoardRecommendation”sectionabove,intheeventsuchactionisproposedtobetakeninconnectionwithaSuperiorProposal,theMyoKardiaBoardoranycommitteethereofwillnot,andwillcauseMyoKardianotto,takeanyPermittedAction,unless(a)MyoKardiahasfirstgivenParentatleastthreebusinessdays’priorwrittennoticeofitsintentiontotakesuchaction(whichnoticewillspecifytheidentityofthepartymakingsuchSuperiorProposalandthe material terms and conditions thereof and will include copies of all material documents related thereto), (b)MyoKardiahasnegotiated,andhascauseditsRepresentativestonegotiate,ingoodfaithwithParentduringsuchthreebusinessdaynoticeperiodfollowingParent’sreceiptofthenoticedescribedinclause(a),totheextentParentwishestonegotiate,toenableParenttoproposeinwritinganoffertoeffectrevisionstothetermsoftheMergerAgreementsuchthat it wouldcausesuchSuperior Proposal to nolonger constitute a Superior Proposal, and(c) followingtheendofsuchthreebusiness daynotice period, theMyoKardiaBoardoranycommittee thereof will haveconsideredingoodfaithsuchwrittenoffer,andwillhavedeterminedingoodfaithafterconsultationwithitsfinancialadvisorsandoutsidelegalcounselthat(i)theSuperiorProposalwouldcontinuetoconstituteaSuperiorProposaliftherevisionsproposedin any such revised written offer by Parent were to be given effect and (ii) the failure to take such action wouldcontinue to be inconsistent with the directors’ fiduciary duties under applicable Law (it being understood thatMyoKardia will be required to comply again with its obligations under the foregoing clauses (a), (b) and (c) in theeventofanychangetothefinancialorothermaterialtermsofsuchSuperiorProposal,exceptthatreferencestothreebusinessdaysabovewillbedeemedtobereferencestotwobusinessdays).

PriortotakinganyofthePermittedActions,intheeventanInterveningEventAdverseRecommendationChangeisproposedtobetakeninconnectionwithanInterveningEvent,theMyoKardiaBoardoranycommitteethereofwillnot,andwillcauseMyoKardianotto,makeanInterveningEventAdverseRecommendationChange,unless(a)MyoKardiahasfirst givenParent at least threebusiness days’ prior writtennotice of its intentionto effect anInterveningEventAdverseRecommendationChangeinconnectionwithsuchInterveningEvent,whichnoticewillspecifythenatureofthe Intervening Event in reasonable detail, (b) MyoKardia has negotiated, and has caused its Representatives tonegotiate, in good faith with Parent during such three business day notice period following Parent’s receipt of thenoticedescribedinclause(a),totheextentParentwishestonegotiate,toenableParenttoproposeinwritinganoffertoeffectrevisionstothetermsoftheMergerAgreementthatwouldeliminatetheneedoftheMyoKardiaBoardtoeffectanInterveningEventAdverseRecommendationChangeinconnectionwithsuchInterveningEventand(c)followingtheendofsuchthreebusinessdaynoticeperiod,theMyoKardiaBoardoranycommitteethereofwillhaveconsideredingoodfaithanysuchrevisedwrittenofferbyParentandwillhavedeterminedingoodfaithafterconsultationwithitsfinancialadvisorsandoutsidelegalcounselthatthefailuretoeffectsuchInterveningEventAdverseRecommendationChangewouldcontinuetobeinconsistentwiththedirectors’fiduciarydutiesunderapplicableLaw.

RegulatoryUndertaking

See“Section16—CertainLegalMatters;RegulatoryApprovals—RegulatoryUndertakings.”

AccesstoInformation

Until the earlier of the Merger Effective Time and the valid termination of the Merger Agreement, other than asprohibitedbylawandsubject tocertainconfidentiality andotherexceptionsandlimitations(includingasaresult ofCOVID-19oranyCOVID-19measures),MyoKardiawillgiveParent’sRepresentatives,duringnormalbusinesshoursanduponreasonablenotice,reasonableaccesstothebooksandrecordsofMyoKardiaanditssubsidiariesandfurnishpromptlytoParentallreadilyavailableinformationconcerningitsbusiness,personnel,assets,liabilitiesandpropertiesasParentmayreasonablyrequest.UntiltheMergerEffectiveTime,MyoKardiawill(a)uponParent’srequest,provideParent with a reasonable opportunity to review the material portions of the Key Product NDA, and any materialcorrespondence or other material communication proposed to be submitted or otherwise transmitted to the FDAbyMyoKardia with respect to the Key Product NDA, (b) to the extent reasonably practicable, consult with Parent inconnectionwithanyproposedmeetingwiththeFDArelatingtotheKeyProductNDA,and(c)keepParentreasonablyinformedofanymaterialcommunication(writtenororal)withorfromtheFDAregardingtheKeyProductNDA.

39

TABLE OF CONTENTS

DirectorandOfficerIndemnificationandInsurance

The Merger Agreement provides for certain indemnification and insurance rights in favor of any person who at theMergerEffectiveTimeis,oratanytimepriortotheMergerEffectiveTimewas,adirectororofficerofMyoKardiaoranyof its subsidiaries (each, an “Indemnitee”and, collectively, the“Indemnitees”). Specifically, Parent will fulfillandhonorinallrespectstheobligationsofMyoKardiapursuantto:(a)eachindemnificationagreementineffectasofthe date of the Merger Agreement between MyoKardia and any Indemnitee; and (b) any indemnification provision(including advancement of expenses) and any exculpation provision set forth in MyoKardia’s certificate ofincorporationandbylaws.

From and after the Merger Effective Time, the surviving corporation will (and Parent will cause the survivingcorporationto)ineachcasetothefullestextentpermissiblebyapplicableLaw,(a)indemnifyandholdharmlesseachIndemniteewithrespecttoallclaims,liabilities,losses,damages,judgments,fines,penalties,costs(includingamountspaidinsettlementorcompromise)andexpenses(includingfeesandexpensesoflegalcounsel)inconnectionwithanyactionbasedonorarisingoutof(i) thefactthatanIndemniteeisorwasadirectororofficerofMyoKardiaorsuchsubsidiaryor(ii)actsoromissionsbyanIndemniteeintheIndemnitee’scapacityasadirectororofficerofMyoKardiaorsuchsubsidiaryortakenattherequestofMyoKardiaorsuchsubsidiary(includinginconnectionwithservingattherequestofMyoKardiaorsuchsubsidiaryasarepresentativeofanotherperson(includinganyemployeebenefitplan)),ineachcaseofclauses(i)and(ii),at,oratanytimepriorto,theMergerEffectiveTime(includinganyactionrelatinginwholeorinparttotheTransactions)and(b)assume(inthecaseofthesurvivingcorporation,intheMergerwithoutanyfurtheraction)allobligationsofMyoKardiaandsuchsubsidiariestotheIndemniteesinrespectofindemnification,advancement of expenses and exculpation from liabilities for acts or omissions occurring at or prior to the MergerEffective Time as provided in the certificate of incorporation and bylaws of MyoKardia and the organizationaldocumentsofsuchsubsidiariesasineffectonthedateoftheMergerAgreementorintheagreementsineffectasofthedate of the Merger Agreement providing for indemnification between MyoKardia or any of its subsidiaries and anyIndemnitee. Without limiting the foregoing, from and after the Merger Effective Time, Parent will cause, unlessotherwise required by Law, the certificate of incorporation and bylaws of the surviving corporation to containprovisions no less favorable to the Indemnitees with respect to limitation of liabilities of directors and officers andindemnification than are in certificate of incorporation and bylaws of MyoKardia as in effect as of the date of theMerger Agreement, which provisions will not be amended, repealed or otherwise modified in a manner that wouldadverselyaffecttherightsthereunderoftheIndemnitees. Inaddition,fromtheMergerEffectiveTime,thesurvivingcorporation will (and Parent will cause the surviving corporation to) advance any expenses (including fees andexpenses of legal counsel) of any Indemnitee under this section “— Director and Officer Indemnification andInsurance” as incurred to the fullest extent permitted under applicable Law; provided that the Indemnitee to whomexpenses are advanced provides an undertaking to repay such expenses if it is ultimately determined that suchIndemnitee was not entitled to indemnification under this section “— Director and Officer Indemnification andInsurance”.

EachofParent,thesurvivingcorporationandtheIndemniteeswillcooperatetotheextentreasonablypracticableinthedefenseofanyclaimandwillprovideaccesstopropertiesandindividualsasreasonablyrequestedandfurnishorcausetobefurnishedrecords,informationandtestimony,andattendsuchconferences,discoveryproceedings,hearings,trialsorappeals,asmaybereasonablyrequestedinconnectiontherewith.

For the six-year period commencing immediately after the Merger Effective Time, the surviving corporation willmaintainineffectMyoKardia’scurrentdirectors’andofficers’liabilityinsurancecoveringactsoromissionsoccurringat or prior to the Merger Effective Time with respect to those individuals who are covered by the MyoKardia’sdirectors’andofficers’liabilityinsurancepoliciesontermsandscopewithrespecttosuchcoverage,andinamount,nolessfavorabletosuchindividualsthanthoseofsuchpolicyineffectonthedateoftheMergerAgreement(orParentmay substitute therefor policies, issued by reputable insurers, of at least the same coverage with respect to mattersexistingoroccurringpriortotheMergerEffectiveTime,includinga“tail”policy);providedthatinnoeventwillthesurvivingcorporationberequiredtoexpendinanyoneyearanamountinexcessofthecapagreeduponbythepartiesinconnectionwiththe Merger Agreement (the “PremiumCap”). MyoKardia will have the right prior to the MergerEffective Time to purchase a six-year prepaid “tail policy” on terms and conditions providing at least substantiallyequivalentbenefitsasthecurrentpoliciesofdirectors’andofficers’liabilityinsurancemaintainedbyMyoKardiaandits subsidiaries with respect to matters existing or occurring prior to the Merger Effective Time, covering withoutlimitationtheTransactions,solongastheeffectiveannualpremiumundersuch

40

TABLE OF CONTENTS

policy does not exceed the PremiumCap. If such prepaid “tail policy” has been obtained by MyoKardia, it will bedeemedtosatisfyallobligationstoobtaininsurancepursuanttothisparagraphandthesurvivingcorporationwillcausesuchpolicytobemaintainedinfullforceandeffect,foritsfullterm,andtohonorallofitsobligationsthereunder.

EmployeeBenefits

TheMergerAgreementprovidesthat:

(a) for a period beginning at the Merger Effective Time and ending on the earliest of (such earliest period, the“Continuation Period”) (i) the first anniversary of the Merger Effective Time, (ii) January 1, 2022 and (iii) thetermination of employment of the relevant employee, provided, that, for the avoidance of doubt, such terminationwouldnotaffectanyseveranceprotectionsotherwiserequiredpursuanttothisclause(a),Parentwill,andwillcausethesurvivingcorporationto,providetotheemployeesofMyoKardiaoranyofitsSubsidiariesimmediatelypriorto,andwhoremain so employedimmediately following, the Merger Effective Time(each, a “Continuing Employee”)(A)annualbasesalaryorbasewages(asapplicable)atleastequaltothelevelthatwasprovidedtoeachsuchContinuingEmployee as of immediately prior to the Merger Effective Time, (B) target annual cash bonus opportunity or targetcash commissions opportunity at least equal to the level of target annual cash bonus opportunity or target cashcommissionsopportunitythatwasprovidedtoeachsuchContinuingEmployeeasofimmediatelypriortotheMergerEffectiveTime,(C)severanceandoutplacementbenefitstoeachContinuingEmployeethatarenolessfavorablethan,andpursuanttothetermsof,MyoKardia’sseveranceand/orchangeincontrolplansoroutplacementarrangementssetforthontheMyoKardiaDisclosureLetter(ineachcase,asineffecton,andintheformprovidedtoParentpriorto,thedateoftheMergerAgreement,subjecttoanymodificationspermittedundertheMergerAgreementandtheMyoKardiaDisclosure Letter), and(D)employeebenefit plans andarrangements (other thanbase salaries or base wages, bonusopportunities, severance benefits, defined benefit pension, nonqualified deferred compensation, retiree or post-termination health or welfare benefit, equity or equity based compensation, retention or change in control-relatedcompensationorbenefits,long-termincentiveornonqualifieddeferredcompensationoremployeestockpurchaseplans(collectively,the“Specified Arrangements”)) that are noless favorable in the aggregate thanthe employee benefitplansandarrangements(otherthantheSpecifiedArrangements)providedtoContinuingEmployeesimmediatelypriorto the Merger Effective Timeunder the CompanyPlans. Notwithstanding the foregoing, commencing on January 1,2021throughtheremainderoftheContinuationPeriod,ParentmaysatisfyitsobligationsdescribedinthisparagraphbyeitherprovidingtheContinuingEmployeeswithemployeebenefitplansandarrangements(otherthantheSpecifiedArrangements)thatarenolessfavorableintheaggregatethanthoseprovidedtosimilarlysituatedemployeesofParentorthesameasprovidedtoContinuingEmployeesimmediatelypriortotheMergerEffectiveTimeundertheCompanyPlans,withsuchdeterminationoftheemployeebenefitshereundertobemadebyParentingoodfaith;

(b)if requestedbyParentat least fivebusinessdayspriortotheclosingoftheMerger, MyoKardiawill takeorwillcausetobetakenallactionsnecessary,includingtheadoptionofwrittenresolutionsoftheappropriategoverningbodyinaformreasonablysatisfactorytoParent(copiesofwhichwillbeprovidedtoParentpriortotheclosingdateoftheMerger),toterminateeachCompanyPlanintendedtobequalifiedunderSection401(a)oftheCode(the“MyoKardia401(k) Plan”),andtofullyvestallparticipantsundersuchMyoKardia401(k)Plan,suchterminationandvestingtobeeffective no later than the business day preceding the closing date of the Merger; provided, however, that theMyoKardia 401(k) Plan termination and full vesting of participants thereunder may be made contingent upon theconsummationoftheTransactions;

(c)withrespecttoany401(k)planofParentanditssubsidiariesandanyvacation,paidtime-offandseveranceplansinwhichContinuingEmployeesareeligibletoparticipateaftertheMergerEffectiveTime,forpurposesofeligibilitytoparticipate, level of benefits and vesting, each Continuing Employee’s service with MyoKardia or any of itssubsidiaries (as well as service with any predecessor employer of MyoKardia or any such subsidiary, to the extentservicewiththepredecessoremployerwasrecognizedbyMyoKardiaorsuchsubsidiary)willbetreatedasservicewithParentoranyofitssubsidiariestothesameextentsuchservicewasrecognizedforthesamepurposeunderasimilarCompany Plan in which such Continuing Employee participated immediately prior to the Merger Effective Time;provided, however, that such service need not be recognized to the extent that such recognition would result in anyduplicationofbenefitsorcompensationforthesameperiodofservice.NoContinuingEmployeewillbe

41

TABLE OF CONTENTS

creditedwithhisorheryearsofservicewithMyoKardiaanditssubsidiariesandtheirrespectivepredecessorsbeforethe Merger Effective Time for purposes of benefit accruals under any defined benefit pension plans or any retireemedical or life insuranceor other welfare-typebenefits, or for anypurposesunder anyequityor equity-basedplans,thataremaintainedbyParentanditssubsidiaries;

(d)Parentwill,orwillcausethesurvivingcorporationto,usecommerciallyreasonableeffortsto,waive,orcausetobewaived, any pre-existing condition limitations, exclusions, actively-at-work requirements and waiting periods underanygrouphealthbenefitplanmaintainedbyParentoranyofitssubsidiariesinwhichContinuingEmployees(andtheireligible dependents) will be eligible to participate fromandafter the Merger Effective Timeandin the plan year inwhichtheMergerEffectiveTimeoccurs,excepttotheextentthatsuchpre-existingconditionlimitations,exclusions,actively-at-work requirements and waiting periods would not have been satisfied or waived under the comparableCompanyPlanimmediatelypriortotheMergerEffectiveTime.Parentwill,orwillcausethesurvivingcorporationto,use commercially reasonable efforts to recognize the dollar amount of all co-payments, deductibles and similarexpenses paid by each Continuing Employee (and his or her covered, eligible dependents) during the plan year inwhichtheMergerEffectiveTimeoccursforpurposesofsatisfyingsuchyear’sdeductibleandco-paymentlimitationsunder the relevant grouphealth benefit plans in whichtheywill be eligible to participate fromandafter the MergerEffectiveTimeandintheplanyearinwhichtheMergerEffectiveTimeoccurs;

(e)ParentacknowledgesthattheconsummationoftheOfferconstitutesa“changeofcontrol”,a“changeincontrol”ora“saleevent”(oratermofsimilarimport)forpurposesofanyCompanyPlansetforthontheMyoKardiaDisclosureLetter that containsadefinitionof“changeofcontrol”, a“changeincontrol”ora“sale event”(oratermofsimilarimport),asapplicable.Annualcashincentivebonusesforcalendaryear2020andMyoKardia’ssabbaticalprogramwillbetreatedassetforthintheMyoKardiaDisclosureLetter.ForContinuingEmployeesforwhomMyoKardiahasbeensponsoring their work visas and paying the related expenses, in each case as of immediately prior to the MergerEffective Time, Parent will, andwill causethesurvivingcorporationto, duringtheContinuationPeriod, continuetosponsorsuchContinuingEmployees’workvisasonthesametermsasapplytosimilarly-situatedemployeesofParentforwhomParentsponsorsworkvisasandinallrespectssubjecttoapplicableLaw;

(f)nothingcontainedinthe“employeematters”sectionoftheMergerAgreement,whetherexpressorimplied,willbetreated as an establishment, termination, amendment or other modification of any benefit or compensation plan,program,agreement,contract,policyorarrangement,orwilllimittherightofParent,thesurvivingcorporationoranyof their affiliates to establish, amend, terminate or otherwise modify any benefit or compensation plan, program,agreement, contract, policyorarrangementfollowingtheMergerEffectiveTime.Nothinginthe“employeematters”sectionoftheMergerAgreement,whetherexpressorimplied,willcreateanyrightsorremedieswhatsoever,includinganythird-partybeneficiaryorotherrights,inanypersonnotapartytotheMergerAgreement,orwillbeconstruedtocreate anyright toemployment or servicewithParent, thesurvivingcorporationoranyofits affiliates or continuedemployment or to any particular term or condition of employment or to limit the ability of Parent or the survivingcorporation or any of their affiliates to terminate the employment or service of any service provider (including anyContinuingEmployee)atanytimeandforanyornoreason.The“employeematters”sectionoftheMergerAgreementwill not apply to Continuing Employees while they are terminated or temporarily laid off as a result of COVID-19relatedcircumstances.

ForpurposesoftheMergerAgreement,“Company Plan”meanseach(a)“employeebenefitplan”withinthemeaningof Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (regardless ofwhethersuchplanissubjecttoERISA),(b)stockoption,stockpurchase,stockappreciationrightorotherstock-basedor equity-based plan, program, policy, contract, agreement or other arrangement, (c) employment, individualconsulting, severance, termination, retention, change in control or other similar agreement or (d) other benefit orcompensation plan, policy, program, practice, arrangement, contract, promise or agreement, whether written orunwritten, including bonus, incentive, deferred compensation, profit-sharing, retirement, post-retirement, vacation,severanceorterminationpay,retention,changeincontrol,pension,hospitalization,medical,dentalorvisionbenefits,vacation, life insurance, death benefit, sick pay, disability benefit, educational assistance, holiday pay, housingassistance,movingexpensereimbursement,orfringe-benefitplan,program,policy,agreementorotherarrangement,ineach case that is sponsored, maintained or contributed or required to be contributed to by MyoKardia or any of itssubsidiaries, or under or with respect to which MyoKardia or any of its subsidiaries has or would reasonably beexpected to have any current or contingent liability or obligation, except in each case any of the foregoing that aresponsoredormaintainedpursuanttoapplicableLaw.

42

TABLE OF CONTENTS

ApprovalofCompensationArrangements

PursuanttotheMergerAgreement,priortotheOfferAcceptanceTime,thecompensationcommitteeoftheMyoKardiaBoard (the “Compensation Committee”) will cause each employment compensation, severance or other employeebenefitarrangementpursuanttowhichconsiderationispayabletoanyofficer,directororemployeewhoisaholderofany security of MyoKardia to be approved by the Compensation Committee (comprised solely of “independentdirectors”) in accordance with the requirements of Rule 14d-10(d)(2) under the Exchange Act and the instructionsthereto as an “employment compensation, severance or other employee benefit arrangement” within the meaning ofRule14d-10(d)(2)undertheExchangeActandsatisfytherequirementsofthenon-exclusivesafeharborset forthinRule14d-10(d)oftheExchangeAct.

ConditionstotheOffer

See“—Section15—ConditionstotheOffer.”

ConditionstotheMerger

TheobligationsofeachpartytoconsummatetheMergeraresubjecttothesatisfaction(orwaiver,ifpermissibleunderapplicableLaw)ofthefollowingconditions:

• No outstanding order, judgment, injunction, ruling, writ, stipulation, settlement, award, finding,determination or decree of any governmental authority enacted, promulgated, issued, entered, amended orenforced or deemed applicable by any governmental authority of competent jurisdiction or any applicableLaw(“Restraints”)willbeineffectenjoining,makingillegalorotherwiseprohibitingconsummationoftheMerger;and

• PurchaserwillhaveacceptedforpaymentallSharesvalidlytenderedandnotproperlywithdrawnpursuanttotheOffer.

Termination

TheMergerAgreementmaybeterminatedandtheOfferandtheMergermaybeabandonedatanytimepriortotheOfferAcceptanceTime:

• bymutualwrittenconsentofParentandMyoKardia;

• byeitherParentorMyoKardia:

• (a)if(i)theOfferAcceptanceTimehasnotoccurredonorpriortoMarch3,2021;providedthat,ifasoffivebusinessdayspriortosuchdate,anyof(A)theRestraintsCondition(iftheRestraintrelatestoanAntitrust Law), (B) the Actions Conditions (if the Action relates to an Antitrust Law) and (C) theGovernmental Consents Condition has not been satisfied or waived (to the extent permitted by theMerger Agreement and applicable Law), then Parent or MyoKardia may extend the Outside Date toApril1,2021(March3,2021,orassuchdatemaybesoextended,the“Outside Date”)or(ii)theOfferhas expired pursuant to its terms and the terms of the Merger Agreement (after giving effect to anyextensions thereof in accordance with the Merger Agreement) without Purchaser having accepted forpayment the Shares validly tendered and not properly withdrawnpursuant to the Offer in accordancewiththeMergerAgreementonaccountofthefailuretosatisfytheMinimumCondition;providedthatthe right to terminate the Merger Agreement under this clause (a) (such right, the “Outside DateTermination Right”)willnotbeavailabletoanypartytotheMergerAgreementifthebreachbysuchpartyofitsrepresentationsandwarrantiessetforthintheMergerAgreementorthefailureofsuchpartytoperformanyofitsobligationsundertheMergerAgreementhasbeenaprincipalcauseoforprimarilyresultedintheeventsspecifiedinthisclause(a)(itbeingunderstoodthatParentandPurchaserwillbedeemedasinglepartyforpurposesoftheforegoingproviso);or

• (b)ifanyRestraintenjoining,makingillegalorotherwiseprohibitingconsummationoftheOfferortheMerger is in effect and has become final and nonappealable; provided that the right to terminate theMergerAgreementunderthisclause(b)willnotbeavailabletoanypartywhosebreachoftheMergerAgreementhasbeenaprincipalcauseoforprimarilyresultedintheentryofsuchRestraintorthathasfailedtousetherequiredeffortstoremovesuchRestraintinaccordancewithitsobligationssetforthintheMergerAgreement(itbeingunderstoodthatParentandPurchaserwillbedeemedasinglepartyforpurposesoftheforegoingproviso);or

43

TABLE OF CONTENTS

• byParent:

• (a) if MyoKardia has breachedanyof its representations or warranties or failedto performanyof itscovenants or agreements set forth in the Merger Agreement, which breach or failure to perform(i) would give rise to the failure of the Representations Condition or the Compliance Condition and(ii) is incapableof beingcuredprior totheOutsideDate, or if capableof beingcuredbytheOutsideDate,MyoKardiahasnotcuredthebreachorfailuretoperformwithinthirtycalendardays(butinnoeventlaterthantheOutsideDate)followingreceiptbyMyoKardiaofwrittennoticeofsuchbreachorfailure to perform from Parent; provided that Parent will not have the right to terminate the MergerAgreement pursuant to this clause (a) (such right, the “Parent Termination Right”) if Parent orPurchaseristheninbreachofanyofitsrepresentations,warranties,covenantsoragreementshereundersuchthatMyoKardiahastherighttoterminatetheMergerAgreement;or

• (b) if the MyoKardia Board or a committee thereof has made an Adverse Recommendation Change(such right to terminate the Merger Agreement pursuant to this clause (b), the “AdverseRecommendation Change Termination Right”);or

• byMyoKardia:

• (a)ifParentorPurchaserhasbreachedanyofitsrepresentationsorwarrantiesorfailedtoperformanyofits covenantsoragreements set forthintheMergerAgreement, whichbreachorfailuretoperform(i)wouldgiverisetoanyeffect,change,event,fact,circumstanceoroccurrencethat,individuallyorinthe aggregate, would reasonably be expected to prevent or materially delay or materially impair theconsummationbyParentorPurchaserofanyoftheTransactions(a“Parent Material Adverse Effect”)and(ii)isincapableofbeingcuredpriortotheOutsideDate,orifcapableofbeingcuredbytheOutsideDate,ParentandPurchaserhavenotcuredthebreachorfailuretoperformwithinthirtycalendardays(butinnoeventlaterthantheOutsideDate)followingreceiptbyParentorPurchaserofwrittennoticeofsuchbreachorfailuretoperformfromMyoKardia;providedthatMyoKardiawillnothavetherighttoterminatetheMergerAgreementpursuanttothisclause(a)ifMyoKardiaistheninbreachofanyofits representations, warranties, covenants or agreements hereunder such that Parent has the right toterminatetheMergerAgreement;

• (b) if the MyoKardia Board has authorized MyoKardia to substantially concurrently enter into aCompany Acquisition Agreement providing for a Superior Proposal in accordance with the MergerAgreement;providedthatsuchterminationwillnotbevalidunlesspriortoorsubstantiallyconcurrentlywith such termination MyoKardia pays the MyoKardia Termination Fee (such right to terminate theMergerAgreementpursuanttothisclause(b),the“Superior Proposal Termination Right”);or

• (c) if Purchaser fails to commence (within the meaning of Rule 14d-2 under the Exchange Act) theOfferinaccordancewiththeMergerAgreementonorpriortothetenthbusinessdayfollowingthedateoftheMergerAgreementorifPurchaserfailstoacceptforpaymentallSharesvalidlytenderedandnotproperlywithdrawnpursuant totheOffer whenrequiredtodosoinaccordancewiththetermsof theMerger Agreement; provided, however, that the right to terminate the Merger Agreement pursuant tothis clause (c) will not be available to MyoKardia if MyoKardia is in breach of any provision of theMergerAgreementthathasbeenaprincipalcauseoforprimarilyresultedintheeventsspecifiedinthisclause(c).

IftheMergerAgreementisterminatedpursuanttoitsterms,theMergerAgreementwillbeofnofurtherforceoreffectwithout liability of any party to the Merger Agreement (or any representative of such party) to each other party;providedthat, the termination of the Merger Agreement will not relieve any party from any liabilities or damagesarisingoutofitsWillfulandMaterialBreachofanyprovisionoftheMergerAgreementorfraud.The“Willful andMaterial Breach”meansmaterialbreachthatistheconsequenceofanactoromissionbythebreachingpartywiththeactualknowledgethatthetakingofsuchactorfailuretotakesuchact,orthefailuretocuresuchbreach,wouldcauseorconstitutesuchmaterialbreach.

44

TABLE OF CONTENTS

MyoKardiaTerminationFee

MyoKardia will pay Parent a termination fee of $458,000,000 in cash (the “MyoKardia Termination Fee”) in theeventthat:

• (a) the Merger Agreement is terminated (i) by MyoKardia or Parent pursuant to the Outside DateTerminationRight(providedthat(A)atthetimeofanysuchtermination,alloftheRestraintsCondition,theActionsConditionandtheGovernmentalConsentsConditionaresatisfiedandtheMinimumConditionisnotsatisfied,and(B)withrespecttoanysuchterminationbyMyoKardia,theOutsideDateTerminationRightisthenavailabletoParent)orbyParentpursuanttotheParentTerminationRightresultingfromaWillfulandMaterial Breach of the Merger Agreement by MyoKardia, (ii) a bona fide Takeover Proposal has beenpublicly made or otherwise communicated or delivered to the MyoKardia Board and has become publiclyknownafterthedateoftheMergerAgreementandpriortosuchtermination,andsuchTakeoverProposalhasnotbeenirrevocablywithdrawningoodfaithpriortosuchtermination,and(iii)withintwelvemonthsofthedatetheMergerAgreementissoterminated,MyoKardia(A)entersintoaCompanyAcquisitionAgreementwith any person or persons with respect to any Takeover Proposal and such Takeover Proposal issubsequentlyconsummatedor(B)consummatesanyTakeoverProposal;providedthat,forpurposesofsub-clauses(ii)and(iii)ofthisclause(a),thereferencesto“20%”inthedefinitionofTakeoverProposalwillbedeemedtobereferencesto“50%”;or

• (b) the Merger Agreement is terminated (i) by Parent pursuant to the Adverse Recommendation ChangeTerminationRightor(ii)byMyoKardiapursuanttotheSuperiorProposalTerminationRight.

ThepartieshaveagreedthatpaymentoftheMyoKardiaTerminationFeewillbedeemedtobeliquidateddamagesforanyandalllossesordamagessufferedorincurredbyParent,Purchaser,anyoftheirrespectiveaffiliatesoranyotherperson in connection with the Merger Agreement (and the termination of the Merger Agreement), the transactionscontemplated by the Merger Agreement (and the abandonment thereof) or any matter forming the basis for suchtermination,andMyoKardiawillhavenofurtherliability,whetherpursuanttoaclaiminlaworinequity,toParent,Purchaser or any of their respective affiliates or any other person, and none of Parent, Purchaser or any of theirrespectiveaffiliatesoranyotherpersonwillbeentitledtobringormaintainanyactionagainstMyoKardiaoranyofitssubsidiariesoraffiliatesfordamagesoranyequitablereliefarisingoutoforinconnectionwiththeMergerAgreement,anyofthetransactionscontemplatedbytheMergerAgreement,oranymattersformingthebasisforsuchtermination;provided that nothing in the Merger Agreement will relieve MyoKardia from liability for damages arising from aWillfulandMaterialBreachoftheMergerAgreementorfromfraud.

FeesandExpenses

Subjecttocertainexceptionsandsubjecttotheprovisionsdescribedin“—MyoKardiaTerminationFee,”whetherornottheTransactionsareconsummated,all feesandexpensesincurredinconnectionwiththeMergerAgreementandthe Transactions will be paid by the party incurring or required to incur such fees or expenses, except as otherwiseexpresslysetforthintheMergerAgreement.

TheConfidentialityAgreement

ParentandMyoKardiapreviouslyenteredintoconfidentialityagreementsdatedMarch26,2019andJune29,2020,inconnection with the exploration of potential strategic partnership opportunities. In connection with the transaction,Parent and the MyoKardia entered into a new confidentiality agreement dated as of September 17, 2020 (the“Confidentiality Agreement”).UnderthetermsoftheConfidentialityAgreement,ParentandMyoKardiaagreedthat,subjecttocertainexceptions,certainnon-public,confidentialand/orproprietaryinformationeachmaymakeavailabletotheotherinconnectionwithdiscussionsconcerningapossibletransactionbetweenthepartieswillnotbedisclosedorusedforanyotherpurpose.TheConfidentialityAgreementalsoincludesastandstill provisionwithatermofoneyearthatissubjecttocertainexceptions.

TheforegoingsummarydescriptionoftheConfidentialityAgreementdoesnotpurporttobecompleteandisqualifiedinitsentiretybyreferencetotheConfidentialityAgreement,acopyofwhichPurchaserhasfiledasExhibit(d)(2)totheTenderOfferStatementonScheduleTOandisincorporatedhereinbyreference.

TheExclusivityAgreement

ParentandMyoKardiaenteredintoaletteragreementdatedasofSeptember25,2020(the“Exclusivity Agreement”).UnderthetermsoftheExclusivityAgreement,MyoKardiaagreednottosolicitorenterinto

45

TABLE OF CONTENTS

discussionsornegotiationswithregardtoanyalternativetransactionuntilthefirsttooccurof:(a)theexecutionofadefinitivemergeragreementbetweenParentandMyoKardiawithrespecttoatransaction;(b)receiptbyMyoKardiaofwrittennoticefromParentadvisingMyoKardiathatParentisnolongeractivelypursuingthetransaction;(c)thetimeatwhichParentreduces,orproposesareductionin,thepersharepurchasepriceofferedbytheChiefExecutiveOfficerofParenttotheChiefExecutiveOfficeroftheMyoKardiaonSeptember25,2020;and(d)8:00a.m.(NewYorktime)onOctober 5, 2020. The obligations under the Exclusivity Agreement terminated upon the execution of the MergerAgreement.

TheforegoingsummarydescriptionoftheExclusivityAgreementdoesnotpurporttobecompleteandisqualifiedinits entirety by reference to the Exclusivity Agreement, a copy of which Purchaser has filed as Exhibit (d)(3) to theTenderOfferStatementonScheduleTOandisincorporatedhereinbyreference.

TheTenderandSupportAgreement

Concurrently with the execution of the Merger Agreement, Parent, Purchaser and Tassos Gianakakos, MyoKardia’sPresident and Chief Executive Officer, entered into the Support Agreement. Under the terms of the SupportAgreement,suchstockholderagreed(a)toirrevocablytenderintotheOfferallSharesbeneficiallyownedorthereafteracquired by such stockholder as promptly as practicable (but in no event later than the Expiration Time) and not toexercise any appraisal rights in connection with the Merger, (b) not to transfer any of such stockholder’s equityinterestsinMyoKardia,includinganyShares,otherthaninaccordancewiththetermsandconditionssetforthintheSupport Agreement, (c) not to take any action that would interfere with the performance of such stockholder’sobligations under, or the transactions contemplated by, the Support Agreement, (d) to vote against any action oragreementthatwouldmateriallyimpede,interferewithorpreventtheOfferortheMerger,and(e)notto,directlyorindirectly, solicit, initiate or knowingly encourage, or participate in discussions with third parties regarding otherproposalstoacquireMyoKardia.TheSupportAgreementwillterminateupontheearliestof(i)thevalidterminationoftheMergerAgreement,(ii)theMergerEffectiveTime,(iii)thedateoftheentry,withoutthepriorwrittenconsentofthestockholder,intoanymaterialmodificationoramendmenttoanyprovisionoftheMergerAgreementthatreducestheamount,changestheformorotherwiseadverselyaffectstheconsiderationpayabletothestockholderpursuanttotheMergerAgreement,and(iv)themutualwrittenconsentofParent,Purchaserandthestockholder.AsofOctober3,2020,theoutstandingsharesofCompanyCommonStockbeneficiallyownedbyMr.Gianakakosrepresented1.2%ofthe total outstanding shares of Company Common Stock. The Support Agreement provides that Mr. Gianakakos’obligationsthereunderaresolelyinhiscapacityasastockholderofMyoKardia,andnotinanyothercapacity,andtheSupport Agreement does not limit or otherwise affect any actions in his capacity as an officer or director ofMyoKardia,includingthetakingofanyactions(orfailuretoact)intheexerciseofhisfiduciarydutiesasadirectororofficerofMyoKardia.

TheforegoingsummarydescriptionoftheSupportAgreementdoesnotpurporttobecompleteandisqualifiedinitsentirety byreferenceto theSupport Agreement, a copyof whichPurchaser hasfiledas Exhibit (d)(4) to theTenderOfferStatementonScheduleTOandisincorporatedhereinbyreference.

14. Dividends and Distributions

As discussed in “—Section 13—The Transaction Documents—The Merger Agreement—Operating Covenants,”pursuant to the Merger Agreement, fromthe date of the Merger Agreement until the Merger Effective Time, unlessParentotherwiseexpresslyconsentsinwritinginadvance(suchconsentnottobeunreasonablywithheld,conditionedordelayed), except (a) as requiredbyapplicable Law,therules or regulations of NASDAQoranyjudgment, (b) asexpressly required by the Merger Agreement, or (c) as disclosed in the MyoKardia Disclosure Letter, MyoKardia,amongotherthings,subjecttocertainexceptions,willnot,andwillnotpermititssubsidiariesto:

• otherthantransactionsamongMyoKardiaanditswhollyownedsubsidiariesoramongMyoKardia’swhollyownedsubsidiaries, redeem,purchaseorotherwiseacquireanyofits outstandingsharesofcapital stockorotherequityorvotinginterests,oranyrights,warrantsoroptionstoacquireanysharesofitscapitalstockorotherequityorvotinginterests,otherthanpursuanttothecashlessexerciseofMyoKardiaStockOptionsortheforfeiture or withholdingoftaxeswithrespect toMyoKardiaStockOptions, MyoKardiaRSUAwards,MyoKardiaPSUAwardsoroptionsgrantedundertheMyoKardiaESPP;

• establish a record date for, declare, set aside for payment, authorize or pay any dividend on, or make anyotherdistributioninrespectof,anysharesofitscapitalstockorotherequityorvotinginterests,otherthandividends paid by any wholly owned subsidiary of MyoKardia to MyoKardia or any other wholly ownedsubsidiaryofMyoKardia;or

46

TABLE OF CONTENTS

• split,combine,subdivideorreclassifyanysharesofitscapitalstockorotherequityorvotinginterests,exceptfor any such transaction by a wholly owned subsidiary of MyoKardia which remains a wholly ownedsubsidiaryafterconsummationofsuchtransaction.

15. Conditions to the Offer

NotwithstandinganyotherprovisionoftheMergerAgreementortheOfferandinadditionto(andnotinlimitationof)our right to extendandamendthe Offer pursuant to the provisions of the Merger Agreement, Purchaser will not berequired to (and Parent will not be required to cause Purchaser to) accept for payment or, subject to any applicablerulesandregulationsoftheSEC,includingRule14e-1(c)undertheExchangeAct,payforanySharesvalidlytenderedand not properly withdrawnpursuant to the Offer if any of the following conditions exist or have occurred and arecontinuingatthescheduledExpirationTimeoftheOffer:

(a) the number of Shares validly tendered (and not properly withdrawn) prior to the expiration of the Offer (butexcluding Shares tendered pursuant to guaranteed delivery procedures that have not yet been “received”, asdefinedbySection251(h)(6)oftheGeneralCorporationLawoftheStateofDelaware(the“DGCL”)),togetherwiththeSharesthenownedbyParentorPurchaser,doesnotrepresentatleastoneSharemorethan50%ofthethenoutstandingShares(the“Minimum Condition”);

(b) any Restraint is in effect enjoining, making illegal or otherwise prohibiting consummation of the Offer or theMerger(the“Restraints Condition”);

(c) there is an Action instituted or pending by a governmental authority of competent jurisdiction seeking anyjudgment (i) to prevent, prohibit or make illegal the consummation of the Offer or the Merger, (ii) to prohibitParent’sabilitytovote,transfer,receivedividendsorotherwiseexercisefullrightsofownershipwithrespecttothestockofMyoKardiaor(iii)inconnectionwiththeOfferortheMerger,toprohibit,limit,restrainorimpairinanymaterialrespectParent’sabilitytoown,control,direct,manage,oroperateortoretainorchangeanymaterialportionoftheassets,licenses,operations,rights,productlines,businessesorintereststhereinofMyoKardiaoritssubsidiariesoranyofthematerialassets,licenses,operations,rights,productlines,businessesorintereststhereinof Parent or its subsidiaries (other than, in each case, a divestiture action required to be taken by Parent andPurchaser pursuant to the Merger Agreement) (the “Actions Condition”); an “Action” means any pending orthreatened legal or administrative claim, audit, arbitration, proceeding, suit, charge, complaint, arbitration oractionbyorbeforeanygovernmentalauthority;

(d) thewaitingperiod(andanyextensionthereof)applicabletotheconsummationoftheOfferortheMergerunderthe Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulationspromulgated thereunder (the “HSR Act”) has neither expired nor has early termination thereof beengranted orthere is in effect any voluntary agreement between Parent, Purchaser or MyoKardia and the Federal TradeCommissionortheDepartmentofJusticepursuanttowhichParent,PurchaserorMyoKardiawillnotconsummatetheMergerforanyperiodoftime(the“Governmental Consents Condition”);

(e) certain representations and warranties of MyoKardia set forth in the Merger Agreement (i) relating tocapitalization are not true and correct in all respects as of the date of the Merger Agreement and as of thescheduledExpirationTime,withthesameeffectasthoughmadeasofthescheduledExpirationTime(excepttothe extent expressly made as of an earlier date, in which case as of such earlier date), except for de minimisinaccuracies, (ii) relating to organization, standing, authority, noncontravention, rights agreement, anti-takeoverprovisions, opinions of financial advisor, brokers and other advisors are not true and correct (disregarding allqualificationsorlimitationsasto“materiality”, “Material AdverseEffect”andwordsofsimilarimportsetforththerein)inallmaterialrespectsasofthedateoftheMergerAgreementandasofthescheduledExpirationTimewiththesameeffectasthoughmadeasofthescheduledExpirationTime(excepttotheextentexpresslymadeasofanearlierdate,inwhichcaseasofsuchearlierdate),(iii)relatingtoabsenceofcertainchangesarenottrueandcorrectinallrespectsasofthedatethereof,or(iv)setforthintheMergerAgreement,otherthanthosespecificallyidentifiedinclauses(i),(ii)and(iii)ofthisparagraph(e),arenottrueandcorrect(disregardingallqualificationsorlimitationsasto“materiality”, “Material AdverseEffect”andwordsofsimilarimportsetforththerein)asofthedateoftheMergerAgreementandasofthescheduledExpirationTimewiththesameeffectasthoughmadeasofthescheduledExpirationTime(excepttotheextentexpresslymadeasofanearlierdate,inwhichcaseasofsuchearlierdate),except,inthecaseofthisclause(iv),wherethefailuretobetrueandcorrect,individuallyorinthe aggregate, has not had, and would not reasonably be expected to have, a Material Adverse Effect that iscontinuingasofthescheduledExpirationTime(the“Representations Condition”);

47

TABLE OF CONTENTS

(f) MyoKardia has not have complied with or performed in all material respects its obligations required to becomplied with or performed by it prior to the scheduled Expiration Time under the Merger Agreement (the“Compliance Condition”);

(g) sincethedateoftheMergerAgreementtherehasbeenanyeffect,change,event,fact,circumstanceoroccurrencethat,individuallyorintheaggregate,hashadorwouldreasonablybeexpectedtohaveaMaterialAdverseEffectthatiscontinuingasofthescheduledExpirationTime;

(h) ParenthasnothavereceivedacertificatesignedonbehalfofMyoKardiabyanexecutiveofficerofMyoKardiacertifyingthatnoneoftheconditionsintheaboveclauses(e),(f)and(g)hasoccurredandiscontinuing;and

(i) theMergerAgreementhasbeenterminatedinaccordancewithitsterms(the“Termination Condition”).

The Offer Conditions set forth above are for the sole benefit of Parent and Purchaser and, other than the MinimumCondition,theTerminationConditionorasotherwisesetforthintheMergerAgreement,maybewaivedbyParentandPurchaserinwholeorinpartatanytimeandfromtimetotimeintheirsolediscretion,ineachcasesubjecttothetermsandconditionsoftheMergerAgreementandtotheextentsuchwaiverispermittedbyapplicableLaw.ThefailurebyParent,PurchaseroranyotheraffiliateofParentatanytimetoexerciseanyoftheforegoingrightswillnotbedeemedawaiverofanysuchright,thewaiverofanysuchrightwithrespecttoparticularfactsandcircumstanceswillnotbedeemedawaiverwithrespecttoanyotherfactsandcircumstancesandeachsuchrightwillbedeemedanongoingrightthatmaybeassertedatanytimeandfromtimetotime.

The term“Material Adverse Effect” means any effect, change, event, fact, circumstance or occurrence that has orwouldbereasonablyexpectedtohaveamaterialadverseeffectonthebusiness,resultsofoperations,assetsorfinancialconditionofMyoKardiaanditssubsidiariestakenasawhole;provided,however,thatnoneofthefollowing(aloneorincombination)willconstituteorbetakenintoaccountindeterminingwhetheraMaterialAdverseEffecthasoccurredorwouldreasonablybeexpectedtooccur:(a)anyeffect,change,event,fact,circumstanceoroccurrencetotheextentgenerally affecting (i) companies in the industry in which MyoKardia and its subsidiaries operate, (ii) business,economicorpolitical conditionsintheUnitedStatesor elsewhereintheworldor (iii) thecredit, financial, banking,currencyorcapitalmarketsintheUnitedStatesorelsewhereintheworld,includingchangesininterestorexchangeratesoranysuspensionoftradinginsecurities(whetherequity,debt,derivativeorhybridsecurities)onanysecuritiesexchangeorover-the-countermarket;(b)anyeffect,change,event,fact,circumstanceoroccurrencethatresultsfrom(i) changes in law or in GAAP or other accounting standards (or the enforcement or interpretation of any of theforegoingbyagovernmental authority), (ii) thenegotiation, execution, announcement orperformanceoftheMergerAgreement,theidentityofParentastheacquirorofMyoKardia,ortheconsummationoftheTransactions(otherthanfor purposes of certain representation or warranty relating to authority, noncontravention, andgovernment approvalsset forthintheMergerAgreement), includingtheimpactofanyoftheforegoingontherelationships, contractual orotherwise, of MyoKardia and its subsidiaries with employees, customers, investors, contractors, lenders, suppliers,vendors,partners,licensors,licensees,payors,GovernmentalAuthoritiesorotherthirdparties,(iii)actsofhostilities,war(whetherornotdeclared),sabotage,terrorism,cyberterrorismormilitaryactions,oranyescalationorworseningofanyoftheforegoing,(iv)volcanoes,tsunamis,epidemics,pandemics(includingCOVID-19),plagues,otheroutbreaksof illness or public health events, earthquakes, hurricanes, tornados, floods, wild fires, weather conditions or othernaturalorman-madedisastersoractsofGod,oranyescalationorworseningofanyoftheforegoing,(v)anyactiontaken, or failure to take any action, by MyoKardia or its subsidiaries that is expressly required or prohibited (asapplicable) by the Merger Agreement or at Parent’s express written request, or (vi) any claim, demand or action(includinganyclassactionorderivativelitigation)asserted,commencedorthreatenedby,onbehalfoforinthenameof, against or otherwise involving MyoKardia, the MyoKardia Board, any committee thereof and/or any ofMyoKardia’sdirectorsorofficersrelatingdirectlyorindirectlytotheMergerAgreement,theOffer,theMergeroranyoftheTransactions(includinganysuchclaimoractionbasedonallegationsthatMyoKardia’sentryintotheMergerAgreementorthetermsandconditionsoftheMergerAgreementoranyoftheTransactionsconstitutedabreachofthefiduciarydutiesofanymemberoftheMyoKardiaBoardoranyofficerofMyoKardia)(a“Transaction Litigation”)oranydemandoractionforappraisalofthefairvalueofanySharespursuanttotheDGCLinconnectionherewith;(c)(i)anychangeinMyoKardia’screditratings,(ii)anydeclineinthemarketprice,orchangeintradingvolume,ofthecapital stock of MyoKardia or (iii) any failure to meet, or changes to, any internal or public projections, forecasts,guidance, estimates, milestones, budgets or internal or published financial or operating predictions of revenue,earnings,cashfloworcashpositionorotherfinancialorperformancemeasuresoroperatingstatistics(whethermadebyMyoKardiaorthirdparties)(itbeingunderstoodthattheexceptionsinclauses(c)(i),(ii)and(iii)willnotpreventorotherwiseaffectadeterminationthattheunderlying

48

TABLE OF CONTENTS

causeofanysuchchange,declineorfailurereferredtothereinis,orwouldreasonablybeexpectedtobe,aMaterialAdverse Effect); or (d) any regulatory, preclinical or clinical, competitive, pricing, reimbursement or manufacturingeffects, changes, events, facts, circumstances or occurrencesrelatingtoor affectinganyofmavacamten, danicamtiv,MYK-224,LUS-1,ACT-1andtheearlystagetargetscoveredbyMyoKardia’sgeneticcardiomyopathyprograms(the“Products”)oranyproductorproductcandidatecompetitivewithorrelatedtoanyProduct,ineachcase,notinvolvingany wrongdoing by MyoKardia or any of its affiliates or Representatives (including (i) any suspension, rejection,refusal of, or request to refile any regulatory application, filing or approval or delay in obtaining, making ormaintaininganysuchregulatoryapplication,filingorapprovalorlaunchingcommercialsalesofanyProduct,(ii)anyregulatory actions, requests, recommendations, determinations or decisions of any governmental authority related toanyProduct,(iii)anydelay,holdorterminationofanypreclinicalorclinicalstudy,trialortestrelatedtoanyProduct,(iv) any results, outcomes, data, adverse events, side effects or safety observations arising from any preclinical orclinicalstudies,trialsortestsrelatedtoanyProduct,(v)approvalbytheUnitedStatesFoodandDrugAdministrationoranysuccessoragency(the“FDA”)oranothergovernmental authority, market entryorthreatenedmarket entryofany product or product candidate competitive with or related to any Product, (vi) any production or supply chaindisruption affecting the manufacture of any Product, and (vii) any recommendations, statements, decisions or otherpronouncements made, published or proposed by professional medical organizations, payors, GovernmentalAuthorities or representatives of any of the foregoing related to any Product); provided further, however, that anyeffect, change, event, fact, circumstance or occurrence referred to in clause (a) or clauses (b)(i), (iii) or (iv) maybetakenintoaccountindeterminingwhethertherehasbeen,orwouldreasonablybeexpectedtobe,aMaterialAdverseEffecttotheextentsucheffect,change,event,fact,circumstanceoroccurrencehasadisproportionateadverseeffectonthebusiness,resultsofoperations,assetsorfinancialconditionofMyoKardiaanditssubsidiaries,takenasawhole,ascomparedtoothercompaniesintheindustryinwhichMyoKardiaanditssubsidiariesoperate.

16. Certain Legal Matters; Regulatory Approvals

RegulatoryMatters

General

BasedonourexaminationofpubliclyavailableinformationfiledbyMyoKardiawiththeSECandareviewofcertaininformationfurnishedbyMyoKardiatoPurchaser,wearenotawareofanygovernmentallicenseorregulatorypermitthat appears to be material to MyoKardia’s business that might be adversely affected by our acquisition of SharespursuanttotheOfferor,exceptassetforthbelow,ofanyapprovalorotheractionbyanygovernmentorgovernmentalauthority or agency, domestic, foreign or supernational, that would be required for our acquisition or ownership ofShares pursuant to the Offer. Should any such approval or other action be required or desirable, we currentlycontemplatethatsuchapprovalorotheractionwillbesought.Exceptasdescribedbelow,thereisnocurrentintenttodelaythepurchaseofSharestenderedpursuanttotheOfferpendingtheoutcomeofanysuchmatter.WeareunabletopredictwhetherwewilldeterminethatwearerequiredtodelaytheacceptanceforpaymentoforpaymentforSharestenderedpursuanttotheOfferpendingtheoutcomeofanyapprovalorotheractionnotdescribedbelow.Therecanbeno assurance that any such approval or other action, if needed, would be obtained (with or without substantialconditions) or that if such approvals were not obtained or such other actions were not taken adverse consequencesmightnotresulttoMyoKardia’sbusinessorcertainpartsofMyoKardia’sbusinessmightnothavetobedisposedof,any of which could cause Purchaser to elect to terminate the Offer without the purchase of Shares thereunder. OurobligationundertheOffertoacceptforpaymentandpayforSharesissubjecttotheconditionssetforthin“—Section15—ConditionstotheOffer.”

State Takeover Statutes

AsaDelawarecorporation,MyoKardiaissubjecttoSection203oftheDGCL.Ingeneral,Section203oftheDGCLpreventsaDelawarecorporationfromengagingina“businesscombination”(definedtoincludemergersandcertainotheractions)withan“interestedstockholder”(includingapersonwhoownsorhastherighttoacquire15%ormoreof a corporation’s outstanding voting stock) for a period of three years following the date such person became an“interestedstockholder”unless,amongotherthings,the“businesscombination”isapprovedbytheboardofdirectorsofsuchcorporationbeforesuchpersonbecamean“interestedstockholder.”MyoKardiahasrepresentedtoPurchaserintheMerger Agreement that, assumingtheaccuracyof certain representations andwarranties madebyPurchaser, theMyoKardiaBoardhastakenallactionnecessarytorenderSection203oftheDGCLinapplicabletotheOfferandtheMergerandtheothertransactionscontemplatedbytheMergerAgreement.

49

TABLE OF CONTENTS

InadditiontoSection203oftheDGCL,anumberofotherstateshaveadoptedlawswhichpurport,tovaryingdegrees,to apply to attempts to acquire corporations that are incorporated in, or which have substantial assets, stockholders,principal executive offices or principal places of business or whose business operations otherwise have substantialeconomiceffectsin,suchstates.MyoKardia,directlyorthroughsubsidiaries,conductsbusinessinanumberofstatesthroughouttheUnitedStates,someofwhichmayhaveenactedsuchlaws.Exceptasdescribedherein,wedonotknowwhetheranyoftheselawswill,bytheirterms,applytotheOfferortheMerger,andwehavenotattemptedtocomplywithanysuchlaws.TotheextentthatcertainprovisionsoftheselawspurporttoapplytotheOfferortheMerger,webelievethattherearereasonablebasesforcontestingtheapplicationofsuchlaws.

In 1982, inEdgar v. MITE Corp., the SupremeCourt of the United States invalidated on constitutional grounds theIllinoisBusinessTakeoverStatutewhich,asamatterofstatesecuritieslaw,madetakeoversofcorporationsmeetingcertainrequirementsmoredifficult.However,in1987,inCTS Corp. v. Dynamics Corp. of America,theSupremeCourtheldthattheStateofIndianacould,asamatterofcorporatelaw,constitutionallydisqualifyapotentialacquirerfromvoting shares of a target corporation without the prior approval of the remaining stockholders where, among otherthings,thecorporationisincorporated,andhasasubstantialnumberofstockholders,inthestate.Subsequently,inTLXAcquisition Corp. v. Telex Corp., a U.S. federal district court in Oklahoma ruled that the Oklahoma statutes wereunconstitutionalasappliedtocorporationsincorporatedoutsideOklahomainthattheywouldsubjectsuchcorporationstoinconsistent regulations. Similarly, inTyson Foods, Inc. v. McReynolds, a U.S. federal district court in Tennesseeruled that four Tennessee takeover statutes were unconstitutional as applied to corporations incorporated outsideTennessee.ThisdecisionwasaffirmedbytheUnitedStatesCourtofAppealsfortheSixthCircuit.InDecember1988,aU.S.federaldistrictcourtinFloridaheldinGrand Metropolitan PLC v. ButterworththattheprovisionsoftheFloridaAffiliated Transactions Act and the Florida Control Share Acquisition Act were unconstitutional as applied tocorporationsincorporatedoutsideofFlorida.

IfanygovernmentofficialorthirdpartyseekstoapplyanystatetakeoverlawtotheOfferortheMerger,wewilltakesuchactionasthenappearsdesirable,whichactionmayincludechallengingtheapplicabilityorvalidityofsuchstatuteinappropriatecourtproceedings.IfitisassertedthatoneormorestatetakeoverstatutesisapplicabletotheOfferortheMerger and an appropriate court does not determine that it is inapplicable or invalid as applied to the Offer or theMerger,wemayberequiredtofilecertaininformationwith,ortoreceiveapprovalsfrom,therelevantstateauthoritiesorholdersofShares,andwemaybeunabletoacceptforpaymentorpayforSharestenderedpursuanttotheOffer,orbedelayedincontinuingorconsummatingtheOfferortheMerger.Insuchcase,wemaynotbeobligatedtoacceptforpaymentorpayforanytenderedShares.See“—Section15—ConditionstotheOffer.”

U.S. Antitrust

UndertheHSRActandtherulesthathavebeenpromulgatedthereunder,certainacquisitiontransactionsmaynotbeconsummated unless Premerger Notification and Report Forms have been filed with the Federal Trade Commission(the“FTC”) and the Antitrust Division of the United States Department of Justice (the “Antitrust Division”)andcertainwaitingperiodrequirementshavebeensatisfied.ThepurchaseofSharespursuanttotheOfferandtheMergerissubjecttosuchrequirements.

EachofParentandMyoKardiawillfileaPremergerNotificationandReportFormundertheHSRActwithrespecttotheOfferandtheMergerwiththeAntitrustDivisionandtheFTConOctober19,2020.ThewaitingperiodapplicabletothepurchaseofSharespursuanttotheOfferwillexpireat11:59p.m.,NewYorkCitytime,onNovember3,2020,butthisperiodmaybeshortenediftheFTCortheAntitrustDivision,asapplicable,grants“earlytermination”ofthewaitingperiod,oritmaychangeifParentvoluntarilywithdrawsandrefilesitsPremergerNotificationandReportFormin order to restart the 15-day waiting period, or if the reviewing agency issues a formal request for additionalinformationanddocumentarymaterial.Ifsucharequestismade,thewaitingperiodwillbeextendeduntil11:59p.m.,NewYorkCitytime,tencalendardaysaftersubstantialcompliancewithsuchrequest.Thereafter,suchwaitingperiodcanbeextendedonlybycourtorderoragreementofParent,MyoKardia,PurchaserandtheAntitrustDivisionortheFTC, as applicable. See “—Section 15—Conditions to the Offer” for certain conditions to the Offer, includingconditionswithrespecttocertaingovernmentalactionsand“—Section13—TheTransactionDocuments—TheMergerAgreement—Termination” for certain termination rights pursuant to the Merger Agreement with respect to certaingovernmental actions. It is also possible that Parent and MyoKardia could enter into a timing agreement with thereviewingagencythatcouldaffectthetimingoftheclosingofthetransactionscontemplatedbytheMergerAgreement.

50

TABLE OF CONTENTS

Other Antitrust Approvals

MyoKardiaanditssubsidiariesalsotransactbusinessoutsideoftheUnitedStates.Undertheantitrustormergercontrolstatutes or regulations of certain of these foreign countries, certain acquisition transactions require the filing ofinformationwith,ortheobtainingoftheapprovalof,antitrustorcompetitionauthoritiestherein.WedonotbelievethatthepurchaseofSharesbyPurchaserintheOfferortheMergerissubjecttosuchrequirements.

Regulatory Undertakings

ThepartiestotheMergerAgreementhaveagreedthat:

(a) subject to the terms and conditions of the Merger Agreement, each of the parties will cooperate with the otherpartiesanduse(andwillcausetheirrespectivesubsidiariesandaffiliatestouse)theirrespectivereasonablebestefforts(unless, with respect to any action, another standard of performance is expressly provided for in the MergerAgreement)topromptly(i)take,orcausetobetaken,allactions,anddo,orcausetobedone,andassistandcooperatewiththeotherpartiesindoing,all thingsnecessary, properoradvisabletocausetheconditionstotheclosingoftheMerger to be satisfied as promptly as reasonably practicable and to consummate and make effective, in the mostexpeditious manner reasonably practicable, the Transactions, including preparing and filing promptly and fully alldocumentationtoeffect all necessaryfilings, notices, petitions, statements, registrations, submissionsofinformation,applications and other documents, (ii) obtain all approvals, consents, registrations, waivers, permits, authorizations,orders and other confirmations from any governmental authority or third party necessary, proper or advisable toconsummate the Transactions and (iii) execute and deliver any additional instruments necessary to consummate theTransactions, other than, in the case of each of clauses (i) through (iii), with respect to filings, notices, petitions,statements, registrations, submissions of information, applications and other documents, approvals, consents,registrations,permits,authorizationsandotherconfirmationsrelatingtoAntitrustLaws(asdefinedbelow),whichareaddressedintheparagraph(c)below.NotwithstandinganythingtothecontraryintheMergerAgreement,priortotheMergerEffectiveTime,nopartywillberequiredto,andMyoKardiawillnotwithouttheconsentofParent,payanyconsent or other similar fee, “profit-sharing” or other similar payment or other consideration in anyform(includingincreased rent or other similar payments or commercial accommodation or agree to enter into any amendments,supplementsorothermodificationsto(orwaiversof)theexistingtermsofanycontract),orprovideadditionalsecurity(includingaguaranty)orotherwiseassumeorincuroragreetoassumeorincuranyliability,toobtainanyconsentofanyperson(otherthananygovernmentalauthority)underanycontract;

(b) eachof theparties will useits reasonable best efforts to makeanappropriate filingof a NotificationandReportFormpursuanttotheHSRActwithrespecttotheTransactions,assoonaspracticableandadvisableafterthedateofthe Merger Agreement, but in no event later than ten business days after the date of the Merger Agreement, and toutilize reasonable best efforts to supply as promptly as practicable any additional information and documentarymaterial that may be requested pursuant to the HSRAct. Parent will pay all filing fees applicable for filings madepursuant to this paragraph (b). Further, each party will use its reasonable best efforts to eliminate each and everyimpedimentandobtainallconsentsundertheHSRActoranyothersuchAntitrustLawsthatmayberequiredbyanyforeignorU.S.federal,stateorlocalgovernmentalauthoritypursuantthereto,ineachcasewithcompetentjurisdiction,soastoenablethepartiestoconsummatetheTransactionspriortotheOutsideDate.Withoutlimitingtheforegoing,Parent’s and Purchaser’s reasonable best efforts will include (i) committing to or effecting, by consent decree, holdseparate order, trust, or otherwise, the divestiture, sale, license, transfer, assignment or other disposition of assets orbusinesses of MyoKardia or its subsidiaries, (ii) terminating, relinquishing, modifying, transferring, assigning,restructuring,orwaivingexistingagreements,collaborations,relationships,ventures,contractualrights,obligationsorother arrangements of MyoKardia or its subsidiaries, and (iii) creating or consenting to create any relationships,ventures, contractual rights, obligations, behavioral undertakings or other arrangements of MyoKardia or itssubsidiaries (and, in each case, to enter, or offer to enter, into agreements and stipulate to the entry of an order ordecreeorfileappropriateapplicationswithanygovernmentalauthorityinconnectionwithanyoftheforegoingandinthecaseofactionsbyorwithrespecttoanyofMyoKardiaoritsbusinessesorassets,byconsentingtosuchactionbyMyoKardia) (each a “Divestiture Action”); provided, that Parent and Purchaser will not be required to take aDivestiture Action or any other action pursuant to this paragraph (b) (A) if such Divestiture Action or other actionwouldreasonablybeexpectedtohave,individuallyorintheaggregate,amaterialadverseimpacton,orasmeasuredincomparison to, the expected benefits of the Transactions to Parent and Purchaser and (B) unless such DivestitureActionorotheractionisnecessarytoconsummatetheTransactionspriortotheOutsideDate.InnoeventwillParent,MyoKardiaortheirrespectiveaffiliatesberequiredtoproffer,consenttooragreetooreffectanyundertakingorotheractionrelatingtoanyobjectionsassertedbyanygovernmentalauthoritywithrespecttothe

51

TABLE OF CONTENTS

Transactions under any Antitrust Laws unless such action is conditioned upon the consummation of the Merger.NeitherMyoKardianorits subsidiaries will, withouttheexpresswrittenconsent ofParent, takeoragreetotakeanyaction relating to any objections asserted by any governmental authority with respect to the Transactions under anyAntitrustLawswithrespecttoitsbusinessoroperations,but,ifrequestedbyParentinwriting,MyoKardiawill, andwill cause its subsidiaries to, subject to this paragraph (b), take any such actions to obtain any of the governmentalapprovalscontemplatedinthisparagraph(b);

(c)eachofthepartieswilluseitsreasonablebesteffortsto(i)cooperateinallrespectswitheachotherinconnectionwith any filing or submission with a governmental authority in connection with the Transactions and in connectionwithanyinvestigation or other inquiry byor before a governmental authority relating to the Transactions, includingany proceeding initiated by a private person, and (ii) subject to applicable Laws relating to the exchange ofinformation,consultwiththeotherpartieswithrespecttoinformationrelatingtotheotherpartiesandtheirrespectivesubsidiaries, as the case may be, that appears in any filing made with, or written materials submitted to, any thirdperson or any governmental authority in connection with the Transactions, other than “4(c) documents” and “4(d)documents” as these terms are used in the rules and regulations under the HSR Act. To the extent reasonablypracticable, all telephone calls and meetings with a governmental authority regarding the Transactions will includerepresentatives of Parent and MyoKardia, and each party must inform the other of any communications with agovernmentalauthorityrelatingtoanyAntitrustLaws.Exceptasotherwiserestrictedbythisparagraph(c),ParentandMyoKardia or their outside counsel will have the right to review in advance all written materials submitted orcommunicationsmadetoanygovernmentalauthorityinconnectionwiththeTransactions,ineachcase,totheextentsuchmaterials orcommunicationsarerelatedtoanyAntitrust Laws;providedthat materials requiredtobeprovidedpursuanttothisparagraph(c)mayberedacted(A)toremovereferencesconcerningthevaluationofMyoKardia,(B)asnecessary to comply with contractual arrangements, (C) as necessary to comply with applicable Law, and (D) asnecessary to address reasonable privilege or confidentiality concerns; provided further, that a party may reasonablydesignateanycompetitivelysensitivematerialprovidedtoanotherpartyunderthisparagraph(c)as“OutsideCounselOnly”. Notwithstanding the foregoing, Parent will, following consultation with MyoKardia and after giving dueconsiderationtoitsviewsandactingreasonablyandingoodfaith,directandcontrolallaspectsofeachparty’seffortsto gain regulatory clearance either before any governmental authority or in any action brought to enjoin theTransactionspursuanttoanyAntitrustLaws;and

(d)neitherParentnorPurchaserwill,norwilltheypermittheirsubsidiariesorcontrolledaffiliatesto,acquireoragreetoacquireanyrights,interests,assets,business,personordivisionthereof(throughacquisition,license,jointventure,collaboration or otherwise), if such acquisition would reasonably be expected to materially increase the risk of notobtaining any applicable clearance, consent, approval or waiver under the HSR Act or other Antitrust Laws withrespect to the Offer or the Merger or the other Transactions or otherwise not complying with the requirementsdescribedinthissection“—RegulatoryUndertakings.”

“Antitrust Laws” means the Sherman Act, the Clayton Act, the HSR Act, the Federal Trade Commission Act, allapplicableforeignantitrustlawsandallotherapplicableLawsissuedbyagovernmentalauthoritythataredesignedorintendedtoprohibit,restrictorregulateactionshavingthepurposeoreffectofmonopolizationorrestraintoftradeorlesseningofcompetitionthroughmergeroracquisition.

NotificationofCertainMatters;LitigationRelatedtotheMerger

Prior to the Merger Effective Time, Parent and MyoKardia will give prompt notice to the other of (a) any Actionscommencedor,tosuchparty’sKnowledge,threatenedagainstsuchpartywhichrelatestotheMergerAgreementortheTransactions, (b) any fact, event or circumstance that (i) has had or would reasonably be expected to result in anyMaterialAdverseEffectorParentMaterialAdverseEffect,asapplicable,or(ii)isreasonablylikelytoresultinanyoftheOfferConditionsnotbeingabletobesatisfiedpriortotheOutsideDate,and(c)anyClinicalEvent.

“Clinical Event”meansanyaction,oranyadverseinspectionoraudit findingthatwouldreasonablybeexpectedtoresult inanaction, byagovernmental authoritytoplaceaclinical holdorderon, or otherwiseterminate, suspendorrestrict in any material respect, any ongoing clinical trial conducted by MyoKardia or any of its subsidiaries withrespecttoanymavacamten,danicamtiv,MYK-224,LUS-1,ACT-1andtheearlystagetargetscoveredbyMyoKardia’sgenetic cardiomyopathy programs (each, a “Product”) which would reasonably be expected to result in a materialdelay or material impairment in the ability of MyoKardia to obtain any regulatory authorizations from anygovernmentalauthorityrelatingtosuchProduct.

52

TABLE OF CONTENTS

MyoKardia(a)will(i)giveParenttheopportunitytoparticipatein,butnotcontrol,thedefenseandsettlementofanyTransactionLitigationagainstMyoKardiaoritsdirectorsrelatingtotheMergerAgreementortheTransactions(totheextent that the attorney-client privilege is not undermined or otherwise adversely affected) and (ii) keep Parentreasonablyinformedwithrespecttothestatusthereof,and(b)willnotofferorproposetosettle,settleoragreetosettleany such Transaction Litigation without Parent’s prior written consent (which will not be unreasonably withheld,conditionedordelayed).

LawsuitsarisingoutoforrelatingtotheOffer,theMergeroranyothertransactionsreferencedhereinmaybefiledinthefuture.

17. Fees and Expenses

WehaveretainedMacKenziePartners,Inc.toactastheInformationAgentandEquinitiTrustCompanytoactastheDepositaryinconnectionwiththeOffer.TheInformationAgentmaycontactholdersofSharesbymail,telephoneandpersonal interviews and may request brokers, dealers, commercial banks, trust companies and other nominees toforward materials relating to the Offer to beneficial owners. The Information Agent and the Depositary each willreceivereasonableandcustomarycompensationfortheirrespectiveservices,willbereimbursedforcertainreasonableout-of-pocket expenses and will be indemnified against certain liabilities in connection therewith, including certainliabilitiesundertheU.S.federalsecuritieslaws.

Wewillnotpayanyfeesorcommissionstoanybrokerordealeroranyotherperson(otherthantheInformationAgentand the Depositary) for soliciting tenders of Shares pursuant to the Offer. Brokers, dealers, commercial banks, trustcompaniesandothernomineeswill,uponrequest,bereimbursedbyPurchaserforreasonableandnecessarycostsandexpensesincurredbytheminforwardingmaterialstotheircustomers.

18. Miscellaneous

TheOffer is not beingmadeto, nor will tenders beacceptedfromoronbehalf of, holders of SharesinanyU.S. orforeignjurisdictioninwhichthemakingoftheOfferoracceptancethereofwouldnotbeincompliancewiththelawsofsuchjurisdiction.InthosejurisdictionswheretheapplicableLawsrequirethattheOfferbemadebyalicensedbrokeror dealer, the Offer will bedeemedtobemadeonbehalf of Purchaser byoneor more registeredbrokers or dealerslicensedunderthelawsofsuchjurisdictiontobedesignatedbyPurchaser.WearenotawareofanyjurisdictionwherethemakingoftheOfferisprohibitedbyanyadministrativeorjudicialactionpursuanttoanyvalidstatestatute.IfwebecomeawareofanyvalidstatestatuteprohibitingthemakingoftheOfferortheacceptanceoftheShares,wewillmakeagoodfaithefforttocomplywiththatstatestatute.If,afteragoodfaitheffort,wecannotcomplywiththestatestatute, wewillnotmaketheOfferto,norwill weaccepttendersfromoronbehalfof, theholdersofSharesinthatstate.

No person has been authorized to give any information or make any representation on behalf of Purchaser,Parent or any of their respective affiliates, not contained in this Offer to Purchase or in the related Letter ofTransmittal and, if given or made, such information or representation must not be relied upon as having beenauthorized.

WehavefiledwiththeSECaScheduleTO,together withexhibits thereto, furnishingcertainadditional informationwithrespecttotheOffer,andmayfileamendmentstoourScheduleTO.Inaddition,MyoKardiahasfiledtheSchedule14D-9,togetherwiththeexhibitsthereto,settingforththeMyoKardiaBoardRecommendationandfurnishingcertainadditionalrelatedinformation.OurScheduleTO,theSchedule14D-9andanyexhibitsoramendmentstheretomaybeexaminedandcopies maybeobtainedfromtheSECinthe manner describedin “—Section8—Certain InformationConcerningMyoKardia”and“—Section9—CertainInformationConcerningPurchaserandParent”above.

Gotham Merger Sub Inc.

October19,2020

53

TABLE OF CONTENTS

SCHEDULE I

DIRECTORS AND EXECUTIVE OFFICERS OF PARENT

Thename,age,countryofcitizenship,currentprincipaloccupationoremploymentandmaterialoccupations,positions,offices or employment for the past five years of each director and executive officer of Parent are set forth below.Unlessotherwiseindicated, eachoccupationset forthopposite anindividual’s namerefers toa positionwithParent.Unlessotherwiseindicated,thebusinessaddressofeachdirector,executiveofficeris430E.29thStreet,14FL,NewYork,NY10016.Directorsareidentifiedbyanasterisk.

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

GiovanniCaforio,M.D.* Dr.CaforiohasservedasChairmanoftheBoardsinceMay2017andChiefExecutiveOfficersinceMay2015.Hehasbeenadirectorsince2014.HeservedasChiefOperatingOfficerfromJune2014toMay2015,ExecutiveVicePresidentandChiefCommercialOfficerfromNovember2013toJune2014,President,U.S.fromOctober2011toNovember2013,SeniorVicePresident,GlobalCommercializationandImmunologyfromMay2010toOctober2011,SeniorVicePresident,Oncology,U.S.andGlobalCommercializationfromMarch2009toMay2010,SeniorVicePresident,U.S.OncologyfromJanuary2007toMarch2009,SeniorVicePresident,EuropeanMarketingandBrandCommercializationfromMay2004toJanuary2007.

USAandItaly

VickiL.Sato,Ph.D.* Dr.SatoisaLeadIndependentDirector.Shehasservedasadirectorsince2006.ShehasservedasChairmanoftheBoardofDenaliTherapeutics,Inc.sinceAugust2016andadirectorofthatcompanysinceApril2015.SheservedasProfessorofmanagementpracticeattheHarvardBusinessSchoolfromJuly2005toJune2017andProfessorofthepracticeofmolecularandcellbiologyatHarvardUniversityfromJuly2005toOctober2014.

USA

PeterJ.Arduini* Mr.Arduinihasservedasadirectorsince2016.HehasservedasPresidentandChiefExecutiveOfficeratIntegraLifeSciencesHoldingsCorporation,aglobalmedicaltechnologycompanysinceJanuary2012andPresidentandChiefOperatingOfficeratthatcompanyfromNovember2010toJanuary2012.HeservedasCorporateVicePresidentandPresidentofMedicationDeliveryatBaxterHealthcarefrom2005to2010.

USA

RobertBertolini* Mr.Bertolinihasservedasadirectorsince2017.HeservedasPresidentandChiefFinancialOfficerofBausch&LombIncorporatedfromFebruary2013toAugust2013.Priortothat,heservedasExecutiveVicePresidentandChiefFinancialOfficeratScheringPloughCorp.throughitsmergerwithMerck&Co.,Inc.fromNovember2003toNovember2009.

USA

SchI-1

TABLE OF CONTENTS

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

MichaelW.Bonney* Mr.Bonneyhasservedasadirectorsince2019.HepreviouslyservedasChiefExecutiveOfficerandChairmanofKaleidoBiosciences,Inc.fromJune2017toAugust2018andhasservedastheExecutiveChairoftheBoardofthatcompanysinceAugust2018.Priortothat,Mr.BonneywasPartnerofThirdRockVentures,LLCfromJanuary2016toJuly2016.Beforethat,hewasChiefExecutiveOfficerandamemberoftheBoardofDirectorsofCubistPharmaceuticalsInc.untilitwasacquiredbyMerck&Co.,Inc.fromJune2003toDecember2014.Mr.BonneyservedasChairoftheBoardofTrusteesofBatescollegefrom2010to2019.

USA

MatthewW.Emmens* Mr.Emmenshasservedasadirectorsince2017.From2003to2008,heservedasChiefExecutiveOfficerofShirePLCandsubsequentlyservedasChairmanoftheBoardfrom2008to2014.Mr.EmmenswasalsoChairman,PresidentandChiefExecutiveOfficerofVertexPharmaceuticalsIncorporatedfrom2009to2012.Beforethat,heservedasPresident,WorldwidePharmaceuticalsofMerckKGaAfrom1999to2003.Priortothat,hewasChiefExecutiveOfficer,CommercialOperationsofAstraMerckInc.from1992to1999.

USA

JuliaA.Haller,M.D.* Dr.Hallerhasservedasadirectorsince2019.Dr.HallerhasservedasOphthalmologist-in-ChiefofWillsEyeHospitalinPhiladelphia,PA,wheresheholdstheWilliamTasman,M.D.EndowedChairsince2007.SheiscurrentlyProfessorandChairoftheDepartmentofOphthalmologyatSidneyKimmelMedicalCollegeatThomasJeffersonUniversityandThomasJeffersonUniversityHospitals.PriortothatshewasamemberoftheJohnsHopkinsfaculty,wheresheheldtheKatharineGrahamChairinOphthalmologyuntil2007.

USA

DineshC.Paliwal* Mr.Paliwalhasservedasadirectorsince2013.HeservedasPresidentandChiefExecutiveOfficeratHarmanInternationalfrom2007toApril2020andservedasChairmanofthatcompanyfromJuly2008untilMarch2017.Mr.PaliwaliscurrentlyservingasSeniorAdvisortotheHarmanInternationalboardofdirectorsandchiefexecutiveofficeruntilDecember2020.Priortothat,Mr.PaliwalwasamemberoftheGroupExecutiveCommitteeofABBLtd.fromJanuary2001toJune2007,PresidentofGlobalMarketsandTechnologyofthatcompanyfromJanuary2006toJune2007,ChairmanandChiefExecutiveOfficerofABBNorthAmericafromJanuary2004toJune2007,andservedasPresidentandChiefExecutiveOfficerofABBAutomationTechnologiesDivisionfromOctober2002toDecember2005.

USA

SchI-2

TABLE OF CONTENTS

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

PaulaA.Price* Ms.PricehasservedasadirectorsinceSeptember2020.Mostrecently,sheservedasExecutiveVicePresidentandChiefFinancialOfficerofMacy’s,Inc.untilMay2020.Shecurrentlyremainsanadvisortotherenownedretailer.Priortothat,shewasafull-timeSeniorLecturerforHarvardBusinessSchoolintheAccountingandManagementUnitfrom2014-2018.Beforethat,Ms.PricealsoservedasEVPandCFOforAholdUSA,ControllerandChiefAccountingOfficer(CAO)ofCVSCaremarkCorporation,andinseniorleadershippositionsatJPMorganChase,PrudentialFinancial,Diageo,andKraftFoods.ACertifiedPublicAccountant(CPA),shebeganhercareeratArthurAndersen&Co.Ms.PricecurrentlyservesontheBoardsofDirectorsofAccentureplcandWesternDigitalCorp.ShepreviouslyservedontheBoardofDirectorsofDollarGeneralCorporation.

USA

DericaW.Rice* Mr.RicehasservedasadirectorsinceSeptember2020.FromMarch2018toFebruary2020,heservedasEVPofCVSHealthandPresidentofitspharmacybenefitsmanagement(PBM)business,CVSCaremark,whereheledthePBMbusiness.Priortothat,heservedastheEVPofglobalservicesandCFOforEliLillyandCompanyfrom2006to2017.HeiscurrentlyamemberofTheWaltDisneyCompany’sBoardofDirectorsandpreviouslyservedontheBoardofDirectorsofTargetCorporation.

USA

TheodoreR.Samuels* Mr.Samuelshasservedasdirectorsince2017.HewasPresidentoftheCapitalGuardianTrustCompanyfrom2010to2016.HewasalsoarepresentativeofCapitalGroupforFocusingCapitalontheLongTermfrom2014to2015.AtCapitalGroup,Mr.Samuelsservedasamemberoftheboardfrom2005to2009,servedonboththeAuditandFinanceCommitteesfrom2013to2016.

USA

GeraldL.Storch* Mr.Storchhasservedasadirectorsince2012.Mr.StorchhasservedasChiefExecutiveOfficerofStorchAdvisorssinceNovember2017andalsoheldthepositionfromNovember2013toJanuary2015.FromJanuary2015toNovember2017,hewasChiefExecutiveOfficerofHudson’sBayCompany,aleadingownerandoperatorofdepartmentstores,includingSaksFifthAvenue,Lord&Taylor,Hudson’sBayDepartmentStores,HomeOutfitters,SaksOFF5th,Kaufhof,InnoandtheecommercebusinessGilt.Beforethat,Mr.StorchwasChairmanofToys“R”Us,Inc.,fromFebruary2006toNovember2013andwasChiefExecutiveOfficerFebruary2006toMay2013.

USA

SchI-3

TABLE OF CONTENTS

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

KarenH.Vousden,Ph.D.* Dr.Vousdenhasbeenadirectorsince2018.ShehasalsobeenSeniorGroupLeaderattheFrancisCrickInstituteinLondonsinceFebruary2017andhasbeenChiefScientistofCancerResearchUKsinceJuly2016.Priortothat,Dr.VousdenwasDirectoroftheCancerResearch—UK(CRUK)BeatsonInstituteinGlasgowfrom2002to2016.

UnitedKingdom

PhyllisR.Yale* Ms.Yalehasservedasdirectorsince2019.SheisanAdvisoryPartneratBain&Company.Ms.YalejoinedBainin1982whereshehasbeenaleaderinbuildingBain’shealthcarepracticeandhasservedinanumberofleadershiproles.SheisChairoftheBoardofBlueCrossBlueShieldofMassachusettsandamemberoftheadvisoryboardofHarvardBusinessSchoolHealthcareInitiative.

USA

NadimAhmed Mr.AhmedhasservedasExecutiveVicePresidentandPresident,Hematologysince2019.HewasExecutiveVicePresident/PresidentHematology/OncologyatCelgenefrom2017to2019,SeniorVicePresidentWorldwideMarketsatCelgenefrom2016to2017andCorporateVicePresident,U.S.CommercialatCelgenefrom2014to2016.

USA

ChristopherBoerner,Ph.D. Dr.BoernerhasservedasExecutiveVicePresidentandChiefCommercializationOfficersince2018.HewasPresidentandHead,InternationalMarketsfrom2017to2018,PresidentandHeadofU.S.Commercialfrom2015to2017andExecutiveVicePresidentatSeattleGeneticsfrom2014to2015.

USA

AdamDubow Mr.DubowhasservedasSeniorVicePresident,ChiefComplianceandEthicsOfficersince2018.HewasVicePresidentandAssociateGeneralCounsel,ResearchandDevelopmentfrom2015to2018andVicePresidentandAssistantGeneralCounsel,China,JapanandInterconRegionandEMACRegionfrom2013to2015.

USA

JosephE.Eid,M.D. Dr.EidhasservedasSeniorVicePresidentandHeadofGlobalMedicalAffairssince2017.HewasHeadofGlobalMedicalfrom2017to2019andVicePresident,HeadofOncologyGlobalMedicalAffairsatMerckfrom2014to2017.

USA

DavidV.Elkins Mr.ElkinshasservedasExecutiveVicePresidentandChiefFinancialOfficersince2019.HewasChiefFinancialOfficeratCelgenefrom2018to2019,WorldwideVicePresidentandChiefFinancialOfficer,ConsumerProducts,MedicalDevelopmentandCorporateFunctionsatJohnson&Johnsonfrom2017to2018andGroupVicePresidentandChiefFinancialOfficer,ConsumerandConsumerMedicinesatJohnson&Johnsonfrom2014to2017.

USA

SchI-4

TABLE OF CONTENTS

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

SamitHirawat,M.D. Dr.HirawathasservedasExecutiveVicePresident,ChiefMedicalOfficer,GlobalDrugDevelopmentsince2019.HewasExecutiveVicePresident,HeadofOncologyDevelopmentatNovartisfrom2017to2019andSeniorVicePresident&GlobalProgramHeadatNovartisfrom2012to2016.

USA

SandraLeung Ms.LeunghasservedasExecutiveVicePresidentandGeneralCounselsince2015.ShewasExecutiveVicePresident,GeneralCounselandCorporateSecretaryfrom2014to2015andGeneralCounselandCorporateSecretaryfrom2007to2014.

USA

KathrynMetcalfe Ms.MetcalfehasservedasExecutiveVicePresident,CorporateAffairssince2020.ShewasChiefCommunicationsOfficeratCVSHealthCorporationfrom2018to2019,ChiefCommunicationsOfficeratAetna,Inc.from2016to2018andChiefCommunicationsOfficeratDeloitte,LLPfrom2011to2016.

USA

ElizabethA.Mily Ms.MilyhasservedasExecutiveVicePresident,Strategy&BusinessDevelopmentsinceMarch2020.

USA

AnnM.Powell Ms.PowellhasservedasExecutiveVicePresident,ChiefHumanResourcesOfficersince2019.ShewasSeniorVicePresident,ChiefHumanResourcesOfficerfrom2016to2019,SeniorVicePresident,GlobalHumanResourcesfrom2013to2016andChiefHumanResourcesOfficeratShirePharmaceuticalsfrom2009to2013.

USA

LouSchmukler Mr.SchmuklerhasservedasExecutiveVicePresidentandPresident,GlobalProductDevelopment&Supplysince2019.HewasSeniorVicePresidentandPresident,GlobalProductDevelopmentandSupplyfrom2017to2019andPresident,GlobalProductDevelopmentandSupplyfrom2011to2017.

USA

RupertVessey,D.Phil. Dr.VesseyhasservedasExecutiveVicePresidentandPresident,ResearchandEarlyDevelopmentsince2019.HewasPresidentofResearchandEarlyDevelopmentatCelgenefrom2015to2019.

USA

PaulvonAutenried Mr.vonAutenriedhasservedasExecutiveVicePresident,ChiefInformationOfficersince2019.HewasSeniorVicePresident,ChiefInformationOfficerfrom2016to2019andSeniorVicePresident,EnterpriseServicesandChiefInformationOfficerfrom2012to2016.

USA

SchI-5

TABLE OF CONTENTS

DIRECTORS AND EXECUTIVE OFFICERS OF PURCHASER

Thename,age,countryofcitizenship,currentprincipaloccupationoremploymentandmaterialoccupations,positions,officesoremploymentforthepastfiveyearsofeachdirectorandexecutiveofficerofPurchaseraresetforthbelow.Unlessotherwiseindicated,eachoccupationsetforthoppositeanindividual’snamereferstoapositionwithPurchaser.Unless otherwise indicated, the business address of each director and executive officer of Purchaser is 430 E. 29thStreet,14FL,NewYork,NY10016.Directorsareidentifiedbyanasterisk.

NameCurrent Principal Occupation or Employment

and Five-Year Employment HistoryCountry of Citizenship

ElizabethA.Mily* Ms.MilyhasservedasDirector,PresidentandChiefExecutiveOfficerofPurchasersinceOctober2020.Ms.MilyhasalsoservedasExecutiveVicePresident,Strategy&BusinessDevelopmentforParentsinceMarch2020.

USA

JeffreyGalik* Mr.GalikhasservedasDirectorandVicePresidentandTreasurerofPurchasersinceOctober2020.Mr.GalikhasalsoservedasSeniorVicePresidentandTreasurerforParentsince2010.

USA

BrianHeaphy* Mr.HeaphyhasservedasDirectorandVicePresidentofPurchasersinceOctober2020.Mr.HeaphyhasalsoservedasVicePresident,CorporateDevelopment,Cardiovascular&NeuroscienceBusinessDevelopmentsince2019forParent,andExecutiveDirector,BusinessDevelopment,since2011forParent.

USA

KatherineKelly Ms.KellyhasservedasSecretaryofPurchasersinceOctober2020.Ms.KellyhasalsoservedasVicePresidentandCorporateSecretaryforParentsince2015.

USA

SchI-6

TABLE OF CONTENTS

Manually signed facsimile copies of the Letter of Transmittal will be accepted. The Letter of Transmittal andcertificatesforSharesandanyotherrequireddocumentsshouldbesenttotheDepositaryatoneoftheaddressessetforthbelow:

The Depositary for the Offer is:

Equiniti Trust Company

***By Mail:By5:00p.m.NYCtimeonExpirationDate

EquinitiTrustCompanyShareownerServices

VoluntaryCorporateActionsP.O.Box64858

St.Paul,Minnesota55164-0858

***By Overnight Courier:By5:00p.m.NYCtimeonExpirationDate

EquinitiTrustCompanyShareownerServices

VoluntaryCorporateActions1110CentrePointeCurve,Suite101MendotaHeights,Minnesota55120

IfyouhavequestionsorneedadditionalcopiesofthisOffertoPurchaseandtheLetterofTransmittal,youcancalltheInformation Agent at their respective addresses and telephone numbers set forth below. You may also contact yourbroker,dealer,commercialbank,trustcompanyorothernomineeforassistanceconcerningtheOffer.

The Information Agent for the Tender Offer is:

 

1407BroadwayNewYork,NewYork10018

(212)929-5500or

Call Toll-Free 1-800-322-2885Email:tenderoffer@mackenziepartners.com

Exhibit (a)(1)(ii)

LETTER OF TRANSMITTAL to Tender Shares of Common Stock

of

MYOKARDIA, INC.

at $225.50 Net per Share

Pursuant to the Offer to Purchase Dated October 19, 2020

by

GOTHAM MERGER SUB INC.

a wholly owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONEMINUTE AFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE

OFFER IS EXTENDED OR EARLIER TERMINATED.

The Depositary for the Offer is:

Equiniti Trust Company

***By Mail: ***By Overnight Courier:

By5:00p.m.NYCtimeonExpirationDateEquinitiTrustCompanyShareownerServices

VoluntaryCorporateActionsP.O.Box64858

St.Paul,Minnesota55164-0858

By5:00p.m.NYCtimeonExpirationDateEquinitiTrustCompanyShareownerServices

VoluntaryCorporateActions1110CentrePointeCurve,Suite101MendotaHeights,Minnesota55120

DELIVERY OF THIS LETTER OF TRANSMITTAL TO AN ADDRESS OTHER THAN AS SET FORTHABOVE, OR TRANSMISSION OF INSTRUCTIONS TO A FACSIMILE NUMBER OTHER THAN AS SETFORTH ABOVE, WILL NOT CONSTITUTE A VALID DELIVERY.

ACCOUNTNUMBER CERTSHARES BOOKSHARES TOTALSHARES ISSUENUMBER

FOR OFFICE USE ONLY Approved       W-9 Completed      

DESCRIPTION OF SHARES TENDERED

Account Registration (Please Fill in, if blank)

Please make any address correction belowShare Certificate(s) and Share(s) Tendered

(Please attach additional signed list, if necessary)

 ☐indicatespermanentaddresschangeCertificateNumber(s)

and/orindicateBook-Entry

TotalNumberofSharesRepresentedbyCertificate(s)

NumberofShares

Tendered(1,2)

TotalSharesTendered(1) IfsharesareheldinBook-Entryform,youmust indicatethenumberofsharesyouaretendering.Otherwise,allSharesrepresentedby

Book-Entry delivered to the Depositary Agent will be deemed to have been tendered.By signing and submitting this Letter ofTransmittal you warrant that these shares will not be sold, including through limit order request, unless properly withdrawnfrom the Offer. SeeInstruction4.

(2) If youwishto tender fewerthanall shares representedbyanycertificate listedabove, pleaseindicate in this columnthenumberofsharesyouwishtotender.Otherwise,allSharesrepresentedbyShareCertificatesdeliveredtotheDepositaryAgentwillbedeemedtohavebeentendered.SeeInstruction4.

THE INSTRUCTIONS ACCOMPANYING THIS LETTER OF TRANSMITTAL SHOULD BE READCAREFULLY BEFORE THIS LETTER OF TRANSMITTAL IS COMPLETED. REQUESTS FORASSISTANCE OR ADDITIONAL COPIES OF THE OFFER TO PURCHASE AND THIS LETTER OFTRANSMITTAL MAY BE MADE TO OR OBTAINED FROM THE INFORMATION AGENT AT ITSADDRESS OR TELEPHONE NUMBER SET FORTH BELOW.

If the certificate(s) representing Shares (as defined below) to be tendered have been mutilated, lost, stolen ordestroyed, stockholders should contact MyoKardia, Inc.’s transfer agent, Computershare Trust Company, N.A.,immediately by calling 1-800-564-6253 (toll-free). This Letter of Transmittal and related documents cannot beprocessed until the procedures for replacing such certificate(s) have been followed. You may be required to posta bond to secure against the risk that the Share certificate(s) may be subsequently recirculated. See Instruction9.

You must sign this Letter of Transmittal in the appropriate space provided below, with signature guarantee ifrequired, and complete the enclosed IRS Form W-9 or provide the appropriate IRS Form W-8.

The Offer (as defined below) is not being made to, nor will tenders be accepted from or on behalf of, holders ofShares in any jurisdiction in which the making of the Offer or acceptance thereof would not be in compliancewith the laws of such jurisdiction.

This Letter of Transmittal is to be used by stockholders of MyoKardia, Inc. (a) if certificates are to be forwardedherewithor(b)ifSharesareheldinbook-entryformontherecordsoftheDepositary.

HoldersofoutstandingShares,whosecertificatesforsuchSharesarenotimmediatelyavailableorwhocannotdeliversuch certificates and all other required documents to the Depositary at or prior to the Expiration Time (as definedbelow)orwhocannotcompletetheprocedureforbook-entrytransferatorpriortotheExpirationTime,musttendertheir Shares according to the guaranteed delivery procedure set forth in Section 3 of the Offer to Purchase. SeeInstruction2.Delivery of documents to The Depository Trust Company (the “Book-Entry Transfer Facility” or“DTC”) does not constitute delivery to the Depositary.

NOTE: SIGNATURES MUST BE PROVIDED BELOW PLEASE READ ACCOMPANYING INSTRUCTIONS CAREFULLY

 ☐ CHECK HERE IF TENDERED SHARES ARE BEING DELIVERED PURSUANT TO A NOTICE OFGUARANTEED DELIVERY PREVIOUSLY SENT TO THE DEPOSITARY AND COMPLETE THEFOLLOWING:

Name(s)ofTenderingStockholder(s)                               

DateofExecutionofNoticeofGuaranteedDelivery                ,20    

NameofInstitutionwhichGuaranteedDelivery                            

Ifdeliveryisbybook-entrytransfer:                                

NameofTenderingInstitution                                     

AccountNumber                                         

TransactionCodeNumber                                    

LadiesandGentlemen:

The undersigned hereby tenders to Gotham Merger Sub Inc., a Delaware corporation (“Purchaser”) and a whollyownedsubsidiaryofBristol-MyersSquibbCompany,aDelawarecorporation(“Parent”),theabove-describedsharesofcommon stock, par value $0.0001 per share (the “Shares”), of MyoKardia, Inc., a Delaware corporation(“MyoKardia”),pursuanttoPurchaser’soffertopurchasealloutstandingSharesat$225.00perShare,incash,withoutinterest,subjecttoanyrequiredwithholdingoftaxesanduponthetermsandsubjecttotheconditionssetforthintheOffer to Purchase dated October 19, 2020 (together with any amendments or supplements thereto, the “Offer toPurchase”), receipt of which is hereby acknowledged, and in this Letter of Transmittal (which, together with anyamendments or supplements thereto, collectively constitute the “Offer”). The Offer expires at midnight (New YorkCitytime),oneminuteafter11:59p.m.NewYorkCitytime,onNovember16,2020,unlessextendedbyPurchaserasdescribedintheOffertoPurchase(asitmaybeextended,the“ExpirationTime”).TotheextentpermittedundertheMergerAgreement(asdefinedbelow),Purchaserreservestherighttotransferorassign,inwholeorfromtimetotimeinpart,tooneormoreofitsaffiliatestherighttopurchaseSharestenderedpursuanttotheOffer,butanysuchtransferor assignment will not relieve Purchaser of its obligations under the Offer or prejudice the undersigned’s rights toreceivepaymentforSharesvalidlytendered(andnotproperlywithdrawn)andacceptedforpayment.

UponthetermsandsubjecttotheconditionsoftheOffer(including,iftheOfferisextendedoramended,thetermsandconditions of such extension or amendment), and effective upon acceptance for payment for the Shares validlytenderedherewithinaccordancewiththetermsoftheOffer,theundersignedherebysells,assignsandtransfersto,orupontheorder of, Purchaser all right, title andinterest inandtoall of theSharesthat arebeingtenderedhereby. Inaddition, the undersigned hereby irrevocably appoints Equiniti Trust Company as the depositary for the Offer (the“Depositary”) and the true and lawful agent and attorney-in-fact and proxy of the undersigned with respect to suchShares, withfull powerof substitution(suchproxyandpowerof attorneybeingdeemedtobeanirrevocable powercoupledwithaninterestintheSharestenderedbythisLetterofTransmittal),to(a)delivercertificatesforsuchShares,ortransferownershipofsuchSharesontheaccountbooksmaintainedbytheBook-EntryTransferFacility,together,inany such case, with all accompanying evidences of transfer and authenticity, to or upon the order of Purchaser, (b)presentsuchSharesfortransferonthebooksofMyoKardiaand(c)receiveallbenefitsandotherwiseexerciseallrightsofbeneficialownershipofsuchShares,allinaccordancewiththetermsoftheOffer.

TheundersignedherebyirrevocablyappointseachofthedesigneesofPurchasertheattorneys-in-factandproxiesoftheundersigned, each with full power of substitution, to exercise all voting and other rights of the undersigned in suchmanneraseachsuchattorney-in-factandproxyorhissubstituteshallinhissolediscretiondeemproper,withrespecttoalloftheSharestenderedherebywhichhavebeenacceptedforpaymentbyPurchaserpriortothetimeofanyvoteorotheraction,atanymeetingofstockholdersofMyoKardia(whetherannualorspecialandwhetherornotanadjournedmeeting), by written consent or otherwise. This proxy and power of attorney is irrevocable and is granted inconsiderationof,andiseffectiveupon,theacceptanceforpaymentofsuchSharesbyPurchaserinaccordancewiththetermsoftheOffer.Suchacceptanceforpaymentshallrevokeanyotherproxies,powersofattorney,orwrittenconsentgrantedbytheundersignedatanytimewithrespecttosuchShares,andnosubsequentproxiesorpowersofattorneywillbegiven,orwrittenconsentswillbeexecutedbytheundersigned(andifgivenorexecuted,willnotbedeemedtobe effective). Purchaser reserves the right to require that, in order for Shares to be deemed validly tendered,immediately upon Purchaser’s acceptance for payment of such Shares, Purchaser or its designees must be able toexercise full voting, consent and other rights with respect to such Shares, including voting at any meeting ofMyoKardia’sstockholders.

Theundersignedherebyrepresentsandwarrantsthattheundersignedhasfullpowerandauthoritytotender,sell,assignandtransfertheSharestenderedhereinandthatwhenthesameareacceptedforpaymentbyPurchaser,Purchaserwillacquire good, marketable and unencumbered title thereto, free and clear of all liens, restrictions, charges andencumbrances and that the same will not be subject to any adverse claims. The undersigned hereby represents andwarrantsthattheundersignedistheregisteredowneroftheShares,ortheSharecertificate(s)havebeenendorsedtotheundersignedinblank,ortheundersignedisaparticipantintheBook-EntryTransferFacilitywhosenameappearsonasecurity position listing as the owner of the Shares. The undersigned will, upon request, execute and deliver anyadditional documents deemed by the Depositary or Purchaser to be reasonably necessary to complete the sale,assignmentandtransferoftheSharestenderedhereby.

All authority herein conferred or agreed to be conferred shall not be affected by, and shall survive, the death orincapacity of the undersigned, and any obligation of the undersigned hereunder shall be binding upon the heirs,executors,administrators, personalrepresentatives,trusteesinbankruptcy,successorsandassignsoftheundersigned.ExceptasstatedintheOffer,thistenderisirrevocable.

TheundersignedherebyacknowledgesthatdeliveryofanySharecertificate(s)shallbeeffected,andriskoflossandtitletosuchSharecertificate(s)shallpass,onlyupontheproperdeliveryofsuchSharecertificate(s)ortransferoftheuncertificatedSharesrepresentedbybookentrytotheDepositary.

TheundersignedunderstandsthattendersofSharespursuanttoanyoneoftheproceduresdescribedinSection3oftheOffertoPurchaseandintheInstructionsheretowillconstituteanagreementbetweentheundersignedandPurchaseruponthetermsandsubjecttotheconditionsoftheOffer.Withoutlimitingtheforegoing,ifthepricetobepaidintheOffer is amended in accordance with the terms of the Agreement and Plan of Merger dated as of October 3, 2020amongParent, Purchaser andMyoKardia (the “MergerAgreement”) pursuant to which the Offer is being made, thepricetobepaidtotheundersignedwillbetheamendedpricenotwithstandingthefactthatadifferentpriceisstatedinthisLetterofTransmittal.

Unlessotherwiseindicatedunder“SpecialPaymentInstructions,”pleaseissuethecheckforthepurchasepriceofanyShares purchased, and, if appropriate, return any certificates evidencing Shares not tendered or not accepted forpayment in the name(s) of the undersigned. Similarly, unless otherwise indicated under “Special DeliveryInstructions,” please mail the check for the purchase price of any Shares purchased and any certificates evidencingSharesnottenderedornotacceptedforpayment(andaccompanyingdocuments,asappropriate)totheundersignedatthe address shown below the undersigned’s signature(s). In the event that both “Special Payment Instructions” and“SpecialDeliveryInstructions”arecompleted,pleaseissuethecheckforthepurchasepriceofanySharespurchasedand return any Shares not tendered or not accepted for payment in the name(s) of, and mail said check and anycertificatesto,theperson(s)soindicated.TheundersignedrecognizesthatPurchaserhasnoobligation,pursuanttothe“SpecialPaymentInstructions,”totransferanySharesfromthenameoftheregisteredholder(s)thereofifPurchaserdoesnotacceptforpaymentanyoftheSharessotendered.

SPECIAL PAYMENT INSTRUCTIONS (See Instructions 1, 6, 7 and 8)

TobecompletedONLYifthecheckforthepurchasepriceofSharespurchased(lesstheamountofanyfederalincomeandbackupwithholdingtaxrequiredtobewithheld)istobeissuedinthenameofsomeoneotherthantheundersigned.

Issueto:

Name

(Please Print)

Address

(Include Zip Code)

SPECIAL DELIVERY INSTRUCTIONS

TobecompletedONLYifthecheckforthepurchasepriceofSharespurchased(lesstheamountofanyfederalincomeandbackupwithholdingtaxrequiredtobewithheld)istobemailedtosomeoneotherthantheundersignedortotheundersignedatanaddressotherthanthatshownbelowtheundersigned’ssignature(s).

Mailto:

Name

(Please Print)

Address

(Include Zip Code)

IMPORTANT

STOCKHOLDER: SIGN HERE (U.S. Holders: Please complete and return the IRS Form W-9 included herein)

(Non-U.S. Holders: Please obtain, complete and return appropriate IRS Form W-8)

(Must besignedbyregisteredholder(s) exactlyas name(s) appear(s) onstockcertificate(s) or ona securitypositionlistingorbyperson(s)authorizedtobecomeregisteredholder(s)bycertificatesanddocumentstransmittedherewith.Ifsignature is by a trustee, executor, administrator, guardian, attorney-in-fact, agent, officer of a corporation or otherpersonactinginafiduciaryorrepresentativecapacity,pleasesetforthfulltitleandseeInstruction5.)

Signature(s) of Stockholder(s)

Dated                                   ,20       

Name(s)                                           

(Please Print)

Capacity(fulltitle)(SeeInstruction5):                                 

Address                                            

(Include Zip Code)

Guarantee of Signature(s)  

(If required; see Instructions 1 and 5) (For use by Eligible Institutions only. Place

medallion guarantee in space below)

NameofFirm                                          

Address                                           

(Include Zip Code)

AuthorizedSignature                                      

Name(s)                                           

(Please Print)

AreaCodeandTelephoneNumber                                  

Dated                                    ,20      

INSTRUCTIONS  

Forming Part of the Terms and Conditions of the Offer

1.Guarantee of Signatures.Exceptasotherwiseprovidedbelow,allsignaturesonthisLetterofTransmittalmustbe guaranteed by a financial institution (including most banks, savings and loan associations and brokerage houses)thatisamemberofarecognizedMedallionProgramapprovedbyTheSecuritiesTransferAssociation,Inc.,includingtheSecuritiesTransferAgentsMedallionProgram(STAMP),theStockExchangeMedallionProgram(SEMP)andtheNewYorkStockExchange,Inc.MedallionSignatureProgram(MSP)oranyother“eligibleguarantorinstitution”(assuch term is defined in Rule 17Ad-15 under the Securities Exchange Act of 1934, as amended) (each, an “EligibleInstitution”).SignaturesonthisLetterofTransmittalneednotbeguaranteed(a)ifthisLetterofTransmittalissignedbytheregisteredholder(s)oftheShares(whichterm,forpurposesofthisdocument,shallincludeanyparticipantintheBook-Entry Transfer Facility whose name appears on a security position listing as the owner of Shares; trustees,executors,administrators,guardians,attorney-in-fact,officersofacorporationorotherpersonsactinginafiduciaryorrepresentative capacity see Instruction 5) tendered herewith and such holder(s) have not completed the box entitled“Special PaymentInstructions”onthis Letter of Transmittal or (b)if suchSharesaretenderedfor theaccountof anEligibleInstitution.SeeInstruction5.

2.Delivery of Letter of Transmittal and Shares.ThisLetterofTransmittalistobeusedeitherifcertificatesaretobe forwarded herewith or Shares are held in book-entry form on the records of the Depositary. Certificates for allphysicallydeliveredShares,aswellasaproperlycompletedanddulyexecutedLetterofTransmittal,togetherwithanyrequiredsignatureguaranteesandanyotherdocumentsrequiredbythisLetterofTransmittal,mustbereceivedbytheDepositaryatoneofitsaddressessetforthonthefrontpageofthisLetterofTransmittalbytheExpirationTime.

StockholderswhosecertificatesforSharesarenotimmediatelyavailableorstockholderswhocannotdelivertheircertificates andall other requireddocuments totheDepositaryor whocannot complywiththeproceduresfor book-entrytransferbytheExpirationTimemaytendertheirSharespursuanttotheguaranteeddeliveryproceduresetforthinSection3oftheOffertoPurchase.Undertheguaranteeddeliveryprocedure:

(a)aproperlycompletedanddulyexecutedNoticeofGuaranteedDeliverysubstantiallyintheformprovidedbyPurchaserwiththeOffertoPurchasemustbereceivedbytheDepositarybytheExpirationTime;and

(b) the certificates for all physically delivered Shares, as well as a properly completed and duly executedLetter of Transmittal with anyrequired signature guarantee andanyother documents required bythis Letter ofTransmittal,mustbereceivedbytheDepositarywithintwoNASDAQGlobalSelectMarkettradingdaysafterthedateofexecutionofsuchNoticeofGuaranteedDelivery,allasprovidedinSection3oftheOffertoPurchase.

The method of delivery of Shares, this Letter of Transmittal and all other required documents is at theelection and sole risk of the tendering stockholder. Shares will be deemed delivered only when actually receivedby the Depositary. If certificates for Shares are sent by mail, we recommend registered mail with return receiptrequested, properly insured, in time to be received on or prior to the Expiration Time. In all cases, sufficienttime should be allowed to ensure timely delivery.

Noalternative,conditionalorcontingenttenderswillbeacceptedandnofractionalshareswillbepurchased.Byexecuting this Letter of Transmittal (or a manually signed facsimile thereof), the tendering stockholder waives anyrighttoreceiveanynoticeoftheacceptanceforpaymentoftheShares.

3.Inadequate Space. If the space provided herein is inadequate, the certificate numbers and/or the number ofSharesshouldbelistedonaseparatesignedscheduleattachedhereto.

4.Partial Tenders.IffewerthanalloftheSharesrepresentedbyanycertificatedeliveredtotheDepositaryaretobetendered,fillinthenumberofShareswhicharetobetenderedintheboxentitled“NumberofSharesTendered.”Insuchcase,anewcertificatefortheremainderoftheSharesrepresentedbytheoldcertificatewillbeissuedandsenttothe person(s) signing this Letter of Transmittal, unless otherwise provided in the appropriate box on this Letter ofTransmittal,aspromptlyaspracticablefollowingtheexpirationorterminationoftheOffer.AllSharesrepresentedbycertificatesdeliveredtotheDepositarywillbedeemedtohavebeentenderedunlessotherwiseindicated.InthecaseofSharestenderedbybook-entrytransferatDTC(orSharesheldinadirectregistrationaccount

maintained by MyoKardia’s transfer agent), any tendered but unpurchased Shares (including as a result of anynecessaryproration)willbecreditedtotheappropriateaccountmaintainedbythetenderingstockholderatDTC(orbyMyoKardia’stransferagent).Ineachcase,Shareswillbereturnedorcreditedwithoutexpensetothestockholder.

5.Signatures on Letter of Transmittal; Stock Powers and Endorsements.IfthisLetterofTransmittalissignedbytheregisteredholder(s)oftheSharestenderedhereby,thesignature(s)mustcorrespondwiththename(s)aswrittenonthefaceofthecertificateswithoutalterationoranychangewhatsoever.

IfanyoftheSharestenderedherebyareheldofrecordbytwoormorepersons,all suchpersonsmustsignthisLetterofTransmittal.

IfanyoftheSharestenderedherebyareregisteredindifferentnamesondifferentcertificates,itwillbenecessarytocomplete,signandsubmitasmanyseparateLettersofTransmittalastherearedifferentregistrationsofcertificates.

IfthisLetterofTransmittalissignedbytheregisteredholder(s)oftheSharestenderedhereby,noendorsementsofcertificatesorseparatestockpowersarerequiredunlesspaymentofthepurchasepriceistobemade,orSharesnottenderedornotacceptedforpaymentaretobereturned,inthenameofanypersonotherthantheregisteredholder(s).SignaturesonanysuchcertificatesorstockpowersmustbeguaranteedbyanEligibleInstitution.

IfthisLetterofTransmittalissignedbyapersonotherthantheregisteredholder(s)oftheSharestenderedhereby,certificatesmustbeendorsedoraccompaniedbyappropriatestockpowers,ineithercase,signedexactlyasthename(s)oftheregisteredholder(s)appear(s)onthecertificatesforsuchShares.Signature(s)onanysuchcertificatesorstockpowersmustbeguaranteedbyanEligibleInstitution.

If this Letter of Transmittal or any certificate or stock power is signed by a trustee, executor, administrator,guardian,attorney-in-fact,officerofacorporationorotherpersonactinginafiduciaryorrepresentativecapacity,suchpersonshouldsoindicatewhensigning,andproperevidencesatisfactorytoPurchaseroftheauthorityofsuchpersonsotoactmustbesubmitted,orinlieuofevidence,aGuaranteeofSignature(seeInstruction1).

6.Stock Transfer Taxes. Purchaserwill payanystocktransfertaxeswithrespecttothesaleandtransferofanySharestoitoritsorderpursuanttotheOffer.If,however,paymentofthepurchasepriceistobemadeto,orSharesnottenderedornotacceptedforpaymentaretobereturnedinthenameof,anypersonotherthantheregisteredholder(s),orifatransfertaxisimposedforanyreasonotherthanthesaleortransferofSharestoPurchaserpursuanttotheOffer,then the amount of any stock transfer taxes (whether imposed on the registered holder(s), such other person orotherwise) will be deducted from the purchase price unless satisfactory evidence of the payment of such taxes, orexemptiontherefrom,issubmittedherewith.

7.Special Payment and Delivery Instructions.IfthecheckforthepurchasepriceofanySharespurchasedistobeissuedinthenameofapersonotherthantheperson(s)signingthisLetterofTransmittalorifthecheckistobemailedto someone other than the person(s) signing this Letter of Transmittal or to the person(s) signing this Letter ofTransmittal at anaddressotherthanthat shownabove,theappropriate boxesonthis Letter ofTransmittal shouldbecompleted.

8.Backup Withholding.UndertheU.S.federalincometaxlaws,unlesscertaincertificationrequirementsaremet,theDepositarygenerallywillberequiredtowithholdattheapplicablebackupwithholdingrate(currently24%)fromanypaymentsmadetoastockholderpursuanttotheOffer.Inordertoavoidsuchbackupwithholding,eachtenderingstockholder, and, if applicable, each other payee, must provide the Depositary with such stockholder’s or payee’scorrect taxpayer identification number and certify that such stockholder or payee is not subject to such backupwithholdingbycompletingtheIRSFormW-9enclosedherein.Ingeneral,ifastockholderorpayeeisanindividual,thetaxpayeridentificationnumberisthesocialsecuritynumberofsuchindividual.IfthestockholderorpayeedoesnotprovidetheDepositarywithits correct taxpayer identificationnumber, thestockholder or payeemaybesubject to apenalty imposed by the Internal Revenue Service. Certain stockholders or payees (including, generally, domesticcorporationsandforeignstockholders)arenotsubjecttothesebackupwithholdingandreportingrequirements.InordertosatisfytheDepositarythataforeignstockholderisexempt,suchstockholderorpayeemustsubmittotheDepositaryaproperlycompletedIRSFormW-8,signedunderpenaltiesofperjury,attestingtothatstockholder’sforeignstatus.SuchIRSFormW-8canbeobtainedfromtheDepositaryortheInternalRevenue

Service (www.irs.gov/formspubs/index.html). The instructions to the enclosed IRS Form W-9 contain furtherinformation concerning backup withholding and instructions for completing the IRS Form W-9 (including how toobtainataxpayeridentificationnumberifyoudonothaveoneandhowtocompletetheIRSFormW-9ifSharesareheldinmorethanonename).

Failure to provide an IRS Form W-9 or the appropriate IRS Form W-8 will not, by itself, cause Shares to bedeemedinvalidlytendered,butmayrequiretheDepositarytowithholdfromanypaymentsmadepursuanttotheOffer.Backup withholding is not an additional U.S. federal income tax. Rather, the U.S. federal income tax liability of aperson subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in anoverpayment of taxes, a refund may be obtained provided that the required information is furnished to the InternalRevenue Service.Failure to complete and provide an IRS Form W-9 or the appropriate IRS Form W-8 mayresult in backup withholding on any payments made to you pursuant to the Offer.

9.Mutilated, Lost, Stolen or Destroyed Certificates.Ifanycertificate(s)representingSharestobetenderedhavebeenmutilated,lost,stolenordestroyed,stockholdersshouldcontactMyoKardia’stransferagent,ComputershareTrustCompany,N.A.,immediatelybycalling1-800-564-6253(toll-free).WithrespecttoSharesrepresentedbycertificates,thestockholderwillthenbeinstructedastothestepsthatmustbetakeninordertoreplacethecertificate(s).ThisLetterofTransmittalandrelateddocumentscannotbeprocesseduntiltheproceduresforreplacinglost,mutilated,destroyedorstolencertificate(s)havebeenfollowed.

10.Requests for Assistance or Additional Copies. Requests for assistance or additional copies of the Offer toPurchase and this Letter of Transmittal may be obtained from the Information Agent at its address or telephonenumberssetforthbelow.

11.Waiver of Conditions. Subject to applicable law, Purchaser reserves the right to waive any of the specifiedconditions of the Offer in the case of any Shares tendered, subject in certain cases to the prior written consent ofMyoKardia.

12.Irregularities. All questions as to Offer Price, theformof documents andthevalidity, eligibility (includingtime of receipt) and acceptance for payment of any tender of Shares will be determined by Purchaser in its solediscretion,whichdeterminationshallbefinalandbindingonyou.PurchaserreservestheabsoluterighttorejectanyoralltendersofSharesitdeterminesnottobeinproperformortheacceptanceofwhichorpaymentsforwhichmay,intheopinionofPurchaser,beunlawful.PurchaseralsoreservestheabsoluterighttowaiveanydefectorirregularityinthetenderofanySharesbyanyparticularstockholder,whetherornotsimilardefectsorirregularitiesarewaivedinthecase of other stockholders. No tender of shares will be deemed to have been validly made until all defects andirregularities havebeencuredorwaivedtothesatisfactionofPurchaser. NoneofMyoKardia, Purchaser, Parent, theDepositary,theInformationAgent(asdefinedintheOffertoPurchaser)oranyotherpersonwillbeunderanydutytogivenotificationofanydefectsofirregularitiesintendersorincuranyliabilityorfailuretogiveanysuchnotifications.

IMPORTANT: This Letter of Transmittal (or a manually signed facsimile thereof) together with anysignature guarantees and any other required documents, must be received by the Depositary on or prior to theExpiration Time and either certificates for tendered Shares must be received by the Depositary or Shares mustbe delivered pursuant to the procedures for book-entry transfer, in each case on or prior to the ExpirationTime, or the tendering stockholder must comply with the procedures for guaranteed delivery.

TheInformationAgentfortheOfferis:

 

1407BroadwayNewYork,NewYork10018

(212)929-5500or

Call Toll-Free 1-800-322-2885Email:tenderoffer@mackenziepartners.com

 

 

 

 

 

 

Exhibit (a)(1)(iii)

NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock

of  

MYOKARDIA, INC.   at

$225.00 Net Per Share Pursuant to the Offer to Purchase

Dated October 19, 2020 by  

GOTHAM MERGER SUB INC.  

a wholly owned subsidiary of Bristol-Myers Squibb Company

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONE MINUTEAFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE OFFER IS EXTENDED OR

EARLIER TERMINATED.

ThisNoticeofGuaranteedDelivery,oronesubstantiallyintheformhereof,mustbeusedtoaccepttheOffer(asdefinedbelow)ifthecertificates for shares of common stock, par value $0.0001 per share (the “Shares”), of MyoKardia, Inc., a Delaware corporation(“MyoKardia”)andanyotherdocumentsrequiredbytheLetterofTransmittal(asdefinedbelow)cannotbedeliveredtoEquinitiTrustCompany,thedepositaryfortheOffer(the“Depositary”),ortheprocedurefordeliverybybook-entrytransfercannotbecompleted,ineachcasepriortotheexpirationoftheOffer.SuchformmaybedeliveredbyfacsimiletransmissionormailtotheDepositary.SeeSection3oftheOffertoPurchase(asdefinedbelow).

TheDepositaryfortheOfferis: 

Equiniti Trust Company

By Mail:By5:00p.m.NYCtimeonExpirationDate

EquinitiTrustCompanyShareownerServices

VoluntaryCorporateActionsP.O.Box64858

St.Paul,Minnesota55164-0858

By Facsimile Transmission:  

EquinitiTrustCompanyShareownerServices

VoluntaryCorporateActions(800)468-9716(phone)(866)734-9952(fax)

By Hand or Overnight Courier:By5:00p.m.NYCtimeonExpirationDate

EquinitiTrustCompanyShareownerServices

VoluntaryCorporateActions1110CentrePointeCurve,Suite101MendotaHeights,Minnesota55120

DELIVERY OF THIS NOTICE OF GUARANTEED DELIVERY TO AN ADDRESS OR FACSIMILE NUMBER OTHERTHAN AS SET FORTH ABOVE WILL NOT CONSTITUTE A VALID DELIVERY TO THE DEPOSITARY.

ThisNoticeofGuaranteedDeliveryisnottobeusedtoguaranteesignatures.IfasignatureonaLetterofTransmittalisrequiredtobeguaranteedbyan“eligibleguarantorinstitution”(assuchtermisdefinedinRule17Ad-15undertheSecuritiesExchangeActof1934,as amended (the “Exchange Act”)), under the instructions thereto, such signature guarantee must appear in the applicable spaceprovidedinthesignatureboxontheLetterofTransmittal.Do not send share certificates with this notice. Share certificates shouldbe sent with your Letter of Transmittal.

NumberofSharesTendered:           

 ☐ Checkifsecuritieswillbetenderedbybook-entrytransfer.

NameofTenderingInstitution:

AccountNo.:                  

Dated:                   ,20

Name(s)ofRecordHolder(s)

                       (pleaseprint)

Address(es):

(ZipCode)

AreaCodeandTelephoneNo(s):

Signature(s):

LadiesandGentlemen:

TheundersignedherebytenderstoGothamMergerSubInc.,aDelawarecorporationandawhollyownedsubsidiaryofBristol-MyersSquibb company, a Delaware corporation, upon the terms and subject to the conditions set forth in the Offer to Purchase datedOctober 19, 2020 (as it may be amended or supplemented from time to time, the “Offer to Purchase”) and the related Letter ofTransmittal (as it may be amended or supplemented fromtime to time, the “Letter of Transmittal” and, together with the Offer toPurchase,the“Offer”),receiptofwhichisherebyacknowledged,sharesofcommonstock,parvalue$0.0001pershare,ofMyoKardia,Inc.,aDelawarecorporation,pursuanttotheguaranteeddeliveryproceduresetforthinSection3oftheOffertoPurchase.

GUARANTEE  

(Not to be used for signature guarantee)

Theundersigned,afinancialinstitutionthatisamemberingoodstandingofarecognizedMedallionProgramapprovedbyTheSecuritiesTransferAssociation,Inc., includingtheSecuritiesTransferAgentsMedallionProgram(STAMP),the Stock Exchange Medallion Program (SEMP) and the New York Stock Exchange, Inc. Medallion SignatureProgram (MSP), or any other “eligible guarantor institution” (as such term is defined in Rule 17Ad-15 under theSecuritiesExchangeActof1934,asamended(the“ExchangeAct”)), guarantees(a)thattheabovenamedperson(s)“own(s)”theSharestenderedherebywithinthemeaningofRule14e-4undertheExchangeAct,(b)thatsuchtenderofSharescomplieswithRule14e-4and(c)thedeliverytotheDepositaryofthecertificatesforallsuchtenderedShares(or a confirmation of a book-entry transfer of such Shares into the Depositary's account at the Book-Entry TransferFacility(asdefinedintheOffertoPurchase)inthecaseofabook-entrydelivery),togetherwithaproperlycompletedand duly executed Letter of Transmittal (or a manually signed facsimile thereof) and with any required signatureguarantee(oranAgent’sMessage(asdefinedintheOffertoPurchase)inthecaseofabook-entrydelivery)andanyotherrequireddocuments,allwithintwoNASDAQGlobalSelectMarkettradingdaysofthedatehereof.

(NameofFirm)

(Address)

(ZipCode)

(AuthorizedSignature)

(Name)(PleasePrint)

(AreaCodeandTelephoneNumber)

Dated:      

DO NOT SEND CERTIFICATES FOR SHARES WITH THIS NOTICE. CERTIFICATES FOR SHARES SHOULD BE SENT WITH YOUR LETTER OF TRANSMITTAL.

Exhibit (a)(1)(iv)

Offer to Purchase for Cash All Outstanding Shares of Common Stock

of  

MyoKardia, Inc.   at

$225.00 Net per Share Pursuant to the Offer to Purchase Dated October 19, 2020

by  

Gotham Merger Sub Inc.  

a wholly owned subsidiary of Bristol-Myers Squibb Company

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONEMINUTE AFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE

OFFER IS EXTENDED OR EARLIER TERMINATED.

October19,2020

ToBrokers,Dealers,CommercialBanks,TrustCompaniesandOtherNominees:

WehavebeenengagedbyGothamMergerSubsidiary,Inc.,aDelawarecorporation(“Purchaser”)andawhollyowned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), to act as the informationagent(the“InformationAgent”) in connection with Purchaser’s offer to purchase all outstanding shares of commonstock, par value $0.0001per share (the “Shares”), of MyoKardia, Inc., a Delaware corporation (“MyoKardia”), at apurchase price of $225.00 per Share (the “Offer Price”), net to the seller in cash, without interest, subject to anyrequiredwithholdingoftaxesanduponthetermsandsubjecttotheconditionssetforthintheOffertoPurchasedatedOctober19,2020(asitmaybeamendedorsupplementedfromtimetotime,the“OffertoPurchase”)andtherelatedLetter of Transmittal (as it may be amended or supplemented from time to time, the “Letter of Transmittal” and,togetherwiththeOffertoPurchase,the“Offer”)enclosedherewith.

Please furnish copies of the enclosed materials to those of your clients for whose accounts you hold Sharesregisteredinyournameorinthenameofyournominee.

Enclosed herewith for your information and forwarding to your clients for whose accounts you hold Sharesregisteredinyournameorinthenameofyournomineearecopiesofthefollowingdocuments:

1. TheOffertoPurchase.

2. The related Letter of Transmittal for your use in accepting the Offer and tendering Shares and for theinformationofyourclients.FacsimilecopiesoftheLetterofTransmittalmaybeusedtotenderShares.

3. IRSFormW-9andinstructionsprovidinginformationrelatingtofederalincometaxbackupwithholding.

4. NoticeofGuaranteedDeliverytobeusedtoaccepttheOfferifcertificatesforSharesandallotherrequireddocumentscannotbedeliveredtoEquinitiTrustCompany,thedepositaryfortheOffer(the“Depositary”),oriftheproceduresforbook-entrytransfercannotbecompleted,priortotheexpirationoftheOffer.

5. Aformof letter whichmaybesent to your clients for whoseaccounts youholdShares registered in yourname or in the name of your nominee, with space provided for obtaining such clients’ instructions withregardtotheOffer.

6. MyoKardia’sSolicitation/RecommendationStatementonSchedule14D-9datedOctober19,2020.

YOUR PROMPT ACTION IS REQUESTED. WE URGE YOU TO CONTACT YOUR CLIENTS ASPROMPTLY AS POSSIBLE. PLEASE NOTE THAT THE OFFER AND WITHDRAWAL RIGHTS EXPIREAT MIDNIGHT (NEW YORK CITY TIME, ONE MINUTE AFTER 11:59 P.M. NEW YORK CITY TIME,ON NOVEMBER 16, 2020, UNLESS THE OFFER IS EXTENDED OR EARLY TERMINATED.

TheOfferisbeingmadepursuanttotheAgreementandPlanofMerger,datedasofOctober3,2020(the“MergerAgreement”),byandamongMyoKardia,ParentandPurchaser.TheMergerAgreementprovides,amongotherthings,thatassoonaspracticablefollowing(butinanyeventonthesamedateas)theacceptanceoftheSharesforpayment(the“Offer Acceptance Time”), subject to the satisfaction or waiver of the other conditions set forth in the MergerAgreement and in any event no later than one business day following the satisfaction or waiver of such conditions,Purchaser will merge with and into MyoKardia (the “Merger”), with MyoKardia continuing as the survivingcorporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each outstanding Share(other thanShares held byMyoKardia, anyof its subsidiaries, Parent, Purchaser or anysubsidiary of Parent, or anystockholders who have properly exercised their appraisal rights under Section 262 of the Delaware GeneralCorporationLaw(the“DGCL”))will beconvertedintotheright toreceivetheOffer Price, net totheseller incash,withoutinterest,subjecttoanyrequiredwithholdingoftaxes.NoappraisalrightsareavailableinconnectionwiththeOffer.However,pursuanttotheDGCL,iftheMergerisconsummated,stockholderswhodonottendertheirSharesintheOffer,whoareentitledtodemandandproperlydemandappraisalofsuchSharespursuantto,andwhofullycomplyinallrespectswith,theapplicableprovisionsofSection262oftheDGCL,willhavetherighttochoosenottoaccepttheconsiderationpayablefortheirSharespursuanttotheMerger,andinsteadtodemandanappraisaloftheirSharesbytheCourtofChanceryoftheStateofDelawareandreceiveacashpaymentofthe“fairvalue”oftheirSharesasoftheeffectivetimeoftheMergerasdeterminedbytheCourtofChanceryoftheStateofDelaware.The“fairvalue”ofsuchShares as of the effective time of the Merger maybe more than, less than, or equal to the Offer Price. The MergerAgreementismorefullydescribedinSection13oftheOffertoPurchase.

The board of directors of MyoKardia (the “MyoKardia Board”), at a meeting duly called and held,unanimously adopted resolutions (a) determining that the Merger Agreement and the transactions contemplatedby the Merger Agreement, including the Offer and the Merger (the “Transactions”), are advisable, fair to and inthe best interests of MyoKardia and its stockholders, (b) authorizing and approving the execution, delivery andperformance by MyoKardia of the Merger Agreement and the consummation by MyoKardia of theTransactions, (c) resolving that the Merger will be effected under Section 251(h) of the DGCL and that theMerger will be consummated as soon as practicable following the Offer Acceptance Time and (d) recommendingthat MyoKardia’s stockholders accept the Offer and tender their Shares in the Offer. MyoKardia has beenadvised that all of its directors and executive officers intend to tender all of their transferrable Shares pursuantto the Offer.

Purchaser will not be required to consummate the Offer if any of the following conditions, among otherconditions,existorhaveoccurredandarecontinuingatthescheduledExpirationTimeoftheOffer:(a)thenumberofShares validly tendered (and not properly withdrawn) prior to the expiration of the Offer (but excluding Sharestenderedpursuanttoguaranteeddeliveryproceduresthathavenotyetbeen“received”,asdefinedbySection251(h)(6)oftheDGCL),togetherwiththeSharesthenownedbyParentorPurchaser,doesnotrepresentatleastoneSharemorethan50%ofthethenoutstandingShares;(b)anyrestraintisineffectenjoining,makingillegalorotherwiseprohibitingconsummationoftheOfferortheMerger;(c)thereisanactioninstitutedorpendingbyagovernmentalauthorityofcompetentjurisdictionseekinganyjudgment(i)toprevent,prohibitormakeillegaltheconsummationoftheOfferorthe Merger, (ii) to prohibit Parent’s ability to vote, transfer, receive dividends or otherwise exercise full rights ofownershipwithrespecttothestockofMyoKardiaor(iii)inconnectionwiththeOfferortheMerger,toprohibit,limit,restrain or impair in any material respect Parent’s ability to own, control, direct, manage, or operate or to retain orchangeanymaterial portionoftheassets, licenses,operations,rights,productlines,businessesorintereststhereinofMyoKardia or its subsidiaries or any of the material assets, licenses, operations, rights, product lines, businesses orintereststhereinofParentoritssubsidiaries(otherthan,ineachcase,aDivestitureAction(asdefinedintheOffertoPurchase)requiredtobetakenbyParentandPurchaserpursuanttotheMergerAgreement);(d)thewaitingperiod(andany extension thereof) applicable to the consummation of the Offer or the Merger under the Hart-Scott-RodinoAntitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder has neitherexpirednorhasearlyterminationthereofbeengrantedorthereis ineffect anyvoluntaryagreementbetweenParent,Purchaser or MyoKardia andthe Federal Trade Commission or the Department of Justice pursuant to whichParent,Purchaser or MyoKardia will not consummate the Merger for any period of time; (e) there is an inaccuracy in therepresentationsandwarrantiesmadebyMyoKardiaintheMergerAgreement,subject

tothematerialityandotherqualificationssetforthintheMergerAgreement;(f)MyoKardiahasnotcompliedwithorperformedinallmaterialrespectsitsobligationsrequiredtobecompliedwithorperformedbyitpriortothescheduledExpiration Time under the Merger Agreement; and (g) since the date of the Merger Agreement there has been aMaterialAdverseEffect(asdefinedintheOffertoPurchase)thatiscontinuingasofthescheduledExpirationTime.TheseandotherconditionstotheOfferaredescribedinSections15and16oftheOffertoPurchase.

Purchaser will not pay any fees or commissions to any broker, dealer or any other person (other than to theInformationAgentandtheDepositaryasdescribedintheOffertoPurchase)forsolicitingtendersofSharespursuanttotheOffer.Purchaserwill,however,uponrequest,reimbursebrokers,dealers,commercialbanks,trustcompaniesandothernomineesforreasonableandnecessarycostsandexpensesincurredbytheminforwardingtheenclosedmaterialstotheirclients.

Purchaser will payall stock transfer taxes applicable to its purchase of Shares pursuant to the Offer, subject toInstruction6oftheLetterofTransmittal.

In order to take advantage of the Offer, a duly executed and properly completed Letter of Transmittal (or amanuallysignedfacsimilethereof),oranAgent’sMessage(asdefinedintheOffertoPurchase)inconnectionwithabook-entry transfer of Shares, and any other required documents, should be sent to the Depositary, and certificatesrepresentingthetenderedSharesshouldbedeliveredorsuchSharesshouldbetenderedbybook-entrytransfer,allinaccordancewiththeinstructionscontainedintheLetterofTransmittalandtheOffertoPurchase.

IfholdersofShareswishtotender,butitisimpracticableforthemtoforwardtheircertificatesorotherrequireddocuments or to complete the procedures for delivery by book-entry transfer prior to the expiration of the Offer, atender may be effected by following the guaranteed delivery procedures described in Section 3 of the Offer toPurchase.

Any inquiries you may have with respect to the Offer should be addressed to, and additional copies of theenclosedmaterialsmaybeobtainedfrom,theInformationAgentatitsaddressandtelephonenumberssetforthonthebackcoveroftheOffertoPurchase.

Verytrulyyours,

MacKenziePartners,Inc.

NOTHING CONTAINED HEREIN OR IN THE ENCLOSED DOCUMENTS SHALL RENDER YOUTHE AGENT OF PARENT, PURCHASER, THE INFORMATION AGENT OR THE DEPOSITARY, ORANY AFFILIATE OF ANY OF THEM, OR AUTHORIZE YOU OR ANY OTHER PERSON TO USE ANYDOCUMENT OR MAKE ANY STATEMENT ON BEHALF OF ANY OF THEM IN CONNECTION WITHTHE OFFER OTHER THAN THE DOCUMENTS ENCLOSED HEREWITH AND THE STATEMENTSCONTAINED THEREIN.

Exhibit (a)(1)(v)

Offer to Purchase for Cash All Outstanding Shares of Common Stock

of

MyoKardia, Inc.

at $225.00 Net per Share

Pursuant to the Offer to Purchase Dated October 19, 2020 by

Gotham Merger Sub Inc.

a wholly owned subsidiary of Bristol-Myers Squibb Company

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONEMINUTE AFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE

OFFER IS EXTENDED OR EARLIER TERMINATED.

ToOurClients:

EnclosedforyourconsiderationaretheOffertoPurchasedatedOctober19,2020(the“OffertoPurchase”)andtherelatedLetterofTransmittal(asitmaybeamendedorsupplementedfromtimetotime,the“LetterofTransmittal”and,togetherwiththeOffertoPurchase,collectivelythe“Offer”)inconnectionwiththeofferbyGothamMergerSubInc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Bristol-Myers Squibb Company, aDelawarecorporation(“Parent”),topurchasealloutstandingsharesofcommonstock,parvalue$0.0001pershare(the“Shares”),ofMyoKardia,Inc.,aDelawarecorporation(“MyoKardia”),for$225.00perShare(the“OfferPrice”),nettothesellerincash,withoutinterest,subjecttoanywithholdingoftaxesrequiredbyapplicablelawanduponthetermsand subject to the conditions set forth in the Offer. Also enclosed is MyoKardia’s Solicitation/RecommendationStatementonSchedule14D-9.

WeorournomineesaretheholderofrecordofSharesheldforyouraccount.AtenderofsuchSharescanbemadeonly by us or our nominees as the holder of record and pursuant to your instructions. The enclosed Letter ofTransmittalisfurnishedtoyouforyourinformationonlyandcannotbeusedbyyoutotenderSharesheldbyusorournomineesforyouraccount.

WerequestinstructionsastowhetheryouwishustotenderanyoralloftheSharesheldbyusorournomineesforyouraccount,uponthetermsandsubjecttotheconditionssetforthintheOffer.

Yourattentionisdirectedtothefollowing:

1. The Offer Price is $225.00 per Share, net to the seller in cash, without interest, subject to any requiredwithholdingoftaxesanduponthetermsandsubjecttotheconditionssetforthintheOffer.

2. TheOfferisbeingmadeforalloutstandingShares.

3. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of October 3, 2020(the “Merger Agreement”), by and among MyoKardia, Parent and Purchaser. The Merger Agreementprovides,amongotherthings,thatassoonaspracticablefollowing(butinanyeventonthesamedateas)theacceptanceoftheSharesforpayment(the“OfferAcceptanceTime”),subjecttothesatisfactionorwaiverofthe other conditions set forth in the Merger Agreement and in any event no later than one business dayfollowingthesatisfactionorwaiverofsuchconditions,PurchaserwillmergewithandintoMyoKardia(the“Merger”), with MyoKardia continuing as the surviving corporation and a wholly owned subsidiary ofParent.AttheeffectivetimeoftheMerger,eachoutstandingShare(otherthanSharesheldbyMyoKardia,any of its subsidiaries, Parent, Purchaser or any other subsidiary of Parent, or any stockholders who haveproperly exercised their appraisal rights under Section 262 of the Delaware General Corporation Law(the“DGCL”))willbeconvertedintotherighttoreceivetheOfferPrice,nettothesellerincash,withoutinterest,subjecttoanyrequiredwithholdingoftaxes.Noappraisalrightsareavailablein

connection with the Offer. However, pursuant to the DGCL, if the Merger is consummated, stockholderswhodonottendertheir SharesintheOffer, whoareentitledtodemandandproperlydemandappraisal ofsuchSharespursuantto,andwhofullycomplyinallrespectswith,theapplicableprovisionsofSection262oftheDGCL,willhavetherighttochoosenottoaccepttheconsiderationpayablefortheirSharespursuanttotheMerger,andinsteadtodemandanappraisaloftheirSharesbytheCourtofChanceryoftheStateofDelawareandreceiveacashpaymentofthe“fairvalue”oftheirSharesasoftheeffectivetimeoftheMergerasdeterminedbytheCourtofChanceryoftheStateofDelaware.The“fairvalue”ofsuchSharesasoftheeffectivetimeoftheMergermaybemorethan,lessthan,orequaltotheOfferPrice.TheMergerAgreementismorefullydescribedinSection13oftheOffertoPurchase.

4. The board of directors of MyoKardia (the “MyoKardia Board”), at a meeting duly called and held,unanimously adopted resolutions (a) determining that the Merger Agreement and the transactionscontemplated by the Merger Agreement, including the Offer and the Merger (the “Transactions”), areadvisable, fair to and in the best interests of MyoKardia and its stockholders, (b) authorizing andapproving the execution, delivery and performance by MyoKardia of the Merger Agreement and theconsummation by MyoKardia of the Transactions, (c) resolving that the Merger will be effected underSection 251(h) of the DGCL and that the Merger will be consummated as soon as practicable followingthe Offer Acceptance Time and (d) recommending that MyoKardia’s stockholders accept the Offerand tender their Shares in the Offer.

5. The Offer and withdrawal rights expire at midnight (New York City time), one minute after 11:59 p.m.New York City time, on November 16, 2020, unless the Offer is extended (as it may be extended, the“ExpirationTime”).

6. Purchaser will not be required to consummate the Offer if any of the following conditions, among otherconditions,existorhaveoccurredandarecontinuingatthescheduledExpirationTimeoftheOffer:(a)thenumber of Shares validly tendered (and not properly withdrawn) prior to the expiration of the Offer (butexcludingSharestenderedpursuanttoguaranteeddeliveryproceduresthathavenotyetbeen“received”,asdefined by Section 251(h)(6) of the DGCL), together with the Shares then owned by Parent or Purchaser,doesnotrepresent at least oneSharemorethan50%ofthethenoutstandingShares; (b) anyrestraint is ineffectenjoining,makingillegalorotherwiseprohibitingconsummationoftheOfferortheMerger;(c)thereis an action instituted or pending by a governmental authority of competent jurisdiction seeking anyjudgment(i)toprevent,prohibitormakeillegaltheconsummationoftheOfferortheMerger,(ii)toprohibitParent’sabilitytovote,transfer,receivedividendsorotherwiseexercisefullrightsofownershipwithrespecttothestockofMyoKardiaor(iii) inconnectionwiththeOfferortheMerger,toprohibit, limit, restrainorimpair in any material respect Parent’s ability to own, control, direct, manage, or operate or to retain orchangeanymaterial portionof theassets, licenses, operations, rights, product lines, businesses or intereststherein of MyoKardia or its subsidiaries or any of the material assets, licenses, operations, rights, productlines, businesses or interests therein of Parent or its subsidiaries (other than, in each case, a DivestitureAction (as defined in the Offer to Purchase) required to be taken by Parent and Purchaser pursuant to theMerger Agreement); (d) the waiting period (andanyextension thereof) applicable to the consummation oftheOfferortheMergerundertheHart-Scott-RodinoAntitrustImprovementsActof1976,asamended,andtherulesandregulationspromulgatedthereunderhasneitherexpirednorhasearlyterminationthereofbeengranted or there is in effect any voluntary agreement between Parent, Purchaser or MyoKardia and theFederalTradeCommissionortheDepartmentofJusticepursuanttowhichParent,PurchaserorMyoKardiawillnotconsummatetheMergerforanyperiodoftime;(e)thereisaninaccuracyintherepresentationsandwarrantiesmadebyMyoKardiaintheMergerAgreement,subjecttothematerialityandotherqualificationsset forth in the Merger Agreement; (f) MyoKardia has not complied with or performed in all materialrespects its obligations required to be complied with or performed by it prior to the scheduled ExpirationTimeundertheMergerAgreement;and(g)sincethedateoftheMergerAgreementtherehasbeenaMaterialAdverseEffect(asdefinedintheOffertoPurchase)thatiscontinuingasofthescheduledExpirationTime.TheseandotherconditionstotheOfferaredescribedinSections15and16oftheOffertoPurchase.

7. AnystocktransfertaxesapplicabletothesaleofSharestothePurchaserpursuanttotheOfferwillbepaidbythePurchaser,exceptasotherwisesetforthinInstruction6oftheLetterofTransmittal.However,

federalincometaxbackupwithholdingatacurrentrateof24%mayberequired,unlesstherequiredtaxpayeridentificationinformationisprovidedandcertaincertificationrequirementsaremet,orunlessanexemptionisestablished.SeeInstruction8oftheLetterofTransmittal.

IfyouwishtohaveusorournomineestenderanyorallofyourShares,pleasecomplete,sign,detachandreturntheinstructionformbelow.Anenvelopetoreturnyourinstructionstousisenclosed.IfyouauthorizetenderofyourShares, all such Shares will be tendered unless otherwise specified on the instruction form. Your prompt action isrequested.YourinstructionsshouldbeforwardedtousinampletimetopermitustosubmitatenderonyourbehalfbytheExpirationTime.

The Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of Shares in anyjurisdictioninwhichthemakingoftheOfferoracceptancethereofwouldnotbeincompliancewiththelawsofsuchjurisdiction. In those jurisdictions where the applicable laws require that the Offer be made by a licensed broker ordealer, the Offer will be deemed to be made on behalf of Purchaser by one or more registered brokers or dealerslicensedunderthelawsofsuchjurisdictiontobedesignatedbyPurchaser.

Instruction Form with Respect to Offer to Purchase for Cash

All Outstanding Shares of Common Stock of

MyoKardia, Inc.

at $225.00 Net per Share

Pursuant to the Offer to Purchase Dated October 19, 2020 by

Gotham Merger Sub Inc.

a wholly owned subsidiary of Bristol-Myers Squibb Company

Theundersignedacknowledge(s)receiptofyourletterandtheenclosedOffertoPurchasedatedOctober19,2020andtherelatedLetterofTransmittal(collectively,asmaybeamendedorsupplementedfromtimetotime,the“Offer”),inconnectionwiththeofferbyGothamMergerSubInc.,aDelawarecorporation(“Purchaser”)andawhollyownedsubsidiaryofBristol-MyersSquibbCompany,aDelawarecorporation(“Parent”),topurchasealloutstandingsharesofcommon stock, par value $0.0001 per share (the “Shares”), of MyoKardia, Inc., a Delaware corporation(“MyoKardia”), at a purchase price of $225.00 per Share, net to the seller in cash, without interest, subject to anyrequiredwithholdinganduponthetermsandsubjecttotheconditionssetforthintheOffer.

The undersigned hereby instruct(s) you to tender to Purchaser the number of Shares indicated below (or if nonumberisindicatedbelow,allShares)heldbyyouoryournomineesfortheaccountoftheundersigned,uponthetermsand subject to the conditions set forth in the Offer furnished to the undersigned. The undersigned understands andacknowledgesthat all questionsastothevalidity, formandeligibility (includingtimeofreceipt) andacceptanceforpaymentofanytenderofSharesmadeonmybehalfwillbedeterminedbyPurchaserinitssolediscretion.

The method of delivery of this Instruction Form is at the election and risk of the tendering stockholder.This Instruction Form should be delivered to us in ample time to permit us to submit the tender on your behalfprior to the expiration of the Offer.

NumberofSharestobeTendered: SIGN HERE

Shares*

Dated Signature(s)

Name(s)(PleasePrint)

Address(es)

(ZipCode)

AreaCodeandTelephoneNumber

TaxpayerIdentificationorSocialSecurityNumber

* Unless otherwise indicated, it will be assumed that all Shares held for the undersigned’s account are to betendered.

Exhibit (a)(1)(vi)

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).The Offer (as defined below) is made solely pursuant to the Offer to Purchase dated October 19, 2020 and the relatedLetter of Transmittal and any amendments or supplements thereto and is being made to all holders of Shares. The Offeris not being made to, nor will tenders be accepted from or on behalf of, holders of Shares in any U.S. or foreignjurisdiction in which the making of the Offer or acceptance thereof would not be in compliance with the laws of suchjurisdiction. In those jurisdictions where the applicable laws require that the Offer be made by a licensed broker ordealer, the Offer will be deemed to be made on behalf of Purchaser (as defined below) by one or more registeredbrokers or dealers licensed under the laws of such jurisdiction to be designated by Purchaser.

Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock

of  

MYOKARDIA, INC.  

at

 

$225.00 Net Per Share

 

by

 

GOTHAM MERGER SUB INC. a wholly owned subsidiary of

 

BRISTOL-MYERS SQUIBB COMPANYGothamMergerSubInc.,aDelawarecorporation(“Purchaser”)andawhollyownedsubsidiaryofBristol-Myers

SquibbCompany,aDelawarecorporation(“Parent”),isofferingtopurchasealloutstandingsharesofcommonstock,parvalue$0.0001pershare(the“Shares”),ofMyoKardia,Inc.,aDelawarecorporation(“MyoKardia”),atapurchasepriceof$225.00perShare,nettothesellerincash,withoutinterest(the“OfferPrice”),andsubjecttodeductionforanyrequiredwithholdingtaxes,uponthetermsandsubjecttotheconditionssetforthintheOffertoPurchasedatedOctober 19, 2020 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), and in therelated letter of transmittal (as amended or supplemented fromtime to time, the “Letter of Transmittal” and which,together with the Offer to Purchase, constitutes the “Offer”). Tendering stockholders whose Shares are registered intheirnamesandwhotenderdirectlytoPurchaserwillnotbechargedbrokeragefeesorsimilarexpensesonthesaleofSharesforcashpursuanttotheOffer.TenderingstockholderswhoseSharesareregisteredinthenameoftheirbroker,bank or other nominee should consult such nominee to determine if any fees may apply. The Offer is being madepursuanttotheAgreementandPlanofMerger,datedasofOctober3,2020(the“MergerAgreement”),byandamongMyoKardia, Parent and Purchaser. Following the consummation of the Offer, and under the terms of the MergerAgreementasdescribedintheOffertoPurchase,PurchaserintendstoeffecttheMerger(definedbelow)asdescribedbelow.

THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT MIDNIGHT (NEW YORK CITY TIME), ONEMINUTE AFTER 11:59 P.M. NEW YORK CITY TIME, ON NOVEMBER 16, 2020, UNLESS THE

OFFER IS EXTENDED OR EARLIER TERMINATED.

TheMergerAgreementprovides,amongotherthings,thatassoonaspracticablefollowing(butinanyeventonthesamedateas)acceptanceoftheSharesforpayment(the“OfferAcceptanceTime”),subjecttothesatisfactionorwaiver of the other conditions set forth in the Merger Agreement and in any event no later than one business dayfollowingthesatisfactionorwaiverofsuchconditions,PurchaserwillmergewithandintoMyoKardia(the“Merger”),withMyoKardiacontinuingasthesurvivingcorporationandawhollyownedsubsidiaryofParent.AttheeffectivetimeoftheMerger,eachoutstandingShare(otherthanSharesheldbyMyoKardia,anyofitssubsidiaries,Parent,PurchaseroranyothersubsidiaryofParent,oranystockholderswhohaveproperlyexercisedtheirappraisalrightsunderSection262oftheDelawareGeneralCorporationLaw(the“DGCL”))willbeconvertedintotherighttoreceivetheOfferPriceincash,withoutinterestandlessanyrequiredwithholdingtaxes.TheMerger

is subject to the satisfaction or waiver of certain conditions described in “The Offer—Section 13—The TransactionDocuments—TheMergerAgreement”oftheOffertoPurchase.

IftheOfferisconsummated,PurchaserdoesnotanticipateseekingtheapprovalofMyoKardia’sremainingpublicstockholders before effecting the Merger. The parties to the Merger Agreement have agreed that, subject to theconditions specified in the Merger Agreement, the Merger will become effective as soon as practicable after theconsummation of the Offer, without a vote of MyoKardia stockholders, in accordance with Section 251(h) of theDGCL.

The board of directors of MyoKardia (the “MyoKardia Board”), at a meeting duly called and held,unanimously adopted resolutions (a) determining that the Merger Agreement and the transactions contemplatedby the Merger Agreement, including the Offer and the Merger (the “Transactions”), are advisable, fair to and inthe best interests of MyoKardia and its stockholders, (b) authorizing and approving the execution, delivery andperformance by MyoKardia of the Merger Agreement and the consummation by MyoKardia of theTransactions, (c) resolving that the Merger will be effected under Section 251(h) of the DGCL and that theMerger will be consummated as soon as practicable following the Offer Acceptance Time and (d) recommendingthat MyoKardia’s stockholders accept the Offer and tender their Shares in the Offer. MyoKardia has beenadvisedthatallofitsdirectorsandexecutiveofficersintendtotenderalloftheirtransferrableSharespursuanttotheOffer.

On the date of the Offer to Purchase, MyoKardia will file its Tender Offer Solicitation/RecommendationStatement on Schedule 14D-9 (the “Schedule14D-9”) with the United States Securities and Exchange Commission(the“SEC”)anddisseminatetheSchedule14D-9toMyoKardiastockholderswiththeOffertoPurchase.TheSchedule14D-9willincludeamorecompletedescriptionoftheMyoKardiaBoard’sreasonsforauthorizingandapprovingtheMergerAgreementandthetransactionscontemplatedtherebyandthereforestockholdersareencouragedtoreviewtheSchedule14D-9carefullyandinitsentirety.

Purchaser will not be required to consummate the Offer if any of the following conditions, among otherconditions,existorhaveoccurredandarecontinuingatthescheduledExpirationTime(asdefinedbelow)oftheOffer:(a) the number of Shares validly tendered (and not properly withdrawn) prior to the expiration of the Offer (butexcludingSharestenderedpursuanttoguaranteeddeliveryproceduresthathavenotyetbeen“received”,asdefinedbySection 251(h)(6) of the DGCL), together with the Shares thenownedbyParent or Purchaser, does not represent atleastoneSharemorethan50%ofthethenoutstandingShares(the“MinimumCondition”);(b)anyrestraintisineffectenjoining, making illegal or otherwise prohibiting consummation of the Offer or the Merger (the “RestraintsCondition”);(c)thereisanactioninstitutedorpendingbyagovernmentalauthorityofcompetentjurisdictionseekingany judgment (i) to prevent, prohibit or make illegal the consummation of the Offer or the Merger, (ii) to prohibitParent’s ability to vote, transfer, receive dividends or otherwise exercise full rights of ownershipwithrespect to thestock of MyoKardia or (iii) in connection with the Offer or the Merger, to prohibit, limit, restrain or impair in anymaterialrespectParent’sabilitytoown,control,direct,manage,oroperateortoretainorchangeanymaterialportionoftheassets,licenses,operations,rights,productlines,businessesorintereststhereinofMyoKardiaoritssubsidiariesoranyofthematerialassets,licenses,operations,rights,productlines,businessesorintereststhereinofParentoritssubsidiaries(otherthan,ineachcase,aDivestitureAction(asdefinedintheOffertoPurchase)requiredtobetakenbyParent andPurchaser pursuant totheMerger Agreement) (the“ActionsCondition”); (d) thewaitingperiod(andanyextensionthereof) applicable totheconsummationof theOffer or theMerger under theHart-Scott-RodinoAntitrustImprovementsActof1976,asamended,andtherulesandregulationspromulgatedthereunderhasneitherexpirednorhasearlyterminationthereofbeengrantedorthereisineffectanyvoluntaryagreementbetweenParent,PurchaserorMyoKardia andthe Federal Trade Commission or the Department of Justice pursuant to whichParent, Purchaser orMyoKardia will not consummate the Merger for any period of time (the “Governmental Consents Condition”);(e)thereisaninaccuracyintherepresentationsandwarrantiesmadebyMyoKardiaintheMergerAgreement,subjecttothe materiality and other qualifications set forth in the Merger Agreement; (f) MyoKardia has not complied with orperformedinallmaterialrespectsitsobligationsrequiredtobecompliedwithorperformedbyitpriortothescheduledExpiration Time under the Merger Agreement; and (g) since the date of the Merger Agreement there has been aMaterialAdverseEffect(asdefinedintheOffertoPurchase)thatiscontinuingasofthescheduledExpirationTime.TheseandotherconditionstotheOffer(the“OfferConditions”)aredescribedinSections15and16oftheOffertoPurchase.

To the extent permitted by law, Purchaser also expressly reserves the exclusive right to (a) increase the OfferPrice,(b)waiveanyoftheOfferConditionsotherthantheMinimumCondition,theTerminationCondition(as

definedintheOffertoPurchase),theRestraintsConditionortheGovernmentalConsentsConditionand(c)makeanyother changes to the terms and conditions of the Offer not inconsistent with the terms of the Merger Agreement,provided that MyoKardia’s consent is required for Purchaser to (i) except in connection with a stock split,recapitalization or other like change with respect to the Shares, decrease the Offer Price, (ii) change the form ofconsiderationpayableintheOffer,(iii)decreasethemaximumnumberofSharessoughttobepurchasedintheOffer,(iv)imposeanyconditionstotheOfferotherthantheOfferConditions,(v)amend,modifyorsupplementanyoftheOfferConditionsinamannerthatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholdersofShares,(vi)amend,modifyorwaivetheMinimumCondition,theTerminationCondition,theRestraintsConditionorthe Governmental Consents Condition, (vii) extend or otherwise change the expiration date of the Offer, except asdescribedunder“—Section13—TheTransactionDocuments—TheMergerAgreement—ExtensionsoftheOffer”ofthe Offer to Purchase or (viii) otherwise amend, modify or supplement any of the other terms of the Offer in anymannerthatadverselyaffects,orwouldreasonablybeexpectedtoadverselyaffect,theholdersofShares.

Upon the terms and subject to the conditions of the Offer, Purchaser will accept for payment and pay for allSharesthatarevalidlytenderedandnotvalidlywithdrawnatorpriortomidnight(NewYorkCitytime),oneminuteafter 11:59p.m.NewYorkCitytime,onNovember16,2020(suchinitial expirationdateandtimeoftheOffer, the“InitialExpirationTime”)or,iftheOfferhasbeenextendedpursuanttoandinaccordancewiththeMergerAgreement,thedateandtimetowhichtheOfferhasbeensoextended(theInitialExpirationTime,orsuchlaterexpirationdateandtimetowhichtheOfferhasbeensoextended,the“ExpirationTime”).

Pursuant to the terms of the Merger Agreement, if, at the then-scheduled Expiration Time, any of the OfferConditionshasnotbeensatisfiedorwaivedbyParentandPurchaser(totheextentsuchwaiverispermittedundertheMerger Agreement and applicable law), then (a) Purchaser may, in its sole discretion (and without the consent ofMyoKardia or any other person) and (b) upon MyoKardia’s written request, Purchaser will, and Parent will causePurchaser to, extend the Offer on one or more occasions in consecutive increments of up to ten business days each(eachsuchincrementtoendat5:00p.m.,NewYorkCitytime,onthelastbusinessdayofsuchincrement)inordertopermitthesatisfactionofsuchOfferCondition(s);provided,however,that(i)PurchaserwillnotberequiredtoextendtheOffertoadatelaterthanMarch3,2021(butifasoffivebusinessdayspriortosuchdate,anyof(A)theRestraintsCondition(if therestraint relates toanantitrust law), (B)theActionsConditions(if theactionrelates toanantitrustlaw) and(C) the Governmental Consents Conditionhas not beensatisfied or waived(to the extent permitted bytheMergerAgreementandapplicablelaw),thenParentorMyoKardiamayextendsuchdatetoApril 2, 2021(March3,2021,orassuchdatemaybesoextended,the“OutsideDate”))andPurchaserwillnotbepermittedtoextendtheoffertoadatelaterthantheOutsideDatewithoutthepriorwrittenconsentofMyoKardiaand(ii)ifatanythenscheduledexpirationoftheOffer,alloftheOfferConditions(otherthantheMinimumConditionandanyOfferConditionsthatarebytheirnaturetobesatisfiedattheOfferAcceptanceTime)havebeensatisfiedorwaived(totheextentpermittedbytheMergerAgreementandapplicablelaw)andtheMinimumConditionhasnotbeensatisfied,Purchaserwillnotberequired to (and Parent will not be required to cause Purchaser to) extend the Offer for more than three additionalconsecutive increments of ten business days (or such shorter periods as may be agreed to by MyoKardia andPurchaser). Purchaser will extend the Offer for the minimum period required by applicable law, interpretation orpositionoftheSECoritsstafforTheNASDAQGlobalSelectMarketoritsstaff.See“TheOffer—Section1—TermsoftheOffer”oftheOffertoPurchase.

Anyextension, termination or amendment of the Offer will be followedas promptly as practicable by a publicannouncementthereof.InthecaseofanextensionoftheOffer,wewillmakeapublicannouncementofsuchextensionnolaterthan9:00a.m.,NewYorkCitytime,onthenextbusinessdayafterthepreviouslyscheduledExpirationTime.

In order to take advantage of the Offer, you must either (a) complete and sign the Letter of Transmittal inaccordancewiththeinstructionsintheLetterofTransmittal,haveyoursignatureguaranteed(ifrequiredbyInstruction1totheLetterofTransmittal),mailordelivertheLetterofTransmittal(oramanuallysignedfacsimilecopy)andanyotherrequireddocumentstoEquinitiTrustCompany,thedepositaryfortheOffer(the“Depositary”),andeitherdeliverthecertificatesforyourSharesalongwiththeLetterofTransmittaltotheDepositaryortenderyourSharespursuanttothe procedures for book-entry transfer set forth in “TheOffer—Section 3—Procedures for Tendering Shares” of theOffertoPurchaseor(b)request yourbroker, dealer, commercial bank,trust companyorothernomineetoeffect thetransactionforyou.IfyourSharesareregisteredinthenameofabroker,dealer,commercialbank,trustcompanyorothernominee,youmustcontactsuchbroker,dealer,commercialbank,trustcompanyorothernomineetotenderyourShares.IfyoudesiretotenderyourShares,andcertificatesevidencingyour

Shares are not immediately available or youcannot deliver suchcertificates andall other requireddocuments to theDepositary or youcannot complywith the procedures for book-entry transfer described in “TheOffer—Section 3—ProceduresforTenderingShares”oftheOffertoPurchase,ineachcasepriortotheExpirationTime,youmaytenderyourSharesbyfollowingtheproceduresforguaranteeddeliverysetforthin“TheOffer—Section3—ProceduresforTenderingShares”oftheOffertoPurchase.

ForpurposesoftheOffer,PurchaserwillbedeemedtohaveacceptedforpaymentSharestenderedwhen,asandifPurchaser gives oral or written notice of Purchaser’s acceptance to the Depositary. Purchaser will pay for SharesacceptedforpaymentpursuanttotheOfferbydepositofthepurchasepricethereforwiththeDepositary,whichwillactasagentfortenderingstockholdersforthepurposeofreceivingpaymentsandtransmittingsuchpaymentstotenderingstockholders.UndernocircumstanceswillPurchaserpayinterestontheconsiderationpaidforSharespursuanttotheOffer,regardlessofanyextensionoftheOfferoranydelayinmakingsuchpayment.

Exceptasotherwiseprovidedin“TheOffer—Section4—WithdrawalRights”oftheOffertoPurchase,tendersofShares made in the Offer are irrevocable. However, you may withdraw some or all of the Shares that you havepreviouslytenderedintheOfferatanytimebeforetheExpirationTimeasexplainedbelow.

Foryourwithdrawaltobeeffective,awrittenorfacsimiletransmissionnoticeofwithdrawalwithrespecttotheapplicableSharesmustbetimelyreceivedbytheDepositaryatoneofitsaddressessetforthonthebackcoveroftheOffer toPurchase, andthenotice of withdrawal must specifythenameof thepersonwhotenderedtheSharestobewithdrawn,thenumberofSharestobewithdrawnandthenameoftheregisteredholderofShares,ifdifferentfromthatofthepersonwhotenderedsuchShares.IftheSharestobewithdrawnhavebeendeliveredtotheDepositary,asignednoticeofwithdrawalwith(exceptinthecaseofSharestenderedbyanEligibleInstitution(asdefinedintheOffertoPurchase)) signatures guaranteed by an Eligible Institution must be submitted before the release of such Shares. Inaddition,suchnoticemustspecify,inthecaseofSharestenderedbydeliveryofcertificates,theserialnumbersshownon the specific certificates evidencing the Shares to be withdrawn or, in the case of Shares tendered by book-entrytransfer,thenameandnumberoftheaccountattheBook-EntryTransferFacility(asdefinedintheOffertoPurchase)tobecreditedwiththewithdrawnShares.Withdrawalsmaynotberescinded,andShareswithdrawnwillthereafterbedeemednotvalidlytendered.However,withdrawnSharesmayberetenderedatanytimebeforetheExpirationTimebyagainfollowinganyoftheproceduresdescribedintheOffertoPurchase.

Subject to applicable law as applied by a court of competent jurisdiction, Purchaser will determine, in itssole discretion, all questions as to the form of documents and the validity, eligibility (including time of receipt)and acceptance for payment of any tender of Shares, and its determination will be final and binding.

Ingeneral, yourexchangeofSharesforcashpursuanttotheOfferwillbeataxabletransactionforU.S.federalincometaxpurposesandmayalsobeataxabletransactionunderapplicablestate,localorforeignincomeorothertaxlaws.YoushouldconsultyourtaxadvisoraboutthetaxconsequencestoyouofexchangingyourSharespursuanttotheOffer in light of your particular circumstances. See “The Offer—Section 5—Material U.S. Federal Income TaxConsequences” of the Offer to Purchase for a more detailed summary of the material U.S. federal income taxconsequencesofthesaleofSharesintheOfferandtheMerger.

Theinformationrequiredtobedisclosedbyparagraph(d)(1)ofRule14d-6promulgatedundertheExchangeActiscontainedintheOffertoPurchaseandisincorporatedhereinbyreference.

MyoKardia has provided Purchaser with its stockholder list, security position listings and certain otherinformationregardingthebeneficialownersofSharesforthepurposeofdisseminatingtheOffertoholdersofShares.TheOffertoPurchase,therelatedLetterofTransmittalandotherrelatedmaterialswillbemailedtorecordholdersofSharesandwillbefurnishedtobrokers,dealers,commercialbanks,trustcompaniesandothernomineeswhosenamesappearonMyoKardia’sstockholderlistor,ifapplicable,whoarelistedasparticipantsinaclearingagency’ssecuritypositionlistingforsubsequenttransmittaltobeneficialownersofShares.

The Offer to Purchase and the related Letter of Transmittal contain important information that should beread carefully before any decision is made with respect to the Offer.

QuestionsandrequestsforassistanceandcopiesoftheOffertoPurchase,theLetterofTransmittalandallothertenderoffermaterialsmaybedirectedtotheInformationAgent,atitsaddressandtelephonenumberssetforthbelowandwillbefurnishedpromptlyatPurchaser’sexpense.NeitherParentnorPurchaserwillpayanyfeesorcommissionstoanybrokerordealeroranyotherperson(otherthantotheInformationAgentandtheDepositary,

as describedin the Offer to Purchase) in connectionwith the solicitation of tenders of Shares pursuant to the Offer.Brokers, dealers, commercial banks, trust companies and other nominees will, upon request, be reimbursed byPurchaserforreasonableandnecessarycostsandexpensesincurredbytheminforwardingmaterialstotheircustomers.

The Information Agent for the Offer is:

 

1407BroadwayNewYork,NewYork10018(212)929-5500

orCall Toll-Free 1-800-322-2885

Email:tenderoffer@mackenziepartners.com

October19,2020

Exhibit 99(D)(2)

PERSONAL AND CONFIDENTIAL

September17,2020

Bristol-MyersSquibbCompany430East29thStreet,14thFloorNewYork,NewYork10016

LadiesandGentlemen:

1. In connection with your consideration of a possible negotiated business combination transaction betweenMyoKardia, Inc. (the “Company”) and you (the “Possible Transaction”), you have requested informationrelating to the Company that is confidential and proprietary. As a condition to your being furnished suchinformation,youagreetotreatanyinformation,inanyformormedium,whetherwrittenororal,relatingtotheCompanyoranyofitssubsidiaries,affiliatesordivisions(whetherpreparedbytheCompany,itsadvisorsorotherwise)thatisfurnishedtoyoubyoronbehalfoftheCompany(hereincollectivelyreferredtoasthe“EvaluationMaterial”)inaccordancewiththeprovisionsofthisletteragreementandtotakeorabstainfromtakingcertainotheractionshereinsetforth.Theterm“EvaluationMaterial”includes,withoutlimitation,allnotes, analyses, compilations, spread sheets, data, reports, studies, interpretations or other documentsfurnishedtoyouoryourRepresentatives(asdefinedbelow)orpreparedbyyouoryourRepresentativestothe extent suchmaterials reflect or are based upon, in whole or in part, the Evaluation Material. Theterm“Evaluation Material” does not include information that (a) is or becomes available to you on anonconfidentialbasisfromasourceotherthantheCompanyoritsRepresentatives;providedthatsuchsourceisnotknownbyyoutobeboundbyaconfidentialityagreementwith,orothercontractual,legalorfiduciaryobligationto,theCompanythatprohibitssuchdisclosure,(b)isorbecomesgenerallyavailabletothepublicotherthanasaresultofadisclosurebyyouoryourRepresentativesinviolationofthisletteragreement,(c)has been or is independently developed by you or your Representatives without the use of the EvaluationMaterialorinviolationofthetermsofthisletteragreement,or(d)isalreadyinyouroryourRepresentatives’possession,providedthatsuchinformationisnotknownbyyoutobesubjecttoaconfidentialityagreementwith, or other contractual, legal or fiduciary obligation to, the Company that prohibits disclosure of suchinformation (includingthe Prior Confidentiality Agreement (as definedbelow)). For purposes of this letteragreement, the term “Representatives” shall include (i) when used in relation to the Company, theCompany’ssubsidiariesandAffiliates(assuchtermisdefinedinRule12b-2oftheSecuritiesExchangeActof 1934, as amended (the “Exchange Act”)) and its and their respective directors, officers, employees,consultants, attorneys, accountants, financial advisors and other professional representatives, and (ii) whenused in relation to you, your subsidiaries and Affiliates and your and their respective directors, officers,employees,consultants,attorneys,accountants,financialadvisorsandotherprofessionalrepresentatives.Youhereby agree that the Evaluation Material will be kept confidential and used solely for the purpose ofevaluatingandnegotiatingthePossibleTransaction;provided,however,thattheEvaluationMaterialmaybedisclosed(i)toyourRepresentativeswhoneedtoknowsuchinformationforthesolepurposeofevaluatingandnegotiatingaPossibleTransaction,(ii)pursuanttoanExternalDemandinaccordancewithparagraph4ofthisletteragreement,and(iii)astheCompanymayotherwiseconsentinwriting.AllsuchRepresentativesshall(A)beinformedbyyouoftheconfidentialnatureoftheEvaluationMaterial,(B)bedirectedtokeeptheEvaluation Material strictly confidential, and (C) be advised of the terms of this letter agreement and bedirected to comply with all applicable terms of this letter agreement. You agree to be responsible for anybreachesofanyoftheprovisionsofthisletteragreementbyanyofyourRepresentatives(itbeingunderstoodthat such responsibility shall be in addition to and not by way of limitation of any right or remedy theCompanymayhaveagainst yourRepresentatives withrespect tosuchbreach). It is understoodandagreedthat the Company may, in its sole discretion, from time to time determine that disclosure of certainEvaluation Material to certain of your Representatives may be inappropriate, in which event at theCompany’srequest,youshallrefrainfromdisclosingsuchEvaluationMaterialtosuchRepresentativesfromand after receipt of such request. You agree to notify the Company in writing of any actual or suspectedmisuse, misappropriation or unauthorized disclosure of Evaluation Material which may come to yourattention.

2. Each party will not, and will direct its Representatives not to, disclose to any person (including anygovernmentalagency,authorityorofficialoranythirdparty)eitherthefactthatdiscussionsornegotiationsaretakingplace(orhavetakenplace)concerningthePossibleTransactionoranyoftheterms,conditionsorotherfactswithrespecttothePossibleTransaction,includingthestatusthereoforthatEvaluationMaterialhasbeenmadeavailabletoyou(suchinformation,“TransactionInformation”);provided,

however, that disclosureofTransactionInformationpursuant toanExternal Demandshall begovernedbyparagaph 4 of this letter agreement; providedfurther,however, that, other than in the case of an ExternalDemand,(a)youandyourAffiliatesmaydiscloseTransactionInformation(a“PermittedDisclosure”)ifbutonlyif(i)suchdisclosureisrequiredunderapplicablesecuritiesorantitrustlawsorunderapplicablestockexchangerulesasdeterminedbasedonadviceofoutsidelegalcounseland(ii)suchdisclosurerequirementdoes not arise froma breach of this letter agreement and (b) the Companyandits Affiliates maydiscloseTransaction Information if required under applicable securities or antitrust laws or under applicable stockexchangerulesasdeterminedbasedonadviseofoutsidelegalcounsel.Withoutlimitingthegeneralityoftheforegoing,andotherthanyourRepresentativeswhoneedtoknowsuchinformationforthesolepurposeofevaluatingandnegotiatingaPossibleTransaction,youfurtheragreethatyouwillnot,directlyorindirectly,contact, share the Evaluation Material or Transaction Information with or enter into any agreement,arrangement or understanding, or any discussions which would reasonably be expected to lead to anagreement, arrangement or understanding, with any other person, including financing sources, regarding aPossible Transaction involving the Company without the prior written consent of the Company and onlyuponsuchpersonexecutingaconfidentialityagreementinfavoroftheCompanywithtermsandconditionsconsistentwiththisletteragreement.

3. You hereby acknowledge that you and your Representatives are aware that the Evaluation Material andTransaction Information may contain material, non-public information about the Company, and thatapplicablesecuritieslawsprohibitcertainactionsbypersonswhohavereceivedfromanissuermaterial,non-publicinformation.

4. Notwithstandinganythingtothecontraryprovidedinthisletteragreement,(x)intheeventeitherpartyoranyofitsRepresentativesreceivearequestorarerequiredbydeposition,interrogatory,requestfordocuments,subpoena, civil investigative demand or similar process or pursuant to a formal request from a regulatoryexaminer(anysuchrequestedorrequireddisclosure,an“ExternalDemand”)todisclosealloranypartoftheEvaluationMaterial orTransactionInformation,asapplicable, or(y)inthecaseofaPermittedDisclosure,suchpartyorits Representatives, asthecasemaybe,agree(totheextent reasonablypracticableunderthecircumstancesandnotprohibitedbylaw)to(a)promptlynotifytheotherpartyoftheexistence, termsandcircumstancessurroundingsuchExternal DemandorPermittedDisclosure, (b)consult withtheotherpartyon the advisability of taking legally available steps to resist or narrow such request or disclosure, and (c)assisttheotherparty,attheotherparty’sexpense,inseekingaprotectiveorderorotherappropriateremedytotheextentavailableunderthecircumstances.Intheeventthatsuchprotectiveorderorotherremedyisnotobtainedorthat thenon-disclosingpartywaivescompliancewiththeprovisionshereof, (i) suchdisclosingpartyoritsRepresentatives,asthecasemaybe,maydiscloseonlythatportionoftheEvaluationMaterialorTransaction Information which such disclosing party or its Representatives are advised by outside legalcounsel is legally required to be disclosed and to only those persons to whomsuch disclosing party or itsRepresentatives are advised by outside legal counsel are legally required to receive such information, andsuch disclosing party or its Representatives shall exercise reasonable best efforts to obtain assurance thatconfidential treatment will be accorded suchEvaluation Material or Transaction Information, and (ii) suchdisclosing party or its Representatives shall not be liable for such disclosure, unless such disclosure wascausedbyorresultedfromapreviousdisclosurebysuchdisclosingpartyoritsRepresentativesnotpermittedbythisletteragreement.

5. You agree that (a) all communications regarding the Possible Transaction, (b) requests for additionalinformation, (c) requests for management meetings, and(d) discussionsor questionsregardingprocedures,timingandtermsofthePossibleTransaction,shallbesubmittedordirectedonlytothosepersonsdesignatedbytheCompanyinwriting,itbeingunderstoodthatcontactanddiscussionsintheordinarycourseconsistentwithpast practices andunrelatedtothePossible Transaction(andinwhichthePossible Transactionis notdiscussed)shallnotbeprohibitedorotherwiserestrictedbythisparagraph5.

6. Eachpartyagreesthat,foraperiodofone(1)yearfromthedatehereof,neitherit noranyofitsAffiliateswhoareprovidedwithEvaluationMaterialorTransactionInformation,oranyofitsRepresentativesactingonitsbehalforatitsdirection,will,directlyorindirectly,solicitforemploymentoremployorcausetoleavetheemployoftheotherparty(a)anyindividualservingasanofficeroftheotherparty,or(b)anyemployeeoftheotherpartyoranyofitssubsidiarieswithwhomsuchfirstpartyhashadsubstantialcontactinsuchfirstparty’sevaluationofthePossibleTransaction,ineachcasewithoutobtainingthepriorwritten

consent of the other party; providedthat each party may (i) make general advertisements or generalsolicitationsforemploymentorsearchesbyasearchfirmnotspecificallydirectedattheforegoingpersonsand employ any person who responds to such solicitations or searches, (ii) hire any person whoseemploymentwiththeotherpartywasterminatedpriortoanysolicitationforemploymentbythehiringparty,and (iii) hire any person who contacts the hiring party at his or her own initiative without any priorsolicitationspecificallytargetedatsuchemployeebythehiringparty.

7. Youherebyacknowledgeandagreethat,unlessotherwiseagreedinwritingbytheCompany,foraperiodofone (1) year from the date of this letter agreement (the “Standstill Period”), neither you nor any of yourAffiliates who are provided with Evaluation Material or Transaction Information, or any of yourRepresentatives acting on your behalf or at your direction, will, directly or indirectly: (a) propose (i) anymerger,consolidation,businesscombination,tenderorexchangeoffer,purchaseoftheCompany’sassetsorbusinesses, or similar transactions involving the Company or (ii) any recapitalization, restructuring,liquidation or other extraordinary transaction with respect to the Company; (b) (i) acquire beneficialownership of any securities (including in derivative form) of the Company (collectively, a transactionspecified in (a)(i), (a)(ii) and (b)(i) involving a majority of the Company’s outstanding capital stock orconsolidated assets, is referred to as a “BusinessCombination”), (ii) propose or seek, whether alone or inconcert with others, any “solicitation” (as such term is used in the rules of the Securities and ExchangeCommission) of proxies or consents to vote anysecurities (including in derivative form) of the Company,(iii)nominateanypersonasadirectoroftheCompany,or(iv)proposeanymattertobevoteduponbythestockholdersoftheCompany;(c)form,joinorinanywayparticipateinathirdparty“group”(assuchtermisusedintherulesoftheSecuritiesandExchangeCommission)(ordiscusswithanythirdpartythepotentialformation of a group) with respect to any securities (including in derivative form) of the Company or aBusiness Combination involving the Company; (d) request the Company (or any of its Representatives),directlyorindirectly,toamendorwaiveanyprovisionofthisparagraph(includingthissentence);or(e)takeany action that could reasonably be expected to require the Company to make a public announcementregarding a potential Business Combination; provided, however, that the Standstill Period shall terminate(x)upontheCompany’sentryintoadefinitiveagreementprovidingforaBusinessCombinationor(y)ifanythird party commences a tender or exchange offer which, if consummated, would result in such person’sacquisitionofbeneficialownershipofmorethan50%oftheoutstandingvotingsecuritiesoftheCompany,andin connection therewith, the Companyfiles with the Securities andExchangeCommission a Schedule14D-9 with respect to such offer that recommends that the Company’s stockholders accept such offer.NotwithstandinganythingtothecontrarysetforthinthisSection7,(x)youandyourRepresentativesactingon your behalf shall be permitted to make an unsolicited, confidential, non-public (i) proposal to theCompany’sChiefExecutiveOfficerorBoardofDirectors(oranydulyconstitutedcommitteethereof)withrespect to a Business Combination or (ii) request to the Company’s Chief Executive Officer or Board ofDirectors (or any duly constituted committee thereof) for a waiver of the provisions of this Section 7;providedthat no such proposal or request shall be made that could reasonably be expected to require anypublicdisclosurebytheCompanyoryouoranyofyourAffiliateswithrespect thereto; and(y)nothinginthisSection7shallbeconstruedtoprohibitpassiveinvestmentsmadeintheordinarycourseofbusinessinconnectionwithretirementplans,401(k)plans,mutualfunds,pensionplans,orsimilararrangements,ineachcase, only if not specifically targeted to an investment in the Company and not resulting in any filingobligationunderSection13oftheExchangeAct.

8. You understand that neither the Company nor any of its Representatives has made or make anyrepresentationorwarranty,expressorimplied,astotheaccuracyorcompletenessoftheEvaluationMaterialand that any such representations or warranties will be made only as set forth in any definitive agreementregardingthePossibleTransaction.Youagreethat,exceptpursuanttoanydefinitiveagreementregardingthePossibleTransaction, neithertheCompanynoranyofitsRepresentativesshall haveanyliabilitytoyouoranyofyourRepresentativesresultingfromtheselection,useorcontentoftheEvaluationMaterialbyyouoryourRepresentatives.

9. UpontheCompany’sdemand,youshalleitherpromptly(a)destroytheEvaluationMaterialandanycopiesthereof (including material that references Transaction Information), or (b) return to the Company allEvaluationMaterialandanycopiesthereof(includingmaterialthatreferencesTransactionInformation),and,ineither case, confirminwritingtotheCompanythat all suchmaterial hasbeendestroyedorreturned, asapplicable,incompliancewiththisletteragreement.Itisunderstoodthatinformationinanintangible

orelectronicformatcontainingEvaluationMaterialorTransactionInformationcannotberemoved,erasedorotherwise deleted from archival systems (also known as “computer or system back-ups”) but that suchinformation will continue to be protected under the confidentiality requirements and non-use limitationscontained in this letter agreement and you and such Representatives shall not purposefully access suchinformation except as required by law. Notwithstanding the foregoing, you and your Representatives mayretain one copy of any work product prepared by you or them that contains Evaluation Material orTransaction Information to the extent necessary pursuant to applicable legal or regulatory requirements;providedthat you and such Representatives shall reference such work product solely for such foregoingpurposesandshallcontinuetobeboundbytheobligationsofconfidentialityandnon-usehereunderforsuchperiodoftimeasyouandsuchRepresentativesretainsuchworkproduct.

10. Youagreethat,excepttotheextentexpresslyauthorizedbytheCompanyinadvance,neitheryounoranyofyourRepresentativesactingonyourbehalforatyourdirectionwilldirectlyorindirectlyhaveanyformalorinformal discussions or other communications, or directly or indirectly enter into any agreement,arrangement or understanding, whether formal or informal and whether or not binding, with any director,officerorotheremployeeoftheCompanyoranyofitssubsidiariesrelatingto(i)anyretention,severance,equityorothercompensation,incentivesorbenefitsthatmaybeorbecomepayabletoanydirectors,officersor employees of the Company or any of its subsidiaries in connection with a Possible Transaction orfollowingtheconsummationthereof, or(ii) anydirectorship,employment, consultingarrangementorothersimilarassociationorinvolvementofanydirectors,officersorotheremployeesoftheCompanyoranyofitssubsidiaries withtheCompanyoranyAffiliate oftheCompanyfollowingtheconsummationofaPossibleTransaction.

11. TotheextentthatanyEvaluationMaterialmayincludematerialsubjecttotheattorney-clientprivilege,workproduct doctrine or any other applicable privilege concerning pending or threatened legal or regulatoryproceedings or governmental investigations, the parties hereto understand and agree that they have acommonalityofinterestwithrespecttosuchmattersanditistheirdesire,intentionandmutualunderstandingthat the disclosure of such material is not intended to, and will not, waive or diminish in any way theconfidentialityofsuchmaterialoritscontinuedprotectionundertheattorney-clientprivilege,workproductdoctrineorotherapplicableprivilegeandanysuchEvaluationMaterialwillremainentitledtoallprotectionundertheseprivileges,thisletteragreementandthejointdefensedoctrine.Nothinginthisletteragreementobligatesanypartytoreveal material subject totheattorney-client privilege, workproduct doctrineoranyotherapplicableprivilege,andintheeventofaninadvertentdisclosureofanymaterialswhichmayhavetheeffect of waiving any such privilege, you and your Representatives agree to destroy any such materialspromptlyupontherequestoftheCompanyoritsRepresentatives.

12. You represent and warrant that, as of the date hereof, neither you nor any of your controlled AffiliatesbeneficiallyownanysecuritiesoftheCompany(asdeterminedundertheExchangeAct)orhaveanyotherpecuniaryorvotinginterestinthesecuritiesoftheCompany(otherthanthroughinvestmentsinbroad-basedindexfunds,pensions,benefitplansorothersimilarpassiveinvestments).

13. Nothinginthisletteragreementshallbeconstruedasgrantinganyrightsunderanypatent,copyrightorotherintellectualpropertyrightoftheCompanyoranyofitssubsidiaries,norshallthisletteragreementgrantanyrightsinortotheEvaluationMaterialotherthanthelimitedrighttoreviewsuchEvaluationMaterialsolelyforthepurposeofevaluatingandnegotiatingthePossibleTransaction.

14. Eachpartyacknowledgesandagreesthatmoneydamagesmaynotbeasufficientremedyforanybreach(orthreatenedbreach)ofthisletteragreementbytheotherpartyoritsRepresentativesandthateachpartyshallbeentitledtoseekequitablerelief,includinginjunctionandspecificperformance,asaremedyforanysuchbreach(or threatenedbreach), without proof of damages, andeachpartyfurther agrees towaive, andshallcause its Representatives to waive any requirement for the securing or posting of any bond in connectionwithanysuchremedy.Suchremediesshallnotbetheexclusiveremediesforabreachofthisletteragreementbutwillbeinadditiontoallotherremediesavailableatlaworinequity.

15. EachpartyagreesthatunlessanduntiladefinitiveagreementbetweenthepartieswithrespecttothePossibleTransaction has been executed and delivered, neither party will be under any legal obligation of any kindwhatsoeverwithrespecttoanytransactionbyvirtueofthisoranywrittenororalexpressionexcept,inthecaseofthisletteragreement,forthemattersspecificallyagreedtoherein.Inaddition,each

partyherebywaives,inadvance,anyclaims(including,withoutlimitation,breachofcontract)inconnectionwith any Possible Transaction other than claims under any definitive agreement relating to a PossibleTransaction or under this letter agreement. For purposes of this letter agreement, the term “definitiveagreement”doesnotincludeanexecutedletterofintentoranyotherpreliminarywrittenagreement,nordoesit includeanyoralacceptanceofanofferorbidbyyou.TheagreementsetforthinthisparagraphmaybemodifiedorwaivedonlybyaseparatewritingbytheCompanyandyouexpresslysomodifyingorwaivingsuchagreement.

16. Youacknowledgethat(a)theCompanyshallbefreetoconducttheprocessforatransactionastheCompanyinitssolediscretionshalldetermine(including,withoutlimitation,negotiatingwithanyprospectivebuyersand entering into a definitive agreement without prior notice to you or to any other person), and (b) anyproceduresrelatingtosuchtransactionmaybeimplementedorchangedatanytimewithoutnoticetoyouoranyotherperson,ineachcase,exceptasotherwisemaybesetforthinanydefinitiveagreementregardingthePossibleTransaction.

17. NofailureordelaybyapartyoranyofitsRepresentativesinexercisinganyright,powerorprivilegeunderthisletteragreementshalloperateasawaiverthereofunlessinwritingandsignedbyanofficerofthepartyor other authorized person on its behalf. No modification or amendment of this letter agreement shall beeffectiveunlessinwritingandsignedbyanofficeroftheCompany,orotherauthorizedpersononitsbehalf,andyou,oranauthorizedpersononyourbehalf.

18. Theillegality,invalidityorunenforceabilityofanyprovisionhereofunderthelawsofanyjurisdictionshallnot affect its legality, validity or enforceability under the laws of any other jurisdiction, nor the legality,validityorenforceabilityofanyotherprovision.

19. This letter agreement shall be governed by, and construed in accordance with, the laws of the State ofDelaware. The parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of theChanceryCourtsintheStateofDelawareandtheUnitedStatesDistrictCourtfortheDistrictoftheStateofDelawareforanyaction,suitorproceedingarisingoutoforrelatingtothisletteragreementandthePossibleTransaction,andagreenottocommenceanyaction,suitorproceedingrelatedtheretoexceptinsuchcourts.

20. Thisletteragreementconstitutestheentireagreementbetweenthepartieswithrespecttothesubjectmatterhereof and supersedes all other prior agreements and understandings, both written and oral, between theparties with respect to the subject matter hereof. Notwithstanding the foregoing, nothing contained in thisletter agreement shall modify or impair any of the rights or obligations of the parties under the MutualConfidentialDisclosureAgreementdatedasofJune29,2020(the“PriorConfidentialityAgreement”),withrespecttoanyConfidentialInformation(asdefinedtherein)provided(i)bytheCompanythereunderpriortothedateofthisletteragreementor(ii)byyouthereunderpriortoorafterthedateofthisletteragreement(itbeingunderstoodthatanyTransactionInformationshallbegovernedbythetermsofthisAgreement).

21. This letter agreement may be executed in two or more counterparts, each of which shall be deemed anoriginal, but all of which shall constitute the same agreement. One or more counterparts of this letteragreement may be delivered by facsimile or pdf electronic transmission, with the intention that they shallhavethesameeffectasanoriginalcounterparthereof.

22. Except as otherwise expressly provided herein, this letter agreement and the obligations hereunder shallterminate on the date that is seven (7) years from the date hereof;provided that the obligations ofconfidentiality and non-use of Manufacturing Information (as defined in the Prior ConfidentialityAgreement) that is identified in writing by the Company as Manufacturing Technology before it is sharedwithyoushallterminateonthedatethatisten(10)yearsfromthedatehereof;andprovidedfurtherthatanysuchterminationshallnotrelieveanypartyforanybreachofthisletteragreementpriortosuchtermination.

[Signature Page Follows]

Verytrulyyours,

MYOKARDIA,INC.

By: /s/JacobBauer

Name: JacobBauer

Title: ChiefBusinessOfficer

ConfirmedandAgreedto:

BRISTOL-MYERSSQUIBBCOMPANY

By: /s/BrianHeaphy

Name: BrianHeaphy

Title: VicePresident,CorporateDevelopment,Cardiovascular&NeuroscienceBusinessDevelopment

Date: 9/18/20

Exhibit 99(D)(3)

 

430East29thStreet,14thFloor,NewYork,NY,10016

September25,2020

VIA E-MAIL

MyoKardia,Inc.1000SierraPointParkwayBrisbane,CA94005 Attention: TassosGianakakos,PresidentandChiefExecutiveOfficer

STRICTLY CONFIDENTIAL

DearMr.Gianakakos:

In consideration for the substantial time and effort that Bristol-Myers Squibb Company (“Bristol-Myers Squibb” or“BMS”) has invested and is expected to invest in connection with the potential acquisition (the “Transaction”) ofMyoKardia, Inc. (“Gotham” or the “Company”), and for other good and valuable consideration (the receipt andsufficiencyofwhichareherebyacknowledged),BMSandtheCompanyherebyagreetothefollowing.

Foraperiod(the“ExclusivityPeriod”)beginningatthetimeofthisletteragreementbeingcountersignedbyGothamand ending on the first to occur of: (i) the execution of a definitive merger agreement with BMSwith respect to aTransaction; (ii) receipt by Gotham of written notice from BMS advising Gotham that BMS is no longer activelypursuingtheTransaction;(iii)thetimeatwhichBMSreduces,orproposesareductionin,thepersharepurchasepriceofferedbytheChiefExecutiveOfficerofBMStotheChiefExecutiveOfficeroftheCompanyonSeptember25,2020;and (iv) 8:00 a.m. (New York time) on October 5, 2020, (x) Gotham shall and shall direct its controlled affiliates,directors,officers,employees,agents,advisorsandanyotherpersonsactingunderthedirectionoronbehalfofanyofthe foregoing (collectively “Representatives”) to, immediately terminate and cease all existing discussions,communicationsornegotiationswithanypersonotherthanBMSanditsRepresentativesconcerningorrelatingtoanyactual or potential Alternative Transaction (as definedbelow), and(y) Gothamshall not, andshall direct eachof itsRepresentatives not to, (A) knowingly encourage, solicit, initiate or engage in discussions or negotiations with anypersonorentityotherthanBMSandits Representatives concerningorrelatingtoanyactual orpotential AlternativeTransaction; (B)knowinglyencourageor solicit anyoffer, inquiryor proposal fromanypersonor entity(other thanBMSanditsRepresentatives)concerningorrelatingtoanyactualorpotentialAlternativeTransaction;(C)provideanyinformation with respect to Gotham or any of its subsidiaries to any person or entity (other than BMS and itsRepresentatives) in connection with an actual or potential Alternative Transaction; or (D) enter into any agreement(whetherornotbindingordefinitive)withanypersonorentity(otherthanBMSanditsRepresentatives)concerningorrelating to an Alternative Transaction. For the purposes of this letter agreement, an “Alternative Transaction” shallmeanany(1)purchase,sale,exclusivelicenseorotherdispositionof20%ormoreofthebusinessorassetsofGothamandits subsidiaries, takenasawhole, (2) purchase, issuance, saleor otherdispositionof20%ormoreoftheequityinterests in Gothamor anyof its subsidiaries, (3) merger, acquisition, consolidation or similar business combinationtransactioninvolvingGothamoranyofitssubsidiaries,or(4)anyacquisitionorexclusivelicensebyanythirdpartyofMavacamtenoranyotherlicensegrantingcommercializationrightstoanythirdpartywithrespecttoMavacamten.

EachpartyagreesthatunlessanduntiladefinitiveagreementbetweenthepartieswithrespecttotheTransactionhasbeenexecutedanddelivered,neitherpartywill beunderanylegalobligationofanykindwhatsoeverwithrespecttoanytransactionbyvirtueofthisoranywrittenororalexpression,exceptforthemattersspecificallyagreedtohereinandintheconfidentialityagreementbetweenthepartiesdatedSeptember17,2020.

ThisletteragreementshallbegovernedbyandconstruedinaccordancewiththeinternallawsoftheStateofDelaware,without giving effect to applicable principles of conflicts of law. Each party herebyirrevocably and unconditionallyconsentstosubmittothejurisdictionoftheDelawareChanceryCourt,or,ifsuchcourtshallnothavejurisdiction,thestatecourtlocatedinWilmington,DelawareortheU.S.DistrictCourtforthedistrictinwhichWilmington,Delawareislocated,ineachcasewithrespecttoanyaction,suit,orproceedingarisingoutoforrelating

tothisletteragreement.Thisletteragreementmaybeexecutedincounterparts,eachofwhichshallbedeemedtobeanoriginal, but both of which shall constitute the same agreement. Delivery of a signed counterpart of this letteragreementbye-mailorfacsimiletransmissionshallconstitutevalidandsufficientdeliverythereof.

Verytrulyyours,

BRISTOL-MYERS SQUIBB COMPANY

By: /s/BrianHeaphy

Name: BrianHeaphy

Title: VP,CorporateDevelopment

AGREEDANDACCEPTED:

MYOKARDIA, INC.

By: /s/JacobBauer

Name: JacobBauer

Title: ChiefBusinessOfficer

Exhibit 99(D)(4)

TENDER AND SUPPORT AGREEMENT

ThisTENDER AND SUPPORT AGREEMENT(this “Agreement”), dated as of October 3, 2020, is by andamong Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), Gotham Merger Sub Inc., a DelawarecorporationandawhollyownedsubsidiaryofParent(“MergerSub”),andTassosGianakakos(the“Stockholder”).

WHEREAS, as of thedate hereof, theStockholder is thebeneficial owner(asdefinedinRule13d-3undertheExchangeAct)of(i)thenumberofsharesofcommonstock,parvalue$0.0001pershare(“CommonStock”),oftheCompany(asdefinedbelow)setforthonScheduleI(allsuchshares,togetherwithanysharesofCommonStockoftheCompany that are hereafter issued to, or otherwise acquired or owned (including beneficial ownership) by, theStockholder prior to the termination of this Agreement, being referred to herein as the “ Subject Shares”), (ii) thenumberofCompanyStockOptionssetforthonScheduleIand(iii)thenumberofCompanyRSUAwardssetforthonScheduleI;

WHEREAS, concurrently with the execution hereof, Parent, Merger Sub and MyoKardia, Inc., a Delawarecorporation(the“Company”),areenteringintoanAgreementandPlanofMerger,datedasofthedatehereofandasitmaybeamendedfromtimetotime(the“MergerAgreement”),whichprovides,amongotherthings,forMergerSubtocommenceacashtenderoffertopurchasealltheoutstandingsharesofCommonStockoftheCompany(the“Offer”)and,followingthecompletionoftheOffer,themergerofMergerSubwithandintotheCompany(the“Merger”),uponthe termsandsubject to the conditions set forth in the Merger Agreement (capitalized termsusedbutnototherwisedefinedhereinshallhavetherespectivemeaningsascribedtosuchtermsintheMergerAgreement);and

WHEREAS,asaconditiontotheirwillingnesstoenterintotheMergerAgreement,ParentandMergerSubhaverequired that the Stockholder, and as an inducement and in consideration therefor, the Stockholder (solely in theStockholder’s capacity as a beneficial owner of the Subject Shares, Company Stock Options and Company RSUAwards)hasagreedto,enterintothisAgreement.

NOW, THEREFORE,inconsiderationoftheforegoingandtherespectiverepresentations,warranties,covenantsandagreementssetforthbelowandforothergoodandvaluableconsideration,thereceiptandsufficiencyofwhichareherebyacknowledged,thepartieshereto,intendingtobelegallybound,doherebyagreeasfollows:

ARTICLE I  

AGREEMENT TO TENDER AND VOTE

Section 1.1  Agreement to Tender. SubjecttothetermsofthisAgreement,theStockholderagreestovalidlyandirrevocablytenderorcausetobetenderedintheOfferalloftheSubjectSharespursuanttoandinaccordancewiththetermsoftheOffer,freeandclearofallLiens(otherthanLiensarisinghereunderorasmaybeapplicableundertheSecurities Act or other applicable securities Laws). Without limiting the generality of the foregoing, aspromptlyaspracticableafterthecommencement(withinthemeaningofRule14d-2promulgatedundertheExchangeAct)oftheOffer,butinnoeventlaterthantheExpirationTime,theStockholdershall(a)deliverpursuanttothetermsoftheOffer(i)aletteroftransmittalwithrespecttotheSubjectSharescomplyingwiththetermsoftheOffer,(ii)aCertificate(oraffidavits oflossinlieuthereof)representingtheSubjectSharesoran“agent’smessage”(orsuchotherevidence,ifany, of transfer as the Paying Agent may reasonably request) in the case of a Book Entry Share, and(iii) all otherdocumentsorinstruments,totheextentapplicable,requiredtobedeliveredbystockholdersoftheCompanypursuanttothetermsoftheOfferinordertoeffectthevalidtenderoftheSubjectSharesor(b)instructtheStockholder’sbrokerorsuchotherPersonthatistheholderofrecordofanySubjectSharesbeneficiallyownedbytheStockholdertotendertheSubject Sharespursuant toandinaccordancewithclause(a)ofthis Section1.1and thetermsoftheOffer. TheStockholderagreesthat,onceanyoftheSubjectSharesaretendered,theStockholderwillnotwithdrawandwillnotcauseordirecttobewithdrawnanyoftheSubjectSharesfromtheOffer,unlessanduntilthisAgreementshallhavebeenvalidlyterminatedinaccordancewithSection5.2.

Section 1.2  Agreement to Vote. Subject to thetermsof this Agreement, theStockholder herebyirrevocablyandunconditionally agrees that, duringthe timethis Agreement is in effect, at anyannual or special meetingof thestockholdersoftheCompany,howevercalled,includinganyadjournmentorpostponementthereof,andinconnectionwithanyactionproposedtobetakenbywrittenconsentofthestockholdersoftheCompany,theStockholdershall,ineachcasetothefullestextentthattheSubjectSharesareentitledtovotethereon:(a)causealloftheSubjectSharestobecountedaspresentthereatforpurposesofdeterminingaquorum;and(b)bepresent(inpersonorbyproxy)

andvote(orcausetobevotedifanotherPersonistheholderofrecordofanySubjectSharesbeneficiallyownedbytheStockholder),ordeliver(orcausetobedelivered)awrittenconsentwithrespectto,allofhisSubjectShares(i)againstanyTakeoverProposaland(ii)againstanyotheractionthatisintendedorwouldreasonablybeexpectedtomateriallyimpede or interfere with or materially delay the Offer, the Merger or any other transactions contemplated by theMergerAgreement.UntiltheSubjectSharesareacceptedforpaymentintheOffer,theStockholdershallretainatalltimestherighttovotetheSubjectSharesintheStockholder’ssolediscretion,andwithoutanyotherlimitation,onanymatters other than those set forth in this Section 1.2that are at any time or from time to time presented forconsiderationtotheCompany’sstockholdersgenerally.

Section 1.3  Irrevocable Proxy.TheStockholderherebyrevokes(oragreestocausetoberevoked)anyandallpreviousproxiesgrantedwithrespecttotheSubjectShares.ByenteringintothisAgreement,theStockholderherebygrantsaproxyappointingParentastheStockholder’sattorney-in-fact andproxy,withfull powerofsubstitution,forand in the Stockholder’s name, to vote, express consent or dissent, or otherwise to utilize such voting power in themannercontemplatedbySection1.2aboveasParentoritsproxyorsubstituteshall,inParent’ssole discretion,deemproperwithrespecttotheSubjectShares. Theproxyandrelatedinterest grantedbytheStockholderpursuanttothisSection1.3isirrevocableandisgrantedinconsiderationofParentandMergerSubenteringintothisAgreementandtheMergerAgreementandincurringcertainrelatedfeesandexpenses.TheproxygrantedbytheStockholdershallnotbeexercisedtovote,consentoractonanymatterexceptascontemplatedbySection1.2above.TheproxygrantedbytheStockholdershallberevoked,terminatedandofnofurtherforceoreffect,automaticallyandwithoutfurtheraction,immediatelyuponterminationofthisAgreementinaccordancewithSection5.2hereof.

ARTICLE II  

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER

TheStockholderrepresentsandwarrantstoParentandMergerSubthat:

Section 2.1  Authority; Binding Agreement.TheStockholderhasfullpowerandauthoritytoexecute,deliverand perform his obligations under this Agreement and to consummate the transactions contemplated hereby. ThisAgreement has been duly and validly executed and delivered by the Stockholder, and constitutes a legal, valid andbindingobligationoftheStockholderenforceableagainsttheStockholderinaccordancewithitsterms(subjecttotheBankruptcyandEquityExceptions).

Section 2.2  Non -Contravention.TheexecutionanddeliveryofthisAgreementbytheStockholderdoesnot,and the performance by the Stockholder of the Stockholder’s obligations hereunder and the consummation by theStockholder of the transactions contemplated hereby will not (a) violate any Law or Judgment applicable to theStockholder or the Subject Shares, Company Stock Options or Company RSU Awards, or (b) except as may berequiredbyapplicableU.S.FederalsecuritiesLaws,requireanyconsent,approval,order,authorizationorotheractionby,orfilingwithornoticeto,anyPerson(includinganyGovernmentalAuthority)under,violateorconstituteadefault(with or without the giving of notice or the lapse of time or both) under, or give rise to any right of termination,cancellation or acceleration under, or result in the creation of any Liens on the Stockholder’s properties or assets(including the Subject Shares, Company Stock Options or Company RSU Awards) pursuant to, any Contract orJudgment binding on the Stockholder or the Subject Shares, Company Stock Options or Company RSUAwards, incaseof eachofclauses(a)and (b), except aswouldnot, individuallyor intheaggregate, reasonablybeexpected toadverselyaffectinanymaterialrespecttheabilityoftheStockholdertoperformhisobligationsunderthisAgreementortoconsummatethetransactionscontemplatedherebyinatimelymanner.

Section 2.3  Ownership of Subject Shares, Company Stock Options and Company RSU Awards; TotalShares.Asofthedatehereof,theStockholderisthebeneficialowner(asdefinedinRule13d-3undertheExchangeAct)oftheSubjectShares,CompanyStockOptionsandCompanyRSUAwards(togetherwithStockholder’sspousetotheextentthattheSubjectShares,CompanyStockOptionsandCompanyRSUsconstitutecommunitypropertyunderapplicableLaw)andhasgoodandmarketabletitletotheSubjectShares,CompanyStockOptionsandCompanyRSUAwardsfreeandclearofanyLiens,exceptforLiensarisinghereunderorasmaybeapplicableundertheSecuritiesActorotherapplicablesecuritiesLaws.ExceptpursuanttothisAgreement,noPersonhasanycontractualorotherrightorobligation to purchase or otherwise acquire all or any portion of the Subject Shares, Company Stock Options orCompanyRSUAwards.ExceptfortheSubjectShares,CompanyStockOptionsorCompanyRSUAwardsorpursuanttotheCompanyESPP,asofthedatehereof,theStockholderisnottherecordorbeneficialownerofany(a)CommonStockorvotingsecuritiesoftheCompanyor(b)options,warrantsorotherrightstoacquire,orsecuritiesconvertibleintoorexchangeablefor(ineachcase,whethercurrently,uponlapseof

time, following the satisfaction of any conditions, upon the occurrence of any event or any combination of theforegoing), any capital stock, voting securities or securities convertible into or exchangeable for Common Stock orvotingsecuritiesoftheCompany.

Section 2.4  Voting Power. Other thanas providedin this Agreement, the Stockholder has full votingpowerwithrespecttoalloftheSubjectShares,andfullpowerofdisposition,fullpowertoissueinstructionswithrespecttothematterssetforthhereinandfullpowertoagreetoallofthematterssetforthinthisAgreement,ineachcasewithrespecttoalloftheSubjectShares,CompanyStockOptionsandCompanyRSUAwards.NoneoftheSubjectSharesaresubjecttoanystockholders’agreement,proxy,votingtrustorotheragreementorarrangementwithrespecttothevotingoftheSubjectShares,exceptasprovidedhereunder.

Section 2.5  Reliance. The Stockholder has been represented by or had the opportunity to be represented byindependentcounselofhisownchoosingandhashadtherightandopportunitytoconsultwithhisattorney,andtotheextent, if any, that the Stockholder desired, the Stockholder availed itself of such right and opportunity. TheStockholder understands and acknowledges that Parent and Merger Sub are entering into the Merger Agreement inrelianceupontheStockholder’sexecution,deliveryandperformanceofthisAgreement.

Section 2.6  Absence of Litigation.WithrespecttotheStockholder,asofthedatehereof,thereisnoActionpending against, or, to the knowledge of the Stockholder, threatened in writing against, and there is no Judgmentimposedupon,theStockholderortheSubjectShares,CompanyStockOptionsandCompanyRSUAwardsthatwouldreasonably be expected to prevent or materially delay or impair the consummation by the Stockholder of thetransactions contemplated by this Agreement or otherwise adversely impact the Stockholder’s ability to performhisobligationshereunderinanymaterialrespect.

Section 2.7  Brokers.Nobroker,finder,financialadvisor,investmentbankerorotherPersonisentitledtoanybrokerage,finder’s,financialadvisor’sorothersimilarfeeorcommissionfromParentortheCompanyinconnectionwiththetransactionscontemplatedherebybaseduponarrangementsmadebytheStockholder.

ARTICLE III  

REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

EachofParentandMergerSubrepresentandwarranttotheStockholder,jointlyandseverally,that:

Section 3.1  Organization; Authorization. Each of Parent and Merger Sub is duly organized or formed, asapplicable,validlyexistingandingoodstandingunderthelawsofthejurisdictioninwhichitisorganized(inthecaseofgoodstanding,totheextenttheconceptisrecognizedbysuchjurisdiction).TheconsummationofthetransactionscontemplatedherebyarewithineachofParent’sandMergerSub’scorporatepowersandhavebeendulyauthorizedbyallnecessarycorporateactionsonthepartofParentandMergerSub.EachofParentandMergerSubhasallrequisitecorporatepowerandauthoritytoexecute,deliverandperformtheirrespectiveobligationsunderthisAgreementandtoconsummatethetransactionscontemplatedhereby.

Section 3.2  Binding Agreement. Each of Parent and Merger Sub has duly executed and delivered thisAgreement, and this Agreement constitutes its legal, valid and binding obligation of Parent and Merger Sub,enforceable against Parent and Merger Sub in accordance with its terms (subject to the Bankruptcy and EquityExceptions).

ARTICLE IV  

ADDITIONAL COVENANTS OF THE STOCKHOLDER

The Stockholder hereby covenants and agrees that until the valid termination of this Agreement in accordancewithSection5.2:

Section 4.1  No Transfer; No Inconsistent Arrangements.ExceptasprovidedhereunderorundertheMergerAgreement, fromandafterthedatehereofanduntil thisAgreementisvalidlyterminatedinaccordancewithSection5.2, the Stockholder shall not, directly or indirectly, (a) create or permit to exist anyLiens, other than LiensarisinghereunderorasmaybeapplicableundertheSecuritiesActorotherapplicablesecuritiesLaws,onalloranyportionoftheSubjectShares,CompanyStockOptionsorCompanyRSUAwards,(b)transfer,sell,assign,gift,hedge,pledgeorotherwisedispose(whetherbysale,liquidation,dissolution,dividendordistribution)of,orenter

into any derivative arrangement with respect to (collectively, “Transfer“), all or any portion of the Subject Shares,CompanyStockOptionsorCompanyRSUAwards,oranyrightorinteresttherein(orconsenttoanyoftheforegoing),(c)enter intoanyContract withrespect toanyTransferoftheSubject Shares, CompanyStockOptionsorCompanyRSU Awards, or any interest therein, (d) grant or permit the grant of any proxy, power-of-attorney or otherauthorization or consent in or with respect to all or any portion of the Subject Shares, Company Stock Options orCompanyRSUAwards,(e)depositorpermitthedepositofalloranyportionoftheSubjectSharesintoavotingtrustor enter into a voting agreement or arrangement with respect to all or any portion of the Subject Shares, or(f)knowinglytakeanyotheractionthatwouldrestrict,limitorinterfereinanymaterialrespectwiththeperformanceof the Stockholder’s obligations hereunder or the transactions contemplated hereby or otherwise make anyrepresentationorwarrantyoftheStockholderhereinuntrueorincorrectinanymaterialrespectorseektodoorsolicitany of the foregoing actions. Without limiting the generality of the foregoing, during the time this Agreement is ineffect, the Stockholder shall not tender, agree to tender or cause or permit to be tendered all or any portion of theSubjectSharesintoorotherwiseinconnectionwithanytenderorexchangeoffer,exceptpursuanttotheOffer.IfanyinvoluntaryTransfer of all or anyportionoftheSubject Shares, CompanyStockOptionsor CompanyRSUAwardsshalloccur(including,ifapplicable,asalebytheStockholder’strusteeinanybankruptcy,orasaletoapurchaseratany creditor’s or court sale), the transferee (which term, as used herein, shall include any and all transferees andsubsequent transferees of the initial transferee) shall take and hold such Subject Shares, CompanyStock Options orCompany RSU Awards subject to all of the restrictions, liabilities and rights under this Agreement, which shallcontinue in full force and effect until the valid termination of this Agreement in accordance with Section5.2.TheStockholderagreesthat it shall not, andshall causeeachofhisAffiliatesnotto, becomeamemberofa“group”(asdefined under Section 13(d) of the Exchange Act) with respect to any securities in the Companyfor the purpose ofopposing or competing with or taking any actions inconsistent with the Transactions contemplated by the MergerAgreement. Notwithstandingthe foregoing, the Stockholder maymakeTransfers of Subject Shares, CompanyStockOptionsandCompanyRSUAwards(andanysharesofCommonStockunderlyingsuchCompanyStockOptionsandCompany RSU Awards) (i) to any “Permitted Transferee” (as defined below), in which case any such transferredSubjectShares,CompanyStockOptionsand/orCompanyRSUAwardsshallcontinuetobeboundbythisAgreementand provided that any such Permitted Transferee agrees in writing to be bound by the terms and conditions of thisAgreementpriortotheconsummationofanysuchTransfer,(ii)byusingalready-ownedsharesofCommonStock(oreffecting a “net exercise” of a Company Stock Option or a “net settlement” of a Company RSU) either to pay theexercisepriceupontheexerciseofaCompanyStockOptionortosatisfytheStockholder’staxwithholdingobligationupontheexerciseofaCompanyStockOptionorsettlementofaCompanyRSU,ineachcaseaspermittedpursuanttothetermsofanyCompanyStockPlan,(iii)bywillorthelawsofintestacy,or(iv)asParentmayotherwiseagreeinwriting in its sole discretion. A“PermittedTransferee”means, with respect to anyStockholder, (A)a spouse, linealdescendant or antecedent,brother or sister, adopted child or grandchild, or the spouse of any child, adopted child,grandchild,oradoptedgrandchildoftheStockholder,(B)anycharitableorganizationdescribedinSection170(c)oftheCode,(C)anytrust,thebeneficiariesofwhichincludeonlytheStockholderand/orthePersonsnamedinclause(A)or(B)ofthisdefinition,or(D)anycorporation,limitedliabilitycompany,orpartnership,thestockholders,members,andgeneralorlimitedpartnersofwhichincludeonlytheStockholderand/orthePersonsnamedinclause(A)or(B)ofthisdefinition.

Section 4.2  No Exercise of Appraisal Rights; Actions.TheStockholder(a)waivesandagreesnottoexerciseany appraisal or dissenters’ rights (including under Section 262 of the General Corporation Law of the State ofDelaware)inrespectofalloranyportionoftheSubjectSharesthatmayarisewithrespecttotheOfferandtheMergerand(b)agreesnottocommenceorjoinin,andagreestotakeallactionsnecessarytooptoutofanyclassinanyclassaction with respect to, any claim, derivative or otherwise, against Parent, Merger Sub, the Companyor any of theirrespectivesuccessorsrelatingtothenegotiation,executionordeliveryofthisAgreementortheMergerAgreementorthe makingor consummation of the Offer or consummation of the Merger, includinganyAction(i) challenging thevalidity of, or seeking to enjoin the operation of, any provision of this Agreement or the Merger Agreement or(ii) allegingbreachofanyfiduciarydutyofanyPersoninconnectionwiththenegotiationandentryintotheMergerAgreementortheTransactionscontemplatedthereby.

Section 4.3  Documentation and Information.ExceptasrequiredbyapplicableLaw(includingthefilingofaSchedule13DwiththeSECwhichmayincludethisAgreementasanexhibitthereto),theStockholdershallnot,andshall direct his Representatives not to, make any public announcement regarding this Agreement, the MergerAgreement or the transactions contemplated hereby or thereby without the prior written consent of Parent. TheStockholderconsentstoandherebyauthorizesParentandMergerSubtopublishanddiscloseinalldocumentsand

schedulesfiledwiththeSEC,andanypressreleaseorotherdisclosuredocumentthatParentorMergerSubreasonablydeterminestobenecessaryinconnectionwiththeOffer,theMergerandanytransactionscontemplatedbytheMergerAgreement, the Stockholder’s identity and ownership of the Subject Shares, Company Stock Options and CompanyRSUAwards,theexistenceofthisAgreementandthenatureoftheStockholder’scommitmentsandobligationsunderthis Agreement; providedthat the Stockholder shall have a reasonable opportunity to review and approve suchdisclosure prior to any such filing, such approval not to be unreasonably withheld, conditioned or delayed, and theStockholderacknowledgesthatParentandMergerSubmayfilethisAgreementoraformhereofwiththeSECoranyotherGovernmentalAuthorityasrequiredunderapplicableLaw.TheStockholderagreestopromptlygiveParentanyinformation the Stockholder may reasonably require for the preparation of any such disclosure documents, and theStockholder agrees to promptly notify Parent of any required corrections with respect to any written informationsupplied by it specifically for use in any such disclosure document, if and to the extent that the Stockholder shallbecomeawarethatanysuchinformationshallhavebecomefalseormisleadinginanymaterialrespect.

Section 4.4  No Solicitation. Subject to Section 5.15, the Stockholder shall not, directly or indirectly,(a)initiate,solicitorknowinglyencourage(includingbywayoffurnishingnon-publicinformation)thesubmissionofany inquiries regarding, or the making of any inquiry, proposal or offer that constitutes, or would reasonably beexpected to lead to, a Takeover Proposal, or (b) engage in, continue or otherwise participate in any discussions ornegotiations regarding, or furnish to any other Person any non-public information in connection with, or for thepurposeof,encouraginganyinquiry,proposalorofferthatconstitutes,orwouldreasonablybeexpectedtoleadto,aTakeover Proposal. The Stockholder shall immediately cease any solicitation, discussions or negotiations with anyPersonsthatmaybeongoingwithrespecttoaTakeoverProposal,ceaseprovidinganyinformationwithrespecttotheCompany and its Subsidiaries to such Person and request the prompt return or destruction of all confidentialinformationconcerningtheCompanyanditsSubsidiariesinsuchPerson’spossessionorcontrol.

Section 4.5  Adjustments; Additional Shares. In the event of any stock split, stock dividend, merger,reorganization,recapitalization,reclassification,combination,exchangeofsharesorsimilartransactionwithrespecttothe capital stock of the Company that affects the Subject Shares, the terms of this Agreement shall apply to theresultingsecurities.IntheeventthattheStockholderacquiresanyadditionalCommonStockoftheCompanyorotherinterestsinorwithrespecttotheCompany,suchCommonStockorotherinterestsshall,withoutfurtheractionofthepartieshereto,besubjecttotheprovisionsofthisAgreement,andthenumberoftheSubjectSharesoftheStockholderwillbedeemedamendedaccordingly.TheStockholdershallpromptlynotifyParentandMergerSubofanysuchevent.

ARTICLE V  

MISCELLANEOUS

Section 5.1  Notices. All notices, requests, claims, demands andother communications under this Agreementshallbeinwritingandshallbegiven(andshallbedeemedtohavebeendulygivenuponreceipt)bydeliverybyhand,byfacsimile, byregisteredor certifiedmail (postageprepaid, returnreceipt requested), or byemail totherespectivepartiesheretoatthefollowingaddresses(oratsuchotheraddressforapartyheretoasshallbespecifiedbylikenotice):(a) if to Parent or Merger Sub, in accordance with the provisions of the Merger Agreement and (b) if to theStockholder,totheStockholder’saddress,facsimilenumberore-mailaddresssetforthonasignaturepagehereto,ortosuchother address, facsimile numberor e-mail addressas suchpartyheretomayhereafter specifyinwriting forthepurposebynoticetoeachotherpartyhereto.

Section 5.2  Termination.ThisAgreementshallterminateautomatically,withoutanynoticeorotheractionbyanyPerson,uponthefirsttooccurof(a)thevalidterminationoftheMergerAgreementinaccordancewithitsterms,(b) the Effective Time, (c) the entry, without the prior written consent of the Stockholder, into any materialmodification or amendment to the Merger Agreement that reduces the amount, changes the form or otherwiseadversely affects theconsideration payable to the Stockholder pursuant to the Merger Agreement as in effect onthedate hereof, and (d) the mutual written consent of all of the parties hereto. Upontermination of this Agreement, nopartyheretoshallhaveanyfurtherobligationsorliabilitiesunderthisAgreement;provided,however,that(i)nothingset forth in thisSection5.2shall relieve any party hereto fromliability for any Willful and Material Breach of thisAgreementpriortoterminationofthisAgreementand(ii)theprovisionsofthisArticleVshallsurviveanyterminationofthisAgreement.

Section 5.3  Amendments and Waivers.AnyprovisionofthisAgreementmaybeamendedorwaivedifsuchamendmentorwaiverisinwritingandissigned,inthecaseofanamendment,byeachpartyheretoor,inthecaseofawaiver, by each party hereto against whomthe waiver is to be effective. Nofailure or delay by any party hereto inexercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partialexercisethereofprecludeanyotherorfurtherexercisethereofortheexerciseofanyotherright,powerorprivilege.

Section 5.4  Expenses.Allfeesandexpensesincurredinconnectionherewithandthetransactionscontemplatedhereby shall be paid by the party hereto incurring such expenses, whether or not the Offer or the Merger isconsummated.

Section 5.5  Binding Effect; No Third Party Beneficiaries; Assignment.Thepartiesheretoherebyagreethattheirrespectiverepresentations,warrantiesandcovenantssetforthhereinaresolelyforthebenefitoftheotherpartieshereto,inaccordancewithandsubjecttothetermsofthisAgreement,andthisAgreementisnotintendedto,anddoesnot,conferuponanyPersonotherthanthepartiesheretoanyrightsorremedieshereunder,includingtherighttorelyupon the representations and warranties set forth herein. Neither this Agreement nor any of the rights, interestsorobligationshereundershallbeassignedbyanyofthepartieshereto(whetherbyoperationofLaworotherwise)withouttheprior writtenconsent of theother parties hereto, except totheextent that suchrights, interestsorobligationsareassignedpursuanttoaTransferexpresslypermittedunderSection4.1.Noassignmentbyanypartyheretoshallrelievesuchpartyheretoofanyofitsobligationshereunder.Subjecttotheforegoing,thisAgreementwillbebindingupon,inuretothebenefitofandbeenforceablebythepartiesheretoandtheirrespectivesuccessorsandpermittedassigns.

Section 5.6  Governing Law; Jurisdiction.

(a) This Agreement and any matters or disputes relating thereto shall be governed by, and construed inaccordance with, the laws of the State of Delaware applicable to contracts executed in and to be performedentirelywithinthatState,regardlessofthelawsthatmightotherwisegovernunderanyapplicableconflictofLawsprinciples.

(b) All Actions arising out of or relating to this Agreement shall be heard and determined in the Court ofChanceryoftheStateofDelaware(or,iftheCourtofChanceryoftheStateofDelawaredeclinestoacceptjurisdictionoveranyAction,anystateorfederalcourtwithintheStateofDelaware),andineachcase,appellatecourtstherefrom,and the parties hereto hereby irrevocably submit to the exclusive jurisdiction and venue of such courts in any suchActionandirrevocablywaivethedefenseofaninconvenientforumorlackofjurisdictiontothemaintenanceofanysuchAction.TheconsentstojurisdictionandvenuesetforthinthisSection5.6(b)shallnotconstitutegeneralconsentsto service of process in the State of Delaware and shall have no effect for any purpose except as provided in thisparagraph and shall not be deemed to confer rights on any Person other than the parties hereto. Each party heretoagreesthatserviceofprocessuponsuchpartyheretoinanyActionarisingoutoforrelatingtothisAgreementshallbeeffectiveifnoticeisgivenbyovernightcourierattheaddresssetforthinSection5.1ofthisAgreement.ThepartiesheretoagreethatafinaljudgmentinanysuchActionshallbeconclusiveandmaybeenforcedinotherjurisdictionsbysuit on the judgment or in any other manner provided by applicable Law; provided, however, that nothing in theforegoingshallrestrictanypartyhereto’srightstoseekany post-judgmentreliefregarding,oranyappealfrom,afinaltrialcourtjudgment.

(c)  EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICHMAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULTISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THEFULLESTEXTENTPERMITTEDBYAPPLICABLELAW,ANYRIGHTITMAYHAVETOATRIALBYJURYINRESPECTOFANYLITIGATIONDIRECTLYORINDIRECTLYARISINGOUTOFORRELATINGTOTHISAGREEMENTANDANYOFTHEAGREEMENTSDELIVEREDINCONNECTIONHEREWITH(INCLUDINGTHEMERGERAGREEMENT)ORTHETRANSACTIONSCONTEMPLATEDHEREBYORTHEREBY.EACHPARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT ORATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCHOTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOINGWAIVER,(II)ITUNDERSTANDSANDHASCONSIDEREDTHEIMPLICATIONSOFSUCHWAIVER,(III)ITMAKES SUCH WAIVER VOLUNTARILY AND (D) IT HAS BEEN INDUCED TO ENTER INTO THISAGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THISSECTION5.6(c).

Section 5.7  Counterparts. This Agreement may be executed in one or more counterparts (including byfacsimileorelectronicmail)andbyelectronicordigitalsignature,eachofwhichshallbedeemedtobeanoriginalbutallofwhichtakentogethershallconstituteoneandthesameagreement,andshallbecomeeffectivewhenoneormorecounterpartshavebeensignedbyeachofthepartiesheretoanddeliveredtotheotherpartieshereto.SignaturestothisAgreementtransmittedbyfacsimiletransmission,byelectronicmailin“portabledocumentformat”(.pdf)form,orbyanyotherelectronicmeansintendedtopreservetheoriginalgraphicandpictorialappearanceofadocument,willhavethesameeffectasphysicaldeliveryofapaperdocumentbearinganoriginalsignature.

Section 5.8  Entire Agreement.ThisAgreementconstitutestheentireagreement,andsupersedesallotherprioragreements andunderstandings, bothwrittenandoral, amongthe parties hereto andtheir Affiliates, or anyof them,withrespecttothesubjectmatterofthisAgreement.

Section 5.9  Severability.Ifanyterm,conditionorotherprovisionofthisAgreementisdeterminedbyacourtofcompetentjurisdictiontobeinvalid,illegalorincapableofbeingenforcedbyanyruleofLaworpublicpolicy,allotherterms,provisionsandconditionsofthisAgreementshallneverthelessremaininfullforceandeffect.Uponsuchdeterminationthatanyterm,conditionorotherprovisionisinvalid,illegalorincapableofbeingenforced,thepartiesheretoshallnegotiateingoodfaithtomodifythisAgreementsoastoeffecttheoriginalintentofthepartiesheretoascloselyaspossibletothefullestextentpermittedbyapplicableLaw.

Section 5.10  Specific Performance. The parties hereto hereby agree that irreparable damage for whichmonetary relief, even if available, would not be an adequate remedy, would occur to Parent and Merger Sub if anyprovisionofthisAgreementwerenotperformedbytheStockholderinaccordancewiththetermshereoforisotherwisebreached,includingiftheStockholderfailtotakeanyactionrequiredofthemhereunder,and,accordingly,thateachofParentandMergerSubshallbeentitledtoseekaninjunctionorinjunctionstopreventbreachesofthisAgreementortoenforce specifically the Stockholder’s performance of the termsand provisions hereof, without proofofdamagesorotherwise,inadditiontoanyotherremedytowhichParentorMergerSubareentitledatlaworinequity.Eachofthepartiesagreesthatitwillnotopposethegrantingofaninjunction,specificperformanceorotherequitablereliefonthebasisthatthepartieshaveanadequateremedyatlaworanawardofspecificperformanceisnotanappropriateremedyfor any reason at law or equity. In any Action for specific performance, the Stockholderwill waive the defense ofadequacy of any other remedy at law or in equity, and the Stockholder waive any requirement for the securing orpostingofanybondorothersecurityinconnectionwiththeremediesreferredtointhisSection5.10.

Section 5.11  Headings.TheSectionheadingscontainedinthisAgreementareforreferencepurposesonlyandshallnotaffectinanywaythemeaningorinterpretationofthisAgreement.

Section 5.12  Mutual Drafting. Each party hereto has participated in the drafting of this Agreement, whicheachpartyheretoacknowledgesistheresultofextensivenegotiationsbetweenthepartieshereto;accordingly,intheeventanambiguityorquestionofintentorinterpretationarises,thisAgreementshallbeconstruedasifdraftedjointlybythe parties hereto, andnopresumptionor burdenof proof shall arise favoringor disfavoringanyparty hereto byvirtueoftheauthorshipofanyprovisionsofthisAgreement.

Section 5.13  Further Assurances. Parent, Merger Sub and, upon the reasonable request of Parent, theStockholderwillexecuteanddeliver,orcausetobeexecutedanddelivered,allfurtherdocumentsandinstrumentsandusetheirrespectivereasonablebesteffortstotake,orcausetobetaken,allactionsandtodo,orcausetobedone,allthings necessary, proper or advisable under applicable Laws and regulations, to performtheir respectiveobligationsunderthisAgreement.

Section 5.14  Interpretation.Unlessthecontextotherwiserequires,asusedinthisAgreement:(a)“or”isnotexclusive;(b)“including”anditsvariantsmean“including,withoutlimitation”anditsvariants; (c)wordsdefinedinthesingularhavetheparallelmeaninginthepluralandviceversa;(d)wordsofonegendershallbeconstruedtoapplytoeachgender;and(e)theterms“Article,”“Section”and“Schedule”refertothespecifiedArticle,SectionorScheduleofortothisAgreement.

Section 5.15  Capacity as Stockholder. Notwithstandinganythinghereintothecontrary, (a) theStockholdersigns this Agreement solely in the Stockholder’s capacity as a Stockholder of the Company, and not in any othercapacity and this Agreement shall not limit or otherwise affect the actions of the Stockholder in his capacity as anofficeranddirectoroftheCompany,and(b)nothinghereinshallinanywayrestrictadirectororofficerofthe

Companyinthetakingofanyactions(orfailuretoact)inhisorhercapacityasadirectororofficeroftheCompany,orintheexerciseofhisorherfiduciarydutiesasadirectororofficeroftheCompany,orpreventorbeconstruedtocreateanyobligationonthepartofanydirectororofficeroftheCompanyfromtakinganyactioninhisorhercapacityassuchdirectororofficer.

Section 5.16  No Agreement Until Executed. This Agreement shall not be effective unless and until (a) theMergerAgreementisexecutedbyallpartiesthereto,and(b)thisAgreementisexecutedbyallpartieshereto.

Section 5.17  No Ownership Interest. Except as otherwise provided herein, nothing contained in thisAgreementshallbedeemedtovestinParentorMergerSubanydirectorindirectownershiporincidenceofownershipof or with respect to the Subject Shares. All rights, ownership and economic benefits of and relating to theSubjectShares shall remain vested in and belong to the Stockholder, and neither Parent nor Merger Sub shall have anyauthoritytomanage,direct,restrict,regulate,govern,oradministeranyofthepoliciesoroperationsoftheCompanyorexercise any power or authority to direct the Stockholder in the voting of any of the Shares, except as otherwiseprovidedherein.

[SignaturePageFollows]

ThepartiesheretoareexecutingthisAgreementonthedatesetforthintheintroductoryclause.

BRISTOL-MYERS SQUIBB COMPANY

By: /s/ElizabethA.Mily

Name: ElizabethA.Mily

Title: ExecutiveVicePresident,StrategyandBusinessDevelopment

GOTHAM MERGER SUB INC.

By: /s/BrianP.Heaphy

Name: BrianP.Heaphy

Title: VicePresident

[SignaturePagetoTenderandSupportAgreement]

ThepartiesheretoareexecutingthisAgreementonthedatesetforthintheintroductoryclause.

By: /s/TassosGianakakos

Name: TassosGianakakos

Address: 1000SierraPointParkwayBrisbane,CA94005

[SignaturePagetoTenderandSupportAgreement]

Schedule I

624,790sharesofCommonStock(directlyorthroughtrusts)

122,283CompanyRSUAwards

361,622CompanyStockOptions(unvested)

727,290CompanyStockOptions(vested)

[ScheduleItoTenderandSupportAgreement]